


Preliminary Programme

36th Congress of the European
Society of Clinical Microbiology
and Infectious Diseases

Munich, Germany

17–21 April 2026

**20
26**

EW006	08:30 – 10:30	Hall A1-4
 2-hour Educational Session		

Outbreak investigation: through the eyes of a field epidemiologist and public health microbiologist

Chairs Angela Novais (Porto, Portugal)
Yassen Tcholakov (Montréal, Canada)

W0081	08:30	Field epidemiology: principles and the 10 steps of outbreak investigation Ricardo Mexia (Lisbon, Portugal)
W0082	08:50	Public health microbiology: practical applications of epidemiological markers and key tools for outbreak response João Pires (Oslo, Norway)
W0083	09:10	Real case study of healthcare-associated infection outbreak, Vera Manageiro (Lisbon, Portugal), Alma Tostmann (Nijmegen, The Netherlands)

Co-organised with: EPIET alumni network (EAN), ESCMID Study Group for Epidemiological Markers (ESGEM)


EW004	08:30 – 10:30	Hall B0-1
 2-hour Educational Session		

The antibiogram: from theory to clinical practice

Chairs Giulia De Angelis (Rome, Italy)
Holger Rohde (Hamburg, Germany)

W0073	08:30	The antibiogram demystified: principles, methods, and clinical significance Paul Christoffer Lindemann (Bergen, Norway)
W0074	08:50	Interpreting Gram-negative antibiograms Katy Jeannot (Besançon, France)
W0075	09:10	Interpreting Gram-positive antibiograms Stefania Stefani (Catania, Italy)
W0076	09:30	From the antibiogram to antibiotic choice: clinical reasoning in action Robin Howe (Cardiff, United Kingdom)

Co-organised with: ESCMID AMR Action Subcommittee


EW005	08:30 – 10:30	Hall B0-2
 2-hour Educational Session		

Prevention and treatment for specific intra-abdominal infections

Chairs Alida C.M. Veloo (Groningen, The Netherlands)
Birgit Willinger (Vienna, Austria)

W0077	08:30	Prevention of postoperative infection in bowel surgery: mechanical and/or oral antibiotics: what and when? Christian Eckmann (Hannover, Germany)
W0078	08:50	Selective decontamination: benefits and resistance development Nick Daneman (Ontario, Canada)
W0079	09:10	Necrotising pancreatitis and antibiotics: prophylaxis or early therapy? Hjalmar Van Santvoort (Utrecht, The Netherlands)
W0080	09:30	Diverticulitis: exact diagnosis and indications for antibiotic therapy Massimo Sartelli (Macerata, Italy)

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), ESCMID Study Group for Anaerobic Infections (ESGAI)

EW001	08:30 – 10:30	Hall ICM 13a
 2-hour Educational Session		

Strategies to tackle biofilm-associated infections


Chairs Arnaldo Lopes Colombo (São Paulo, Brazil)
Luis Melo (Coimbra, Portugal)

W0061	08:30	Pathogenesis of biofilm-associated infections Kimberly
-------	-------	--

Kline (Geneva, Switzerland)

W0062	08:50	Viral therapies to tackle biofilm-associated infections Joana Azeredo (Braga, Portugal)
W0063	09:10	Molecular basis of tolerance and resistance in biofilms Tom Coenye (Ghent, Belgium)
W0064	09:30	Assessing <i>in vivo</i> anti-biofilm activity Valerie Waters (Toronto, Canada)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)


EW002	08:30 – 10:30	Hall ICM 13b
 2-hour Educational Session		

Overcoming ongoing challenges in CM/ID publishing

Chairs Kirsten Bibbins-Domingo (Chicago, United States)
Leonard Leibovici (Yahud, Israel)

W0065	08:30	Peer-review: the future? Amelia Joseph (Nottingham, United Kingdom)
W0066	08:50	Preparing the next generation of peer reviewers Preeti Malani (Ann Arbor, United States)
W0067	09:10	Efforts to make the literature unbiased Ursula Hofer (London, United Kingdom)
W0068	09:30	From authors to peer reviewers to editors: how should we handle the use of AI in publishing? Robert C. Read (Southampton, United Kingdom)

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

EW003	08:30 – 10:30	Hall ICM 5
 2-hour Educational Session		

A gentle introduction to bioinformatics for microbial genomics

Chair John W. A. Rossen (Groningen, The Netherlands)
TBA

W0069	08:30	Quality control of whole genome sequencing data Tarah Lynch (Calgary, Canada)
W0070	08:50	Genome assembly, read mapping and variant calling Torsten Seemann (Melbourne, Australia)
W0071	09:10	Species determination, genotyping and AMR prediction Andreas Stroehlein (Berlin, Germany)
W0072	09:30	Understating trees: phylogenomics for infection control Zoe Anne Dyson (London, United Kingdom)

TEST2	10:00 – 11:00
1-hour Case Session	

TEST2FB


TESTPC01	Test intervention 01 Pauline Cazanova (Nice, France)
TESTPC02	Test PC02 Florence Boinnot (Nice, France)
TESTPC03	Test PC02 assigned to Flo 2 Florence Boinnot Test (France)

ME013	11:00 – 12:00	Hall A1-4
 Meet-the-Expert		

Legionnaires' disease: insights from recent large outbreaks

M0001	11:00	Maria Scaturro (Rome, Italy)
M0002	11:12	Florian Heger (Vienna, Austria)

Co-organised with: ESCMID Study Group for Legionella Infections (ESGLI)

ME010	11:00 – 12:00	Hall B0-1
 Meet-the-Expert		

Useful endpoints for antimicrobial therapy and stewardship: what if not only mortality mattered?

M0025 11:00 *Esther Calbo (Terrassa, Spain)*
M0026 11:12 *Antonios Katsounas (Bochum, Germany)*

ME012 11:00 – 12:00 Hall B0-2

Meet-the-Expert

AMR DX IPC

How best to detect ESBL and carbapenemase producers

M0029 11:00 *Orjan Samuelsen (Tromso, Norway)*

M0030 11:12 *Shiri Navon-Venezia (Ariel, Israel)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), EUCAST Steering Committee

ME007 11:00 – 12:00 Hall ICM 13a

Meet-the-Expert

CLN IPC

Nosocomial infections in ECMO: clinical challenges and case-based discussion

M0019 11:00 *Konstanty Szuldrzynski (Mazowieckie, Poland)*

M0020 11:12 *Marta Hernández-Meneses (Barcelona, Spain)*

Co-organised with: European Extracorporeal Life Support Organization

ME008 11:00 – 12:00 Hall ICM 13b

Meet-the-Expert

PED PRO

Designing and conducting clinical trials in paediatric infectious diseases: barriers and challenges

M0021 11:00 *Emmanuel Roilides (Thessaloniki, Greece)*

M0022 11:12 *Irja Lutsar (Tartu, Estonia)*

ME009 11:00 – 12:00 Hall ICM 5

Meet-the-Expert

CLN DX

Travel, migration and immunosuppression: a two-way challenge

M0023 11:00 *Martin Peter Grobusch (Amsterdam, The Netherlands)*

M0024 11:12 *Maria Velasco (Madrid, Spain)*

Co-organised with: Federation of European Societies for tropical medicine and international health (FESTMIH)

EW018 13:30 – 15:30 Hall A1-4

2-hour Educational Session

PRO

Method morsels: breaking trial methodology down into digestible components

Chairs *Amelia Joseph (Nottingham, United Kingdom)*
Navaneeth Narayanan (New Brunswick, United States)

W0015 13:30 **How much is enough? Old and new methods for calculating sample size** *Yin Mo (Singapore, Singapore)*

W0016 13:50 **Bayesian versus frequentist statistics: differences and advantages** *Tom Snelling (Sydney, Australia)*

W0017 14:10 **Immortal time bias: avoiding, recognising, and addressing it** *Emily McDonald (Montreal, Canada)*

W0018 14:30 **Open the DOOR and win? How to understand and interpret novel outcome measures** *Sean Wei Xiang Ong (Toronto, Singapore)*

Co-organised with: CMI Communications Board of Editors

EW017 13:30 – 15:30 Hall B0-1

2-hour Educational Session

CLN DX PED

Advancing paediatric infectious disease management: from stewardship to precision therapeutics

Chairs *Luise Martin (Berlin, Germany)*
João Paulo Telles (São Paulo, Brazil)

W0011 13:30 **Paediatric antimicrobial stewardship: evidence-based interventions and practical barriers** *Johannes Hübner (Munich, Germany)*

W0012 13:50 **Optimising treatment in infants with access to newer antimicrobials** *Aspasia Katragkou (Morristown, United States)*

W0013 14:10 **Modelling and simulation for optimising initial paediatric and neonatal dosing** *Agathe Béranger (Paris, France)*

W0014 14:30 **Rapid identification and resistance profiling in neonates** *Surbhi Malhotra-Kumar (Antwerp, Belgium)*

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW016 13:30 – 15:30 Hall ICM 5

2-hour Educational Session

CLN DX

Clinical challenges in tropical medicine: lessons for global health

Chairs *Hilmir Asgeirsson (Stockholm, Sweden)*
Maria Cristina Loader (London, United Kingdom)

W0007 13:30 **Clinical impact of hybrid *Leishmania* strains** *Özgür Kurt (Istanbul, Türkiye)*

W0008 13:50 **Hybrid *Schistosoma*: what's the real picture?** *Bonnie Webster (London, United Kingdom)*

W0009 14:10 **Therapeutic challenges for nematode and trematode infections** *Carlos Seas (Lima, Peru)*

W0010 14:30 **Imported tropical diseases: what clinicians need to know** *Camilla Rothe (Munich, Germany)*

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V., ESCMID Study Group for Clinical Parasitology (ESGCP)

ME015 13:30 – 14:30 Hall B0-2

Meet-the-Expert

DX IPC

Genomics in clinical microbiology and virology across settings: hype, hope, or a game-changer?

M0005 13:30 *Abhilasha Karkey (Kathmandu, Nepal)*

M0006 13:42 *Judith Breuer (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), European Society of Clinical Virology

ME011 13:30 – 14:30 Hall ICM 13a

Meet-the-Expert

ANT CLN

Different sets of diagnostic tools for endocarditis: how to resolve discrepancies and make them work?

M0027 13:30 *Thomas Wouter Van Der Vaart (Amsterdam, The Netherlands)*

M0028 13:42 *Marta Hernández-Meneses (Barcelona, Spain)*

ME014 13:30 – 14:30 Hall ICM 13b

Meet-the-Expert

CLN DX

How to approach pneumonia in patients with neutropenia

M0003 13:30 *Mark Reinwald (Brandenburg, Germany)*

M0004 13:42 Johan Maertens (Leuven, Belgium)

ME021 14:45 – 15:45 Hall B0-2

Meet-the-Expert

AMR CLN

Optimising treatment of severe infections due to DTR organisms

M0035 14:45 Jean-Francois Timsit (Paris, France)

M0036 14:57 Lowell Ling (Hong Kong, Hong Kong)

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCI), European Society of Intensive Care Medicine

ME019 14:45 – 15:45 Hall ICM 13a

Meet-the-Expert

CLN IPC PRO

Ethical discourse on isolation precautions: to isolate or not to isolate that is the question!

M0031 14:45 Babette Rump (Middelburg, The Netherlands)

M0032 14:57 Angelo Pan (Cremona, Italy)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

ME020 14:45 – 15:45 Hall ICM 13b

Meet-the-Expert

CLN DX

Hepatitis in the immunocompromised host: is it infection?

M0033 14:45 Susanne Gjeruldsen Dudman (Oslo, Norway)

M0034 14:57 Oana Sandulescu (Bucharest, Romania)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Viral Hepatitis (ESGVH), Viral Hepatitis Society of Türkiye (VHSD)

EW027 16:15 – 18:15 Hall B0-1

2-hour Educational Session

AMR DX

Overcoming resistant *Candida* infections

Chairs Alexandre Alanio (Paris, France)
Nelesh Govender (Johannesburg, South Africa)

W0051 16:15 Global epidemiology of antifungal resistance in *Candida*: trends and hotspots Arnaldo Lopes Colombo (São Paulo, Brazil)

W0052 16:35 Next-generation diagnostics: rapid tests and molecular methods Cornelia Lass-Flörl (Innsbruck, Austria)

W0053 16:55 *Candida auris* and *Candida parapsilosis* resistance and transmission Anuradha Chowdhary (Delhi, India)

W0054 17:15 Adopting guidelines and resources for *Candida* diseases in LMICs Methee Chayakulkeeree (Bangkok, Thailand)

Co-organised with: German-Speaking Mycological Society, ÖGACH, EFISG, Portuguese Society of Infectious Diseases and Clinical Microbiology, Hellenic Society of Medical Mycology, Turkish Society of Paediatric Infectious Diseases

EW025 16:15 – 18:15 Hall ICM 13a

2-hour Educational Session

IPC PRO

Enhancing infection prevention and control through implementation science: the REVERSE experience

Chairs Tatjana Lejko Zupanc (Ljubljana, Slovenia)
Walter Zingg (Zurich, Switzerland)

W0043 16:15 Embedding implementation science in infection prevention and control Kathrin Blum (Zurich, Switzerland)

W0044 16:35 Culture as a determinant of IPC implementation Diana

Gabriela Iacob (Bucharest, Romania)

W0045 16:55 Boundary spanning as a prerequisite to IPC implementation María Teresa Pérez-Rodríguez (Vigo, Spain)

W0046 17:15 When implementation leadership facilitates IPC implementation Davide Mangioni (Milan, Italy)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP), Swiss Society for Infectious Diseases (SSID), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

EW026 16:15 – 18:15 Hall ICM 5

2-hour Educational Session

PED VAX

Vaccines for children: innovations, impact, and future directions

Chairs Ilias P. Iosifidis (Thessaloniki, Greece)
Hanna M. Nohynek (Helsinki, Finland)

W0047 16:15 New and emerging frontiers in paediatric vaccinology Paolo Palma (Antwerp, Italy)

W0048 16:35 Beyond the needle: innovative delivery systems for paediatric vaccines Ulrich Heininger (Basel, Switzerland)

W0049 16:55 Direct and indirect roles for vaccines against antimicrobial resistance Vana Spoulou (Athens, Greece)

W0050 17:15 Vaccines and innate immunity: harnessing trained immunity in early life Elisabeth Dulfer (Nijmegen, The Netherlands)

ME024 16:15 – 17:15 Hall A1-4

Meet-the-Expert

AMR DX

Quality controlled AST: use your cell phone and your data

M0041 16:15 Onur Karatuna (Växjö, Sweden)

M0042 16:27 Iva Butic (Zagreb, Croatia)

Co-organised with: Médecins Sans Frontières (MSF), CAESAR Network, ESCMID Education Subcommittee

ME023 16:15 – 17:15 Hall B0-2

Meet-the-Expert

ANT CLN

PK/PD-based dose optimisation in challenging patient groups

M0039 16:15 Birgit Koch (Rotterdam, The Netherlands)

M0040 16:27 Christina König (Hamburg, Germany)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

ME022 16:15 – 17:15 Hall ICM 13b

Meet-the-Expert

TRN

Multi-omics dissection of bacterial pathogenesis and host-microbiome interactions

M0037 16:15 Virginie Stévenin (Toulouse, France)

M0038 16:27 Romain Guérillot (Melbourne, Australia)

ME030 17:30 – 18:30 Hall A1-4

Meet-the-Expert

DX PHEI

How to prepare for pathogen X emergence: a practical approach

M0059 17:30 David Chien Lye (Singapore, Singapore)

M0060 17:42 David Hayman (Palmerston North, New Zealand)

ME029 17:30 – 18:30 Hall B0-2

Meet-the-Expert

ANT CLN

Overcoming challenges to implementing system-wide antimicrobial stewardship

M0057 17:30 Sara Cosgrove (Baltimore, United States)

M0058 17:42 Paul Turner (Oxford, United Kingdom)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

ME028 17:30 – 18:30 Hall ICM 13b

Meet-the-Expert

CLN DX

De-escalation or escalation: using rapid diagnostics in patients with sepsis

M0055 17:30 Pierluigi Viale (Bologna, Italy)

M0056 17:42 Ana Gales (São Paulo, Brazil)

Saturday, 18 April 2026

EW040 08:30 – 10:30 Hall A2-1

2-hour Educational Session

ANT TRN

Next-generation therapies against infectious diseases

Chairs Nicolas Mueller (Zurich, Switzerland) Sebastian Wicha (Hamburg, Germany)

W0204 08:30 Cellular therapies targeting infectious diseases Lukas Jeker (Basel, Switzerland)

W0205 08:50 Discovery of new antibody-based anti-infectives Jan Rybniker (Köln, Germany)

W0206 09:10 Proteasome-derived defence peptides Yifat Merbl (Rehovot, Israel)

W0207 09:30 Neutralising antibodies for treatment of vector borne pathogens Davide Filippo Robbiani (Bellinzona, Switzerland)

Co-organised with: Swiss Society for Infectious Diseases (SSID), ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group of Forensic and Post-Mortem Microbiology (ESGFOR)

EW039 08:30 – 10:30 Hall ICM 13a

2-hour Educational Session

PHEI TRN

Milk matters: risks and safe practices in a changing global landscape

Chairs Sally Jane Cutler (London, United Kingdom) Ana Raquel Freitas (Porto, Portugal)

W0200 08:30 Raw milk misconceptions: health benefits vs risks Enda Cummins (Dublin, Ireland)

W0201 08:50 Brucellosis and bovine tuberculosis in LMICs Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)

W0202 09:10 Coxiella burnetii in milk and cheese Loïc Epelboin (Cayenne, French Guiana)

W0203 09:30 Unexpected surprises in milk: avian influenza to Listeria monocytogenes Nicole Martin (Ithaca, United States)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM)

OS001 08:30 – 10:30 Hall A1-2

2-hour Oral Session

AMR DX IPC

Novel insights and tools to tackle hospital outbreaks

Chairs Fusun Can (Istanbul, Türkiye) Rekha Pai Mangalore (Melbourne, Australia)

O0001 08:30 A pathogen-agnostic machine learning framework

for precision outbreak detection in hospital and community settings K. Ko* (Singapore, Singapore), C. Suphavitai, P. Boonsimma, H. Yingtaeesittikul, K.M. Lim, U. Shanmugam, W.E. Ong, J.H. Yeo, T.H.N. Wong

O0002 08:42 Towards data-driven refinement of an automated hospital outbreak detection system: validation of expert classification through genotypic evidence in neonatology wards F.D. Ruether* (Berlin, Germany), B. Piening, F. Maechler, A. Weber, C. Geffers, S.J.S. Aghdassi

O0003 08:54 Designing and evaluating an infection prevention and control (IPC) dashboard to track and interrupt spread of healthcare-associated infections A. Luk* (Oxford, United Kingdom), D. Adlard, H. Thai, G. Durant, S.A. Walker, D. Eyre

O0004 09:06 Ceftazidime/avibactam-resistant Klebsiella pneumoniae driven by multiple beta-lactamase mutation: a hospital outbreak report W. Yang* (Shanghai, China), C. Tang, Q. Shi, H. Ou, D. Yin, R. Han, J. Chen, Y. Guo, F. Hu

O0005 09:18 Comparative evaluation of the IR Biotyper and whole genome sequencing for detecting bacterial outbreak C. Sakr* (Creteil, France), C. Subramanian, F. Cizeau, D. Ducellier, M. Danjean, J.W. Decusser

O0006 09:30 Nosocomial outbreak by NDM- and OXA-48-producing hypermucoviscous high-risk ST383 Klebsiella pneumoniae clone J. Sanchez Calvo* (Jerez De La Frontera, Spain), J.M. Sánchez-Calvo, S. López-Cárdenas, J.A. Córdoba Doña, M. Murillo-Pineda, R. Lobato-Cano, I.M. Santiago Soler, I. Pozo Jiménez, M. Coppi, I. Baccani, A. Antonelli, G.M. Rossolini, N. Zuabi, J. Rodríguez-Baño, P. Retamar

O0007 09:42 Chasing accuracy: does 1% really change the story in an ExPEC outbreak? T. Severs* (Zwolle, The Netherlands), A.J. Gebbink, A.K.P.K. Bari, H. Gremmels, S. Debast, J.H.E. De Lange, B. Sinha, J.W.A. Rossen, B.B. Xavier

O0008 09:54 Whole genome sequencing (WGS) and improved diagnostics uncover a multispecies plasmid-borne GES-5/OXA-917 carbapenemase outbreak driven by the Citrobacter freundii complex A. Rath* (Regensburg, Germany), N. Förster, N. Pfennigwerth, C. Keller, B. Neumann, A. Caplunik-Pratsch, B. Lenker, A. Eichner, J. Fritsch, W. Schneider-Brachert, B. Kieninger

O0009 10:06 Development of outbreak-specific TaqMan PCR assays for tracking vancomycin-resistant Enterococcus faecium in Dutch hospitals A.J. Sabat* (Groningen, The Netherlands), J. Flipse, C.J.H. Von Wintersdorff, A. Pettersson, V. Akkerboom, W.C. Van Der Zwet, P.H.M. Savelkoul, A. Voss, E. Bathoorn

O0010 10:18 Beyond species: integrated bacterial and OXA-48 plasmid clustering with EPISEQ@ reveals a polyclonal, multi-species hospital outbreak L. Aguilera Muros* (Granada, Spain), M.A. Roldán Ruiz, A. Badiño Carrasco, C. Roldán Fontana, F. García García, N. Chueca Porcuna

OS002 08:30 – 10:30 Hall A1-3

2-hour Oral Session

ANT CLN TRN

Three viruses, one winter: what we miss, what we treat, what comes next

Chairs Christopher Chiu (London, United Kingdom) Neven Papic (Zagreb, Croatia)

O0011 08:30 Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multi-centre surveillance study, 2024–2025 (id.DRIVE) K. Newell* (Rotterdam, The Netherlands), N. Vroom, C. Marques, E. Maslova, F. Khan, K.Y. Ngew, H.R. Volkman, C. Wang, J.V. Hernandez-Villena, N. Aliabadi, E. Begier, J. Nguyen, H. Dunford, S. Basu, A. Antón, I. Casas, B. Grüner, G. Icardi, F.M. Torres, A. Mira-Iglesias, C.M. Oñoro López, A. Orrico-Sánchez, O. Parés-Badell, W. Gleiber, A. Torres, K. Bollaerts

O0012 08:42 Predictors of severe outcomes in hospitalised patients with viral respiratory tract infections: a prospective cohort study O. Usta* (Istanbul, Türkiye), Ö. Aktaş, B. Çakan, A. Ardali, Y. Beşli, Ö. Ergönül, Ş. Keske

O0013 08:54 Zelicapavir decreases symptom duration,

(Cambridge, United States), J. Cardona, S. Khetan, S. Mehta, A. Kapoor, A. Okparavero, Z. Lin, F. Priddy

L0007	09:42	A double-blind randomised controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalised influenza infection <i>W. Chu*</i> (Hong Kong, Hong Kong), <i>I.F. Hung, J. Choi, T. Anthony</i>
L0008	09:54	First-in-human study of EVT894, a monoclonal antibody against chikungunya virus <i>H. Watson*</i> (Lyon, France), <i>K. Miller, A. Safder, S. Raja, L. Jordan, M. Mack, X. Boulenc, M. Mandron, M. Gordon, M. Jahromi, S. Woodson</i>
L0009	10:06	Sequential administration of an mRNA-based seasonal influenza vaccine in older adults <i>E. Malkin*</i> (Cambridge, United States), <i>A. Kohli, R. Chen, E. Du, A. Pucci, R. Das, E. Wilson</i>
L0010	10:18	Longitudinal B cell immunity after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients <i>M. Kern-Smith*</i> (Toronto, Canada), <i>P.M. Lavoie, A. Humar, D. Kumar, J. Mattsson, V.G. Hall, V.H. Ferreira</i>

SY035	08:30 - 10:30	Hall A1-1
	2-hour Symposium	

Microbial interactions and bacterial adaptation in the microbiome

Chairs	<i>Zuzanna Drulis-Kawa (Wroclaw, Poland)</i> <i>Mauricio Farfan (Santiago, Chile)</i>
--------	--

S0183	08:30	The interplay of genetic drift and bacterial adaptation in skin microbiomes <i>Julia Oh (Durham, United States)</i>
S0184	09:00	Pathways of adaptive evolution in chronic lung infections <i>Helle Krogh Johansen (Copenhagen, Denmark)</i>
S0185	09:30	Bacteriophages and their interaction with the gut microbiome <i>Naama Geva-Zatorsky (Haifa, Israel)</i>
S0186	10:00	Quantifying microbiome-host interactions in the human gut <i>Markus Arnoldini (Zurich, Switzerland)</i>

SY036	08:30 - 10:30	Hall A1-5
	2-hour Symposium	

Recent advances in malaria molecular surveillance: experiences from malaria endemic countries

Chairs	<i>Abdoulaye Djimde (Bamako, Mali)</i> <i>Martin Peter Grobusch (Amsterdam, The Netherlands)</i>
--------	---

S0187	08:30	Malaria molecular surveillance in the Horn of Africa using the MAD4HatTeR amplicon sequencing panel <i>Fitsum Tadesse (Addis Ababa, Ethiopia)</i>
S0188	09:00	A field-based nanopore amplicon sequencing (NOMADS) assay for malaria parasites and vectors <i>Mulenga Chilumba Mwenda (Lusaka, Zambia)</i>
S0189	09:30	Molecular surveillance in Africa using the Pf-SMARRT assay <i>Ronald Futala Kyong-Shin (Chapel Hill, United States)</i>
S0190	10:00	Genetic surveillance of <i>P. vivax</i> in the Greater Mekong Subregion using the Pv microhaplotype AmpSeq assay <i>Thanh Thuy Nhien Nguyen (Ho Chi Minh City, Vietnam)</i>

SY037	08:30 - 10:30	Hall A3-2
	2-hour Symposium	

Unmet SDGs: Europe's struggle with HIV, TB, hepatitis and STIs

Chairs	<i>Tomislav Mestrovic (Varaždin, Croatia)</i> <i>Anastasia Pharris (Stockholm, Sweden)</i>
--------	---

S0191	08:30	Current epidemiological concerns and key gaps in progress towards the SDGs: where should Europe focus efforts to achieve maximum impact? <i>Anastasia Pharris (Stockholm, Sweden)</i>
S0192	09:00	Prevention of STIs across Europe: what is working and how to stem the tide? <i>Nicola Low (Bern, Switzerland)</i>
S0193	09:30	Equity in treatment: why is Europe lagging behind in

S0194	10:00	Migration and the importance of an international approach to tackling the SDGs for TB, HIV and hepatitis <i>Dominik Zenner (London, United Kingdom)</i>
Co-organised with: European Centre for Disease Prevention and Control (ECDC)		

SY033	08:30 - 10:30	Hall B0-1
	2-hour Symposium	

AI-enhanced sepsis care: from early detection to long-term follow-up

Chairs	<i>Michele Bartoletti (Milan, Italy)</i> <i>Damien Ming (London, United Kingdom)</i>
--------	---

S0175	08:30	Early recognition and decision-making in sepsis: the role of AI-enhanced clinical pathways <i>Sylvain Meylan (Lausanne, Switzerland)</i>
S0176	09:00	Initial and adaptive antimicrobial therapy in sepsis: personalisation and stewardship in the age of AI <i>Shruti Gohil (Irvine, United States)</i>
S0177	09:30	From stabilisation to supportive care: integrating the ICU-level multimodal strategy <i>Eric Kipnis (Lille, France)</i>
S0178	10:00	Beyond survival: post-sepsis care, risk stratification, and AI-driven follow-up models <i>Hannah Wozniak (Geneva, Switzerland)</i>

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

SY034	08:30 - 10:30	Hall B0-2
	2-hour Symposium	

Rapid pathogen sequencing for patient management: advancing diagnostic implementation

Chairs	<i>Claudio Neidhöfer (Basel, Switzerland)</i> <i>Torsten Seemann (Melbourne, Australia)</i>
--------	--

S0179	08:30	State-of-the-art methodologies for clinical pathogen sequencing: bridging technology and application <i>Oon Tek Ng (Singapore, Singapore)</i>
S0180	09:00	Ensuring reliability: validation, regulation, and quality control in pathogen sequencing <i>Paula Mölling (Örebro, Sweden)</i>
S0181	09:30	From data to decision: clinical interpretation and integration of pathogen sequencing in patient pathways <i>Luke Blagdon Snell (London, United Kingdom)</i>
S0182	10:00	Genotypic predictions of antimicrobial resistance: unlocking the power of sequencing for treatment decisions <i>Lorena Diaz (Santiago, Chile)</i>

Co-organised with: UK National Health Service Genomic Network of Excellence; Consortium for Clinical Metagenomics in Infectious Diseases (CCMID), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

SY031	08:30 - 10:30	Hall ICM 13b
	2-hour Symposium	

Biofilms, the hidden threat in healthcare environment: unveiling detection, control and prevention strategies

Chairs	<i>Joana Azeredo (Braga, Portugal)</i> <i>Claus Moser (Copenhagen, Denmark)</i>
--------	--

S0167	08:30	Tackling dry surface biofilms <i>Jean-Yves Maillard (Cardiff, United Kingdom)</i>
S0168	09:00	That slimy stuff in water pipes! <i>Michael Weinbren (London, United Kingdom)</i>
S0169	09:30	Skin and soft tissue microbiomes and biofilms <i>Blaine Fritz (Copenhagen, Denmark)</i>
S0170	10:00	Biofilm coats catheters <i>Gordon Ramage (Glasgow, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

SY032	08:30 – 10:30	Hall ICM 5
	2-hour Symposium	
	CLN DX VAX	
Beyond recovery: post-acute syndromes after respiratory viral infections		
Chair	Paraskevi C. Fragkou (Markopoulo Mesogeion, Greece) TBA	
S0171	08:30	Post-COVID-19 syndrome: respiratory and multisystem sequelae Ziyad Al-Aly (Saint Louis, United States)
S0172	09:00	Post-influenza syndromes: a hidden burden in clinical practice Sotirios Tsiodras (Athens, Greece)
S0173	09:30	RSV and other endemic respiratory viruses: what comes after acute infection? Chrysanthi Skevaki (Marburg, Germany)
S0174	10:00	Genetic basis of post-acute viral syndromes Hanna Ollila (Helsinki, Finland)
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), European Respiratory Society (ERS)		

EW038	08:30 – 11:30	Hall ICM 1
	3-hour Educational Session	
	AMR DX	
EUCAST user workshop		
Chairs	Marlene Amara (Paris, France) Alasdair Peter Macgowan (Bristol, United Kingdom)	
W0195	08:30	EUCAST Update Sören Gatermann (Bochum, Germany)
W0196	09:00	Challenges of testing beta-lactam/beta-lactamase inhibitors Mandy Wootton (Cardiff, United Kingdom)
W0197	09:30	When do you need an MIC Barbara Juliane Holzknecht (Copenhagen, Denmark)
W0198	10:00	Challenges of setting up a NAC in a large country Qiwen Yang (Beijing, China)
W0199	10:30	The role of clinical data in setting breakpoints Jesús Rodríguez-Baño (Seville, Spain)
Co-organised with: EUCAST Steering Committee		

EF004	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	ANT	
Beyond guidelines: how behaviour and social context shape antimicrobial prescribing		
Chair	Jaap Ten Oever (Nijmegen, The Netherlands)	
E0031	08:30	Prescribing inequities: evaluating under- and over-treatment across patient and neighborhood factors C. Evans* (Chicago, United States), S. Reddy, M. Dhanani, A. Rivera, D. Glover, G. Wilson, S. Balbale, M. Keintz, K. Suda, J. Marcelin
E0032	08:36	Understanding what matters to patients in antimicrobial stewardship in hospitals: a mixed-method study B. Jacob* (Dublin, Ireland), A. Kurian, A. Walsh, E. De Barra
E0033	08:42	Impact in capacity building of an online training program and evaluation of factors related to behavioural change in infection prevention and control and antimicrobial stewardship practices O. Neth* (Seville, Spain), W. Goycochea-Valdivia, A. Gâchet, M. Amores, I. Kopsidas, G. Brigadoi, E. Barbieri, M. Bason, D. Kousi, M. Aboza, V. Serena, D. Daniele, T. Grammatiki-Christina, A. Arias, L. Cantarutti, C. Gianquinto, I. Gastesi, P. Rojo, C. Epalza
E0034	08:48	Reframing antimicrobial stewardship by empowering stakeholders through the One Health lens C. Mulrooney* (Waterford, Ireland), Z. Ramsamaroo, J. Britton, H. Awad, G. Rothwell-Kelly, M. Doyle, G. Chan
E0035	08:54	Evaluating primary care antimicrobial stewardship through simulated patient visits: a scoping review and application of patient management indicators in an intervention evaluation in two LMIC B. Ingelbeen* (Antwerpen, Belgium), D. Valia, V. Bertels, B. Mbangi, E. Tiendrebeogo, S. Declercq, D. Phanuz, H. Tinto

E0036	09:00	Beyond the algorithm: human factors driving AI-adoption in antimicrobial stewardship (AMS) D. Yii* (Singapore, Singapore), S. Tang, L. Loo, J. Chung, W. Lee, A. Kwa, E. Lum
E0037	09:06	Knowledge and attitudes of allied healthcare professionals towards antibiotic use and antimicrobial resistance: questionnaire-development and a quantitative, cross-sectional study M. Gajdács* (Szeged, Hungary), Z.L. Szabó, E.R. Major, R. Finta, E. Paulik
E0038	09:12	Patients' and the public's knowledge and understanding of antimicrobial resistance and antimicrobial stewardship: a systematic review and meta-analysis B. Jacob* (Dublin, Ireland), A. Kurian, A. Walsh, E. De Barra
E0039	09:18	Behavioural determinants of hospital antimicrobial prescribing in Italy: a multi-centre COM-B and TDF-informed study M. Torre* (Rome, Italy), A. Bandera, S. Leone, A. Tedesco, A. Capone, S. Tedeschi, A. Mularoni, A. Cona, R. Murri, C. Torti, S. Cicalini

EF005	08:30 – 09:30	Arena 2
	ePoster Flash Session	
	ANT TRN	
Old viruses, new weapons: emerging antiviral therapies from bench to bedside		
Chair	Heli Harvala (Turku, Finland)	
E0040	08:30	MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates single-agent efficacy against HCV/HBV co-infection <i>in vitro</i> , and achieves HCV and HBV preclinical proof-of-concept D. Haders* (San Diego, United States), V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, W. Brubaker, P. Gallay, D. Smith
E0041	08:36	Real-world effectiveness of extended use of letermovir among adult allogeneic haematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies R. Chemaly* (Houston, United States), A. Vyas, H. Appaneal, A. Beyer
E0042	08:42	Antiviral efficacy of a single dose of EV25, a novel antibody recruiting molecule, in a human influenza A/H3N2 challenge trial A. Cohen* (The Sea Ranch, United States), A. Wozniak, M. Niedrauer, S. Low, A. Blouin, C.L. Campbell, I. Shahriar, J. Nielsen, P.S. Low
E0043	08:48	Zelicapavir demonstrates high clinical and functional barrier against antiviral resistance: results from a randomised double-blind placebo-controlled paediatric RSV antiviral clinical trial J. Devincenzo* (Watertown, Ma, United States), M. Rhodin, T. Ngo, A. Ahmad, C. Harris, R. Levene, S. Rottinghaus
E0044	08:54	Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam H. Koshimichi* (Osaka, Japan), T. Sonoyama, R. Yonemoto, R. Kubota
E0045	09:00	Identification and structural characterisation of CID-375076 as a promising small molecule inhibitor of HCV NS3 protease D. Diksha* (Rishikesh, India), S.K. Gupta, Y.P. Mathuria
E0046	09:06	Next-generation alkaloid entry inhibitors against emerging flaviviruses and coronaviruses: a step toward broad-spectrum antivirals S. Sadhu* (Faridabad, India), A. Awasthi
E0047	09:12	DEN-HOST: a randomised, adaptive phase III trial evaluating host-directed therapeutics for moderate and severe dengue A. McBride* (Oxford, United Kingdom), L. Peto, H.Q. Chanh, P.K. Lam, J. Catrall, N.L. Vuong, P.Y. Chia, A. Rojek, J. Whitehorn, L. Villar, P. Horby, T.W. Yeo, J. Watson, E. Kestelyn, S. Yacoub
E0048	09:18	Factors influencing ganciclovir trough concentrations during prophylaxis or therapy of CMV infections O. Epaulard* (Grenoble, France), C. Massebeuf, L. Liaigre, C. Chapuis, R. Le Cras, R. Germi, E. Gautier-Veyret
EF006	08:30 – 09:30	Arena 4
	ePoster Flash Session	
	CLN DX PHEI	
Trending topics in TB and other mycobacterial infections		
Chair	Hanif Esmail (London, United Kingdom)	

OS010	11:00 – 12:00	Hall A1-1
	1-hour Oral Session	
	ANT TRN	
Exploiting biology for therapy: novel approaches against antimicrobial-resistant pathogens		
<i>Chairs</i>	Katy Jeannot (Besançon, France) Robert C. Read (Southampton, United Kingdom)	
00077	11:00	Calcium phosphate nanostructures: alternative approach against antibiotic-resistant <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> M. Mariotti* (Rome, Italy), D. Squitieri, L. Degli Esposti, C. Fusacchia, R. Torelli, M. Sanguinetti, M. Iafisco, F. Bugli
00078	11:12	AMR-endemic flies represent an underexplored reservoir of lytic bacteriophages W. Martins* (Oxford, United Kingdom), C. Rubio, K. Cook, T. Iannetelli, S. Premchand-Branker, E. Portal, G. Jordao, T. Beard, A. Lankapalli, K. Iregbu, S. Afegbua, A. Aliyu, Y. Mohammed, I. Nwafia, O. Oduyebo, A. Ibrahim, Z. Tanko, T. Walsh, C. Achi, K. Sands
00079	11:24	Neutrophil peptidyl-arginine deiminase enzymes as dual anti-bacterial and anti-biofilm agents R. Baird* (Dublin, Ireland), D. Gogoi, L. Forde, M. Niu, S.W. Ahmed, F. Fitzpatrick, E.P. Reeves
00080	11:36	Af-DAP10-CD3z-CAR-NK92 cells exert enhanced antifungal activity against <i>A. fumigatus</i> M. Mauget* (Rennes, France), A.L. Schmitt, H. Einsele, M. Hudecek, J. Löffler, M. Seif
00081	11:48	Characterisation of novel vibrio phages as biocontrol agents against <i>Vibrio alginolyticus</i> and insights into its phage-resistant mutant R. Nepal* (Battery Point, Australia), T. Charles, R. Taylor, J. Wynne

OS011	11:00 – 12:00	Hall A1-2
	1-hour Oral Session	
	TRN VAX	
Mechanisms of hypervirulence and resistance in <i>Klebsiella pneumoniae</i>		
<i>Chairs</i>	Alessandra Carattoli (Rome, Italy) Yunn-Hwen Gan (Singapore, Singapore)	
00082	11:00	Immunotherapeutic monoclonal antibodies against antibiotic-resistant <i>Klebsiella pneumoniae</i> derived from glycoconjugate-based immunisation B. Fries* (Yes, United States), K. Mihooliya, C. Boniche-Alfaro, T. Imeraj
00083	11:12	The plasmid-borne lytic transglycosylase PLT-1 augments virulence in ST11 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> by exacerbating immune responses and macrophage death P. Jia* (Beijing, China), W. Yu, Q. Yang
00084	11:24	Differences in basal adaptation of core proteome expression between hypervirulent and multidrug-resistant <i>Klebsiella pneumoniae</i> lineages P. Miguela-Villoldo* (Madrid, Spain), D. Fousteris, I. Alonso-González, L. Vaughan, A. Tajuelo, B. Cano-Castaño, S. Prieto Martín-Gil, E. Gato, A. Peláez-García, V. Martín, A. Pérez, A.J. Martín-Galiano
00085	11:36	The virulence related response of Hypervirulent <i>Klebsiella pneumoniae</i> to phagocytosis by murine macrophage S. Belge* (Istanbul, Türkiye), C. Vatansever, Ö. Albayrak, S. Yalçın, A. Akpınar, F. Can
00086	11:48	Genetically-defined hypervirulent carbapenem-resistant <i>Klebsiella pneumoniae</i> (Hv-CRKP) exhibited diverse biological phenotypes: evidence from different clades of ST11-KL64, the most prevalent hv-CRKP strains in China X. Chu* (Beijing, China), Q. Zhang, W. Yu, Y. Zhu, X. Jia, Q. Yang

OS012	11:00 – 12:00	Hall A1-3
	1-hour Oral Session	
	CLN	
Sexually transmitted infections: typing to therapy		
<i>Chairs</i>	Nicola Low (Bern, Switzerland) Aaron Schembri (Attard, Malta)	
00087	11:00	Optimising multi-modal surveillance of drug-resistant <i>Neisseria gonorrhoeae</i> N. Sherry* (Melbourne,

00088	11:12	Towards global harmonisation of the mgpB typing scheme for <i>Mycoplasma genitalium</i> : updating the PubMLST platform to enable effective surveillance S. Manoharan-Basil* (Antwerp, Belgium), I. De Baetselier, S. Pereyre, J. Guiraud, L. Piñeiro, J. Danielewski, M.J. Borrego, N. Adriaens, J.S. Jensen, N. Nordal-Budinsky, K. Imai, R. Dumke, O. Harrison
00089	11:24	Benzathine penicillin G plus doxycycline vs benzathine penicillin G alone for early syphilis in people with HIV: interim analysis K.Y. Lin* (Taipei, Taiwan), C.P. Chen, C.S. Tsai, M.S. Tsai, P.L. Lu, K.H. Chen, P.L. Chen, Y.W. Weng, H.J. Tang, C.C. Hung
00090	11:36	Advancing STI care in low- and middle-income countries: development of a multiplex lateral flow assay for gonorrhoea and chlamydia B. Blumel* (Geneva, Switzerland), H. Ramachandriah, B. Gleeson, V. Chuchu, S. Mchugh, M. Lear, E. Cruz-Andres, K. Keith, J. D. Klausner
00091	11:48	Syphilis in bone and joint: what the skeletons tell us and why it matters today F. Spada* (Naples, Italy), N. Schiano Moriello, J. Kowalska, G. Monsel, K. Roberts, M. Augello, F.B. Farkas, M. Farajova, A. Harxhi, A. Fidji Glaria Campo, I. Gentile

OS014	11:00 – 12:00	Hall A1-5
	1-hour Oral Session	
	ANT CLN	
Turning AMS evidence to action		
<i>Chairs</i>	Sara Cosgrove (Baltimore, United States) Flaminia Olearo (Berlin, Germany)	
00092	11:00	Bridging surveillance and stewardship: using the ECRAID Emerging Resistance Index to prioritise reserve antibiotics when guidelines offer equivalent options M.D. Pezzani* (Verona, Italy), D. Ortiz, J. Garlasco, K. Odoj, F. Arieti, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, A. Savoldi, E. Tacconelli
00093	11:12	A cluster-randomised controlled pragmatic trial to evaluate antibiotic stewardship strategies for short-course and oral-switch antibiotic therapy for Enterobacteriales bloodstream infections C.Y.G. Lui* (Hong Kong, Hong Kong), C.M.T. Li, M. Mung, C. Cheung, C.T. Au-Yeung, H.Y. Ho, W.L.F. Luk, C.M. Leung, C. Lai, V. Chow
00094	11:24	Active auditing in antimicrobial stewardship programs improves appropriateness of prescribing: an observational cohort study C. Chen* (Melbourne, Australia), N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson, L. Hall, K. Thursday
00095	11:36	Multidrug-resistant Gram-negative bacteria screening to guide perioperative prophylaxis in colorectal surgery: a multi-centre quasi-experimental study D. Fasan* (Verona, Italy), M. Morra, M. Da Meda, M.D. Pezzani, M. Tebon, V. Mengardo, A. Di Gioia, M. Genna, S. Zerva, A.R. Andritsos, I.M. Fieraru, D. Costin, I. Salcedo-Leal, C. Diaz-López, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi-García, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara
00096	11:48	An electronic medical record-based 'persuasive' antimicrobial stewardship intervention to align bloodstream infection treatment duration with evidence from the BALANCE trial J. Bramwell* (Melbourne, Australia), J. Hinh, S. Koning, K. Horne, L. Upjohn, J. Hughes, R. Junckerstorff, B. Rogers

OS015	11:00 – 12:00	Hall A2-2
	1-hour Oral Session	
	CLN TRN VAX	
Burden, immunity and management of viral infections in immunocompromised hosts		
<i>Chairs</i>	Jon Salmanton-García (Cologne, Germany) Carla Walti (Basel, Switzerland)	
00097	11:00	Durability of immunity six months after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients V. Hall* (Melbourne, Australia), A. Alexander, F. Mavandadnejad, M.

			Kern-Smith, R. Kang, X. Dang, P. Lavoie, S. Humar, P. Winichakoon, R. Johnstone, M. Aversa, I. Novitzky-Basso, D. Kumar, J. Mattsson, V.H. Ferreira
00098	11:12	Adoptive transfer of polyomavirus-specific T cells in progressive multifocal leukoencephalopathy: a multi-centre retrospective real-world analysis G. Martin-Blondel* (Toulouse, France), A. Chevalier, B. Bonneau, L. Grote-Levi, N. Möhn, P. Cinque, J. Rubinstein, R. Wicklein, T. Pfeiffer, B. Ormer, M. Steinhardt, J.J. Tudesq, N. Testard, P. Chevallier, R. Bernard-Valnet, M. Le Maréchal, G. Catalano, B. Pignolet, A. Sommet, B. Eiz-Vesper, P. Comoli, T. Skripuletz, I. Cortese, D. Bensoussan	
00099	11:24	Cytomegalovirus infections after bispecific antibodies for relapsed/refractory multiple myeloma J.S. Little* (Boston, United States), I.A. Perez Villa, E. Arbona Haddad, E.B. Kim, A.J. Yee, O. Nadeem, S. Midha, A.S. Sperling, N. Munshi, N.S. Raje, D.D. Cirstea, S.P. Hammond	
00100	11:36	Therapeutic drug monitoring of letermovir in allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients: a prospective, two-centre observational study J.S. Tang* (Taipei, Taiwan), T.Y. Pai, Y.W. Wang, C.Y. Chen, H.A. Hou, B.S. Ko, P.Y. Chen, Y.J. Liu, H.Y. Lin, Y.H. Wu, Y.J. Chen, S.W. Lin	
00101	11:48	Target trial emulation of viral infection vs no infection and risk of invasive fungal disease after haematopoietic stem cell transplantation L. Bussini* (Pieve Emanuele, Milan, Italy), D.F. Bavaro, D. Sacchet, F. Medioli, F. Berardi, M. Ronconi, P. Crombie, F.M.P. Tordato, B. Varisco, L. Diella, D. Mannina, J. Mariotti, C. Scuderi, M. Calabrò, R. Renzulli, V. Cento, S. Bramanti, M. Bartoletti	

OS016	11:00 – 12:00	Hall A3-2
	1-hour Oral Session	

AMR

Resistance trends in *Candida* species

Chairs	Maiken Cavling Arendrup (Copenhagen, Denmark) Jean-Pierre Gangneux (Rennes, France)
--------	--

00102	11:00	Activity of comparator antifungal agents against drug-resistant <i>Candida glabrata</i> M. Winkler* (North Liberty, United States), A. Klauer, S. Edeker, H. Kimbrough, P. Rhomberg, M. Castanheira	
00103	11:12	Clinical emergence and spread of <i>Candidozyma auris</i> outbreak-adapted lineages harboring mutations in RBA1 L. Doorley* (Memphis, United States), A. La Bella, S. Jones, G. Zhao, M. Asadzadeh, G. Choudhury, S. Ahmad, E. Mokaddas, I. Al-Obaid, W. Alfouzan, K. Al-Banwan, T. O'meara, F. Santiago-Tirado, A. Flores-Mireles, J. Rybak	
00104	11:24	Genomic analysis of <i>Candida parapsilosis</i> over a decade across multiple hospitals highlights clonal persistence and increasing fluconazole resistance S. Srivastava* (Delhi, India), N. Shukla, P. Kagra, K. Jain, A. Chowdhary	
00105	11:36	Calcineurin mediates caspofungin heteroresistance, a precursor to stable resistance in <i>Nakaseomyces glabratus</i> Y. Su* (Beijing, China), Y. Li, Y. Xu	
00106	11:48	Comparison of manogepix activity against 8,722 community-acquired and nosocomial yeast isolates from the SENTRY Antimicrobial Surveillance Program (2017-2024) M. Winkler* (North Liberty, United States), M. Huband, P. Rhomberg, S. Edeker, A. Klauer, M. Castanheira	

OS009	11:00 – 12:00	Hall ICM 13b
	1-hour Oral Session	

ANT

Tomorrow's antibiotics today: from first-in-human to phase III

Chairs	Daniele Roberto Giacobbe (Genoa, Italy) Erin McCreary (Pittsburgh, United States)
--------	--

00107	11:00	Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial R. Takaya* (Tokyo, Japan), K. Yanagihara, K. Tateda, H. Huang, H. Mukae, H. Ohge, Y. Doi, S. Takahashi, M. Yasuda, K.	
-------	-------	---	--

Matsumoto, M. Sumiya, K. Suwada, S. Kamiyabu, Y. Sasagawa, T. Minamida, S. Kato, K. Kondo, T. Naruse, H. Mikamo

00108	11:12	Subgroup analysis of tebipenem pivoxil efficacy in patients with complicated urinary tract infection or acute pyelonephritis: results from the phase III PIVOT-PO study S. Ascioğlu* (London, United Kingdom), D. Hong, T. Otiker, Y. Sánchez-Pearson, A.J. Sheets, M. Sprys, N.E. Scangarella-Oman, N. Bhatt, I.A. Critchley, L.B. Gasink, K.A. Hamed, D. Sotolongo, K. Wrzosek, A. Peppercorn	
00109	11:24	Characterisation of <i>Pseudomonas aeruginosa</i> isolates from bronchiectasis patients in a phase II trial of a bispecific monoclonal antibody: GREAT-2 R.C. Hull* (Dundee, United Kingdom), M.B. Long, A. Gilmour, I. Petrou, R. Galloway, K. Viligorska, H. Richardson, J.M. New, C. Hennayake, E. Johnson, E. Mcintosh, Z. Eke, H. Lind, M. Band, H. Bandara, G. Martin, S. Aliberti, M. Vendrell, E. Polverino, G. Suarez-Cuartin, M.R. Loebinger, M. Tunney, K. Cartwright, R. Hughes, A. Digiandomenico, M.G. Belvisi, W. Brailsford, C. Haworth, O. Sibila, J. Stobo, J.D. Chalmers	
00110	11:36	Overall response and microbiological eradication of cefepime/enmetazobactam vs piperacillin/tazobactam in patients with acute pyelonephritis: a post-hoc subgroup analysis from the ALLIUM phase III trial J. Quevedo Marin* (Cartagena, United Kingdom), J. Quevedo, N. Dunkel, N. Jemmely, S. Cure	
00111	11:48	Evaluating the efficiency of platform trial designs relative to stand-alone trials: a simulation study for the evaluation of new antibacterials M. Hardy* (Herston, Australia), P. Harris, Y. Mo, D. Paterson	

SY046	11:00 – 12:00	Hall A2-1
	1-hour Symposium	

PHEI

Engaging citizens in infectious disease surveillance, prevention, and research

Chairs	Tyra Grove Krause (Copenhagen, Denmark) Joel Mossong (Luxembourg, Luxembourg)
--------	--

S0105	11:00	Digital countermeasures for epidemic control Emmanuel André (Leuven, Belgium)
S0106	11:30	Virus monitoring at workplaces Tine Graakjær Larsen (Værløse, Denmark)

SY047	11:00 – 12:00	Hall A3-1
	1-hour Symposium	

CLN DX

Diagnostic stewardship: asking the right questions to measure clinical impact - a pro/con debate

Chairs	Adarsh Bhimraj (Houston, Texas, United States) Bhanu Sinha (Groningen, The Netherlands)
--------	--

S0107	11:00	Diagnostic stewardship is an important part of quality of care and has clinical impact Heiman Wertheim (Nijmegen, The Netherlands)
S0108	11:30	Diagnostic stewardship is an auxiliary to antimicrobial stewardship, but has no impact on quality of care Evelina Tacconelli (Verona, Italy)

SY044	11:00 – 12:00	Hall B0-1
	1-hour Symposium	

AMR IPC

The hospital bathroom as a hotspot for AMR

Chairs	Fidelma Fitzpatrick (Dublin, Ireland) Juliette Severin (Rotterdam, The Netherlands)
--------	--

S0101	11:00	The sink: design and behavioural aspects to mitigate risks: towards a "sink bundle" Hillary Craddock (Dublin, Ireland)
S0102	11:30	Toilets: flushing and spread of pathogens Kalisvar Marimuthu (Singapore, Singapore)

SY045	11:00 – 12:00	Hall B0-2
	1-hour Symposium	

CLN

Updates on severe pneumonia

<i>Chairs</i>	<i>Antonios Katsounas (Bochum, Germany)</i> <i>Preeti Malani (Ann Arbor, United States)</i>
S0103	11:00 Severe community-acquired pneumonia <i>Pedro Povo</i> (Lisbon, Portugal)
S0104	11:30 Severe hospital-acquired pneumonia <i>Jordi Rello</i> (Barcelona, Spain)

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCI), ESCMID Study Group for Infections in the Elderly (ESGIE), European Extracorporeal Life Support Organization, European Society of Intensive Care Medicine

SY043 **11:00 – 12:00** **Hall ICM 13a**

CLN DX

1-hour Symposium

Top papers in imported tropical diseases and diagnosis of parasitic infections

<i>Chairs</i>	<i>Miriam José Alvarez Martinez (Barcelona, Spain)</i> <i>Ferenc Balázs Farkas (Budapest, Hungary)</i>
S0099	11:00 Top papers in tropical diseases <i>Pedro Legua</i> (Lima, Peru)
S0100	11:30 Top papers in diagnosis of imported parasitic diseases <i>Charlotte Siruttan-Nel</i> (Johannesburg, South Africa)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EF017 **11:00 – 12:00** **Arena 2**

PHEI VAX

ePoster Flash Session

Update in mosquito-borne infections and vector control

<i>Chair</i>	<i>Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)</i>
E0112	11:00 A one health regional framework for predictive dengue surveillance and early warning in Southeast Asia <i>S. Sidhik* (Phnom Penh, Cambodia)</i> , <i>S. Boyer</i>
E0113	11:06 Blood-stage controlled human malaria infection in Tanzanian adults to assess the protective effect of the malaria vaccine candidates R78C and/or RH5.1 in a matrix adjuvant <i>J. Van Heerden* (Oxford, United Kingdom)</i> , <i>A.E. Kahatano</i> , <i>S. Silk</i> , <i>C. Rigby</i> , <i>S. Pollock</i> , <i>N. Lilolime</i> , <i>L. Batao</i> , <i>J. Salkeld</i> , <i>N. Kamau</i> , <i>R. Roberts</i> , <i>H. Msami</i> , <i>N. Urasa</i> , <i>E. Kenya</i> , <i>M. Mohamed</i> , <i>I. Mtaka</i> , <i>C. Carnrot</i> , <i>C. Nielsen</i> , <i>M. Mpina</i> , <i>S. Draper</i> , <i>A. Minassian</i> , <i>A. Olotu</i>
E0114	11:12 Humoral and cellular immune responses to an intradermal live attenuated tetravalent dengue vaccine: a pilot study among healthy adults <i>T. Khaimook* (Hat Yai, Thailand)</i> , <i>S. Chusri</i> , <i>N. Pinpathomrat</i> , <i>P. Siripaitoon</i> , <i>N. Kositpantawong</i> , <i>S. Kanchanasuwan</i> , <i>S. Chittrakarn</i> , <i>S. Uppanisakorn</i>
E0115	11:18 Immune response to TAK-003: updated results from the DENG-VAC Study <i>A. D'abramo* (Rome, Italy)</i> , <i>L. Ponzetta</i> , <i>F. Colavita</i> , <i>S. Vita</i> , <i>E. Cimini</i> , <i>P. De Marco</i> , <i>L. Rosa</i> , <i>M. Tiberi</i> , <i>F. Maggi</i> , <i>D. Goletti</i> , <i>E. Nicastri</i>
E0119	11:24 Rollout of seasonal R21 malaria vaccination and chemoprevention for children in Kule Refugee Camp in Gambela, Ethiopia during the 2024 malaria season <i>Y. Atnafu* (Addis Ababa, Ethiopia)</i> , <i>Y. Girma</i> , <i>K. Siferaw</i> , <i>K. Lavilla</i> , <i>A. Tawassar</i> , <i>D. Koang</i> , <i>D. Tugizimana</i> , <i>A. Dirks</i> , <i>M. Ayalew</i> , <i>J. Loonen</i> , <i>C. Ariti</i> , <i>G. Mapiye</i> , <i>W. Mulanda</i> , <i>A.D.L. Pereira</i> , <i>A. Bestman</i> , <i>K. Velivela</i> , <i>B. Rao</i> , <i>B. Stringer</i> , <i>R. Wilson</i> , <i>A. Abbara</i> , <i>P. Keating</i>

EF018 **11:00 – 12:00** **Arena 4**

AMR PHEI

ePoster Flash Session

Socioeconomic and structural drivers of AMR

<i>Chair</i>	<i>Sara Tomczyk (Berlin, Germany)</i>
E0121	11:00 National priority assessment of multidrug-resistant microorganisms based on the multicriteria decision analysis <i>Y.K. Yoon* (Seoul, Korea, Republic of)</i> , <i>S.Y. Yu</i> , <i>E.Y. Bae</i> , <i>H. Seok</i> , <i>Y.J. Choe</i> , <i>S.J. Choi</i> , <i>H.S. Oh</i> ,

J.W. Suh, *J.Y. Kim*

E0122	11:06 Socioeconomic inequality and corruption as determinants of antibiotic access and AMR burden <i>S. Saeedi Moghaddam* (Kiel, Germany)</i> , <i>M. Stolpe</i>
E0123	11:12 Everyday realities of antibacterial drug resistance in Uganda: an ethnographic study of social and economic impacts <i>S. Nayiga* (London, United Kingdom)</i> , <i>A. Namajja</i> , <i>C. Chandler</i>
E0124	11:18 "Bacteria and the Resistance": a microbial comic book <i>G. Greub* (Lausanne, Switzerland)</i> , <i>C. Aubry</i>
E0125	11:24 Critical levels of multidrug resistance in pathogens circulating in the Niger river: implications for public health surveillance <i>C. Touré* (Bamako, Mali)</i> , <i>T. Cheick</i>
E0126	11:30 A case study on effective student engagement in antimicrobial resistance: the Makerere University AMR club model <i>V. Nabisere* (Kampala, Uganda)</i> , <i>C. Akello</i>
E0127	11:36 Sex, gender, and antimicrobial resistance: evidence and gaps across infection, selection and transmission <i>G. Knight* (London, United Kingdom)</i> , <i>O. Edun</i> , <i>A. Kjaersgaard</i> , <i>K. Horton</i> , <i>K. Keenan</i> , <i>J. Robotham</i> , <i>C. Wenham</i> , <i>C. Chandler</i>
E0128	11:42 Caste-based disparities and AMR risks <i>S. Goel* (Bengaluru, India)</i> , <i>R. Bhagawati</i> , <i>A. Banerji</i> , <i>D. Batheja</i>
E0129	11:48 Integrating antibiotic stewardship within a One Health framework: a pilot study on knowledge, attitude and practice questionnaire in companion animal veterinary medicine of Northern Italy <i>F. Compostella* (Verona, Italy)</i> , <i>M. Domaschio</i> , <i>D. Fasan</i> , <i>F. Sbardellati</i> , <i>E. Tacconelli</i> , <i>E. Carrara</i>

KN042 **11:00 – 12:00** **Hall ICM 14**

AMR IPC

Keynote lecture

Containment of MRSA in hospitals: past, present, future

<i>Chairs</i>	<i>Robert Leo Skov (Copenhagen, Denmark)</i> <i>Margreet C. Vos (Rotterdam, The Netherlands)</i>
K0098	11:00 <i>Susan Huang (Irvine, United States)</i>

ME048 **11:00 – 12:00** **Hall ICM 5**

IPC PHEI

Meet-the-Expert

Viral threats and antibiotic resistance in wastewater in the postpandemic era

M0109	11:00 <i>Steen Ethelberg (Copenhagen, Denmark)</i>
M0110	11:12 <i>Henry-Michel Cauchie (Belvaux, Luxembourg)</i>

FO049 **11:00 – 12:00** **Arena 1**

PRO

Open Forum

Sharing made simple: how standardised data exchange improves infectious diseases research and care

<i>Chair</i>	<i>Marc J.M. Bonten (Utrecht, The Netherlands)</i>
F0111	11:00 Sharing clinical laboratory and infectious disease data in the European Health Data Space for primary and secondary use <i>Hynek Kruzik (Prague, Czechia)</i>
F0112	11:10 Using standards to bridge the divide between clinical trials and cohort studies: the ECRAID Base experience <i>Ankur Krishnan (Heidelberg, Germany)</i>
F0113	11:20 Standardised sharing of national AMR surveillance data: showcase Netherlands <i>Bram Lestrade (Roermond, The Netherlands)</i>
F0114	11:30 Standardised exchange of microbiological data for patient care, research and surveillance <i>Alexandra Hoffmann (Berlin, Germany)</i>

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), European Clinical Research Alliance on Infectious Diseases (ECRAID), EU Lab Semantic WG HL7

FO050	11:00 – 12:00	Arena 3	through in situ simulation: a feedback-based evaluation R. Francis* (Nottingham, United Kingdom), Y. Milnes, P. Bailey
	Open Forum		
	PRO		
Sharpening communication and leadership skills in CM/ID			00137 13:42 Design and Development of an Educational Card Game on Infectious Diseases for Anaesthesiology Residents: An Innovative Approach to Medical Education P. Lunenborg* (Groningen, The Netherlands), W. Bult, H. Aardema, G. Wietasch, C. Van Den Berg
Chair	Mary Horgan (Dublin, Ireland)		
F0115	11:00	Communication skills for culturally competent infectious disease care Muge Cevik (Edinburgh, United Kingdom)	00138 13:54 Septris 2.0: A Mixed-Methods Multinational Evaluation of a Gamified Digital Tool for Sepsis Education and Quality Improvement S. Meylan* (Lausanne, Switzerland), S. Gupta, I. Pottmeyer, N. Mischler, E. Moulin, R. Williams, L. Shieh
F0116	11:10	Becoming doctor-influencers for better redefining CM/ID professionalism Akshatha Ravindra (Karnataka, India)	00139 14:06 First implementation of an educational escape room for the key symptom "diarrhea" within the course "key symptoms of internal medicine" of the medical curriculum at Christian-Albrechts-University Kiel to strengthen diagnostic and therapeutic reasoning and teamwork skills C. Kujat* (Kiel, Germany), N. Mirwald, U. Macioszek, A. Friedrichs
F0117	11:20	Dealing with the Imposter syndrome Maeve Doyle (Waterford, Ireland)	
Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee, ESCMID Education Subcommittee, TAE Steering Committee			
OS021	13:30 – 14:30	Hall A3-1	
	1-hour Oral Session		
	AMR CLN		
Clinical impact of drug resistance in Gram-negative infections			OS020 13:30 – 14:30 Hall B0-1
Chairs	Lorena Diaz (Santiago, Chile) Helena Zemlickova (Prague, Czechia)		1-hour Oral Session
			CLN IPC
			From risk to resilience: advances in catheter-related infections across care settings
			Chairs Shrutti Gohil (Irvine, United States) Pilar Retamar Gentil (Seville, Spain)
00130	13:30	Clinical Impact of Delayed Appropriate Antibiotic Therapy in Bloodstream Infections Caused by WHO Critical Priority Gram-Negative Pathogens: A Target Trial Emulation L. Mezzadri* (Singapore, Singapore), W.C. Tan, X. Hao, J. Quah, A. Manesh, Y.T. Chang, A.T.K. Nguyen, Y. Ding, Y. Cao, Y. Cai, S. Kitsaran, H.H. Chua, S. Bory, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhilloo, R. Plongla, A.L.H. Kwa, S. Faisal Mahmood, A.D. Roman, L. Thwaites, P.V. Tho, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O. Rehman Khalid, G.M. Salahuddin Mamun, G.S. Rajahram, H. Guterres, H.N. Hon, T. Van Giang, N.T. Pham, A. Karkey, S. Gunasekara, R. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, N.L. Priya, Y. Doi, H. Hitoshi, B. Baljin, U. Gurjav, R. Asli, L. Ling, A. Dhungana, L.Y. Hsu, D. Paterson, Y. Mo	00140 13:30 Risk of catheter-related infections with peripherally vs centrally inserted central catheters in critically ill patients: a propensity score-matched emulated target trial N. Boulet* (Nimes, France), A. Friggeri, A. Gavoille, M. Gautier, B. Louart, A. Machut, A. Lepape, C. Roger
00131	13:42	Impact of third-generation cephalosporin resistance on mortality in Enterobacteriales bloodstream infections: an individual participant data meta-analysis M. Guedes* (Seville, Spain), M.E.A. De Kraker, N. Hassoun-Kheir, E. Salamanca, E. Rubio, A.D.L.S. Bazan, L.B. Pulido, A. Dambrauskiene, J. Rodriguez-Baño	00141 13:42 Incidence, risk factors and mortality of catheter-related bloodstream infections: retrospective single centre study in non-ICU wards L. Gazzola* (Milano, Italy), V. Vitaletti, E. Pezzoli, A. Tavelli, G.C. Marchetti
00132	13:54	Antibiotic prescribing for presumed <i>Stenotrophomonas maltophilia</i> infections in the United States using Epic Cosmos S. Boettcher* (Detroit, United States), R. Kenney, R. Tibbetts, A. Shallal, G. Suleyman, S. Davis, M. Veve	00142 13:54 Impact of a National Quality-Improvement Programme on CLABSI Reduction in Ten Greek Hospitals: Results from the GRIPP-SNF Consortium I. Kopsidas* (Athens, Greece), G.C. Tsopela, A. Moutou, P. Varda, P. Pantelidou, D. Kousi, E. Kourkouni, A. Karaiskou, E. Thireos, D. Kaitelidou, A. Koutsoukou, T. Zaoutis
00133	14:06	Colonisation with multidrug-resistant Gram-negative bacteria in a low endemic country is associated with substantial morbidity: a population-based observational study V. Andrews* (Lund, Sweden), M. Inghammar, E. Senneby, O. Ljungquist	00143 14:06 Epidemiology and Outcomes of Nosocomial Infections in Patients Undergoing ECMO Support: An Eight-Year Retrospective Cohort Study M. Oliveira* (Sao Paulo, Brazil), R. Lobo, F. Galas, C. Sambo, L. Pastore, N. Matos, E. Costa, H. Fernandes, D. Araujo, L. Cardoso, A.R. Guedes
00134	14:18	Comparison of mortality after bloodstream infection with piperacillin/tazobactam-resistant vs -susceptible <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a nationwide cohort study in Denmark, 2018-2024 E. Tusch* (Copenhagen, Denmark), B. Holzknacht, M. Lindegaard, R. Thoft Nielsen, U. S. Justesen, K. Kobberøe Søgaard, T.S. Kostyanov, F. Boetius Hertz, M. Pedersen, R. B. Dessau, S. Skovgaard, J. Gitz Holler, L. Lützen, S. Ellermann-Eriksen, B. Kristensen, R. Skov, L. Engbo Christensen, A. Rhod Larsen, A. Hviid, A. Hammerum, P. Bager	00144 14:18 Genomic characterisation and molecular epidemiology of <i>Ralstonia thomasi</i> catheter-related bloodstream infections: report of an outbreak after disruption of the standardised process for venous catheter care M. Delaye Martinez* (Mexico City, Mexico), M.A. Delaye-Martínez, P. Volkow-Fernández, E. López-Jácome, J. Ortiz-Álvarez, C. Velazquez-Acosta, M.D.L. García-Hernández, M. Hernández-Durán, C.F. Hernández-Pérez, M.D.R. Vázquez-Olivares, C.U. Franco-Frias, P. Cornejo-Juárez, F.M. Medina-Aguilar, D. Vilar-Compte
OS022	13:30 – 14:30	Hall A3-2	
	1-hour Oral Session		
	PRO		
Game on: leveling up education through simulation and serious play			OS019 13:30 – 14:30 Hall ICM 13a
Chairs	Anette Friedrichs (Kiel, Germany) Daniel Grupel (Jerusalem, Israel)		1-hour Oral Session
			AMR PED PHEI
			AMR in paediatric populations: from dynamic acquisition to predictive models
			Chairs Johannes Hübner (Munich, Germany) Theresa J. Ochoa (Lima, Peru)
00135	13:30	Enhancing infectious diseases clinical practice	00145 13:30 Modelling the acquisition of extended-spectrum β -lactamase (ESBL)-producing <i>Enterobacteriaceae</i> in neonates in Madagascar households M. Alexa* (Paris, France), A.L. Beaumont, A. Harimanana, A. Rakotondraso, L. Odile Rivoarilala, A. Criscuolo, E. Fara Nandrasana Rakotomanana, P. Herindrainy, J.M. Collard, T. Crucitti, B.T. Huynh, L. Opatowski
			00146 13:42 Intestinal acquisition and clearance dynamics of extended-spectrum β -lactamase-producing

		Enterobacterales in hospitalised Kenyan children: a longitudinal, multi-site follow-up study <i>R. Aizouk*</i> (Oxford, United Kingdom), <i>C. Tigoi, S. Yan, M. Timbwa, M. Shalton, M. Ngari, R. Musyimi, H. Browne, J. Walton, T. Lawley, N. Stoesser, E. Van Kleef, J. Berkley</i>	
00147	13:54	Global surveillance gaps in maternal antimicrobial resistance: insights from isolate-level data on Gram-negative bacteria in LMICs <i>L. Hookham*</i> (Falmer, United Kingdom), <i>J. Alger, F.A. Dávila Ramírez, O. Dissanayake, J.A. Frem, O. Herrera, O. Makanjuola, I. Martin-Jorge, J. Leach, J.H. Cross, J.R. Price, M. Sekikubo</i>	
00148	14:06	Multidrug-resistant bacterial and fungal colonisation and transmission dynamics in hospitalised neonates <i>R. Kelleghan*</i> (Sydney, Australia), <i>M. Aberoumand, J. Beardsley, L.T. Cao, C. Duc Pham, T.M. Duong Nu, P.T. Hang, M. Harrison, L. Howie, M.H. Le, K. Luu Boi, N. Ngo, T. Ngo, T.M.A. Nguyen, T.A. Nguyen, P.A. Pham Dinh, A.T. Pham, V.A. Nguyen, T.D. Thi Hoang, P. Williams</i>	
00149	14:18	Artificial intelligence to predict antimicrobial resistance in Gram-negative bloodstream infections among paediatric onco-haematology patients <i>I. Sartini*</i> (Bologna, Italy), <i>E. Rocchi, C. Campoli, C. Bonazzetti, D. Leardini, F. Baccelli, L. Chiusaroli, D. Zama, M. Spadea, G. Tridello, P. Viale, S. Cesaro, M. Giannella</i>	

SY052 13:30 - 14:30 Hall A2-2

1-hour Symposium

CLN PED

Mycobacterial infections in childhood

Chairs *Elisabeth Schölvinck (Groningen, The Netherlands)*
Delane Shingadia (London, United Kingdom)

S0087 13:30 **New treatments and management of Tuberculous meningitis in children** *Diana Gibb (London, United Kingdom)*

S0088 14:00 **Optimising the diagnosis of NTM infections in childhood** *Jakko Van Ingen (Nijmegen, The Netherlands)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

YIA 13:30 - 14:30 Hall ICM 1

Awards

Young Investigator Award lecture

Chairs *Jon S. Friedland (London, United Kingdom)*
Jan A.J.W. Kluytmans (Utrecht, The Netherlands)

A001 13:30 **Re-thinking diagnostics to improve care in resource-limited settings** *Grace Androga (Blantyre, Malawi)*

A002 13:42 **Antibiotics on target: predicting efficacious dosing in challenging patient populations** *Iris K. Minichmayr (Vienna, Austria)*

A003 13:54 **Can we develop better tests to measure individual infectiousness in respiratory virus infections?** *Daniel Pan (Leicester, United Kingdom)*

A004 14:06 **Beyond the mould: shifting diagnosis and therapy through host immunity** *Sarah Delliere (Paris, France)*

A005 14:18 **Host-directed therapies and patient stratification for common bacterial diseases** *Clark Russell (Edinburgh, United Kingdom)*

EF023 13:30 - 14:30 Arena 1

ePoster Flash Session

CLN IPC TRN

Gut microbiota-based interventions against gastrointestinal pathogens and antibiotic resistance

Chair *Marcela Krutova (Prague, Czechia)*

E0151 13:36 **Tolerance and efficacy of the *Faecalibacterium prausnitzii* EXL01 strain for preventing recurrence of *Clostridioides difficile* infection: results from a multi-centre phase I study** *N. Benech** (Lyon, France), *P.*

Guarino-Vignon, P. McLellan, S. Truong, A. Delmeule, C. Landman, A. Bourrier, L. Alric, J. Scanzi, N. Cassir, A. Dureault, E. Piet, S. Gallet, E. Botelho-Nevers, M. Guillet, F. Ader, H. Sokol

E0152 13:42 **Impact of a defined bacterial consortium on host immune response and gut function in patients with *Clostridioides difficile* infection (CDI)** *J. Norman** (Cambridge, United States), *R. Menon, S. Bhattarai, A. Prince, Y. Huang, M. Giddins, V. Bucci, B. Olle, J.L. Silber, J. Faith*

E0153 13:48 **A global evaluation of the use of faecal microbiota transplant** *B. Merrick** (Harrow, United Kingdom), *B.H. Mullish, S.D. Goldenberg, S. Khanna, V. Ahuja, C.L. Hvas, G.K. Makharja, H.R.T. Williams*

E0154 13:54 **Investigation of enterococcus colonisation impact on *Clostridioides difficile* disease severity** *T. Eubank** (Houston, United States), *A. Mai, A. Horvath, K. Begum, T. Horvath, K. Garey*

E0155 14:00 **Faecal microbiota transplantation in paediatric patients: the first national experience** *B. Szabo** (Budapest, Hungary), *B.G. Szabó, D. Korózs, J. Czelecz, L. Takács, Á. Visnyovszki, K. Csordás, C. Kassa, G. Kriván*

E0156 14:06 **Faecal microbiota transplantation in patients with irritable bowel syndrome profoundly reshapes the gut microbiome, but does not have any detectable clinical effects** *O. Cinek** (Prague, Czechia), *J. Vejmelka, K. Hubáčková, K. Litosova, L. Hlinakova, M. Kulich, P. Kohout, J. Hurych*

E0157 14:12 **Improved clinical outcomes and shifts in intestinal microbiome and metabolites following intestinal microbiota transplantation in patients colonised with multidrug-resistant organisms** *R. Ghani** (London, United Kingdom), *J. Bilinski, L. Martinez-Gili, P. Takis, J. Miguens Blanco, N. Geva-Zatorsky, H. Bar-Yoseph, M.R. Thursz, F. Davies, B.H. Mullish, J.R. Marchesi*

EF024 13:30 - 14:30 Arena 3

ePoster Flash Session

CLN DX TRN

Molecular insights and surveillance of parasitic diseases

Chair *Özgür Kurt (Istanbul, Türkiye)*

E0160 13:30 **Integrating PCR on Giemsa-Stained Smears for accurate diagnosis of cutaneous leishmaniasis** *F. Maatallah** (Tunis, Tunisia), *W. Aissi, N. Boulehmi, O. Souissi, A. Bouratbine, K. Aoun*

E0161 13:36 **Protein-protein network is responsible for artemisinin induced cyto-toxic effects in liver cells** *E. Dodwani** (Guwahati, India), *V. Trivedi*

E0163 13:42 **Dengue mortality rates in the elderly population of Brazil and Colombia, 2019 and 2020** *A. Rodriguez-Morales** (Pereira, Colombia), *J.A. Cardona-Ospina, C.E. Perez, T.D.S.S. Chaves, P. Quispe, R.N. Angerami*

E0164 13:48 **Proteomic profiling of eluted *Schistosoma* antigens for enhanced diagnostic sensitivity** *B. Babalola** (Ondo, Nigeria), *K. Sulaiman, T. Oriade, O. Oyeyemi*

E0165 13:54 **Molecular characterisation of *Cryptosporidium* infections in a tertiary hospital in Barcelona during three years of post-COVID19 pandemic period** *M. Alguacil Guillén** (Barcelona, Spain), *M. Alguacil-Guillén, P. Köster, S. Sánchez-Prieto, P. Juan-Pardo, C. Aylagas, M.R. Ferré, J. Barrachina, P. Rodriguez, L. Horvath, J. Iglesias, M. Espasa, M.E. Valls, D. Carmena, M.J. Álvarez-Martínez*

E0166 14:00 **Ten-year retrospective surveillance of *Cryptosporidium* spp., *Giardia lamblia* and *Entamoeba histolytica* in the Netherlands** *E.M.J. Groenen** (Bilthoven, The Netherlands), *T.J. Roodsant, A. Al-Dawaf, A. Bart, G.J.H. Bastiaens, M. Berends, D.A.T. Hanssen, J.J. Van Hellemond, S.D. Kuil, S. Lekkerkerk, J.D. Machiels, B. Mulder, M.R. Ramos Diaz, E. Ruizendaal, J.M. Da Silva, S. Slavenburg, D. Souverein, E. Schaftenaar, K. Tassche-Borggreve, E. Vermeer, J.J. Verweij, A.L.M. Vlek, L.J. Wammes, R. Zonneveld, J.J. Hofstra, L. Mughini-Gras, I.H.M. Friesema*

EF025 13:30 - 14:30 Arena 4

Molecular diagnostic innovations across specimens

Chair *Mario Ramirez (Lisbon, Portugal)*

- E0168 13:30 **PCNE: a tool for plasmid copy number estimation** *R. Bollini* (Pavia, Italy), V. Cento*
- E0169 13:36 **Cerebrospinal fluid lipidome in central nervous system infections: A study of diagnostic accuracy** *S. Staal* (Amsterdam, The Netherlands), S. Olie, J.B. Van Klinken, M. Van Weeghel, F. Vaz, J. Bodilsen, H. Nielsen, D. Van De Beek, M. Brouwer*
- E0170 13:42 **Use of a multiplex joint infection PCR panel on non-synovial fluids: comparing PCR vs culture** *G.M. Chuang* (Singapore, Singapore), S.Y.L. Tan, Y.E. Tan, K.S. Chan, L.L.E. Oon*
- E0171 13:48 **Clinical evaluation of the OCEAN Dx culture-free assay for early detection of bacteraemia in critically ill patients** *A. Dewitte* (Bordeaux, France), J. Thierry, S. Cronier, O. Peuchany, V. Dubois, M. Mamani*
- E0172 13:54 **Performance assessment of a real-time test for intrapartum detection of group B *Streptococcus* vaginal colonisation** *A. Tazi* (Paris, France), M. Selmi, S. Snoussi, C. Poyart, C. Plainvert*
- E0173 14:00 **Breath aerosol PCR for detection of lower respiratory tract infections: evaluation of a non-invasive face mask collector in pneumonia patients** *M. Osthoff* (Basel, Switzerland), S. Dräger, K. Tiseo, H. Santhosh Kumar, M. Alkhazashvili, A. Hammann, P. Risch, R. Willi, T. Mkhathvari, C. Fialová, C. Adlhart, D. Szabó, M. Suknidze, I. Pachkoria, T. Broger, E. Ivanova Reipold, K. Varshanidze*
- E0174 14:06 **Enhancing molecular and genomic approaches for *Bordetella pertussis* investigation and public health surveillance in Victoria, Australia** *L. Sadeesh Kumar* (Melbourne, Australia), M. Sait, J. Merrett, J. Lacey, S. Baines, J. Strachan, N. Sherry, B. Howden*
- E0175 14:12 **Viral dominance in CNS infections: five-year epidemiological surveillance using multiplex PCR panel** *Z. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Kagkalou, K. Kouirouxis, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*
- E0176 14:18 **Impact of rapid multiplex PCR testing on the clinical and therapeutic management of pneumonia: a prospective randomised study** *A. Galar* (Madrid, Spain), E. Bouza, A. Álvarez-Uría, P. Martín-Rabadán, E. Cercenado, M. Ferris-Villanueva, L. Martín-Aguilera, J. Serrano, L. Alcalá, M.L. Sánchez-Alegre, J. De La Torre Fernández, J.J. García-López, L. Puente, P. Muñoz*

JS001 13:30 – 14:30 Hall A2-1

Journal Session

Late-breaking research from JAMA: novel insights on treating and preventing infections around the world

Chairs *Kirsten Bibbins-Domingo (Chicago, United States)*
Preeti Malani (Ann Arbor, United States)

- J0001 13:30 **Treatment of sinusitis in adults** *Timothy Savage (Boston, United States)*
- J0002 13:45 **Long term effects of childhood malaria** *Chandy John (Indianapolis, United States)*
- J0003 14:00 **Dalbavancin for *Staphylococcus aureus* bacteraemia** *Thomas Holland (Durham, United States)*
- J0004 14:15 **Rapid susceptibility testing for bacteraemia** *R. Banerjee* (Nashville, United States), L. Komarow, Y. Li, D. Mau, A. Dodd, H. Geres, K. Greenwood-Quaintance, A. Adler, S. Baliga, M. Chowders, G. Chrysos, M. Paul, S. Pournaras, D. Sousa Regueiro, S. Evans, H. Chambers, V. Fowler, Jr, R. Patel*

KN051 13:30 – 14:30 Hall ICM 14

Keynote lecture

Rheumatic heart disease: a global problem

Chairs *Fidelma Fitzpatrick (Dublin, Ireland)*

K0086 13:30 *Liesl Zuhlke (Cape Town, South Africa)*

ME055 13:30 – 14:30 Hall B0-2

Meet-the-Expert

Changing landscape of fungal infections in the solid organ transplant recipient

M0093 13:30 *Alessandra Mularoni (Palermo, Italy)*

M0094 13:42 *John Baddley (Baltimore, United States)*

ME053 13:30 – 14:30 Hall ICM 13b

Meet-the-Expert

***Candida auris* surveillance: when, how and why**

M0089 13:30 *Joseph Meletiadiis (Athens, Greece)*

M0090 13:42 *Giulia De Angelis (Rome, Italy)*

Co-organised with: Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS), International Society of Human and Animal Mycology (ISHAM), EUCIC Steering Committee

ME054 13:30 – 14:30 Hall ICM 5

Meet-the-Expert

LVAD infections: practical approaches to a complex challenge

M0091 13:30 *Saima Aslam (San Diego, United States)*

M0092 13:42 *Margaret Hannan (Dublin, Ireland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Implant-associated Infections (ESGIAI)

FO056 13:30 – 14:30 Arena 2

Open Forum

Moving ahead with the AMR agenda in a changing environment

Chair *Benedikt Huttner (Geneva, Switzerland)*

FO095 13:30 **From 'making the economic case' for AMR to securing financing for core interventions** *Chantal Morel (Bonn, Germany)*

FO096 13:40 **Reaching out to those who need to act: education and pre-service training of health workforce** *Li Yang Hsu (Singapore, Singapore)*

FO097 13:50 **Progress in measuring prevalence and impact on human health** *Olga Tosas Auguet (Geneva, Switzerland)*

Co-organised with: World Health Organisation (WHO)

WT001 13:30 – 14:30 Poster area

Poster Walkthrough

Emerging vector-borne and zoonotic diseases: surveillance, diagnostics, and clinical management in a changing world

Chair *Luisa Barzon (Padua, Italy)*

R0001 P0322 - Identifying emerging vector-borne pathogens in a time of climate change, the ARBO-WATCH network *Silvia Bianchi (Milano, Italy)*

R0002 P0261 - Wolbachia deployment in *Aedes aegypti*: a meta-analysis of dengue reduction in endemic regions *Abdullah Al Owesie (Martin, Slovakia)*

R0003 P0275 - Antibodies to non-structural protein 1 in tick-

	borne encephalitis: long-term kinetics in serum and cerebrospinal fluid <i>Sara Morgardt (Trollhättan, Sweden)</i>	
R0004	P0276 - Clinical course and outcome of tick-borne encephalitis in immunocompromised patients <i>Daša Stupica (Ljubljana, Slovenia)</i>	
R0005	P0320 - Factors associated with death or neurological sequelae in a cohort of patients hospitalised for West Nile virus infection in a non-endemic area in Southern Italy <i>Pierantonio Grimaldi (Naples, Italy)</i>	
R0006	P0317 - Rapid diagnosis by metagenomics analysis of zoonotic orf virus in human cases using a nanopore sequencing workflow <i>Elif Neyligül Arslan (Istanbul, Türkiye)</i>	
R0007	P0280 - Development and external validation of the early mortality score (EMS) for Crimean-Congo haemorrhagic fever, with comparative evaluation against the severity scoring index (SSI) <i>Deniz Güllü (Istanbul, Türkiye)</i>	
R0008	P0283 - Western equine encephalitis outbreak in Argentina 2023–2024: multi-centre clinical and epidemiological analysis of human cases <i>Sofia Elena Echazarreta (CABA (CABA), Argentina)</i>	
R0009	P0297 - Rodent reservoirs and high human exposure to hantaviruses in a rural agricultural area of Sri Lanka: a One Health perspective <i>Rydhnieya Vijeyakumaran (Peradeniya, Sri Lanka)</i>	
R0010	P0306 - Epidemiological overview of local transmission of chikungunya in mainland France in 2025 <i>Clémentine Calba (Marseille, France)</i>	

WT003 13:30 – 14:30 Poster area

PHEI

Poster Walkthrough

Of lice and laundry: data-driven public health around the globe

Chair *Joel Mossong (Luxembourg, Luxembourg)*

R0021	P4435 - Strengthening scientific advice for pandemic decision-making: insights from interdisciplinary tabletop simulation exercises <i>Femke Overbosch (Rotterdam, The Netherlands)</i>
R0022	P4387 - Genomic investigation of crocodile-to-human occupational transmission of <i>Vibrio cholerae</i> <i>Isca Hershkowitz (Jerusalem, Israel)</i>
R0023	P4356 - Learning from the past: historical lessons on non-pharmaceutical interventions in the United Kingdom and Hong Kong <i>Mi Joo Choi (Leicester, United Kingdom)</i>
R0024	P4308 - Parental views towards childhood vaccination in the United States before and after the COVID-19 pandemic <i>Amanda Eiden (Glenside, United States)</i>
R0025	P4298 - Estimating measles containing vaccine-induced immunity waning and future prediction in South Korea: a mathematical modeling study <i>Sol Kim (Seoul, Korea, Republic of)</i>
R0026	P4373 - Pathogen-specific effects of PM2.5 on pneumococcal pneumonia in a low-pollution microstate: a population-based time-series analysis <i>Cristina Royo-Cebrecos (Escaldes-Engordany, Andorra)</i>
R0027	P4324 - Early implementation outcomes of a nurse-led antenatal immunisation service: improving access, experience, and vaccine uptake in a metropolitan health service <i>Dorothy Ling (Victoria, Australia)</i>
R0028	P4486 - Identifying active paragonimiasis in rural Nagaland in North Eastern India: results from a community-based cross-sectional study <i>Rohan Michael Ramesh (Vellore, India)</i>
R0029	P4384 - Genomic diversity of <i>Campylobacter jejuni</i> and <i>Campylobacter coli</i> from human clinical isolates and swine/poultry industry associated sources in Latvia, 2022 – 2025 <i>Inara Kampenusa (Riga, Latvia)</i>

WT004 13:30 – 14:30 Poster area

PHEI

Poster Walkthrough

Changing landscape of parasitic diseases: genes, screens, and scenes

Chair *Carlos Seas (Lima, Peru)*

R0031	P3442 - Visceral leishmaniasis in Northern Brazil (2000–2023): an ageing epidemic with rising case-fatality <i>Lorenzo Brando Lundgren (Varese, Italy)</i>
R0032	P3431 - HLA-linked genetic susceptibility in alveolar echinococcosis <i>Lynn Peters (Ulm, Germany)</i>
R0033	P3457 - Systematic investigation of suspected angiostrongyliasis cases in Réunion Island <i>Wacil Patel (France, France)</i>
R0034	P3453 - Clinical profile and epidemiology of granulomatous <i>Acanthamoeba encephalitis</i> : a systematic review <i>Nitin Gupta (Manipal, India)</i>
R0035	P3447 - CE acquired in England: signs of emergence? <i>Stephanie Harris (London, United Kingdom)</i>
R0036	P3535 - Review of malaria diagnosis, severity, and management, 2019–2023, University Hospital Galway <i>Ellen Sugrue (Kerry, Ireland)</i>
R0037	P3531 - Risk behaviours and health problems in international travellers: prospective questionnaire study <i>Milan Trojanek (Prague, Czechia)</i>
R0038	P3528 - Implementation of a screening programme among migrants to Italy: key challenges and prevalence results <i>Stefania Caronni (Milan, Italy)</i>
R0039	P3484 - Correlation between PCR CT values, microscopy parasitaemia and RDT results in imported malaria <i>Harold Alfredo Bermúdez Marval (Alcalá De Henares, Spain)</i>
R0040	P3443 - Scabies is strongly associated with rheumatic heart disease: evidence from cross-sectional studies of school children in Tonga <i>Saptorshi Gupta (Auckland, New Zealand)</i>

WT002 13:30 – 14:30 Poster area

DX

Poster Walkthrough

Innovations in infectious disease diagnostics and surveillance

Chair *Fusun Can (Istanbul, Türkiye)*

R0011	P0192 - Targeted metagenomic sequencing of respiratory infections from UK healthcare workers in the SIREN study, winter 2023 - 2024 <i>Marissa Knoll (Hinxtan, United Kingdom)</i>
R0012	P2505 - Deep learning model for rapid outbreak detection in a rapid phenotypic AST system <i>Christer Malmberg (Uppsala, Sweden)</i>
R0013	P2439 - Evolution of respiratory virome profile in children under five years with persistent low respiratory symptoms <i>Niloofer Hejazifar (Milan, Italy)</i>
R0014	P4371 - Climate-driven expansion and clinical risk of <i>Vibrio vulnificus</i> : integrating global genomics, environmental reservoirs, and adaptive transcriptomics <i>Yaovi M. Gildas Hounmanou (Frederiksberg, Denmark)</i>
R0015	P2489 - Enhancing urine culture diagnostics with image analysis powered by AI: a novel approach <i>Yasmeen Vincent Marbanian (Etobicoke, Canada)</i>
R0016	P4355 - Uptake of antibacterial vaccines and the effects on antimicrobial resistance associated mortality in children under five in Sub-Saharan Africa <i>Oyewole Oyedele (Abuja, Nigeria)</i>
R0017	P2399 - Global population structure and convergent MDR-hypervirulence in high-risk <i>Pseudomonas aeruginosa</i> lineages <i>Riccardo Bollini (Pieve Emanuele, Italy)</i>
R0018	P2111 - Optimising the blood culture pathway (BCP) through multidisciplinary team collaboration: a two-year quality improvement initiative <i>Suryabrata Banerjee (Newcastle Upon Tyne, United Kingdom)</i>
R0019	P0459 - VEGF-A-induced tissue factor vesicle release as a hallmark of vascular dysregulation in long COVID <i>Samuel Benarroch (Ile-De-France, France)</i>
R0020	P2299 - Real-world diagnostic performance and antimicrobial stewardship impact of the syndromic multiplex PCR panel for meningitis/encephalitis in adult patient <i>Marisa Del Lujan Sanchez (Buenos Aires, Argentina)</i>

OS030 14:45 – 15:45 Hall A2-1

DX

1-hour Case Session

Unmasking infectious diseases through genomic approaches

Chairs		Judith Breuer (London, United Kingdom) Sandra Reuter (Freiburg, Germany)
00177	14:45	Shotgun metagenomics for CSF diagnostics guides targeted therapy in culture-negative bacterial meningitis caused by <i>Capnocytophaga canimorsus</i> G. Lorenzin* (Trento, Italy), M. Bertoldi, F. Bonaffini, M. Carlin, C. Scarparo
00178	14:56	Genomic characterisation of an extensively drug-resistant <i>Shigella sonnei</i> carrying bla _{CTX-M-15} in a sexually transmitted infection in an MSM patient in Spain N. Valcárcel Fraile* (Santander, Spain), N. Fraile-Valcárcel, B.M. Armas-Luján, D. Fernández-Vecilla, M.J. Urrutikoetxea-Gutiérrez, J. Rodríguez Grande, C. Ruiz De Alegria Puig, S. Labrador Descalzo, E. Mesa Santana, S. Riesco Alonso, A. Ocampo-Sosa, M.P. Roiz Mesones
00179	15:07	Dual enterococcal bacteraemia with central nervous system infection by <i>Enterococcus faecium</i> ST117: a whole genome analysis M. Roch* (Geneva, Switzerland), R. Sierra, P. Vetter, D. Neofytos, C. Van Delden, K.A. Kline, D.O. Andrey
00180	15:18	Unmasking the pathogen: how metagenomics enables the diagnosis of hard-to-detect infections A. Belati* (Bergamo, Italy), L.B. Giva, R. Bruschi, T. Perrone, M. Bartoli, M. Mazzoni, G. Albano, P.G.G. Panisi, M. Sampaolo, N. Clementi, V. Cento, M. Bartoletti, C. Filippi
00181	15:29	Chronic <i>Mycobacterium kansasii</i> pleural infection mimicking metastatic breast cancer: a seven-year diagnostic odyssey and the critical role of metagenomic sequencing Q. Miao* (Shanghai, China), T. Fang, P. Hu, Y. Zhang, B. Hu

OS027	14:45 - 15:45	Hall ICM 13b
	1-hour Case Session	

CLN

Unusual causes of broken heart: cardiac infections

Chairs		Diane Ashiru-Oredope (London, United Kingdom) Margaret Hannan (Dublin, Ireland)
00182	14:45	Outbreak investigation of non-tuberculous mycobacteria (NTM) sepsis following cardiac surgery in an LMIC tertiary care centre: implication of contaminated heater-cooler units M. Khan* (Peshawar, Pakistan)
00183	14:56	Beyond the usual suspects: three cases of infective endocarditis by rare pathogens N. Pansari* (Ahmedabad, India), S. Madan, B. Thacker, M. Chag, D. Shah, K. Gupta
00184	15:07	Disseminated BCG infection with cardiac device involvement and immune thrombocytopenia A. Bergas Farrés* (Barcelona, Spain), A. Bergas, R. Vila-Olives, S. Molinos, M.D. Quesada, A. Sarrias, R. Villuendas, A. Peris, A. Antuori, E. Berastegui, N. Fernández-Hidalgo, M.T. Tórtola, J.J. López-González, M.L. Pedro-Botet, R. Paredes, L. Mateu
00185	15:18	<i>Bartonella henselae</i> a great mimicker: endocarditis, bone marrow infiltration and glomerulonephritis mimicking vasculitis ANCA-positive J. Alza Arcila* (Medellín, Colombia), J. Alza-Arcila, S. Coboleda-Cano, C. Rincón-Márquez, J.M. Bacca-Gonzalez
00186	15:29	Intracardiac cysticercosis: a case report and diagnostic challenge R. Manchon* (Paris, France), N. Argy, A. Sivapathasundaram, D. Lussato, J. Feignoux, D. Attias, P. Le Besnerais, J. Rousseau, S. Lariven, N. Peiffer-Smadja

LB002	14:45 - 15:45	Hall A1-4
	1-hour Oral Session	

PHEI

Late-breaking public health challenges

Chairs		David Fisman (Toronto, Canada) Ricardo Mexia (Lisbon, Portugal)
L0011	14:45	Stress testing acute care chains for high-volume war-related trauma and MDROs A. Tostmann* (Nijmegen, The Netherlands), B. Beishuizen, V. Stirlir, E.

Ruizendaal, D. De Jong, E. Tan, C. Rovers

L0012	14:57	Imported MERS-CoV cases in France, November 2025: diagnosis, management and public health response A. Bal* (Lyon, France), L. Van-Den-Bogaart, A. Maisa, S. Dan, M. Bouscambert-Duchamp, S. Burrel, A. Avondo, A. Cossard, E. Fougere, Z. Boudalaa, C. Castor, E. Hope-Rapp, C. Durand, J.S. Casalegno, L. Josset, A. De-Clercq, H. Regue, D. Nguyen, C. Vignals, L. Rojas-Lopez, A. Oblette, A. Brinza, A. Massardier-Pilonchery, C. Dananche, P. Fascia, J. Godon, M. Simon, M.A. Rameix Welti, J.M. Turmel, N. Leveque, D. Perez-Bercoff, B. Lina, A. Lapendry, X. Lescurie, M. Mailhe, F. Ader, B. Coignard, A. Gaymard, T. Perpoint
L0013	15:09	Measles hospitalisations during an outbreak in Jerusalem, 2025 O. Gordon* (Jerusalem, Israel), G. Oren, O. Itamar, S. Dorozhko, S. Zahran, E. Roda, N. Peled, A. Bracha Moshe, N. Juven Wetzler, D. Averbuch, S. Hashavya, U. Pollak, D. Wolf, J. Strahilevitz, Y. Oster, N. Abramson, Z. Mor, N. Bar Zeev, O. Megged, R. Brooks, A. Tenenbaum
L0014	15:21	Epidemic of <i>Chlamydia pneumoniae</i> infections in France in 2024 S. Trombert Paolantoni* (Frepillon, France), S. Trombert-Paolantoni, L. Baussant, K. Sood, E. Hedbaut, A. Bergeron, Y. Tandjaoui-Lambiotte, B. Visseaux
L0015	15:33	Scrub typhus in children: an emerging under-recognised threat: seroprevalence, demographic trends, co-infections and cross-reactions in a tertiary care paediatric institute in North India N. Sumi* (Uttar Pradesh, India), S. Nandwani, J. Sachdev, A. Puri, R. Edoliya, N. Perween, D.K. Singh, D.K. Sahu

OS029	14:45 - 15:45	Hall B0-2
	1-hour Oral Session	

VAX

Respiratory viral infection prevention across age groups

Chairs		Christopher Chiu (London, United Kingdom) Simona Ruta (Bucharest, Romania)
00187	14:45	Maternal RSV vaccination and reduced risk of hospitalisation for babies in England, 2024/25 M. Wilson* (London, United Kingdom), H. Whitaker, J. Walker, E. Heymer, A. Cobbold, C. Watson, N. Andrews
00188	14:57	Impact of universal infant immunisation with nirsevimab on RSV-related hospitalisation beyond the first season: the NIRSE-GAL study F. Martínón-Torres* (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieto, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo, N. Mallah
00189	15:09	Real-world emergence of nirsevimab resistance in RSV-B breakthrough infections S. Fourati* (Créteil, France), A. Reslan, J. Bourret, J.S. Casalegno, Y. Rahou, L. Softic, L. Chollet, P. Tremeaux, B.M. Imbert-Marcille, S. Pilet, N. Veyrenche, A. Boudet, L. Deroche, S. Burrel, L. Mouna, T. Cocherie, A. Schnuriger, C. Pronier, L. Handala, F. Gallais, S. Larrat, A. Regueme, N.C. Dossou, A. Henry, E. Gault, C. Hartard, S. Brichler, A. Moisan, V. Avettand-Fenoel, C. Lefeuvre, I. Engelmann, S. Castelain, A. Mirand, M. Salmona, M.C. Jaffar-Bandjee, P. Cappy, C. Rodríguez, G. Dos Santos, S. Berreira Ibrahim, K. Da Silva, A. Recoing, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti
00190	15:21	Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan L. Kostanyan* (Cambridge, United States), H. Fukase, A. Rumyantsev, O. Kogawara, K. Hashizume, S. Osibajo
00191	15:33	High-dose vs standard-dose influenza vaccination across laboratory-confirmed influenza severity levels in older adults: the DANFLU-2 randomised trial F.S. Davidovski* (Hellerup, Denmark), N.D. Johansen, N. Shaikh, R. Harris, D. Modin, P.S. Wolff, K.G. Skaarup, C.S. Søndergaard, M. Loiacono, Y. Huang, J. Bartelt-Hofer, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B. Claggett, K. Janstrup, R. Jessen, N.

Steenhard, K. Bartholdy, K. Bernholm, J. Borchsenius, L. Davodian, M. Dons, L. Duus, C. Espersen, F. Fussing, A.M. Jensen, N. Landler, A. Langhoff, M. Lassen, A.B. Nielsen, C. Ottosen, M. Sengeløv, S. Solomon, M. Landray, G. Gislason, L. Køber, P. Sivapalan, C. Martel, J.U. Jensen, T.B. Sørensen

OS026 14:45 – 15:45 Hall ICM 13a

1-hour Oral Session

CLN

Redefining care in bacterial meningitis: new approaches and emerging clinical evidence

Chairs Tuyen Nguyen (Laval, Canada)
Charlotte Sriruttan-Nel (Johannesburg, South Africa)

00192 14:45 Continuous intracranial pressure monitoring in acute bacterial meningitis: a nationwide multi-centre cohort study J. Karlsson Valik* (Stockholm, Sweden), A. Grahn, M. Veje, P. Almqvist, C. Åkerlund, J. Widén, G. Westman

00193 14:57 Addition of daptomycin in the treatment of pneumococcal meningitis in adults: results of the phase II AddaMap trial T. Sixt* (Dijon, France), T. Sixt*, I. Fournel, A. Bourredjem, M. Blot, B. Mourvillier*, D. Grandgirard*, S. Leib*, X. Duval, L. Piroth, P. Chavanet*

00194 15:09 Effectiveness of ceftriaxone in the management of neurosyphilis: experience of a UK tertiary centre L. Carson* (Cambridge, United Kingdom), B. Warne, O. Sule, C. Krause, M. Routledge

00195 15:21 Early oral step-down therapy in pyogenic brain abscesses: a bicentric retrospective study J. Brouard* (Clichy, France), D. Morizet, R. Rahli, A. Lefort, P. Decq, H. Kimseng, A.L. Munier, V. De Lastours

00196 15:33 Continued corticosteroids for non-pneumococcal bacterial meningitis in adults: a target trial emulation E. Eriksen* (Aalborg, Denmark), K.F. Greve, S.Ø. Larsen, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, J. Bodilsen

OS028 14:45 – 15:45 Hall ICM 5

1-hour Oral Session

CLN DX

From overuse to optimisation: smarter diagnostics in practice

Chairs Gloria Cordoba (Copenhagen, Denmark)
Polona Maver Vodcar (Ljubljana, Slovenia)

00197 14:45 The implementation of electronic clinical decision tools to reduce inappropriate urine and swab requests: a diagnostic stewardship intervention to reduce the environmental impact of laboratory testing R. Shorten* (Manchester, United Kingdom), S. Shafiq, L. Roberts, G. Williams

00198 14:57 Diagnostic stewardship in critical care: should overexpressed AmpC Enterobacteriales detected on rectal screening be reported? predictive value for infection and comparison with ESBL A. Mizrahi* (Paris, France), G. Péan De Ponfilly, M. Holub, T. Genty, F. Philippart, C. Couzigou, B. Pilmis, A. Le Monnier

00199 15:09 Development of an infectious diseases diagnostic excellence program using the centres for Disease Control and Prevention (CDC) core elements T. Jenkins* (Denver, United States), M. Cooper, K. Shihadeh, L. Triplett, L. Fish, M. Wolfe, A. Penick, M. Wilson

00200 15:21 Optimising blood cultures: a diagnostic stewardship intervention L. Mejdoubi* (Vienna, Austria)

00201 15:33 Reducing CoNStant testing: Impact of a diagnostic stewardship intervention targeting coagulase-negative staphylococci in blood cultures on vancomycin, daptomycin and linezolid consumption K. Tanida* (Hamburg, Germany), B. Berinson, M. Florey, L. Middendorf, C. Sommer, M. Aepfelbacher, H. Rohde, M. Christner

SY060 14:45 – 15:45 Hall A2-2

1-hour Symposium

DX

Precision diagnostics for neonatal sepsis: from biomarkers to the bedside

Chairs Ilias P. Iosifidis (Thessaloniki, Greece)
Birgit Willinger (Vienna, Austria)

S0123 14:45 Rapid diagnostic tools for neonatal sepsis: from biomarkers to AI-powered screening Mohan Pammi (Bellaire, United States)

S0124 15:15 How to differentiate viral vs. bacterial infections in neonates? Marieke Emonts (Newcastle Upon Tyne, United Kingdom)

SY061 14:45 – 15:45 Hall A3-1

1-hour Symposium

AMR CLN

Bridging the gap: aligning EUCAST standards with antimicrobial stewardship practice

Chairs Esther Calbo (Terrassa, Spain)
Paul Christoffer Lindemann (Bergen, Norway)

S0125 14:45 From report to treatment: challenges in applying AST results in clinical practice Benedikt Huttner (Geneva, Switzerland)

S0126 15:15 Enhancing clinical relevance: EUCAST's vision for improving AST interpretability Marlene Amara (Paris, France)

SY062 14:45 – 15:45 Hall A3-2

1-hour Symposium

ANT CLN

Closing the antiviral gap: broadening treatment options for emerging and neglected viruses

Chairs Julie Bines (Parkville, Australia)
Jan Felix Drexler (Berlin, Germany)

S0127 14:45 New host-directed approaches against emerging viral infections Rainer Koenig (Jena, Germany)

S0128 15:15 Outlook of new antiviral molecules in the pipeline Javier Sánchez Céspedes (Seville, Spain)

SY059 14:45 – 15:45 Hall B0-1

1-hour Symposium

PHEI

Climate change, biodiversity loss, and the future of infectious diseases

Chairs Marion Koopmans (Rotterdam, The Netherlands)
Tyra Grove Krause (Copenhagen, Denmark)

S0121 14:45 Impact of climate change on infections Kimberly Fornace (Singapore, Singapore)

S0122 15:15 Biodiversity loss and risk of spill-over events and epidemics Carsten Rahbek (Copenhagen, Denmark)

SY058 14:45 – 15:45 Hall ICM 1

1-hour Symposium

CLN DX PHEI

Chemsex, HIV and STIs: so little time, so much to do

Chairs Ivana Gmizic (Belgrade, Serbia)
Lorenzo Rabbi (Berlin, Germany)

S0119 14:45 Chemsex plus STIs syndemic: how to test and how to treat Zulma Vanessa Rueda (Winnipeg, Canada)

S0120 15:15 Chemsex and the costs of its ignorance: example from Central and Eastern Europe Sime Zekan (Zagreb, Croatia)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Viral Hepatitis (ESGVH), Euroguidelines in Central and Eastern Europe Network Group

EF031 14:45 – 15:45 Arena 1

ePoster Flash Session

CLN TRN

Infection risk, response, and recovery in the immunocompromised host

Chair Michael Boeckh (Seattle, United States)

E0202	14:45	Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy N. Lambert* (Liège, Belgium), M. El Moussaoui, A. Le Guilloux, M. Joly, M.D.C. Garcia Martearena, R. Bernard-Valnet, C. Pinnetti, K.F. Greve, X. Brousse, W.F. Westendorp, M.T. Wijburg, L. Grote-Levi, N. Moehn, V. Pourcher, S. Gressens, C.V. Cruz, V. Van Pesch, M. Vidal, C. Morvan, A. Makinson, A.M. Konitsioti, B. Hoellinger, L. Nitsch, D.E. Ney, E. Faure, K.B. Alstadhaug, M. Martinot, F. Genderini, J. Legras, M. Garzaro, S. Bianchi, S. Gazaigues, S. Borrelli, S. Patrat-Delon, D. Vydrář, P. Nicolas-Vullierme, M. Moutel, T. Cartau, F. London, A. Cabié, K. Bouiller, A. Montcuquet, P. Loubet, N. Sayre, P. Maquet, G. Darcis, M. Le Marechal, D.B. Clifford, T. Skripuletz, M.C. Brouwer, J. Bodilsen, R. Du Pasquier, P. Cinque, A. Sommet, G. Martin-Blondel	E0212	14:51	Efficient and easy preparation of stool specimens for molecular diagnostics without nucleic acid purification T. Schuurman* (Dordrecht, The Netherlands), M. Pellikaan, I. Huijskens
E0203	14:51	Pritelivir demonstrated superior lesion healing with extended treatment compared to investigator's choice for refractory herpes simplex virus infection in immunocompromised patients in the PRIOH-1 phase III trial R. Chemaly* (Houston, United States), J.M. Molina, K. Workowski, R. Avery, Y.J. Lee, K. Peggs, D. Neofytos, M. Yong, J. Sasadeusz, R. Maves, B. Gaborit, D. Teschner, A. Perez-Rios, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, A. Wald, G.A. Papanicolaou	E0213	14:57	A multi-centre clinical trial evaluating molecular mini-panels for bacterial gastrointestinal pathogen detection A. Nenninger* (San Diego, United States), C. Remillard, Y. Liu, A. Menez
E0204	14:57	Impaired type I interferon response early after SARS-CoV-2 infection is associated with the occurrence of persistent COVID-19 in solid organ transplanted recipients Q. Richier* (Paris, France), K. Zafilaza, M. Briard, V. Bondet, M. Robert, V. Leducq, A. Fauchois, E. Ghidaoui, S. Sayon, C. Dorival, C. Lusivika-Nzinga, Y. Yordanov, G. Martin-Blondel, F. Carrat, A.G. Marcelin, C. Soulie, K. Lacombe, D. Duffy	E0214	15:03	Diagnostic efficacy of two immunochromatographic tests for the rapid detection of rotavirus, adenovirus, and norovirus compare G. Sánchez De Luis* (Madrid, Spain), R. Blázquez Batanero, A.I. Peñalver López, H. Bermúdez Marval, V.A. Robles Curvelo, C. Rescalvo-Casas, M. Hernando-Gozalo, A. Rojas Díaz, F. Pérez-García, A. Irigoyen-Von-Sierakowski, B. Rodríguez-Ponga, J.A. Cuadros-González, R. Pérez-Tanoira
E0205	15:03	Blood virome and acute graft vs host disease K. Hosszu-Fellous* (Geneva, Switzerland), S. Cordey, M. Gumowski, F. Laubscher, L. Royston, S. Masouridi-Levrat, Y. Chalandon, D. Neofytos, L. Kaiser	E0215	15:09	Comparative evaluation of diagnostic methods for Entamoeba histolytica: A Four-Year retrospective study B. Dinc* (Ankara, Türkiye), F. Demirel, S. Cebeci, U. Berberoğlu, B. Dinç
E0206	15:09	Towards personalised empirical antibiotic therapy in febrile neutropaenia: a theoretical model based on machine learning and prior colonisation with multidrug-resistant Gram-negative bacilli A. Gallardo-Pizarro* (Barcelona, Spain), C. Teijón-Lumbreras, T.F. Aiello, P. Monzó-Gallo, A. Martínez-Urrea, C. Terrones-Campos, A. Castiella, G. Cuervo, L. Morata, P. Castro, C. Casals, M. Espasa, J. Esteve, J.M. Nicolas, J. Mensa, A. Soriano, C. Garcia-Vidal	E0216	15:15	Bristol-scale guided using a POCT vs non-POCT molecular syndromic testing and clinical outcomes in traveler's diarrhoea M. Bugés Bascompte* (Barcelona, Spain), M. Bugés-Bascompte, S.M. San José Villar, N. Vila-Olmo, P. García-Mellado, M. Muixí-Duran, I. Oliveira-Souto, P. Nadal-Barón, M. Vicente-Ciurans, A. Canals, V. Rodríguez-Garrido, C. Arconada-Rojano, C. Rubio-Maturana, L. Goterris-Bonet, E. Sulleiro
E0207	15:15	Burden and clinical outcomes of hospital-coded respiratory virus infection in patients with haematological malignancy: a longitudinal multi-centre cohort study from 2011-2023 V. Hall* (Melbourne, Australia), T. Spelman, A.P. Ng, M.K. Yong, M.A. Slavin, B.W. Teh	E0217	15:21	Optimising bacterial stool diagnostics: PCR-guided culture improves sensitivity and accelerates result reporting G. Hagn* (Munich, Germany), T. Fleige
E0208	15:21	Steroid-linked invasive fungal infections after CAR-T: insights from a national Australian cohort G. Reynolds* (Heidelberg, Australia), M. Dowling, S. Belbachir, N. Perera, J. Li, J. Valencia-Klug, B.W. Teh, M.A. Anderson, A. Barraclough, C. Tam, P.J. Ho, S.J. Harrison, A.S. Henden, M. Slavin	E0218	15:27	Clinical validation of the BB-ELISA for predicting recurrent Clostridioides difficile infection study E. Basseres* (Houston, United States), H. Yu, R. Lee, S. Kumari, J. Fowler, A. Saint Fleur, T. Eubank, Y. Zhang, E. Von Rosenvinge, K. Garey, Z. Yang, H. Feng
E0209	15:27	Role of colonising multidrug-resistant bacteria in haematological patients: a retrospective observational study A. Lovecchio* (Trieste, Italy), N. Benvenuto, S. Babich, A. Misin, S. Mohamed, G. Sanson, S. Di Bella	EF033	14:45 - 15:45	Arena 3
E0210	15:33	Serious infection risk with advanced therapies across immune-mediated inflammatory diseases V. Allen* (London, United Kingdom), M. Gibson, M. Russell, K. Bechman, M. Adas, S. Norton, I. Muzafar, R. Chavali, S. Muzafar, N. Suresh, Y. Yoon, L. De Gracia, D. Philippo, A. Goodman, J. Galloway			
EF032	14:45 - 15:45	Arena 2			
		ePoster Flash Session			
		Beyond the culture plate: a multi-modal overview of recent advances in gastrointestinal testing			
		Chair Mauricio Farfan (Santiago, Chile)			
E0211	14:45	Evaluation of Copan FecalSwab™ Collection and Transport device for molecular applications F. Bonometti* (Brescia, Italy), S. Savi, C. Sabelli	E0220	14:45	Impact of azithromycin on neutrophil-mediated immune responses against Aspergillus fumigatus R. Manchon* (Paris, France), E. Dudoignon, A. Agathe, W. Sarah, Q. Jessica, D. Sarah
			E0221	14:51	A novel infection model to study immunobiology, antifungal pharmacotherapy, and immunomodulatory therapy of invasive pulmonary aspergillosis in mice with acute myeloid leukemia S. Wurster* (Houston, United States), N.D. Albert, J. Pantaleon Garcia, L. Matula, S. Evans, D.P. Kontoyiannis
			E0222	14:57	Efficacy of BAL2062 in immunosuppressed mice infected with azole-sensitive and azole-resistant Aspergillus fumigatus A. Ibrahim* (Allschwil, Switzerland), T. Gebremariam, S. Alkhazraji, Y. Gu, E. Youssef, S. Nabeela, T. Elsayed, S. Dolati, K. Litherland
			E0223	15:03	Invasive pulmonary mucormycosis is associated with siderophore secretion, neutrophil recruitment, and lipid remodelling in the lungs D. Luptáková* (Prague 4, Czechia), T. Hřivnová Juříková, M. Petřík, K. Dvořáková Bendová, B. Neužilová, H. Marešová, A. Palyzová, M. Lackner, P. Hubáček, V. Havlíček
			E0224	15:09	Once-daily SCY-247 as oral and intravenous formulations has linear pharmacokinetics and is efficacious in a murine model of invasive Candida glabrata infection N. Wiederhold* (San Antonio, United States), L. Najvar, S. Wring, K. Borroto-Esoda, D. Angulo, R. Jaramillo, M. Olivo, T. Patterson
			E0225	15:15	Phenotypic and genotypic characterisation of multiple Candida albicans laboratory-induced drug resistant isolates reveals convergent and divergent responses to resistance R. Khalaf* (Byblos, Lebanon), M. Abbas, S. El Hachem, C. Chedraoui, I. Bitar, N. Fattouh
			E0226	15:21	Engineered CAR-T Cells Targeting Fungal Cell Wall Show Limited Antifungal Activity E. Dolader Ballesteros* (Zaragoza, Spain), E. Dolader-Ballesteros, S. Redrado, D. Sánchez-Navarro, M.P. Domingo, P. Esteban, M. Arias, J. Paul-Bernal, V. Taleb, A. Ramirez, R. Hurtado, J. Pardo, E.M. Gálvez

E0227 15:27 Azole-induced in-host microevolution of *Candida parapsilosis* drives MRR1-mediated antifungal resistance R. Zhang* (Beijing, China)

EF034 14:45 - 15:45 Arena 4

AMR ANT IPC

ePoster Flash Session

Innovations in antimicrobial stewardship across diverse settings

Chair Nathan Peiffer-Smadja (Paris, France)

E0229 14:45 Strengthening infection control and antimicrobial stewardship through quality improvement in a refugee-serving hospital: lessons from Nakivale, Uganda Z. Nahumuza* (Entebbe, Uganda), M. Umar

E0230 14:51 From culture positives to positive culture: changing behaviour around ASB treatment M. Arandjelovic* (Aveiro, Portugal), L. Maia, A. Ribeiro, T. Mariano, M. Santos, F. Freitas

E0231 14:57 "No breakpoints? no problem!" evaluating gentamicin perioperative prophylaxis for *Pseudomonas aeruginosa* asymptomatic bacteriuria before urological surgery N. Reidy* (London, United Kingdom), S. Dewan, A. Saiyed, A. Raza, D. Smith, A. Lima Soares, G. Pollara, R. Ghani

E0232 15:03 A multi-seasonal mixed-method point-prevalence study of antibiotic prescription patterns in a tertiary healthcare facility in India A. Mukherjee* (New Delhi, India), V. Modgil, R. Surial, O. Sinha, S. Kumar, S. Raina, R. Chauhan, S. Sahay

E0233 15:09 TDM (Therapeutic Drug Monitoring)-guided meropenem therapy for bone and joint infections caused by Gram-negative bacilli M. Sanz De Mena* (Barcelona, Spain), M. Sanz-De Mena, S. Luque, L. Sorli, D. Pérez-Prieto, A. Alier, G. Rodriguez-Cabalé, I. Pelegrín, M. Montero, J.P. Horcajada, J. Gómez-Junyent

E0234 15:15 Antimicrobial Stewardship (AMS) program in Lombardy Region: analysis of effectiveness and costs G. Renisi* (Milano, Italy), A. Comelli, L. Scudeller, A. Mazzone, G. Macaluso, M. Zanforlini, S. Schiatti, D. Cereda, G. Del Castillo, U. Restelli, S. Silvola, N. De Fazio, P. Bonfanti, M. Bartoletti, A. Tebaldi, S. Piconi, M. Puoti, A. Castagna, P. Grossi, G.C. Marchetti, A. Regazzetti, F. Castelli, A. Zoncada, B. Castiglioni, L. Pusterla, R. Bruno, S. Rusconi, S. Antinori, A. Muscatello, A. Gori, A. Bandera, S. Chiappetta

E0235 15:21 Disparities in Infection Prevention and Control, and Antimicrobial Stewardship Practices across Healthcare Settings with Varied Resource Levels: Findings from the BALANCE Study R. Farzana* (Oxford, United Kingdom), N. Haque, S.B. Shahid, G. Ferdous, N. Haque, M. Rahman, S. Afroj, E. Carretto, D.B. Roatti, E. Kibaru, L. Kiguongo, G. Ganda, D. Adera, C. Achi, K. Iregbu, P. Nwajiobi-Princewill, O.E. Ben, A. Aminu, F.H. Auwal, I.N. Nwafia, O.S. Ukaegbu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, M. Nawaz, M. Idrees, M. Umair, A. Zukowska, A. Zukowska, M. Zukowski, M. Borowiak, O. Ergonul, L.S. Gucer, Ö.K. Azap, N. Sari, E.T. Tigen, B.E. Sengel, M. De Kraker, S. Harbarth, N. Hassoun-Kheir, K. Onjuro, E. Owinoh, T. Walsh

E0236 15:27 Addressing prescribing behaviour to reduce broad-spectrum antibiotic use V. Chorro-Mari* (Ashford, United Kingdom), A. Dalton, S. Yan, S. Glass, L. White

KN057 14:45 - 15:45 Hall ICM 14

CLN TRN

Keynote lecture

From molecules to ministries: a life in the fight against malaria

Chairs Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)

K0118 14:45 Abdoulaye Djimde (Bamako, Mali)

SY069 16:15 - 17:15 Hall A3-2

TRN VAX

1-hour Symposium

Outsmarting ticks: decoding tick-host-pathogen interactions and advancing vaccines against tick-borne diseases

Chairs Anna J. Henningsson (Jönköping, Sweden)
Ryan Rego (Ceske Budejovice, Czechia)

S0153 16:15 Insights into tick immune-developmental pathways impacting vector biology and pathogen persistence Chrysoula Kitsou (College Park, United States)

S0154 16:45 Counter-attacking the tick bite: anti-tick vaccines to prevent tick-borne diseases Joppe Willem Robert Hovius (Amsterdam, The Netherlands)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

EW072 16:15 - 18:15 Hall A2-1

CLN TRN

2-hour Educational Session

The microbiome and response to cancer treatment

Chairs Nicolas Benech (Lyon, France)
Lina Cavaco (Copenhagen, Denmark)

W0163 16:15 How the microbiome can impact response to cancer treatment Gal Markel (Petach Tikva, Israel)

W0164 16:35 How antibiotic treatment can impact response to immunotherapy Lisa Derosa (Villejuif, France)

W0165 16:55 How to preserve the microbiome during infection management in cancer patients? Arielle Elkrief (Montréal, Canada)

W0166 17:15 How the gut microbiome influences chemotherapy tolerance and efficacy Cindy Neuzillet (Saint Cloud, France)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

EW071 16:15 - 18:15 Hall BO-1

CLN PRO

2-hour Educational Session

Adaptive platform trials in infectious diseases

Chairs Marc J.M. Bonten (Utrecht, The Netherlands)
Dafna Yahav (Ramat-Gan, Israel)

W0159 16:15 One and the same, or two and different? History and definitions of adaptive and platform trials Holly Jackson (Singapore, Singapore)

W0160 16:35 BALANCE PLUS: a platform trial answering challenging questions on Gram-negative infections Nick Daneman (Ontario, Canada)

W0161 16:55 Keeping it going: lessons learned from REMAP-CAP Marc J.M. Bonten (Utrecht, The Netherlands)

W0162 17:15 Getting it off the ground: successes and failures from the SNAP platform Josh Davis (Newcastle, Australia)

Co-organised with: CMI Communications Board of Editors

EW070 16:15 - 18:15 Hall ICM 13b

CLN IPC VAX

2-hour Educational Session

Building a safer journey from candidate to organ transplant recipient

Chairs Wanessa Clemente (Belo Horizonte, Brazil)
Victoria Hall (Melbourne, Australia)

W0155 16:15 Ready for the fight: candidate evaluation and vaccination Maha Alamri (Riyadh, Saudi Arabia)

W0156 16:35 It starts with the donor: minimising the risk of donor-derived infections Oscar Len (Barcelona, Spain)

W0157 16:55 At the table: surgical and perioperative challenges for infection control Maddalena Giannella (Bologna, Italy)

W0158 17:15 Traveling the world and safe living post-transplant Priscilla Rupali (Vellore, India)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY067 16:15 – 18:15 Hall A2-2
2-hour Symposium

CLN PHEI

Can you see me? HIV among underserved populations

Chairs Magdalena Rosińska (Warsaw, Poland)
Milena Stevanovikj (Skopje, North Macedonia)

S0145 16:15 Learning from Malta's experience on HIV care for refugees and migrants Aaron Schembri (Attard, Malta)

S0146 16:45 HIV transmission and intimate partner violence in South America Claudia Cortes (Santiago, Chile)

S0147 17:15 Can people in homelessness crisis be effectively treated for HIV? a voice from Canada Yoav Keynan (Winnipeg, Manitoba, Canada)

S0148 17:45 STIs, HIV and hepatitis in penitentiary system: how to test and treat them all? Justyna Kowalska (Warsaw, Poland)

SY068 16:15 – 18:15 Hall A3-1

IPC PED

2-hour Symposium

Novel approaches to preventing neonatal infections beyond antibiotics

Chairs Angelika Berger (Vienna, Austria)
Pablo Sanchez (Columbus, Ohio, United States)

S0149 16:15 Lactoferrin: a natural defense against neonatal sepsis and necrotising enterocolitis Theresa J. Ochoa (Lima, Peru)

S0150 16:45 Immunometabolic approaches to prevent neonatal sepsis Duc Ninh Nguyen (Frederiksberg, Denmark)

S0151 17:15 Human milk oligosaccharides and the microbiome in preterm infants: mechanisms and evidence for infection protection Moran Yassour (Jerusalem, Israel)

S0152 17:45 Human fortifier to prevent infections in preterm infants: clinical data and future perspectives Boris Kramer (Poznan, Poland)

SY066 16:15 – 18:15 Hall B0-2

AMR PHEI TRN

2-hour Symposium

Barriers, drivers and maintenance: molecular mechanisms behind AMR gene mobility

Chairs Louise Roer (Copenhagen, Denmark)
Jozsef Soki (Szeged, Hungary)

S0141 16:15 Classification and typing of plasmids carrying multi-drug resistance Alessandra Carattoli (Rome, Italy)

S0142 16:45 Plasmid-host co-evolution that stabilises antibiotic resistance Javier De La Fuente (Barcelona, Spain)

S0143 17:15 The evolution and transmission of multi-drug-resistant *Escherichia coli* and *Klebsiella pneumoniae*: complexity of clones and plasmids Alan McNally (Birmingham, United Kingdom)

S0144 17:45 Antibiotic resistance plasmids in a One Health context Michael Brouwer (Utrecht, The Netherlands)

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP)

SY063 16:15 – 18:15 Hall ICM 1

ANT CLN

2-hour Symposium

Cracking the phage code: from clinical insights to precision design

Chairs Tristan Ferry (Lyon, France)
Jean-Paul Pirnay (Brussels, Belgium)

S0129 16:15 Designing clinical trials around phage therapy Pranita Tamma (Philadelphia, United States)

S0130 16:45 Randomised controlled trials of phage therapy in diabetic foot ulcers Ran Nir-Paz (Jerusalem, Israel)

S0131 17:15 AI for host-phage interaction prediction Michiel Stock (Ghent, Belgium)

S0132 17:45 Towards cell-free production and selection of therapeutic phages Antoine Levrier (Montpellier, France)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY064 16:15 – 18:15 Hall ICM 13a

CLN PED TRN

2-hour Symposium

Global perspectives on tuberculosis

Chairs Laura Ferreras-Antolin (London, United Kingdom)
Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)

S0133 16:15 Computer modelling to improve TB outcomes: progress and problems Rada Savic (San Francisco, California, United States)

S0134 16:45 Contribution of asymptomatic TB to the global TB burden Hanif Esmail (London, United Kingdom)

S0135 17:15 The Brazil-wide TBPed study on active and latent tuberculosis in childhood Marcelo Scotta (Porto Alegre, Brazil)

S0136 17:45 Radical shortening of the duration of TB treatment: here and now? Nicholas Paton (Singapore, Singapore)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), International Society of Pediatric Respiratory Diseases (INSPIRED)

SY065 16:15 – 18:15 Hall ICM 5

TRN VAX

2-hour Symposium

Harnessing antibody response against viral and bacterial infections

Chairs Luisa Barzon (Padua, Italy)
Silvio Daniel Brugger (Zurich, Switzerland)

S0137 16:15 Mechanisms and clinical relevance of antibody response during viral infection Irene A Abela (Zürich, Switzerland)

S0138 16:45 Mechanistic insights into human antibody responses to bacterial virulence factors Alexander Simonis (Cologne, Germany)

S0139 17:15 Bacterial cell wall polysaccharides as strategies against invasive bacterial infection Nina Van Sorge (Amsterdam, The Netherlands)

S0140 17:45 Advances in antibody-based strategies for combating HIV infection Florian Klein (Cologne, Germany)

EF035 16:15 – 17:15 Arena 4

DX PHEI

ePoster Flash Session

From surveillance to diagnosis: catching hepatitis viruses before they catch us

Chair Arjan Harxhi (Tirana, Albania)

E0238 16:15 A One Health, pan-European network strengthening surveillance, clinical management and control of zoonotic hepeviruses I. Hasanoglu* (Ankara, Türkiye), A. Elena Anita, F. Abravanel, G. Reuter, S. Dudman, N. Kamar, L. Jemeršič, I. Di Bartolo, N. Cook, S. Ruta, I. Nauwelaers, L. Milojević, E. Todorovska, S. Mojsova, A. Zerja, A. Avellon, R. Hakze, B. Velebit, R. Johnne, J. Mesquita, A. Rivero-Juarez

E0239 16:21 Tracing rat-to-human transmission of hepatitis E virus within a One Health framework H.K.E. Shun* (Hong Kong, Hong Kong), S.F.S. Ho, X. Ma, S. Sridhar

E0240 16:27 Epidemiology of hepatitis E infection in England between 2014/15 and 2024/25 A.A. Dattoo* (London, United Kingdom), A. Yunusa, S. Ijaz, B. Haywood, R. Pudney, D. Chudasama

E0241 16:33 Prospective characterisation of hepatitis delta in Spain: insights from the nationwide DDR cohort A. Alberola* (Granada, Spain), A. Vázquez Blanquiño, A. De Salazar, R. Carracedo, A. Fuentes, L. Chaves Blanco, L. Gozalo Álvarez, W. Sanchez-Yebra, C.

		Freyre, B. Becerril, I. Viciano, I. López Rodríguez, T. Trujillo Soto, A.M. Domínguez Castaño, M.D.P. Luzón-García, E. Ramírez Arellano, C. Liébana, F. Franco Álvarez De Luna, M.C. Lozano, B. Palop, A. Sampedro, A.B. Pérez, S. Algarate, S. Rojo Alba, P. Fraile, D. Ocete, M.J. Alcaraz, J.C. Rodríguez, F.J. Hernández-Felices, O. Martínez, V. Domínguez, N. Orta, D. Gómez, C. Cortell Cortell, J. Camacho Marín, S. Sabater, L.Á. Iglesias Sánchez, Y. Martín, A. Vallejo, L. Molina, M. Aroca, T. Tosco, M. Lara, M.J. Pena, D. Pablo Marcos, A. González Praetorius, J.J. Blas, A. Beteta, C. Gómez, M.J. Rodríguez, M. González, M. Abreu, J. García Díez, I. Beltrán, M. Sandoval Torrientes, R. Sáez, T. Martín, P. Tajada Alegre, B. Lorenzo, M.T. García Valero, I. Jiménez Sansegundo, S. García-De Cruz, S. Garcinuño, M.Á. Sáiz, A.M. Blázquez, I. Fernández, H.M. Lorenzo Juanes, M.R. Vidal-Acuña, L.M. Moldes, N. Calvo, M. Trigo, M.J. Gude, P. Ordóñez, S. Cortizo, M. Blasco, M. Sigcha, I. Falces, L. Martínez, A. Arribi, R. Alonso, A. Iborra, M.J. Del Amor Espín, E. Cascales, C. Pérez, P. Fernández, M.D. Navarro, M.L. Núñez, M. Cámara, L.J. Gil-Gallardo, A. Miquelz, G. Reina, L. Elorduy, M. Macho, C. Gómez, P. Liendo, M. Aranzamendi Zaldumbide, A. Aguilera, F. García	
E0242	16:39	The future of HDV testing: saliva-based PCR for scalable and field-friendly detection S.K. Rawat* (Sagar, India), N. Mishra, R.K. Nema, I. Hasanoğlu	
E0243	16:45	Impact of nucleic acid extraction methods on the quantitative detection of hepatitis delta virus RNA by real-time PCR: a comparative evaluation of manual and automated systems H. Alonso* (San Mateo De Gallego, Spain), M. López, N. Gil	
E0244	16:51	Are we screening or wasting? The hidden burden of repeat anti-HCV testing in the hepatitis elimination era A. Sertçelik* (Ankara, Türkiye), R. Güner, İ. Hasanoğlu, E. Güney, A. Kaya, F. Eser, B. Dinç, B. Kayaaslan	
E0245	16:57	Impact of screening and direct-acting antiviral treatment of hepatitis C among people who inject drugs in Singapore: a mathematical modelling study J.J. Ong* (Singapore, Singapore), W.Y. Lim, S. , B. Choh, C. Gao, C.S. Wong, J. Tay, A. Han	
E0246	17:03	Comparison of lyophilised vs native samples for hepatitis B surface antibody testing across four fully automated immunoassays M. Obermeier* (Berlin, Germany), J. Wenzlaff, J. Geisler, R. Ehret, I. Schellenberg, P. Kaiser, V. Lindig, U. Dühring, S. Samuleit, M. Kammel	
EF036	17:15 - 18:15	ePoster Flash Session	Arena 1
		Skin and soft tissue infections haunting us	
		Chair Angelo Pan (Cremona, Italy)	
E0247	17:15	Mpox-HIV syndemics in the 2024–2025 clade 1b outbreak: a framework for understanding synergistic vulnerabilities, clinical trajectories, and interventions in high-burden African settings U. Muhumuza* (Kampala, Uganda), B.B. Nanyange, Z. Nahumuza	
E0248	17:21	Hand infections: epidemiology and adverse prognostic factors in a six-year retrospective single-centre study of 496 patients M. Pellegrino* (Modena, Italy), G. Franceschi, L. Benassi, S. Generoso, M. Sarti, A. Leti Acciaro, M.C. Gagliano, C. Mussini, A. Bedini	
E0249	17:27	Urease is key factor in the pathogenicity of <i>Staphylococcus aureus</i> in atopic dermatitis M. Araújo* (Oeiras, Portugal), N. A. Faria, M. Gonçalves, J. Nakonieczna, C. Torres, F. Campanile, K. Netto Dos Santos, R. Sobral, M. Miragaia	
E0250	17:33	MSSA-ST398: a lineage highly adapted to the atopic dermatitis skin environment D. Caieiro* (Lisbon, Portugal), N. A. Faria, M. Araújo, A. Botelho, M. Gonçalves, L. Ramos, M. Miragaia	
E0251	17:39	Recurrent facial folliculitis by <i>Klebsiella aerogenes</i> ST117 in men who have sex with men: an emerging sexually transmitted SSTI? A. Bleibtreu* (Paris, France), G. Monsel, C. Emeraud, B. Rached, V. Bérot, L. Porter, N. Yin, J. Krygier, F. Durupt, M. Jachiet, M. Godinot, V. Pourcher, O. Chosidow, L. Dortet	
E0253	17:51	Clinical and inflammatory predictors of treatment failure in uncomplicated skin and soft tissue infections: a multi-centre study from Türkiye M.N.	

		Özçelik* (Tekirdag, Türkiye), M.S. Sayar, N.N. Aydın, D. Başkol Elik, Ö. Günel, P. Yürük Atasoy, A. Tuna, C. Semet, S. Erol, A. Yetişen, Y. Gezer, M.R. Tayşi, N.B. Baysal, G. Eser Karlıdağ, M. Çelik, E. Aydın, Y. Kürekcı, Y. Akkoyunlu, Ö. Akyıldız, A.S. Özel, O. Yapıcı, D. Özer, Ş. Kaya, T. Damar Çakırca, Ş. Balın Özer, İ.N. Hakyemez	
E0254	17:57	Skin and soft tissue infections in UK Armed Forces populations: the past, the present and the future A. Mason* (Camberley, United Kingdom), L. Lamb, W. Nevin, K. Morris, S. Pallett, M. Riley, T. Davey, J. Fallowfield, S. Sriskandan, E. Jauneikaite, S. D'arc, M. Dermont, G. Holden, K. Wilkinson, D. Tupper, H. Taylor	
E0255	18:03	Chronic non-puerperal mastitis: a complex condition, a new multidisciplinary approach M. Arias* (London, United Kingdom), A. Brown, L. Raqad, A. Boyd, C. Shah, G. Weston-Petrides, J. Galloway	
EF037	17:15 - 18:15	ePoster Flash Session	Arena 2
		Hospital surfaces: a touching subject	
		Chair Sinead O'donnell (Dublin, Ireland)	
E0256	17:15	Metagenomics vs Culture: Identification of priority bacterial pathogens on hospital surfaces R. Lins De andrade* (São Paulo, Brazil), R.L. Andrade, R.A. Tavela, M.S. Constância, A.P. Christoff, A.F.R.S. Sereia, B.L. Teixeira, L.F.V. Oliveira, J.F. Ribeiro, T.C.R.L. Nogueira, G.J. Oliveira, A.C. Gales	
E0257	17:21	<i>Klebsiella pneumoniae</i> biofilm formation and biocide tolerance on hospital surface materials: the influence of matrix components M. Nieto Rosado* (Oxford, United Kingdom), M. Nieto-Rosado, K.M. Thomson, L.C. Powell, B. Hassan, R. Zahra, E. Rashid, M.I. Shah, M.H. Hamid, S. Shabbir, M. Bashir, R. Temur, A. Balqees, A. Ali, T.R. Walsh, G. Zaborskytė, K. Sands	
E0258	17:27	Environmental reservoir driving hospital endemicity of a multispecies <i>bla</i>_{NDM-1} IncC plasmid A. Anantharajah* (Brussels, Belgium), F. Goormaghtigh, A. Vanderheeren, W. Abdel Hadi, M. Argudin, N. Olive, E. Nguvuyula Mantu, A. Demur, C. Schirvel, A. Verroken, F. Van Bambeke, H. Rodriguez-Villalobos	
E0259	17:33	Patient-environment transmission dynamics of multidrug resistant <i>Enterobacteriaceae</i> in two Dutch intensive care units: a longitudinal retrospective and prospective analysis in a non-outbreak setting C. Rossel* (Sittard-Geleen, The Netherlands), E.R. Heddema, R.M. Koeck, P.H.M. Savelkoul, L.B. Van Alphen	
E0260	17:39	Genomic comparison of carbapenemase-producing <i>Enterobacter</i> species isolated from patients and hospital environments, 2019-2024, reveals striking overlap between these niches E. Cronin* (Galway, Ireland), A. O'connor, M. Maguire, C. Clarke, A. Tuohy, M. Cormican, M.J. Dorman, L.P. Burke	
E0261	17:45	Bacteriophage-based environmental decontamination to reduce carbapenem-resistant <i>Klebsiella pneumoniae</i>: results from the FagoLimp, a cluster-randomised controlled crossover study A. Gales* (Sao Paulo, Brazil), T. Fagolimp	
E0262	17:51	Gold nanocluster-based bactericidal surface coatings: A novel approach to combat healthcare-associated bacterial infections and antimicrobial resistance K. Burdova* (London, United Kingdom), S. Ali, N. Kapil, M.O. Coppens	
E0263	17:57	Impact of probiotic-based cleaning in intensive care units on the acquisition of <i>Pseudomonas aeruginosa</i> and multidrug-resistant organisms: an interrupted time-series analysis L.A. Denkel* (Berlin, Germany), F. Schwab, S. Wolke, G. Zakonsky, B. Raguse, P. Gastmeier, C. Geffers	
E0264	18:03	Underfloor heating as a potential ally against <i>Candida auris</i> and <i>Candida albicans</i> surface contamination: impact on cleaning and disinfection effectiveness A. Clifford* (Vienna, Austria), B. Leeb-Zatorska, K. Nikolova, J. Zottl, E. Presterl	
EF038	17:15 - 18:15	ePoster Flash Session	Arena 3

Advances in clinical and pre-clinical PK/PD

Chair	Iris K. Minichmayr (Vienna, Austria)	
E0265	17:15	Synergistic activity of Pep16 with cefiderocol against cefiderocol-resistant <i>Escherichia coli</i> I. Bourdalis* (Paris, France), E. O Van Den Daele, I. El Meouche, S. Magreault, M.C. Verdier, F. Guerin, A. Jousset, A. Birgy, B. Fantin, V. Cattoir, V. De Lastours
E0266	17:21	Pharmacodynamic evaluation of aztreonam/avibactam and aztreonam plus ceftazidime/avibactam against clinical <i>Stenotrophomonas maltophilia</i> isolates in hollow fibre infection models C. Wu* (Lexington, United States), A. Kunz Coyne, R. Gray, P. Gonnabathula, E. May
E0267	17:27	Microdialysis Assessment of Gentamicin for Second-Line Antimicrobial Prophylaxis in Abdominal Surgery Q. Saint-Genis* (Poitiers, France), S. Marchand, A. Chauzy, H. Mirfendereski, N. Gregoire, M. Boisson
E0268	17:33	Population pharmacokinetic model of ceftolozane/tazobactam and ceftazidime/avibactam in plasma and ELF administered by continuous infusion in ICU patients with nosocomial pneumonia: are the standard doses adequate? S. Luque Pardos* (Barcelona, Spain), S. Luque, A. Benitez-Cano, A. Araiz, I. Ramos, R. Adalia, E. Navarrete, J.P. Horcajada, M. Montero, J. Gomez-Junyent, R. Barquin, A. Juanes, J. Roberts, L. Sorli
E0269	17:39	Long-acting antibiotics in osteoarticular infections: clinical outcomes and the role of therapeutic drug monitoring and serum bactericidal titre F. Petrucci* (Rome, Italy), G. Iaiani, D. De Meo, A. Lesina, M. Rivano Capparuccia, C. Luceri, A. Lorusso, B.M. Goffredo, S. Cairoli, M. Raponi, F. Sacco, C.M. Mastroianni, A. Oliva
E0270	17:45	PK/PD-based optimisation of temocillin dosing for the treatment of complicated urinary tract infections in non-ICU patients according to their renal function J. Ermtraud* (Hamburg, Germany), G.J. Wijnant, S. Vervaeke, W. Follens, L. Dedeene, L. Goeman, G. Devos, M. Boeykens, V. Miendjedeyi, A. Reschner, C. Necsoi, D. Konopnicki, S. Vandecasteele, V. Grootaert, F. Van Bambeke, S.G. Wicha
E0271	17:51	Daptomycin levels in vancomycin-resistant <i>Enterococcus</i> bloodstream infections (DELIVRE-BSI) K. Cairns* (Melbourne, Australia), Z.X. Mun, A.A. Udy, T.N. Peel, M.J. Dooley, J. Coutsovvelis, S. Patil, B. Mcwhinney, C.B. Landersdorfer, A.Y. Peleg
E0272	17:57	Adapting meropenem administration to the constraints of home nursing care for OPAT: PK/PD evaluation of a new regimen for the administration of 2g 3x/day in non-critically ill patients F. Van Bambeke* (Brussels, Belgium), C. Briquet, P. Ngougni Pokem, X. Liu, G.J. Wijnant, O. Cornu, H. Yildiz, A. Verroken, J.A. Roberts, J.C. Yombi
E0273	18:03	Piperacillin/tazobactam and meropenem exposure-outcomes relationship in patients with Gram-negative sepsis: results from the BLING III PK/PD sub-study J. Roberts* (Brisbane, Australia)

Sunday, 19 April 2026

EW080	08:30 – 10:30	Hall A2-2
2-hour Educational Session		
AMR PHEI		
Modelling approaches to estimate and predict the burden of AMR		
Chairs	Anna Both (Hamburg, Germany) Tomislav Mestrovic (Varaždin, Croatia)	
W0307	08:30	Methodological approach and pressing data need to model the burden of AMR Mohsen Naghavi (Seattle, United States)
W0308	08:50	A comprehensive approach to estimate the AMR burden using IHME data Gisela Robles Aguilar (Oxford, United Kingdom)
W0309	09:10	Expanding use of AMR burden data to influence policy

and practice - the experience of the Fleming Fund Toby Joseph Leslie (London, United Kingdom)

W0310	09:30	Interventions to improve targeted access to effective antibiotics Ert Kalanxhi (Washington, United States)
-------	-------	---

Co-organised with: ESCMID AMR Action Subcommittee

EW079	08:30 – 10:30	Hall B0-2
2-hour Educational Session		
CLN DX PHEI		

Europe's overlooked threat: the rise of zoonotic hepatitis E

Chairs	Gülşen Özkaya Şahin (Lund, Sweden) Sumit Kumar Rawat (Sagar, India)	
W0303	08:30	Zoonotic hepatitis E reservoirs and transmission in Europe from a One Health perspective Hao Wang (Gothenburg, Sweden)
W0304	08:50	When the liver is just the beginning: a zoonotic journey beyond the liver Yasemin Balaban (Ankara, Türkiye)
W0305	09:10	Epidemiological features of hepatitis E virus infection in Sub-Saharan Africa Richard Njuoum (Yaounde, Cameroon)
W0306	09:30	The rise of rat HEV: a new zoonotic herpesvirus Antonio Rivero-Juarez (Córdoba, Spain)
Co-organised with: ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Viral Hepatitis (ESGVH), Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology, Turkish Association for the Study of the Liver (TKAD), Society on Liver Diseases in Africa (SOLDA)		

EW078	08:30 – 10:30	Hall ICM 1
2-hour Educational Session		
CLN		

Duration of IV antibiotics in older adults for various infections

Chairs	Efthymia Giannitsioti (Athens, Greece) Jordi Rello (Barcelona, Spain)	
W0299	08:30	Duration of therapy and oral switch for Gram-positive bacteraemia Giusy Tiseo (Pisa, Italy)
W0300	08:50	Duration of therapy and oral switch for mycobacterial and nocardial infections Ili Margalit (Ramat Gan, Israel)
W0301	09:10	Duration of therapy, suppressive therapy and oral switch for endovascular infections Barbara Hasse (Zurich, Switzerland)
W0302	09:30	Duration of therapy, suppressive therapy and oral switch for orthopaedic infections Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE)		

OS039	08:30 – 10:30	Hall A3-1
2-hour Oral Session		
CLN DX TRN		

Sepsis at the frontline: diagnosis, therapy, and outcome in critical care

Chairs	Despoina Koulenti (London, United Kingdom) Tim Rahmel (Bochum, Germany)	
O0274	08:30	Real-world longitudinal validation of high-income-country-derived sepsis endotypes in Sub-Saharan Africa: a nested prospective multi-centre study O. Turgman* (Amsterdam, The Netherlands), J. Butler, P. Haguma, S. Nyesiga, J. Phulusa, L. Carey, J. Rylance, T. Van Der Poll, J. Wiersinga, S. Jacob
O0275	08:42	ARMOR-BSI: a nationwide analysis of the incidence and risk factors of ICU-acquired bloodstream infections in a multidrug-resistant organisms endemic country C. Genovese* (Milan, Italy), M. Offer, E. Palomba, G. Scaglione, F. Dore, G. Montrucchio, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri
O0276	08:54	Multi-centre quality improvement intervention to optimise blood culture use among adults in medical intensive care units and wards at four university hospitals V. Fabre* (Baltimore, United States), Y.J. Hsu, A. Xie, A. Salinas, E. Gettler, J.K. Johnson, R. Moehring, A. Ressler, G. Rodriguez-Nava, J. Salinas, G. Schrank, A. Wasylshyn, S. Cosgrove

00277	09:06	Diagnostic efficacy and impacts on antibiotic use of digital droplet PCR in patients with suspected sepsis: the PROGRESS randomised, open-labeled, multi-centre trial X. Xu* (Shanghai, China), H. Zhang, K. Lin, J. Ai, R. Wang, W. Zhang
00278	09:18	Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bloodstream infections: a case-control study R. Morena* (Catanzaro, Italy), S. Rotundo, A. Russo, E. Garofalo, H.L. Morrone, G. Mazza, G. Neri, N. Marascio, A. Bruni, G. Matera, A. Quirino, F. Serapide
00279	09:30	Differential expression of miRNAs involved in shock are able to characterise mortality I. Rebollo Mato* (Valladolid, Spain), A. Garcia Concejo, L. Polo Sánchez, R.D. Prieto Utrera, P.J. Martínez De Paz, M. Álvarez Bardón, J. Matesanz Isabel, H. Gonzalo Benito, R.M. Cobo Zubia, E. Gómez Sánchez, M. Martín Fernández, E. Tamayo Gómez
00280	09:42	High-dose vs standard-dose intermittent meropenem in critically ill patients: an observational cohort study F. Bergmann* (Vienna, Austria), M. Prager, L. Pracher, K. Kumpf, M. Zeitlinger, A. Jorda
00281	09:54	Impact of appropriateness and type of empirical antibiotic therapy on outcomes of intensive care unit patients with bacteraemia by carbapenem-resistant <i>A. baumannii</i> S. Karakonstantis* (Heraklion, Greece), E. Kritsotakis, E. Petrakis, N.R. Tziolos, D. Kypraiou, S. Papazisi, S. Anagnostou, E. Kondili, D. Kofteridis
00282	10:06	Therapeutic approaches and predictors of mortality in colistin-resistant <i>Klebsiella</i> bloodstream infections: a real-world study N. Korkmaz* (Ankara, Türkiye), G.Ç. Şentürk, F. Ayca, G. Kul, B. Gülüdoğan, H.M. Yılmaz, F.Z. Şahin, H. Ertekin, A.H. Solay, S. Kuzi, D. Bulut, E.E. Tütüncü
00283	10:18	Mortality attributable to mismatch with <i>in vitro</i> susceptibility of empirical antibiotics in patients with bacterial bloodstream infections G.K. Zheng* (Hong Kong, Hong Kong), W. Zhang, J. Blais, P. Wu, B. Cowling

OS040 08:30 – 10:30 Hall A3-2

ANT TRN

2-hour Oral Session

Expanding the antimicrobial arsenal: from dual-action compounds to predictive AI

Chairs Shampa Das (Liverpool, United Kingdom)
Markus Zeitlinger (Vienna, Austria)

00284	08:30	3A11, an antibacterial molecule that reveals a dual mechanism of action A. Jouault* (Rennes, France), B. Durand, N. Amiot, S. Ray, V. Bordeau, Y. Augagneur, G. Lina, V. Cattoir
00285	08:42	<i>In vitro</i> activity of a new antibiotic derivative of the lactivicin class, FPI-2119, tested against a challenge set of multidrug-resistant Enterobacteriales clinical isolates R. Mendes* (North Liberty, United States), G. Morgan, R. Jankowska, Y. Edah, R. Brianna, S. Charbon, S. Salama
00286	08:54	Antimicrobial activity of short ionic peptides is defined by fibre architecture, not charge N. Dad* (Manchester, United Kingdom), G. Humphreys, A. Pluen, M. Elsayy, A. Mcbain
00287	09:06	OMN6: a novel antimicrobial peptide demonstrating LPS sequestration and <i>in vivo</i> efficacy in LPS-induced sepsis model N. Bachnoff* (Jerusalem, Israel), O. Heyman, O. Mayost Lev-Ari, N. Nur Maymon, S. Mandel, J. Zazoun, A. Ben Dror, T. Shachar, M. Cohen-Kutner
00288	09:18	Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway against <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Streptococcus pneumoniae</i>, and <i>Neisseria meningitidis</i> T. Walsh* (Richmond, United States), Y.M. Ali, M. Yabuki, C. Arachchilage, K. Priyanka, N.J. Lynch, S. Bruchmann, A. Weimann, K. Brown, R.A. Floto, J. Parhill, D.E. Briles, L.S. Macdaniel, H. Utsugi, G. Gragerova, R. Petraitiene, V. Petraitis, A. Misquith, C. Doulami, G. Demopoulos, W. Schwaebler
00289	09:30	Chalcone-based scaffolds as promising antibacterial agents against clinical <i>Staphylococcus aureus</i> strains A. Israyilova* (Baku, Azerbaijan), M. Uygun, N.

00290	09:42	Fighting Carbapenem-resistant <i>Klebsiella pneumoniae</i> (CR-Kp): mechanistic insights into a novel metal-based complex R. Almeida* (Oeiras, Portugal), N.A. Faria, B. Royo, O. Lenis-Rojas, M. Miragaia
00291	09:54	Reviving antibiotic potency: pharmacological assessment of JS238 a newly designed potentiator against <i>P. aeruginosa</i> P. Rasouli* (Brussels, Belgium), J.M. Brunel, H. Rodriguez-Villalobos, J.H. Lorent, F. Van Bambeke
00292	10:06	Integrating <i>in vitro</i>, <i>in silico</i>, and machine learning approaches to identify potent phytochemicals from <i>Phyllanthus amarus</i> leaf extracts with activity against multidrug-resistant pathogens A. Adeniyi* (Kano, Nigeria), O. Olumide, A. Temiloluwa, A. Peter, A. Bolanle, B. Damilola
00293	10:18	A hypergraph neural-network framework for predicting synergistic and antagonistic antimicrobial combinations: a triplet-based approach integrating antimicrobial peptides, antibiotics, and bacterial taxonomy A. Khavaran* (Philadelphia, United States), F. Midjani, M. Malekpour, A.H. Rajabi, F.Z. Keshkar, F. Golabi, A. Abbasi, M. Farhadi, B. Khosravi, A. Amanati

SY077 08:30 – 10:30 Hall A2-1

AMR PHEI

2-hour Symposium

Antimicrobial resistance on the menu: global risks across the food chain

Chairs Yesim Besli (Istanbul, Türkiye)
Merica Carev (Split, Croatia)

S0295	08:30	Global risk mapping of XDR Typhoid: from genomic insights to possible threats Megan Carey (Amsterdam, The Netherlands)
S0296	09:00	Global resistance trend of <i>Campylobacter</i>, predictive modelling and novel intervention strategies Bruno Lopes (Middlesbrough, United Kingdom)
S0297	09:30	Exploring the rise of AMR in invasive NTS: mechanisms, mobility, and global trends Sandra Van Puyvelde (Wilrijk, Belgium)
S0298	10:00	Silent spreaders: tracking carbapenemase-producing Enterobacteriales in the food chain Valeria Bortolaia (Copenhagen, Denmark)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

SY076 08:30 – 10:30 Hall B0-1

CLN TRN VAX

2-hour Symposium

What drugs are missing? Exploring adjuvant therapies in immunosuppressed patients

Chairs Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)
Nina Khanna (Basel, Switzerland)

S0291	08:30	Immunotherapy meets infection: the case for host-directed treatment strategies Patrizia Comoli (Pavia, Italy)
S0292	09:00	Too little or too much? Balancing immune modulation in transplant and oncology patients Carlota Gudiol (Barcelona, Spain)
S0293	09:30	Adjuvant therapies in practice: lessons from mycobacteria Graeme Ayton Meintjes (Observatory, South Africa)
S0294	10:00	What drugs are missing? Unmet needs and promising directions in the immunocompromised host Michael Boeckh (Seattle, United States)

SY073 08:30 – 10:30 Hall ICM 13a

AMR PHEI VAX

2-hour Symposium

Infections with no borders: challenges in South and Central-Eastern Europe in the context of travel, migration and war

Chairs Marco Falcone (Pisa, Italy)
Christian Wejse (Aarhus, Denmark)

- S0279 08:30 **Epidemiology and burden of imported travel related infectious diseases in the CEE region** *Botond Lakatos (Budapest, Hungary)*
- S0280 09:00 **The impact of armed conflicts and migration on antimicrobial resistance** *Vodianyuk Arkadii (Kyiv, Ukraine)*
- S0281 09:30 **Leishmaniasis outbreaks in conflict zones** *Aula Abbara (London, United Kingdom)*
- S0282 10:00 **"Threat of spread": vaccine preventable diseases in the CEE region** *Simona Ruta (Bucharest, Romania)*

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Hungarian Society of Infectious Diseases and Clinical Microbiology, International Society of Antimicrobial Chemotherapy (ISAC), ESCMID Study Group for Epidemiological Markers (ESGEM)

SY074 08:30 – 10:30 Hall ICM 13b

PHEI

2-hour Symposium

The rise of tick-borne diseases: why are things changing?

*Chairs Sally Jane Cutler (London, United Kingdom)
Alice Raffetin (Villeneuve-Saint-Georges, France)*

- S0283 08:30 **Urban green spaces, fragmented forests and the transmission of tick-borne pathogens** *Olaf Kahl (Berlin, Germany)*
- S0284 09:00 **Automated classification of disease vectors** *Rodrigo Gurgel-Gonçalves (Brasília, Brazil)*
- S0285 09:30 **Hitching a ride: role of migratory birds in transferring ticks to new habitats** *Ilaria Pascucci (Pesaro, Italy)*
- S0286 10:00 **'Seek and thou shall find': harnessing the power of citizen science** *Éva S. Szabó (Budapest, Hungary)*

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

SY075 08:30 – 10:30 Hall ICM 5

AMR IPC PED

2-hour Symposium

Protecting the most vulnerable: infection prevention in neonatal and paediatric critical care

*Chairs Bianca Albers (Zurich, Switzerland)
Angelika Berger (Vienna, Austria)*

- S0287 08:30 **Biofilm related infections in children** *Ojan Assadian (Wiener Neustadt, Austria)*
- S0288 09:00 **Multidrug-resistant infections in the neonatal and paediatric ICU: how can we prevent outbreaks?** *Pablo Sanchez (Columbus, Ohio, United States)*
- S0289 09:30 **Surveillance and stewardship in the NICU/PICU: what works and what doesn't?** *Julia Anna Bielicki (London, United Kingdom)*
- S0290 10:00 **Neonatal skin, device, and environmental hygiene: how to translate evidence into practice?** *Andreas F. Widmer (Füllinsdorf, Switzerland)*

EF041 08:30 – 09:30 Arena 2

GLN

ePoster Flash Session

Short- and long-term consequences of viral infections

Chair Bettie Voordouw (Culemborg, The Netherlands)

- E0294 08:30 **Breath-based volatile organic compound signatures for long COVID identification: a machine learning approach for differential diagnosis** *P. Esteban Sánchez* (Zaragoza, Spain), S. Letona, M.P. Domingo, D. Recalde, E. Morte, G. Pellejero, A. Ramirez, R. Sanz-Pamplona, J. Pardo, J.R. Paño, E. Del Corral Beamonte, E.M. Gálvez*
- E0295 08:36 **Time-stratified, variant-specific risks of major adverse cardiovascular events following COVID-19 across α -omicron variants: a nationwide matched cohort study in Japan** *K. Ikeuchi* (Tokyo, Japan), S. Harada, R. Sekiya, Y. Arisato, S. Matsumoto, T. Kishida, A. Kado, K. Okushin, H. Yotsuyanagi, T.*

Tsutsumi

- E0296 08:42 **Metformin and ursodeoxycholic acid for the treatment of post-acute sequelae of COVID-19: a randomised clinical trial** *S.Y. Lim* (Seoul, Korea, Republic of), J. Lee, E. Chang, J.S. Kwon, C.Y. Jang, Y. Seo, J.J. Park, S.H. Na, H. Park, H.M. Jang, S.C. Yun, S.H. Kim*
- E0297 08:48 **T cell exhaustion and gut microbiota in HIV/SARS-CoV-2 co-infection** *X. Yan* (Shanghai, China), X. Zhang, Y. Shen*
- E0298 08:54 **Maternal and fetal outcomes of Crimean-Congo haemorrhagic fever in pregnancy: an individual patient data meta-analysis** *D. Güllü* (Istanbul, Türkiye), B. Donk, A.M. Cirik, H. Alay, F. Karakeçili, K. Özden, F. Kesmez Can, O. Barkay, N. Pshenichnaya, Ö. Ergönül*
- E0299 09:00 **Myocarditis in chikungunya virus infection: a systematic review and meta-analysis** *S. Shah* (Kathmandu, Nepal)*
- E0300 09:06 **Predictors and clinical spectrum of long-term sequelae after tick-borne encephalitis: results of a prospective multi-centre cohort study** *M. Slížek* (Prague, Czechia), D. Smišková, O. Džupová, L. Chovanec, V. Pražák, A. Chrdle, K. Pohludková, L. Petroušová, J. Sečnik*
- E0301 09:12 **Epidemiological, clinical, and virological findings in 1600 patients with West Nile virus infection, Northern Italy, 2008–2025** *L. Barzon* (Padua, Italy), M. Pacenti, S. Vogiatzis, C. Lucca, E. Dal Molin, A. Sinigaglia, A. Giaretta, V. Lisi, S. Simonato, S. Satto, J. Rampazzo, C. Boldrin, M. Cattai*
- E0302 09:18 **Mpox-related ocular disease: a prospective cohort study in South-Kivu, Democratic Republic of Congo** *C. Van Dijck* (Antwerp, Belgium), T. Kabesha, S. Mudwanga, S. Houben, Y. Mujula Kanundey, P. Munganga, S. Yeh, N. Kabedi, V. Nussenblatt, O. Tshiani Mbaya, I. Crozier, S. Sabiti Nundu, J. Kindrachuk, P. Mbala Kingebezi, L. Liesenborghs*

EF042 08:30 – 09:30 Arena 3

DX PED TRN

ePoster Flash Session

How viral and host genomics shape infection and immune response

Chair Victoria Hall (Melbourne, Australia)

- E0303 08:30 **Distinct antigenic signatures and neutralising antibody responses following MVA-BN vaccination and monkeypox virus infection** *U.M. Chan* (Taipei, Taiwan), T.L. Chao, W.D. Liu, C.C. Hung, S.Y. Chang*
- E0304 08:36 **NGS sequencing with application of different methods and phylogenetic analyses in MPXV positive samples in Berlin 2022 to 2025** *R. Ehret* (Berlin, Germany), Ö. Yildirim, M. Lautner, M. Prentice, M. Obermeier*
- E0305 08:42 **Emerging human spillovers of H5N1: viral adaptations and pandemic preparedness** *J. Acosta España* (Quito, Ecuador), J.D. Acosta-España, J.B. Altamirano-Jara, D.K. Bonilla-Aldana, A. Rodriguez-Morales*
- E0306 08:48 **Clinical significance of viral DNA findings by mNGS in a large cohort of patients** *T. Schroeder* (Nuertingen, Germany), J. Baake, M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle*
- E0309 09:06 **Acute hepatitis of unknown origin in the paediatric population: clinical, virological and genetic characterisation in a prospective case series** *D. Henares Bonilla* (Pallejà, Spain), D. Henares, A. Avellon, I. Loverdos, M. Pons-Espinal, M. Muñoz-Chimeno, A. Garcia-Soler, E. Ruiz De Pedro, C. Molera, P. Brotons, M.F. De Sevilla, J. Martinez-Laso, C. Muñoz-Almagro*
- E0310 09:12 **From pol to whole genome: advancing HIV drug resistance testing** *F. Stefanelli* (Genoa, Italy), N. Randazzo, G. Guarona, B. Galano, S. Ferrari, R. Qosja, A. Di Biagio, A. Dornich, N. Nigro, B. Bruzzone*

EF043 09:30 – 10:30 Arena 1

IPC PHEI

ePoster Flash Session

Tracking respiratory virus outbreaks in a changing world: from hospitals to wastewater

Chair		Magdalena Rosińska (Warsaw, Poland)	
E0312	09:30	Comparing COVID-19, influenza, and RSV positivity from a longitudinal cohort with US national surveillance data D. Nash* (New York, United States), M.S. Rane, K. Penrose, K.E. Allen, F.R. Ernst, A. Srivastava, Y. Shen, M.M. Robertson, J. Zamparo, S.G. Kulkarni, L. Puzniak	
E0314	09:36	Hospitalisation and healthcare consumption burden of respiratory syncytial virus (RSV) in older adults in France M. Vacheret* (Paris, France), S. Fievez, E. Blanc, L. Watier, L. Baschet, C. Bignon-Favary, P. Mckelvie-Sebileau, P. Loubet	
E0315	09:42	Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study M. Schmidt* (Portland, Or, United States), H. Groom, N. Smith, J. Meece, R. Mularski, W. Hu, M. O'keeffe-Rosetti, N. Klein, K. Jacobson, C. Oxandale, A. Wiesner, L. Glasser, S. Venkatesan, C. Talarico, J. Kuntz	
E0316	09:48	Using latent class analysis to improve classification of nosocomial SARS-CoV-2 infections in Ontario, Canada N. Wilson* (Toronto, Canada), C.E. Lee, D. Fisman	
E0318	09:54	Self-testing for five respiratory viruses in adults =50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections J.A. Nacov* (Cologne, Germany), J. Salmanton-Garcia, J. Jakobs, M. Anggitakirana, S. Grimm, J. Leckler, K. Köbe, L. Cremer, P. Wipfler, J. Stemler, H.J. Schmitt, U. Bethe, O. Cornely	
E0319	10:00	Comparison of emergency department indoor air and citywide wastewater for respiratory and enteric virus surveillance using hybrid-capture viral metagenomics M. Karatas* (Leuven, Belgium), S. Gorissen, C. Geenen, J. Swinnen, E. Hosten, K. Van Dyck, L. Cuyper, M. Bloemen, E. Wollants, M. Van Ranst, B. Verschuere, M. Sabbe, J. Matthjnsens, E. André	
E0320	10:06	Detection of SARS-CoV-2 variants of concern in Swiss wastewater without prior lineage classification R. Kociurzynski* (Freiburg, Germany), T. Donker	

KN081 09:30 - 10:30 Hall ICM 14

DX PHEI VAX

Keynote Scientific Interview

Integrating technology and capacity building to strengthen disease surveillance and prevention in low-resource settings

Chair Jon S. Friedland (London, United Kingdom)

K0311 09:30 Senjuti Saha (Dhaka, Bangladesh)

OS044 11:00 - 12:00 Hall A1-1

TRN

1-hour Oral Session

Mechanisms of pathogenesis across different pathogens

Chairs Elisa Borghi (Milan, Italy)
Anna Norrby-Teglund (Stockholm, Sweden)

O0321 11:00 A systems serology approach to identify antibodies to PfEMP1 that correlate with protection from paediatric cerebral malaria in Malawi P. Banda* (Blantyre, Malawi), I. Walker, C. Juwawo, W. Hasang, D. Mathanga, T. Taylor, T. Nyirenda, E. Aitken, S. Rogerson, K. Seydel

O0322 11:12 Wzi modulates immune evasion of hypervirulent *Klebsiella pneumoniae* in a CPS-dependent and independent manner K. Zhou* (Shenzhen, China), S. Wei, T. Xu

O0323 11:24 Binding of host glycans and vitronectin drive *Neisseria gonorrhoeae* pathogenesis and reveal potential vaccine targets E. Macdonald* (Bristol, United Kingdom), S. Savino, W. Pansegrau, D. Hill

O0324 11:36 A 3D-Bioprinted human skin model to study *Candida* colonisation and species-dependent phenotypes M. Cacaci* (Rome, Italy), D. Squitieri, G. Artemi, F. Bugli, R. Torelli, M. Papi, V. Palmieri, A. Augello, C. Perfili, M.

De Spirito, R. Benvenuto, E. Stigliano, E. Benini, P. Fazi, M. Sanguinetti

O0325 11:48 Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development F.U. Prodjinotho* (Munich, Germany), J. Ertl, Z. Rao, A. Anisuzzaman, J. Schluckebier, Y. Hamway, P. Baar, M. Haslbeck, C.G. Greveling, S. Haerberlein, F.H. Falcone, S. Schulz, A. Koeberle, C. Prazeres Da Costa

OS045 11:00 - 12:00 Hall A1-3

CLN VAX

1-hour Oral Session

Invasive fungal infections: therapeutic strategies and emerging options

Chairs Oliver A. Cornely (Cologne, Germany)
Cornelia Lass-Flörl (Innsbruck, Austria)

O0326 11:00 Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Case-Control Study B.S. Bisono Garcia* (Rochester, United States), K.G. Rabe, S.A. Parikh, P. Vergidis

O0327 11:12 Olorofim for the treatment of invasive *Aspergillus* in haematology patients with limited or no treatment options: sub-analysis of an open-label, single-arm, phase IIb trial (Study32; NCT03583164) J. Maertens* (Leuven, Belgium), S. Hammond, G. Rahav, A. Bruns, O. Uspenskaya, M. Chayakulkeeree, V. Mehra, A. Spec, J.M. Aguado, J. Fortun, C. Heath, M.H. Nguyen, J. Schaenman, S. Schwartz, M. Miceli, M. Moussa, O. Marin Fernandez, D. Zinzi, J. Rex

O0328 11:24 Fosmanogepix expanded access in patients with invasive mould infections from Germany, Austria, and Switzerland J. Stemler* (Cologne, Germany), J. Prattes, N. Khanna, H. Schlamm

O0329 11:36 Immunisation against *Aspergillus* is associated to poor outcome and higher mortality in patients with idiopathic pulmonary fibrosis: The Asp-IPF study J.P. Gangneux* (Rennes, France), H. Guegan, F. Reizine, P. Chauvin, F. Robert-Gangneux, M. De Saint Jore, T. Guy, A. Mabo, Y. Bazin, M. Kerjoun, S. Jouneau

O0330 11:48 Otseconazole concentrations in plasma and CSF in HIV-related cryptococcal meningitis M. Nicol* (Minneapolis, United States), M. Rutakingirwa, M. Kabahubya, T. Mugabi, J. Gakuru, S. Namombwe, F. Ssekindi, S. Kimuda, C.P. Skipper, M. Abassi, S.R. Brand, D.B. Meya, D.R. Boulware

OS046 11:00 - 12:00 Hall A1-4

CLN TRN

1-hour Oral Session

Translational science in mycobacterial infections

Chairs Deborah Chong (London, United Kingdom)
Delia Goletti (Rome, Italy)

O0331 11:00 Increased cAMP levels compromise cell wall integrity by promoting the production of reactive oxygen species in *Mycobacterium tuberculosis* Y. Li* (Guangzhou, China), J. Wan, X. Xia, X. Deng, G. Tian, L. Zhong, S. Feng

O0332 11:12 Spatial single-cell transcriptomic analysis reveals elevated platelet-neutrophil interaction and platelet-derived MMP-1 secretion in human CNS-TB granulomas Y.H. Wong* (Singapore, Singapore), H. Lee, F.K. Loh, B. Chen, T.H. Hu, H.T. Chong, C.L. Tan, A.F. Vallejo, C.W.M. Ong

O0333 11:24 Characterisation and genetic engineering of a novel mycobacteriophage for therapeutic use A. Bonacorsi* (Pisa, Italy), A. Fusco, D. Manessi, F. Filippini, G. Delogu, I. Palucci, M. Lai, G. Freer, S. Dominici, F. Pratesi, G. Hatfull, A. Tavanti, L. Rindi, M. Di Luca

O0334 11:36 BCG vaccination induces partial NK cell tolerance in people with HIV-1 on suppressive ART C. Dollé* (Zurich, Switzerland), T. Tutumlu, D. Russenberger, M. Zeeb, E. West, D. Braun, H. Günthard, J. Nemeth

O0335 11:48 Persister cells are highly prevalent across *Mycobacterium abscessus* clinical isolates L. Geerts* (Wilrijk, Belgium), L. De Vooght, G.J. Wijnant, E. André, N. Lorent, P. Cos

OS047 11:00 – 12:00 Hall A1-5
1-hour Oral Session

CLN DX

Diagnosing respiratory infections: from PCR to metagenomics

- Chairs* Gilbert Greub (Lausanne, Switzerland)
Qiwen Yang (Beijing, China)
- 00336 11:00 **Machine learning-driven daily VAP risk stratification for real-time ICU decision support** Y. Fromage* (Limoges, France), A. Hernandez Padilla, J. Vaidie, H. Sayadi, A. Barac, O. Cremer, D. Garot, A. Rouz , T. Daix, L. Vintcent, H. Jackson, M. De Karker, H. Van Werkhoven, J.B. Woillard, B. Fran ois
- 00337 11:12 **Novel thermo-induced switching probes enable dual-target detection per fluorescence channel for seven respiratory viral targets in a one-tube multiplex PCR assay** J. Lee* (Jeonju, Korea, Republic of), J. Yoon, H. Kim
- 00338 11:24 **The first national EQA for clinical metagenomics: design, delivery and results** A. Alcolea Medina* (London, United Kingdom), L.B. Snell, R. Doyle, V. Patel, R. Chang, M. Gumbanmarasigan, V. Vorslava, B. Leta, D. Ward, J. Brown, A. Kopec, S. Rock, M. Valappil, K. Laws, S. Parmar, S. May, P. Patel, M. Ibrahim, S. Green, K. Saeed, N. Norton, C. Reid, A. Every, A. Hughes, A. Kottara, K. Nelson, B. Browne, P. Grant, G. Nebbia, R. Batra, J. Edgeworth, A. Alcolea-Medina
- 00339 11:36 **Whole genome sequencing of *Mycoplasma pneumoniae* directly from clinical samples using a novel target sequence capture probe panel** C. Dixon* (Cardiff, United Kingdom), N. Couto, M. Ramirez, R. Mamede, H. Milton, M. Maiwald, C. Moore, S. Sidorov, J. Flipse, R. Nir-Paz, A. Michael-Gayego, J. Moran-Gilad, D. Kese, G. Greub, P.M. Meyer Sauter, M.L. Beeton

OS048 11:00 – 12:00 Hall A2-1
1-hour Oral Session

PHEI

Field investigations of community-acquired infections

- Chairs* Aula Abbara (London, United Kingdom)
Steen Ethelberg (Copenhagen, Denmark)
- 00341 11:00 **Rapid deployment of a large epidemiological investigation: lessons learnt from a mains water outbreak of *Cryptosporidium parvum*, South West UK, 2024** P. Charlotte* (London, United Kingdom), C. Patterson, B. Winer, M. Bardsley, F. Halford, S. Bird, N. Verlander, R. Chalmers, E. Smout, R. Kwiatowska, N. Young
- 00342 11:12 **A national iatrogenic botulism outbreak associated with cosmetic procedures in England, 2025** V. Wong* (London, United Kingdom), S. Gokool, D. Rajendram, B. Ahmed, R. Pebody, I. Hayden, G. Godbole
- 00343 11:24 **Fatal respiratory diphtheria and genomic analysis of *Corynebacterium diphtheriae* ST-574 outbreak, Germany and Poland, 2022–2025** I. Roewer De Porto* (Berlin, Germany), A. Dangel, L. Schneider, A.A. Zasada, J. Haller, I. Abdelgawad, C. Siffczyk, I. Paradowska-Stankiewicz, O. Wichmann, F. Badenschier, A. Berger, C. Rau, A. Sing
- 00344 11:36 **Epidemiological characteristics and outcomes of the 2023–2024 cholera outbreak in South Yemen: a retrospective descriptive study from MSF-supported centres** M. Kassim* (Aden, Yemen), M. Sallam, N.O. Abdulgany, A.M. Farhan, M. Shomasi, A. Abdulhaq, U.Z. Khan, D. Dela Cruz-Diaz, H. De Clerck, S. Lim, K. Moussally, P. Garcia-Vello
- 00345 11:48 **Echoes of *Vibrio*: seasonal context variables, microbial signatures, and critical illness in cholera infections** P. Thummalagunta* (Mangalagiri, India), M. Kumar A, D. Debabrata, C.N. Chithra, H. G, S.V. Kutty, R. Upparakadiyala, A. Rajeev

OS049 11:00 – 12:00 Hall A2-2
1-hour Oral Session

ANT CLN PHEI

From silent malaria infections to severe disease in a globalised world

- Chair* Emmanuel Bottieau (Antwerp, Belgium)

TBA

- 00346 11:00 **Late treatment failures of artemisinin-based combination therapies in imported *Plasmodium falciparum* malaria in France (2013–2024): a case-control and genomic investigation** S. Boufares* (Paris, France), R. Coppee, A. Cossou, N. Mathieuxx, S. Anthony, Z. Rizwana, S. Veronique, T. Nicolas, H. Sandrine
- 00347 11:12 **Prevalence of truly asymptomatic malaria and its determinants in a high burden rural district in India: a community-based study from Uttar Pradesh** R.S. Rath* (Gorakhpur, India), G.R. Dwivedi, H.S. Joshi, A. Singh, P. Kharya, N.M. Agarwal, M. Bish, D. Upadhyaya, A.R. Kopardkar, A.M. Dixit
- 00348 11:24 **Outpatient management of imported non-severe malaria in the UK: a multi-site clinical safety evaluation** J. Milburn* (London, United Kingdom), A. Williamson, S. Baljekar, R. Rachman, A. Daunt, N. Richardson, F. Olcott, C. Rodrigues, R. Thangarajah, S. Yeung, M. Arias, C. Jennings, A. Delmonte Sen, J.L. Klein, A. Odedra, N. Jacobs, C. Drapeau, C. Van Halsema, G. O'hara, A. Checkley
- 00349 11:36 **Host and parasite biomarkers to trigger intravenous antimalarials and prioritise ICU admission in severe imported *Plasmodium falciparum* malaria patients** D. Camprubi-Ferrer* (Barcelona, Spain), J. Pedreira-Rincon, C. Bertran-Cobo, M. Alguacil, L. Balerdi Sarasola, M.J. Alvarez-Martinez, J. Mu oz, C. Parolo, D. Camprubi Ferrer
- 00350 11:48 **Whole genome sequencing to inform the epidemiology of *Plasmodium falciparum* malaria in the elimination setting of Malaysia** K. Tan* (London, United Kingdom), N. Billows, P. Divis, C. Daneshvar, J. Edgeworth, J. Cox-Singh, S. Campino, T. Clark

OS050 11:00 – 12:00 Hall A3-1
1-hour Oral Session

AMR CLN PED

Personalised approaches to infectious diseases in high-risk haematologic and transplant patients

- Chairs* Andreas H. Groll (M nster, Germany)
Stefan Schwartz (Berlin, Germany)
- 00351 11:00 **The role of rectal swabs in driving empirical antibiotic therapy in febrile neutropenic patients: a quasi-experimental multi-centre study within the REVERSE project** R. Scardellato* (Verona, Italy), M. Morra, M. Tebon, A.M. Azzini, M.C. Negulescu, A.L. Mohorea-Neata, A. Araujo, M.T. P rez-Rodr guez, G. Nadali, C. Tecchio, A. Sonpar, J. Rodr guez-Ba o, P. Retamar-Gentil, N. Zuabi Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara
- 00352 11:12 **Antibiotic discontinuation in paediatric low-risk febrile neutropenia: a multi-centre randomised trial (eSTOP)** N. Mendoza Palomar* (Barcelona, Spain), N. Mendoza-Palomar, L. Valero-Arrese, B. Espinosa-L pez, M. Sancosmed-Ron, N. W rner, S. Melendo-P rez, M.N. Larrosa-Escart n, M.B. Vi ado-P rez, J. Esperalba-Esquerria, S. Sim -Nebot, P. Mazorra-Roig, A. Faura-Morros, C. Grasa, P. Guerra-Garcia, C. Echeopar-Parente, E. Cendejas-Bueno, B. Herrero-Velasco, D. Quintero-Garcia, M.T. Garcia-Ascaso, M. Gonz lez-Amores, P. Soler-Palacin
- 00353 11:24 **Efficacy and safety of peri-transplant probiotic supplementation among allogeneic stem cell transplant recipients: a phase IIb randomised controlled trial** S. Selvakumar* (Vellore, Tamil Nadu, India), S. Selva Kumar, J.S. John, A. Arumugam, N. Veerasamy, S. Selvarajan, K. Lakshmi, B. George, P. Rupail
- 00354 11:36 **Quantitative assessment of associations between early antibacterial drug exposure and late infective and noninfective complications after allogeneic stem cell transplantation** M. Yakubovskiy* (Tel-Aviv, Israel), R. Ram, R. Ben-Ami
- 00355 11:48 **Infections after invasive biliary procedures in liver transplant recipients: a retrospective single-centre analysis** A. Lombardi* (Milan, Italy), A. Tonizzo, L. Alagna, G.E. Tontini, M. Michelon, A. Murru, B. Antonelli, G. Viero, A. Celotti, S. Colombo, M. Sagasta, F. Lozio, C. Dibenedetto, V. Scaravilli, P. Lampertico, G. Grasselli, C. Quintini, F. Caprioli, A.

LB003	11:00 – 12:00	Hall B0-2
	1-hour Oral Session	
	ANT CLN	
Late-breaking antiviral drug trials		
<i>Chairs</i>	<i>Laurent Kaiser (Geneva, Switzerland)</i> <i>Marta Mora-Rillo (Madrid, Spain)</i>	
L0016	11:00	Positive treatment response of pritelivir achieved in refractory HSV infections in immunocompromised patients, including haematopoietic stem cell and solid organ transplant recipients and oncology patients: PRIOH-1 phase III trial R. Chemaly* (Houston, United States), K. Peggs, D. Neofytos, K. Workowski, R. Avery, Y.J. Lee, R. Maves, O. Cornely, J. Stemler, D. Teschner, M. Yong, J. Sasadeusz, S. Dadwal, J. Dickter, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, G.A. Papanicolaou
L0017	11:12	Implementing a controlled human infection model (CHIM) with a reverse genetics H3N2 (A/Texas/71/2017, clade 3C.3a) influenza challenge virus in healthy volunteers V. Cnossen* (Leiden, The Netherlands), G. Groeneveld, O. Engelhardt, J. Samolej, G. Piccini, S. Jochems, W. Huisman, T. Muster, M. Roestenberg, I. Kamerling
L0018	11:24	UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF I. Bozkurt* (Samsun, Türkiye), H. Bodur, M. Ertek, F. Altuntaş, N. Elaldi, G. Iskender, D. Mert, Y. Cosgun, E. Beren Tanik, E. Challenger, C.R. Thompson, L. Read, L. Else, L. Marsh, S.A. Büyüktuna, H. Can Bilek, H. Karadeniz, H. Oksuzoglu, A. Haykır Solay, E. Türkoğlu, M. Arslan, A. Torun, S. Kulari, J. Read, C. Rawcliffe, M. Yildiz, S. Khoo, T. Fletcher
L0019	11:36	Long-term viral suppression, and cardiometabolic benefits of switch to aineuvirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study H. Qin* (Yangzhou, China), Z. Jie
L0020	11:40	Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial E. Wall* (London, United Kingdom), G. Prescott, H. Dehbi, C. Watkins, M. Heightman, A. Banerjee

SY086	11:00 – 12:00	Hall A1-2
	1-hour Symposium	
	AMR ANT CLN	
Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally?		
<i>Chairs</i>	<i>Yin Mo (Singapore, Singapore)</i> <i>Pranita Tamma (Philadelphia, United States)</i>	
S0233	11:00	Treating carbapenem-resistant Enterobacteriales in HIC and LMIC Anupa Thampy (Vellore, Tamil Nadu, India)
S0234	11:30	Beyond Enterobacteriales: advances in the management of carbapenem resistant non-fermenters Michele Bartoletti (Milan, Italy)
Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Critically Ill Patients (ESGCIP), European Society of Intensive Care Medicine		

SY087	11:00 – 12:00	Hall A3-2
	1-hour Symposium	
	PED VAX	
The role of the microbiota in vaccine response		
<i>Chairs</i>	<i>Zitta Barrella Harboe (Hillerød, Denmark)</i> <i>Ed J. Kuijper (Leiden, The Netherlands)</i>	
S0235	11:00	The impact of intestinal microbiota on vaccine response Petra Zimmermann (Lucerne, Switzerland)
S0236	11:30	Early-life gut microbiome and infant vaccination Julie Bines (Parkville, Australia)
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Vaccine Study Group (EVASG)		

SY083	11:00 – 12:00	Hall ICM 1
	1-hour Symposium	
	DX TRN	
Can large language models (LLMs) transform clinical diagnostics from start to finish?		
<i>Chairs</i>	<i>Bram Lestrade (Roermond, The Netherlands)</i> <i>Mario Ramirez (Lisbon, Portugal)</i>	
S0227	11:00	LLM validation and integration for AST Christian Giske (Stockholm, Sweden)
S0228	11:30	LLM models in clinical diagnostics: from lab results to patient care De Vito Andrea (Sassari, Italy)
Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), Swiss Society for Microbiology (SSM)		
SY084	11:00 – 12:00	Hall ICM 13a
	1-hour Symposium	
	PRO	
Moving towards patient-centered evidence in infectious diseases		
<i>Chairs</i>	<i>Colin R. Mackenzie (Neuss, Germany)</i> <i>Luigia Scudeller (Pavia, Italy)</i>	
S0229	11:00	Can AI help us to incorporate the patients' perspective into clinical research and guidelines? Bernardo Sousa-Pinto (Porto, Portugal)
S0230	11:30	Our fight too: empowering patients against AMR Vanessa Carter (Altrincham, United Kingdom)
Co-organised with: ESCMID Guidelines Subcommittee		
SY085	11:00 – 12:00	Hall ICM 13b
	1-hour Symposium	
	CLN PED	
Early-life respiratory infections and their association with chronic lung disease		
<i>Chairs</i>	<i>Susanna Esposito (Parma, Italy)</i> <i>Chrysanthi Skevaki (Marburg, Germany)</i>	
S0231	11:00	Long-term impact of early-life exposures including RSV disease on lung function Shaakira Chaya (Cape Town, South Africa)
S0232	11:30	Rhinovirus infections and asthma in children: mechanisms and at-risk phenotypes Manuel E. Soto-Martinez (San Jose, Costa Rica)
Co-organised with: International Society of Pediatric Respiratory Diseases (INSPIRED)		
EF051	11:00 – 12:00	Arena 2
	ePoster Flash Session	
	AMR ANT	
Antibiotic use, misuse and stewardship across settings		
<i>Chair</i>	<i>Rita Murri (Rome, Italy)</i>	
E0356	11:00	Understanding factors associated with antibiotic misuse among persons living with HIV at two large HIV clinics in Uganda F. Magololo Mutesi* (Kampala, Uganda), N. Mukiza, R. Nakalega, E. Twinomuhwezi, H. Macklino, A. Twimukye, F. Kakooza, A. Kambugu, D.M. Byonanebye, H. Kajumbula
E0357	11:06	The global spatiotemporal distribution of substandard and falsified antibiotic medicines L. Adipo* (Oxford, United Kingdom), S. Cavany, C. Caillet, J. Mendes, S.M. Nanyonga, N. Stoesser, C. Dolecek, P. Newton, B. Cooper
E0358	11:12	EU Joint Clinical Assessments: a missed opportunity to recognise the wider benefits of novel antimicrobials? M. Hofer* (London, United Kingdom), A. Macfarlane, G. Bray, E. Hampson, G. Hampson
E0359	11:18	Profile of high-volume antibiotic prescribers, a population-based study from the French National Health Data System, 2023 G. Beraud* (Orleans, France), H. Desmars, A.I. Lecuyer, F. Coustillères, E. Laurent, C. Carvalho, L. Grammatico-Guillon

E0360	11:24	In search of innovative 'alter-biotic treatments': non-traditional therapies and the sociotechnical frameworks they require C. Haddad* (Vienna, Austria), A. Albiez, K. Bentley, E. Paterson
E0361	11:30	Laboratory-based antimicrobial stewardship: an Australian and New Zealand perspective K. Ryan* (St Leonards, Australia), J. Elvy, M. Otormin, M. Jayawardena, M. Graham
E0362	11:36	European multidisciplinary AMR modified Delphi panel: root causes of undervaluation of novel antibiotics and opportunities for alternative payment models E. Broughton* (Berlin, Germany), H. Armstrong, J. Benitez Rodriguez, C. Capdevila, S. Capri, S. Delgado-Collins, L. Diamond, M. Gheorghe, C. Hng, S. Kelly, K.E. Kypreos, M. Laruem, E. Rinaki, N.V. Sipsas, J.P. Stahl, P. Tilleul, J. Torre-Cisneros, A. Townsend, J.A. Valles Callo
E0363	11:42	Achieving Europe's fair share: the need for European countries to complement EU-level pull incentives with national provisions for novel antimicrobials E. Damato* (London, United Kingdom), H. Armstrong, R. Lawlor, T. Wilsdon, D. Zhou
E0364	11:48	Off-label antibiotic consumption behaviour increases the threat of antimicrobial resistance S. Goel* (Bengaluru, India), D. Batheja, S. Reddy, C. Achar

EF052 11:00 – 12:00 **Arena 3**

AMR CLN

ePoster Flash Session

From epidemiology to clinical impact of infections in solid organ transplant recipients

Chair Patricia Munoz Garcia-Paredes (Madrid, Spain)

E0365	11:00	Tuberculosis incidence in solid organ transplant recipients in Europe: a multi-centre TBnet cohort study T.T. Brehm* (Borstel, Germany), B. Lange, S.M. Arend, M. Arias-Guillén, M. Bakker, C. Berastegui, M. Babiker, R. Charif, R. Duarte, H. Flick, R.W. Hofland, J. Ismail, D. Kniepeiss, J. Krepel, N. Krishnan, D. Kuijpers, H. Kunst, F. Van Leth, V. Lezaic, I. Los-Arcos, J. Machová, H. Milburn, S.A. Morais, O.M. Kon, C. Osoro-Suarez, H. Pessegueiro Miranda, D.P. Pesut, A. Rahman, T. Reischig, A. Sánchez-Montalvá, H.E. Spohn, M.T. Stegenga, A.P.J. De Vries, D. Wagner, R. Wobser, C. Lange, M. Sester
E0366	11:06	Comparative risk of tuberculosis in solid organ transplant recipients and matched general population controls S. Hosseini-Moghaddam* (Toronto, Canada), D. Fridman, S.S.M. Drover, S.K. Brode, T.K. Marras, F.B. Jamieson, S. Husain, J.C. Kwong
E0367	11:12	Bacterial respiratory infections in solid organ transplant recipients with a focus on atypical pathogens: data from a prospective national cohort J. Bisch-Karatas* (Bern, Switzerland), I. Abela, A. Boyd, P. Kohler, N. Khanna, A. Koutsokera, M. Schuurmans, O. Manuel, C. Van Delden, N.J. Mueller, C. Hirzel, L.N. Walti
E0368	11:18	Transplantation confers improved survival in ESBL-E BSI compared with non-transplant patients: insights from two multinational matched cohorts (INCREMENT vs INCREMENT-SOT) E. Ruiz Arabi* (Lausanne, Switzerland), E. Ruiz-Arabi, E. Pérez-Nadales, J.A. Marín-Sanz, J.J. Castón, I. Machuca, A. Cano, M. Marín-Sanz, B. Gutiérrez-Gutiérrez, J. Torre-Cisneros
E0369	11:24	Epidemiological patterns of carbapenem resistance in solid organ transplantation: a contemporary multi-centre analysis A. Arslan* (Ankara, Türkiye), T. Yanik-Yalçın, A.Ö. Mete, Ş. Acar, T. Arslan-Gülen, G. Çınar, I. Hasanoğlu, E. Olcucuoglu, E. Günel, T. Turunç, V. Avkan-Oguz, M.C. Ergon, M. Yavuz-Çolak, Ö. Azap
E0370	11:30	Infections in paediatric liver transplantation: risk factors and clinical outcomes L. Romani* (Rome, Italy), A.C. Epifani, F. Fini, C. Tripiciano, S. Mercadante, S. Bernardi, G. Spagnoletti, A.M. Fratti, R. Somma, V. Tuccio Guarna Assanti Vanessa, L. Dei Giudici, T. Alterio, D. Liccardo, F. Chiusolo, C.F. Perno, A. Pietrobattista, M. Spada, M. De Luca
E0371	11:36	Risk factor analysis for early and late invasive <i>Candida</i> infections in solid organ transplant recipients D. Neofytos* (Geneva, Switzerland), L. Meyer, J. Frossard, P. Schreiber, O. Manuel, F. Lamoth, N. Khanna, K. Boggian, L. Walti, C. Garzoni, C. Van Delden, N. Mueller

E0372	11:42	Durability of RSV-specific IgG, neutralising activity and T-cell responses after respiratory syncytial virus vaccination in kidney transplant recipients S. Bronder* (Homburg, Germany), H. Gruell, S. Lennartz, R. Urschel, D. Fliser, T. Schmidt, D. Schmit, M. Sester
E0373	11:48	Systemic absorption and epithelial lining fluid concentration of inhaled vancomycin in lung transplant recipients G. Escudero Arnés* (Barcelona, Spain), G. Escudero, I. Los-Arcos, J. Sacanell, A. Pau, Y. Villena, C. Berastegui, J. Rosado, D. Campany, L. Castellote, B. Saez, L. Domenech, M.T. Martin, M. Culebras, C. Laborda, R. Barquín, S. Luque, O. Len, J. Gavalda

EF053 11:00 – 12:00 **Arena 4**

AMR TRN

ePoster Flash Session

Carbapenem resistance: surveillance, mechanisms, and clinical implications

Chair Rafael Canton (Madrid, Spain)

E0374	11:00	A nationwide survey of carbapenemase-producing Gram-negative bacilli in bloodstream infections in a paediatric population (2015–2024) P.M. Peçanha-Pietrobon* (São Paulo, Brazil), P.Z. Charf, D. Testoni Costa-Nobre, E. Carmo, C.B. Wagner, T.T.F. Rezende, A.S.S. Marinonio, A.P.C. Assef, C.L. Pessoa-Silva, R. Peral, D. Kulek, L. Kraft, M. Pilonetto, C. Kiffer
E0375	11:06	Diffusion of OXA-23 producing <i>Acinetobacter baumannii</i> in Zagreb post-pandemic B. Bedenic* (Zagreb, Croatia), B. Bedenić, D. Bandić-Pavlović, M. Nađ, M. Kasalo, D. Varda-Brkić, N. Beader, V. Bratić, M. Dobrić, H. Car, J. Vraneš
E0376	11:12	Determination of meropenem heteroresistance in a diverse collection of OXA-48-producing <i>Klebsiella pneumoniae</i> clinical isolates M. Alcalde-Rico* (Seville, Spain), A. Angós, F. Docobo-Pérez, M. Delgado-Valverde, J.M. Rodríguez-Martínez, L. López-Cerero, Á. Pascual
E0377	11:18	Human serum albumin (HSA) modulates cefiderocol activity in carbapenem-resistant (CR) pathogens M.S. Ramirez* (Fullerton, United States), A. Varnado, S. Moheb, K. Lopez, C. Rodriguez, S.D. Sanchez, G. Traglia, F. Pasteran, M.E. Tolmasky, R.A. Bonomo, L.A. Actis, G. Rao
E0378	11:24	Sigma E factor transcriptional regulates the expression of metallo-β-lactamase NDM and mediates heteroresistance Y. Wang* (Hangzhou, China), W. Huang, Q. Shi, J. Zhou, R. Weng, H. Hu, J. Quan, Y. Jiang, Y. Yu
E0379	11:30	The role of colistin resistance genes in the formation of colistin-induced tolerant and persister cells in clinical isolates of <i>Klebsiella pneumoniae</i> , <i>Acinetobacter baumannii</i> , and <i>Pseudomonas aeruginosa</i> G. Ozcan Kuyucu* (Ankara, Türkiye), G. Ozcan, C. Vatanserver, J. Boral, A. Akpinar, S. Menekse, M. Gonen, F. Can
E0380	11:36	Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing <i>Klebsiella pneumoniae</i> : a case-control study Y.T. Lin* (Taipei, Taiwan), C. Chuang, S.Y. Liu, Y.C. Ho, S.H. Chou, Y.R. Huang, W. Chin, N.W. Hsu, L. Chen
E0381	11:42	Aztreonam/avibactam resistance due to synergistic interplay of ampC-related mutations in carbapenem-resistant <i>Enterobacter</i> spp. Y. Zeng* (Chengdu, China), Y. He, Z. Zong

KN082 11:00 – 12:00 **Hall ICM 14**

CLN DX

Keynote lecture

Rickettsioses: widespread and neglected

Chairs Li Yang Hsu (Singapore, Singapore) Xavier Lescure (Paris, France)

K0226 11:00 Nicholas Day (Bangkok, Thailand)

ME089 11:00 – 12:00 **Hall B0-1**

Meet-the-Expert

Global health on the move: advances and strategies in travel medicine

M0239	11:00	German Henostroza (Birmingham, AL, United States)
M0240	11:12	Andreas Neumayr (Basel, Switzerland)

ME088 11:00 – 12:00 Hall ICM 5

Meet-the-Expert

To model or not to model? A debate on the role of modelling and simulation in clinical PK trials

M0237	11:00	Markus Zeitlinger (Vienna, Austria)
M0238	11:12	Lena Friberg (Uppsala, Sweden)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

FO090 11:00 – 12:00 Arena 1

Open Forum

IPC nurses corner: building bridges across Europe

Chair: Ermira Tartari (Msida, Malta)

F0241	11:00	Training the invisible workforce: what (still) makes sense in cleaning staff education? Veronica Weterings (Breda, The Netherlands)
F0242	11:10	From recipient to partner: patient involvement in infection prevention Erik Briers (Hasselt, Belgium)
F0243	11:20	Simulation-based IPC training: the real-life test lab Constantinos Tsioutis (Nicosia, Cyprus)
F0244	11:30	Reinventing the wheel: hand hygiene meets AI innovation Silvana Gastaldi (Mazzano, Italy)

Co-organised with: EUCIC Steering Committee

OS056 13:30 – 14:30 Hall A2-2

1-hour Case Session

Not the consult I expected this morning...

Chairs: Flaminia Olearo (Berlin, Germany), Ryan Rego (Ceske Budejovice, Czechia)

O0383	13:30	Hidden pathogen: <i>Mycoplasma hominis</i> as the cause of a prosthetic vascular infection M. Bettencourt Silva* (Lisbon, Portugal), A. Duarte, A.L. Silva, A. Lopes, P. Amorim, L. Mendes Pedro, L. Mendonça, D. Mendes Pedro
O0384	13:41	Non-typhoidal <i>Salmonella</i> brain abscesses in a newly-diagnosed HIV patient: a case report E.K. Barrera* (Metro Manila, Philippines), A. Estuart, C. Valdez, M.F. Tayzon, M. Sanieel
O0385	13:52	A novel case of non-imported <i>Rickettsia akari</i> infection in Ireland T. Coyne* (Dublin, Ireland), A. Brown
O0386	14:03	When you hear hoofbeats, sometimes it's camels not horses J. Anderson* (Edinburgh, United Kingdom), E. Vink, S. Woolley, J. Jervis, R. Sutherland
O0387	14:14	Identification of <i>Pigmentibacter ruber</i> in the peripheral blood of a drowning patient: a case report and literature review H. Jiang* (Changsha, China), T. Li, L. Xie

OS057 13:30 – 14:30 Hall A3-2

1-hour Case Session

Mind your Ps: PK/PD

Chairs: Linda Aulin (Leiden, The Netherlands), Joseph Meletiadiis (Athens, Greece)

O0388 13:30 PK/PD-optimised eravacycline for vancomycin-resistant *Enterococcus faecium* in a liver transplant

O0389 13:41 Therapeutic drug monitoring-guided antimicrobial optimisation in thoraco-omphalopus twins with partially shared hepatic circulation undergoing surgical separation B. Monti* (Monza, Italy), E. Ricci, M. Mariani, G. Mattioli, F. Palo, G. Cangemi, A. Cafaro, C. Saffioti, A. Wolfler, G. Spiga, E. Castagnola, A. Moscatelli, A. Mesini

O0390 13:52 First clinical case of aztreonam/avibactam during venovenous ECMO support: is standard dosing adequate? A. Pau Parra* (Barcelona, Spain), A. Pau-Parra, S. Luque, L. Doménech Moral, M. Martínez Pla, X. Nuvials, M. Sosa, I. Los-Arcos, A. Conto, F. Lasteros, E. Gallart, O. Castillo, A. Sánchez, S. Garcia, E. Del Barrio, M.Q. Gorgas Torner, R. Ferrer, J. Riera

O0391 14:03 TDM-guided antibiotic therapy in a patient with recurrent *Listeria monocytogenes* meningitis and augmented renal clearance (ARC): from hospitalisation to oral home therapy D. Aquilino* (Naples, Italy), P. Grimaldi, L. Alessio, S. De Pascalis, C. Ricozzi, K. Gjeloshi, S. Imbriani, M. Macera, C. Monari, L. Onorato, M. Pisaturo, N. Coppola

O0392 14:14 Virological failure of long-acting cabotegravir/rilpivirine: a multifactorial case involving low drug exposure, high viral reservoir and rapid weight loss A. Andrianaki* (Zurich, Switzerland), P. Thoueille, C. Marzolini, M. Huber, H.F. Günthard, I.A. Abela

OS055 13:30 – 14:30 Hall A2-1

1-hour Oral Session

Susceptibility testing of phages

Chairs: Annika Yanina Classen (Cologne, Germany), Marjolein Hensgens (Utrecht, The Netherlands)

O0393 13:30 Mechanisms of phage-driven resensitisation to aztreonam/avibactam in *Escherichia coli* A.M. Örmälä-Tiznado* (Stockholm, Sweden), M. Razavi, S. Patpatia, A. Garcia Navarro, C.G. Giske, C. Tellapragada

O0394 13:42 Impact of antimicrobials on bacteriophage-host interactions in *Pseudomonas aeruginosa* Y. Chikhani* (São Paulo, Brazil), C. Siqueira, C. Rubio, R. Farzana, E. Portal, K. Sands, O. Spiller, A. Gales, W. Martins

O0395 13:54 Two years (2024–2025) of bacteriophage susceptibility testing of bacterial isolates from persistent bacterial infections: results from the Israeli Phage Therapy Centre R. Nir-Paz* (Jerusalem, Israel), R. Braunstein, O. Yerushalmy, L. Khalifa, A. Rimon, S. Copenhagen-Glazer, R. Hazan

O0396 14:06 Tigecycline-selected tyrosine kinase mutation in *Klebsiella pneumoniae* triggers metabolic rewiring and increased phage susceptibility without affecting virulence N.N. Rakhi* (Oxford, United Kingdom), A.K. Lankapalli, W. Martins, T. Lanyon-Hogg, T.R. Walsh

O0397 14:18 Broth microdilution-based phage/antibiotic synergy in Gram-negative pathogens A.M. Örmälä-Tiznado* (Stockholm, Sweden), A. Williamson, E. Loo, S. Patpatia, C. Tellapragada, C. Giske

OS054 13:30 – 14:30 Hall B0-2

1-hour Oral Session

Harnessing artificial intelligence against AMR

Chairs: Fusun Can (Istanbul, Türkiye), Lorena Lopez Cerero (Seville, Spain)

O0398 13:30 A machine-learning workflow to investigate cefiderocol uptake defects arising from mutations in the siderophore receptor M. Razavi* (Stockholm, Sweden), C. Tellapragada, C.G. Giske

O0399 13:42 Prediction of bacterial antimicrobial resistance based on resistance determinants and whole genome annotation neural networks algorithms M. Pulido Toledano* (Seville, Spain), M.R. Pulido, F. Sola, D. Ayala, L. Monge-Olivares, R. Ayala, I. Portillo-Calderón, I. Hernández, D. Ruiz, L. López-Cerero

O0400 13:54 Seven loci, one threat: Decoding and predicting

		azithromycin resistance in <i>Neisseria gonorrhoeae</i> with machine learning <i>M. Krisna*</i> (Oxford, United Kingdom), <i>F. Rudi</i> , <i>A. Unitt</i> , <i>K. Jolley</i> , <i>O. Harrison</i>
00401	14:06	Domain-aware vs machine-learning imputation for sparse antimicrobial susceptibility data <i>M. Raad*</i> (Strasbourg, France), <i>F. Mutisya</i> , <i>K. Taylor</i> , <i>S. Alavi</i> , <i>T. Yokoyama</i> , <i>S. Boujaafar</i> , <i>P. Berger</i> , <i>C. De Turckheim</i> , <i>C. Moore</i>
00402	14:18	Predicting risk of multidrug-resistant tuberculosis using long short-term memory (LSTM) and multimodal programmatic data in the Philippines <i>M.I. Saldaña*</i> (Metro Manila, Philippines), <i>I.P. Mendoza</i> , <i>G.D. Sison</i> , <i>R. Destura</i> , <i>M. Kato-Maeda</i> , <i>F. Jiang</i> , <i>K.E. Henson</i> , <i>R. Basilio</i> , <i>J.E. Bascuña</i>

SY092	13:30 – 14:30	Hall A3-1
	1-hour Symposium	

Fungi in the flow: wastewater as a hidden threat

Chairs	<i>Mihai Mares</i> (Iasi, Romania) <i>Esther Segal</i> (Tel Aviv, Israel)
--------	--

S0214	13:30	New EU wastewater directive: why fungi must be included <i>Joao Brandao</i> (Lisbon, Portugal)
S0215	14:00	<i>Candida</i> and <i>Aspergillus</i> in the environment: resistance starts here <i>Monika Novak Babič</i> (Ljubljana, Slovenia)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Israel Society for Medical Mycology (ISMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Hellenic Society of Medical Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED)

EW095	13:30 – 15:30	Hall ICM 13b
	2-hour Educational Session	

Updates on emerging and re-emerging vector-borne viral infections

Chairs	<i>Xavier Lescure</i> (Paris, France) <i>Alfonso J. Rodriguez-Morales</i> (Pereira, Colombia)
--------	--

W0220	13:30	Global epidemiological situation and diagnostic challenges of vector-borne viral infections <i>Marta Giovanetti</i> (Rome, Italy)
W0221	13:50	Translational advances about West Nile virus <i>Anna Papa-Konidari</i> (Thessaloniki, Greece)
W0222	14:10	Oropouche virus and its emergence <i>Felipe Naveca</i> (Manaus, Brazil)
W0223	14:30	Changing epidemiology of Dengue: a global outlook <i>Gathsaurie Neelika Malavige</i> (Nugegoda, Sri Lanka)

Co-organised with: SBI, Colombian Association of Infectious Diseases, Latin American Society for Travel Medicine, API, Dominican Society of ID, Ecuatorian Society for MM and Pediatric ID, ESCMID Emerging Infections Subcommittee, ESCMID Scientific Affairs Subcommittee

SY091	13:30 – 15:30	Hall B0-1
	2-hour Symposium	

Screening for multidrug-resistant pathogens in various populations: are we doing good?

Chairs	<i>Rita Ng</i> (Hong Kong, Hong Kong) <i>Spyros Pournaras</i> (Athens, Greece)
--------	---

S0210	13:30	Rectal screening and perioperative prophylaxis <i>Elda Righi</i> (London, United Kingdom)
S0211	14:00	Implications of positive MDR bacterial screen for clinical practice: algorithm for treatment <i>Marco Falcone</i> (Pisa, Italy)
S0212	14:30	Screening for MDR bacteria and <i>Candida auris</i> : lab methods <i>Yesim Besli</i> (Istanbul, Türkiye)
S0213	15:00	Rectal screen for MDR bacteria in haematological and solid organ transplant patients <i>Michael Satlin</i> (New York, United States)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Infections in the Elderly (ESGIE)

EF058	13:30 – 14:30	Arena 1
	ePoster Flash Session	

Predicting complications and outcome of sepsis

Chair	<i>Despoina Koulenti</i> (London, United Kingdom)
-------	---

E0403	13:30	The epidemiology of severe clinical manifestations caused by Group A streptococci in Denmark <i>C. Evald-Schelde*</i> (Copenhagen, Denmark), <i>T.B. Johannesen</i> , <i>S. Hoffmann</i> , <i>P.H. Andersen</i> , <i>S. Hermann</i> , <i>Z.B. Harboe</i> , <i>M. Stegger</i> , <i>L.S. Vestergaard</i> , <i>U. Nygaard</i>
-------	-------	--

E0404	13:36	Subphenotype and complication-guided adjunctive fosfomycin therapy for <i>Staphylococcus aureus</i> bacteraemia: pooled analysis of two randomised trials <i>J. Garcia-Larrauri*</i> (L'hospitalet De Llobregat, Spain), <i>F. Escrihuela-Vidal</i> , <i>J. López-Contreras</i> , <i>G. Euba</i> , <i>A. Vázquez</i> , <i>S. Gómez-Zorrilla</i> , <i>L.E. López-Cortés</i> , <i>O. Gasch</i> , <i>E. Aparicio-Minguijón</i> , <i>R. Escudero-Sánchez</i> , <i>M.T. Pérez-Rodríguez</i> , <i>M.D. Rodríguez Pardo</i> , <i>A. Jover-Sáenz</i> , <i>G. García-Pardo</i> , <i>J. Rodríguez-Baño</i> , <i>M. Pujol</i> , <i>J. Carratalà</i> , <i>B. Gutiérrez-Gutiérrez</i>
-------	-------	--

E0405	13:42	<i>Burkholderia</i> as a silent antimicrobial resistance driver in lower-middle-income countries: genomic insights from the BALANCE study <i>K.J. Hoog*</i> (Oxford, United Kingdom), <i>N. Haque</i> , <i>M. Sultana</i> , <i>J.B. Joyee</i> , <i>F. Humayra</i> , <i>M.R. Tasfia</i> , <i>S. Afroj</i> , <i>C. Abdellaoui</i> , <i>R. Zahra</i> , <i>M. Hamza</i> , <i>B. Hassan</i> , <i>K. Shafique</i> , <i>G. Fatima</i> , <i>K. Onjuro</i> , <i>H. Nerima</i> , <i>C.R. Achi</i> , <i>K. Iregbu</i> , <i>P. Nwajioji-Princewill</i> , <i>I.N. Nwafia</i> , <i>E. Carretto</i> , <i>T.R. Walsh</i> , <i>R. Farzana</i>
-------	-------	--

E0406	13:48	Development and validation of machine learning models for long-term survival prediction in elderly patients admitted to the intensive care unit for acute respiratory infection: the Genially project <i>J. Herbert*</i> (Tours, France), <i>A. Kassa-Sombo</i> , <i>A. Migeon</i> , <i>L. Platel</i> , <i>C. Salpêtrier</i> , <i>A. Guillon</i> , <i>L. Grammatico-Guillon</i>
-------	-------	---

E0407	13:54	Antimicrobial resistance and risk-stratified empiric therapy in community-onset sepsis <i>W. Lee*</i> (London, United Kingdom), <i>H. Rastad</i> , <i>B. Hernandez</i> , <i>N. Zhu</i> , <i>D. Ming</i> , <i>R. Wilson</i> , <i>M. Gilchrist</i> , <i>A. Holmes</i> , <i>V. Cornelius</i> , <i>T. Rawson</i>
-------	-------	--

E0408	14:00	The role of serum cholinesterase levels in monitoring covert immunosuppression in critically ill patients with septic shock: evidence from a monocentric retrospective analysis <i>G. Parruti*</i> (Pescara, Italy), <i>A. Frattari</i> , <i>F. Cedrone</i> , <i>E. Polilli</i> , <i>R. Zocaro</i> , <i>P. Fazii</i> , <i>V. Fortunato</i>
-------	-------	--

E0409	14:06	Risk of dementia after bloodstream infection: propensity score matched cohort study <i>J. Underwood*</i> (Cardiff, United Kingdom), <i>D. Farewell</i> , <i>D. Gillespie</i> , <i>A. Akbari</i> , <i>N. Harrison</i> , <i>H. Ahmed</i>
-------	-------	--

E0410	14:12	Predicting in-hospital mortality in sepsis patients using machine learning methods in low- and middle-income country (LMIC) settings <i>S. Awan*</i> (Karachi, Pakistan), <i>N. Aziz</i> , <i>Z. Nasim</i> , <i>N. Nasir</i>
-------	-------	--

E0411	14:18	Integrated immune and endothelial profiling predicts 90-day mortality in postoperative sepsis and septic shock <i>R.D. Prieto Utrera*</i> (Valladolid, Spain), <i>M. Bardaji-Carrillo</i> , <i>A. Garcia-Concejo</i> , <i>E. Tamayo</i> , <i>D. Bernardo</i>
-------	-------	--

EF059	13:30 – 14:30	Arena 2
	ePoster Flash Session	

Decoding herpesviruses: from bench to bedside

Chair	<i>Sylviane Defres</i> (Liverpool, United Kingdom)
-------	--

E0412	13:30	LY6C+ monocyte derived macrophages contribute to pathological neuroinflammation in herpes simplex encephalitis <i>Q. Xue*</i> (Shanghai, China), <i>Z. Shen</i>
-------	-------	---

E0413	13:36	Development of a risk score to predict encephalitis by herpes simplex virus and varicella zoster virus <i>R. Hasbun*</i> (Houston, United States), <i>J. Portugal</i> , <i>A. Heck</i> , <i>P. Bean</i> , <i>R. Habis</i> , <i>J. Probasco</i> , <i>A. Venkatesan</i>
-------	-------	---

E0414	13:42	Clinical determinants of outcome in chronic active
-------	-------	--

		Epstein-Barr virus infection: derivation of a risk stratification score Q. Yang* (Shanghai, China), Z. Zhou	
E0415	13:48	CXCL9, CXCL10, and CXCL11: sensitive predictors of acute EBV infection A. Nikčević* (Zagreb, Croatia), A. Nikčević, K. Bodulić, L. Radmanić Matotek, G. Tešović, S. Židovec Lepej	
E0416	13:54	Distinguishing clinical significance from latent infection: establishing mNGS-based EBV diagnostic cut-offs in blood and CSF Y. Cao* (Shanghai, China), X. Li, Y. Qinglun	
E0417	14:00	Using QuantiFERON-EBV to measure EBV-specific T-Cell function in thoracic transplant recipients Y. Zhao* (Groningen, The Netherlands), L. Gard, K. Damman, E. Verschuuren, V.L.B. Coretta	
E0418	14:06	Digital PCR enables high-resolution quantification of HCMV UL123 in clinical and experimental samples A.R. Silvain* (Limoges, France), M. Mayeras, E. Guerin, T. Reishig, O. Bestard, L. Cousi, E. Alezra, A. Koenig, C. Roger, N. Kamar, M. Sester, H. Kaminski, S. Alain	
E0419	14:12	Real-world effectiveness of recombinant zoster vaccine in high-risk adult populations in Greece V. Petrakis* (Alexandroupolis, Greece), P. Rafailidis, N. Mpampaka, G. Karagiannis, V. Kyrgiannaki, D. Papapazoglou, P. Panagopoulos	
E0420	14:18	The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera V. Leguizamón* (Madrid, Spain), B. Astibia-Mahillo, E. Mateos, M. Torres, N. Armenteros, A. Fernández-Chávez, M.C. Luengo-Martínez, N. Daza, M. Coiras, V. García-Gutierrez	
EF060	13:30 - 14:30		Arena 4
		ePoster Flash Session	
		Zoonotic infections: expect the unexpected	
		Chair	Manuela Carugati (Durham, United States)
E0421	13:30	Clinical characteristics and treatment strategies in a cohort of patients with tularemia: a retrospective multi-centre analysis of 65 cases in Germany C. Lübbert* (Leipzig, Germany), B. Arnold, N. Kellner, H. Trawinski, H.M. Orth, D. Tominski, A. Mikolajewska, K. Rothfuss, G. Grupe, D. Ruf, F. Reichert, K. Marx, K. Heuner, D. Jacob	
E0422	13:36	Characterisation of tularaemia cases in Southwest Germany and identification of two natural transmission clusters in a clinical high-endemic region Tuniberg/Kaiserstuhl (TuniKa) D. Hornuss* (Freiburg I. Breisgau, Germany), H. Von Buttlar, V. Goetz, P. Mathé, J. Klein, M. Leibenguth, L. Chitimia-Dobler, A.S. Claus, M. Scherer-Lorenzen, G. Dobler, S. Rieg, J. Borde	
E0423	13:42	Paediatric tularemia: clinical outcomes and immunological insights from an endemic region in Türkiye K. Aykac* (Ankara, Türkiye), O. Cakici, B.E. Seyrek, İ.C. Yılmaz, O.O. Demir, İ. Evcili, T. Canavar Yıldırım, M. Yıldırım, E.H. Erdeniz, S.Y. Durmus, A. Sahin, S. Ocal Demir, A.B. Cengiz, M. Gürsel, İ. Gürsel, Y. Ozsarekci	
E0424	13:48	Phylogenetic diversity of Mediterranean spotted fever group Rickettsiales: species-level sequencing in a Spanish tertiary hospital (2021–2025) E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, J.M. Sahuquillo Arce, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz	
E0425	13:54	Diversity of Rickettsia species identified by metagenomics in ticks collected from a Brazilian University F. Carvalho* (São Carlos, Brazil), D.S.F. Guedes, G. Montenegro De Campos, A. Sarana Da Silva, C.V.P. Hernandez, B.M. Begalli, L.C. Barci, J.M. Penedo, R.G.D.S. Taliassaquei, T.K.S. Felipe, S.J. Badra, F.D.F. Anibal, S.N. Slavov	
E0426	14:00	Epidemiology of toxigenic Corynebacterium ulcerans infections in England K. Harman* (London, United Kingdom), C. Robin, E. Mugwagwa, T. Patel, R. Cordery, D. Litt, S. Neale, A. Mackintosh, D. Chudasama, R. Pudney	
E0427	14:06	First insights into the wild, wild west of Borrelia plasmids S. Hepner* (Oberschleissheim, Germany), R.E. Rollins, E. Mourkas, K. Kuleshov, S. Casjens, W. Qiu, A. Dangel, D. Velázquez, S.Y. Kovalev, A. Wieser,	

		J. Hübner, A. Sing, V. Fingerle, G. Margos	
E0428	14:12	The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multi-centre retrospective study O. Evlice* (Van, Türkiye), Y. Ezgi, H. Kir, S. Incecik, D. Ertürk, M. Aydın, A.S. İnal, Y. Çakır, Z. Karazeybek, B.B. Sivrikaya, B. Turaç, E. İnci, S.Y. Kaya, Z. Çelik, A. Şabablı Çetin, İ.D. Alırcı, Ö. Özgen, H. Özsüt, M. Çelik, S. Alkan, S. Surme, A. Mert	
E0429	14:18	Early markers of severe leptospirosis in French Amazonia, 2007–2022 L. Epelboin* (Cayenne, French Guiana), P. Le Turnier, M. Zenou, A. Fremery, H. Kallel, N. Higel, A. Kpangon, P. Abboud, F. Djossou, M. Boutrou, M. Nacher	
JS002	13:30 - 14:30		Hall ICM 5
		Journal Session	
		Late-breaking research from CMI & CMI Comms: on invasive infections and antimicrobial resistance	
		Chairs	Andre Kalil (Omaha, United States) Anne-Grete Mårtson (Leiden, The Netherlands)
J0005	13:30	Estimating antibiotic resistance following antibiotic treatment in outpatients: a retrospective study Michal Chowers (Kfar-Saba, Israel)	
J0006	13:40	Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia: external validation with decision curve analysis Benedetta Varisco (Milan, Italy)	
J0007	13:50	Challenges in nasal and throat microbiota composition during and after mupirocin and chlorhexidine decolonisation treatment in asymptomatic MRSA carriers: a longitudinal observational study Sofie Marie Edslev (Copenhagen, Denmark)	
J0008	14:00	A multicentre evaluation of metagenomic sequencing for pathogen detection in central nervous system infections Rui Zhang (Beijing, China)	
J0009	14:10	Prevalence of submicroscopic malaria parasitemia among migrant pregnant women: a prospective cohort study Léa Docquier (Brussels, Belgium)	
J0010	14:20	Antenatal corticosteroid treatment and infectious diseases in children and adolescents aged 5–16 years Katri Raikonen (Helsinki, Finland)	
		Co-organised with: CMI Board of Editors, CMI Communications Board of Editors	
ME093	13:30 - 14:30		Hall ICM 1
		Meet-the-Expert	
		Novel therapeutics for C. difficile infection	
M0216	13:30	Eugenie Basseres (Houston, United States)	
M0217	13:42	Marek Duricek (Prague, Czechia)	
		Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)	
ME094	13:30 - 14:30		Hall ICM 13a
		Meet-the-Expert	
		Recent evidence on the role of steroids in paediatric bacterial infections: focus on meningitis and pneumonia	
M0218	13:30	George A. Syrogiannopoulos (Larissa, Greece)	
M0219	13:42	Susanna Esposito (Parma, Italy)	
FO096	13:30 - 14:30		Arena 3
		Open Forum	
		Communicating science today: new media, new platforms	
		Chair	Angela Huttner (Geneva, Switzerland)
F0224	13:30	Influencing in infectious diseases and clinical microbiology: tweet or fly? Neil Stone (London,	

United Kingdom)
F0225 13:40 Starting and sustaining a podcast Erin McCreary
(Pittsburgh, United States)
Co-organised with: CMI Communications Board of Editors

WT006 13:30 – 14:30 Poster area

Poster Walkthrough

IPC PHEI

Severe infections in ICU: from novel antibiotics to precision monitoring

Chair Antonios Katsounas (Bochum, Germany)

- R0051 P0753 - Distinct temporal dynamics of host transcriptomic response between patients with persistent and resolving *Staphylococcus aureus* bacteraemia Karishma Chhugani (Los Angeles, United States)
- R0052 P2610 - Impact of acquired broad-spectrum β -lactamases on susceptibility to oral cephalosporin (ceftibuten) and oral carbapenem (tebipenem) in combination with new β -lactamase inhibitors ledaborbactam and xeruborbactam in *Escherichia coli* Christophe Le Terrier (Fribourg, Switzerland)
- R0053 P2602 - Activity of cefiderocol/xeruborbactam against NDM-producing *Escherichia coli* isolates with PBP3 insertions and decreased susceptibility or resistance to aztreonam/avibactam, cefiderocol, and cefepime/taniborbactam Tania Blanco Martín (A Coruña, Spain)
- R0054 P2826 - Population pharmacokinetics of piperacillin/tazobactam in plasma and epithelial lining fluid of ICU patients with pneumonia: the PNEUDOS study Mohd-Hafiz Abdul-Aziz (Brisbane, Australia)
- R0055 P0884 - NETosis-inducing *Staphylococcus aureus* correlate with mortality and elevated IL-10 Warren Rose (Madison, United States)
- R0056 P2669 - Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in *Escherichia coli* Jiao Xie (Xi'an, China)
- R0057 P2777 - Population pharmacokinetic analysis of piperacillin in critically ill women based on multi-centre data Uwe Liebchen (Munich, Germany)
- R0058 P2876 - Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study Sota Iyama (Tokyo, Japan)
- R0059 P2883 - Pharmacokinetics, safety and tolerability of ANT3310 combined with meropenem in participants with impaired renal function Justine Dao (Labège, France)
- R0060 P0797 - Continuous vs intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort study Anselm Jorda (Vienna, Austria)

WT007 13:30 – 14:30 Poster area

Poster Walkthrough

ANT

Digital or traditional Antimicrobial Stewardship interventions

Chair Rita Murri (Rome, Italy)

- R0061 P2907 - Global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): monitoring effectiveness of an EMR-assisted pre-authorisation requirement for non-guideline compliant surgical antimicrobial prophylaxis prescriptions at a tertiary hospital in the Philippines Janelle Gagelonia (Taguig, Philippines)
- R0062 P2933 - Implementation experience of an antimicrobial stewardship program in a resource-limited setting: MSF-MOH collaboration in a Mozambican hospital Shehezady Cruz (Beira, Mozambique)
- R0063 P2964 - A mixed-method evaluation and impact assessment of national secondary care (hospitals) antimicrobial stewardship (AMS) tools Bee Yean Ng (London, United Kingdom)
- R0064 P2978 - Hybrid AI2D and rule-based approach for prospective audit feedback (PAF) of piperacillin/tazobactam in suspected acute bacterial lower respiratory tract infections (aBLRTI) Yvonne Zhou

(Singapore, Singapore)

R0065 P2915 - Sustained improvement in private practice dentists' antibiotic prescribing following stewardship education and electronic antibiotic dashboards Debbie Goff (Westerville, Ohio, United States)

R0066 P2969 - From data silos to strategic action: developing a real-time dashboard to inform a local antimicrobial stewardship (AMS) programme Mark Gilchrist (London, United Kingdom)

R0067 P3010 - Impact of a networked antimicrobial stewardship program with multi-site computer decision support on antibiotic consumption and resistance in four major Australian teaching hospitals 2012-2024 Pamela Konecny (Sydney, Australia)

R0068 P2912 - Optimising antibiotic use in Nigerian secondary hospitals: prescribing patterns, consumption rate and drivers of inappropriate therapy Justin Onyebuchi Nwofe (Abuja, Nigeria)

R0069 P2946 - From restrictive antibiotic stewardship to a handshake model: early outcomes from the REVERSE project in a tertiary hospital in Northern Italy Amina Zaffagnini (Verona, Italy)

R0070 P3071 - Evaluation and knowledge mobilisation of the annual English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report Diane Ashiru-Oredope (London, United Kingdom)

WT005 13:30 – 14:30 Poster area

Poster Walkthrough

CLN VAX

Navigating through infections in immunocompromised hosts

Chair Simona Ruta (Bucharest, Romania)

R0041 P4194 - Long-term outcomes of isoniazid prophylaxis in allogeneic haematopoietic stem-cell transplant recipients: a 15-year cohort study Keon Oh (Seoul, Korea, Republic of)

R0042 P4138 - Human microRNA hsa-125a-5p as biomarker for predicting late CMV infection in high-risk D+/R- kidney transplant recipients Natalia Redondo (Madrid, Spain)

R0043 P4166 - Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* spp. (VRE) in Swiss solid organ transplant recipients Peter W Schreiber (Zurich, Switzerland)

R0044 P4217 - Impact of HHV-6B reactivation on engraftment and outcomes after allogeneic HSCT Seyed M (sasan) Hosseini-Moghaddam (Toronto, Canada)

R0045 P4236 - Central venous catheter (CVC)-related bloodstream infections (CRBSI) in patients with solid tumours (ST) and haematological malignancies (HM): a propensity-score matched (PSM), non-inferiority, registry-based comparison Enrico Schalk (Magdeburg, Germany)

R0046 P4146 - Identification and validation of clinical phenotypes in liver transplant donors and recipients to predict early infections and mortality Cecilia Bonazzetti (Bologna, Italy)

R0047 P4152 - A retrospective analysis of patients receiving organs from HHV-8 positive donors at a large transplant centre Benjamin Ravenhill (Cambridge, United Kingdom)

R0048 P4189 - Long-term outcomes in liver transplant recipients: comparison between patients living with and without HIV infection Adriana Cervo (Modena, Italy)

R0049 P4218 - Antibiotic-induced microbiome disturbances in haematological patients undergoing haematopoietic stem cell transplantation: a prospective observational study Hanna Montelin (Uppsala, Sweden)

R0050 P4148 - Infections and outcomes in elderly solid organ transplant recipients: a multi-centre cohort from Türkiye Sibel Altunisik Toplu (Malatya, Türkiye)

WT008 13:30 – 14:30 Poster area

Poster Walkthrough

AMR PED

Optimising diagnosis and antimicrobial management in paediatric infectious diseases

Chair	Ilias P. Iosifidis (Thessaloniki, Greece)	00433	15:18	An unexpected case of disseminated MAC infection in a non-HIV immunocompromised thymoma patient L. Vos* (Utrecht, The Netherlands), A. Bruns	
R0071	P2866 - Pharmacokinetics, safety, and tolerability of cefiderocol in paediatric patients aged three months to <18 years with suspected or confirmed Gram-negative bacterial infections in the phase Ib-2 APEKS-PEDI study Emmanuel Roilides (Thessaloniki, Greece)	00434	15:29	Mycobacterium riyadhense : a rare emerging NTM in a TB endemic country B. Kumar* (Jodhpur, India), A. Sarangal, D. Meena, N. Midha, G. Bohra	
R0072	P0700 - Sputum-independent T cell activation-based diagnosis of paediatric tuberculosis: a prospective diagnostic accuracy study in five low- and middle-income countries Alia Razid (Munich, Germany)	OS062	14:45 - 15:45	Hall ICM 5	
				1-hour Case Session	
				CLN PHEI	
R0073	P0591 - A clinical prediction score for radiological severity of pulmonary tuberculosis in children: an individual participant data analysis Akshita Gupta (Munich, Germany)			Puzzling parasites	
R0074	P0809 - Causes of neonatal sepsis in low- and middle-income countries: a multi-site international cohort study Kirsty Sands (Oxford, United Kingdom)			Chairs	Rodrigo Gurgel-Gonçalves (Brasilia, Brazil) Tin Tin Myaing (Bangkok, Thailand)
R0075	P0818 - Referral of febrile children in a resource-constrained community settings in Asia (spot sepsis) Arjun Chandna (London, United Kingdom)	00435	14:45	Rapidly progressive parasitic meningoencephalitis: diagnostic challenges C. Silva* (Vila Nova De Gaia, Portugal), C. Nunes-Silva, A. Silva-Pinto, A.S. Santos, C. Gonçalves, R. Baptista, A. Ferreira, S. Xerinda, L. Andrade, J. Ganicho, P. Figueiredo, A. Sarmiento, A. Costa, C. Reis, S. Rebelo, S. Guimarães, L. Santos	
R0076	P2821 - Population pharmacokinetics modelling of daptomycin in paediatric patients Sylvain Goutelle (Lyon, France)	00436	14:56	Double trouble in the liver: amoebic and staphylococcal abscess in a Belgian MSM without travel history M. Moretti* (Jette, Belgium), N. M'rabet, K. Demeyer	
R0077	P4240 - Gut colonisation with MDR Gram-negative organisms and its impact on bacteraemia and sepsis development among children with haematological malignancies Reham Khedr (Cairo, Egypt)	00437	15:07	Eosinophilic liver abscess caused by invasive Fasciola B. Uaudomsataporn* (Bangkok 10330, Thailand), O. Putcharoen	
R0078	P1167 - Comparative effectiveness of clarithromycin and azithromycin for the treatment of pertussis in hospitalised infants: a multi-centre retrospective cohort study in Italy Cristina Moracas (Napoli, Italy)	00438	15:18	Learning from the unusual: three autochthonous paediatric cases of Entamoeba histolytica colitis in Southern Italy suggesting a new challenge for clinical practice and public health R. Astorri* (Casamassima (bari), Italy), M. Bartiromo, R. Melone, A. Di Martino, P. Marzuillo	
R0079	P3024 - Digital training for IPC and AMS in paediatric inpatient units: multicountry implementation and outcomes from TEAM-COACH project Olaf Neth (Sevilla, Spain)	00439	15:29	Reactivation of Trypanosoma cruzi with medullary tropism: an unexpected turn in a patient with HIV J. Mateo Gonzalez* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Garcia-Rodriguez, M. Martinez-Serrano, M.D. Ocete-Mochon, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, C. Ricart-Olmos, M. Garcia-Deltoro	
R0080	P0977 - Incidence of parapneumonic pleural effusion/empyema in children before, during, and after the COVID-19 pandemic (Germany, 2010/11-2024/25) Andrea Streng (Würzburg, Germany)				
SEL	13:30 - 15:30			Hall ICM 14	
	Special Session				
	Selective Pressure				
Chairs	Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel) Annabel Niessen (Utrecht, The Netherlands) Josh Nosanchuk (Bronx, United States) José Ramón Paño-Pardo (Zaragoza, Spain) Jesús Rodríguez-Baño (Seville, Spain) Anja Šterbenc (Ljubljana, Slovenia) David Van Duin (Chapel Hill, United States)				
SEL01	13:30	Selective Pressure	Jesús Rodríguez-Baño (Seville, Spain)		
OS063	14:45 - 15:45	Hall A2-1			
	1-hour Case Session				
	CLN PHEI				
	Malicious Mycobacteria				
Chair	Anupa Thampy (Vellore, Tamil Nadu, India) TBA				
00430	14:45	Donor-derived renal allograft tuberculosis detected by plasma metagenomic sequencing in two kidney transplant recipients A. Diaz Arumir Vergara* (Jackson, United States), A. Diaz-Arumir Vergara			
00431	14:56	Leprosy in an Indonesian patient diagnosed after childbirth in a tertiary hospital in Germany A. Frenz* (Dresden, Germany), R. Kardashi, S. Meisterfeld, P. Spornraft-Ragaller, K. De With			
00432	15:07	XDR-Tuberculosis meningitis in patient with advanced HIV infection: therapeutic challenge with limited treatment options M. Schiuma* (Milan, Italy), F. Fama, A. Piubello, F. Saluzzo, D. Bernasconi, M. Schiavini, A. Covizzi, B. Caloni, D. Zizzo, D. Maddalena, M. Bognetti, A. Rizzo, F. Salari, A. Civati, M. Galimberti, A. Riva, S. Antinori, D. Cirillo, A. Gori, A. Torre			
OS064	14:45 - 15:45	Hall A2-2			
	1-hour Oral Session				
	CLN TRN				
	Rattle my bones - bone and joint infections				
Chairs	Parham Sendi (Bern, Switzerland) Andrej Trampuz (Brisbane, Australia)				
00440	14:45	Validation of the KLIC score and development of a new predictive model in a multi-centre cohort of prosthetic joint infections treated with debridement and implant retention G. Zumbo* (Seville, Spain), I. Martínez Alemany, J.M. Bravo Ferrer, I. Nieto Diaz De Los Bernardos, J. Praena, A. Del Arco, N. Enrique, C.D. Juan Enrique, B. Francisco, C. Natera, A. Romero Palacios, B. Sobrino, J. Rodríguez Baño, M.D. Del Toro Lopez			
00441	14:57	Hypoxia-driven sdhB-mediated antibiotic tolerance impairs prophylactic antibiotics against MRSA in a mouse prosthetic joint infection model O. Gordon* (Jerusalem, Israel)			
00442	15:09	The use of [¹⁸F]FDG-PET/CT and magnetic resonance imaging in the diagnosis of pyogenic vertebral osteomyelitis secondary to Staphylococcus aureus bacteraemia I. Johansen* (Odense C, Denmark), S. Olaf Lindvig, T. Benfield, I. Pedersen, S. Hess, F. Rosenvinge, M. Kehrer, I. Somuncu Johansen			
00443	15:21	Fatty acid profiling of biofilms formed by Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus E. Torrecilla-Sádaba* (Madrid, Spain), D. Carrizo-Gallardo, L. Sánchez-García, L. Salar-Vidal, J. Esteban, J.J. Aguilera-Correa			
00444	15:33	Investigation of Staphylococcus aureus infections in human-derived musculoskeletal ex vivo tissue slices K. Strenger* (Basel, Switzerland), R. Kühn, A.K. Woischnig, L. Sauteur, M. Morgenstern, M. Clauss, D. Bumann, N. Khanna			
OS065	14:45 - 15:45	Hall A3-1			

IPC TRN

1-hour Oral Session

Engineering the gut microbiome: new therapeutics and clinical practice

Chairs		Markus Arnoldini (Zurich, Switzerland) Fidelma Fitzpatrick (Dublin, Ireland)
00445	14:45	Randomised double-blinded clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin vs placebo in the prevention of recurrence of <i>Clostridioides difficile</i> infection in patients receiving systemic antibiotic therapy (PREVAN TRIAL) R. San-Juan* (Madrid, Spain), J. Origüen, M. Fernández-Ruiz, K. Campion, J.T. Silva, F. Lopez-Medrano, J. Villa, B. Diaz-Pollan, A. Callejas, G. Candela, J. Boan, E. Aparicio-Minguñon, M.A. Perez-Jacoiste, I. Rodriguez-Goncer, C. Martin-Arriscado, M. Martínez-Uña, J.M. Ferrari, J.M. Aguado
00446	14:57	Longitudinal tracking of microbial restoration after faecal microbiota transplantation (FMT) D. Guevara Nuñez* (Barcelona, Spain), P. Camps-Massa, L. Saiz-Escobedo, A. Carrera-Salinas, S. Antón, J. Orobitg, M. Bonilla, A. González-Díaz, C. Arajol, J. Guardiola, M.A. Dominguez, S. Martí
00447	15:09	VE707, a live biotherapeutic product, reduces intestinal vancomycin resistant enterococci in a murine model of pathogen colonisation J. Norman* (Cambridge, United States), C. Russell, C. Felix, W. Alsharif, L. Cornacchione, M. Schinn, A. Watson, S. Bedard-Shurtleff, J. Faith, E. Kuijper, B. Olle, G. Medlock, S. Caballero
00448	15:21	Single-donor lyophilised encapsulated faecal microbiota transplant (cFMT) supports home dosing with dose-to-dose heterogeneity driven by inter-donor microbiome differences B. Merrick* (Harrow, United Kingdom), D. Prossomariti, N.M.M. Zain, B. Forbes, C. Sergaki, S.D. Goldenberg
00449	15:33	<i>Clostridioides difficile</i> infection recurrence and antibiotic utilisation following treatment with Food and Drug Administration-approved faecal microbiota products: a multi-centre analysis using Epic Cosmos S. Boettcher* (Detroit, United States), R. Kenney, N. Everson, I. Kashat, G. Tengler, A. Soyad, S. Davis, M. Veve

OS061	14:45 – 15:45	Hall ICM 13a
	1-hour Oral Session	

PRO

AI applications in CM/ID: speaking the new language (model)

Chairs		Riina Richardson (Manchester, United Kingdom) Bernardo Sousa-Pinto (Porto, Portugal)
00450	14:45	Assessing Large Language Model (LLM) performance in abstract screening for an infection-focused systematic review with >16,000 records D. Ashiru-Oredope* (London, United Kingdom), O. Quinn, G. Shannon, H. Ollie, L. Timothy, F. Felix, H. Joshua, L. Leo, N. Toby
00451	14:57	Development of an ESCMID Global AI-based abstract categorisation tool G. De Angelis* (Basel, Switzerland), E. Dexter, J. Moran-Gilad
00452	15:09	AI-assisted infectious disease consultation: concordance analysis between a custom GPT model and specialist recommendations S. Karunakara Ramesh* (Tamil Nadu, India), K. Sarika, D. Suresh Kumar, M. Indumathi, B. Rithik Dharan
00453	15:21	Performance of large language models in management of complex infectious diseases cases A. Pradhan* (Oxford, United Kingdom), B.J. Waxse, W. Matias, K. Bowman, C. Nutt, S. Mercaldo, S. Kanjilal, J. Hillis
00454	15:33	Multimodal artificial intelligence using entire electronic health record and complete pathogen genome data to predict clinical outcomes from life-threatening infection: the SuperbugAI platform A. Peleg* (Melbourne, Australia), S. Tyagi, Y. Ramakrishnaiah, J. Hawkey, J. Wisniewski, T. Christian, V. Sikiric, G. Webb, C. Bain, J. Song, A. Stewardson, T. Peel, N. Maccesic

SY097	14:45 – 15:45	Hall A3-2
	1-hour Symposium	

IPC PHEI

Capacity strengthening in antimicrobial stewardship and infection, prevention and control in LMICs

Chairs		Gloria Cordoba (Copenhagen, Denmark) Syed Faisal Mahmood (Karachi, Pakistan)
S0245	14:45	What is drive-AMS and what have we learned? Jeroen Schouten (Nijmegen, The Netherlands)
S0246	15:15	Drive AMS East Africa, inducing behaviour change in resource-constrained settings Igizenza Acsa (Kigali, Rwanda)

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS), ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

EF066	14:45 – 15:45	Arena 1
	ePoster Flash Session	

DX

The escalating problem of antifungal resistance

Chair		Ana Alastruey (Madrid, Spain)
E0455	14:45	Azole fungicides promote <i>C. auris</i> resistance to manogepix: a new One Health concern A. Bouillier* (Poitiers, France), A. Baillot, J. Moreau, S. Marchand, J. Clarhaut, K. Brunet
E0456	14:51	Clonal emergence and mechanistic insights into amphotericin B resistance in <i>Candida auris</i> from Indian hospitals P. Kagra* (Delhi, India), S. Yadav, N. Shukla, K. Jain, S. Srivastava, S.L. Kelly, M.F. Alomair, D.C. Lamb, N. Chauhan, A. Chowdhary
E0457	14:57	Clinically relevant gene flow leads to substantial loss of antifungal susceptibility in a rare invasive fungal pathogen R. Dai* (Beijing, China), Y. Huang, Y. Xu, M. Zhou, M. Xiao
E0458	15:03	Epidemiological trends and genomic insights from national surveillance of <i>Candida auris</i> in Singapore K.N. Sein Tun* (Singapore, Singapore), G. Lee, B. Tan, G. Toh, X.Y. Ong, L. Cui, M. Ang, Z. Said, C. Huang, K. Marimuthu
E0459	15:09	Detection of fluconazole resistant <i>C. parapsilosis</i> clinical isolates bearing both Y132F and S862C substitutions at MALDI-TOF analysis I. Franconi* (Pisa, Italy), B. Tuvo, L. Maltinti, M. Falcone, L. Mancera, A. Lupetti
E0460	15:15	Tandem gene duplications driven rising azole resistance in expanding <i>Candida orthopsilosis</i> population Y.T. Ning* (Beijing, China), R.C. Dai, Y.C. Xu, T.S. Sun, L. Zhang
E0461	15:21	Nationwide multi-centre surveillance of species distribution and antifungal resistance in <i>Candida</i> and <i>Candida</i> related-bloodstream isolates in Brazil (2023–2025) F. Guinsburg Hamburger* (São Paulo, Brazil), F. De Camargo Ribeiro, K. Rosa Fernandes Beraldo, R. Tigulini De Souza Bogo, A.L. De Abreu, A.P. D'Alincourt Carvalho Assaf, J. Nóbrega De Almeida Júnior, A.L. Colombo
E0462	15:27	Unique genetic clades and frequent zoonotic transmission of <i>Sporothrix brasiliensis</i> with reduced itraconazole susceptibility E.F.J. Meijer* (Nijmegen, The Netherlands), M. Rodrigues Trápaga, B. Spruijtenburg, J. Estefânia Dávila Hidalgo, B. Jacomet, I. Martins Madrid, D. Isabel Brayer Pereira, A. Souza Mattei, A. Reis Gomes, R. Osório De Faria, F. Silveira, C. Bittencourt Severo, V. Rodrigues Aquino, A. Paula Giolo Franz, S. De Ávila Botton, R. Maria Zancopé-Oliveira, V. Rodrigues Poester, T. De Groot, M. Orzechowski Xavier
E0463	15:33	High triazole resistance rates of <i>Aspergillus fumigatus</i> in Belgian composting facilities L. Cuyper* (Leuven, Belgium), L. Vincken, R. Merckx, A. Reséndiz-Sharpe, G. Vande Velde, K. Lagrou

EF067	14:45 – 15:45	Arena 2
	ePoster Flash Session	

ANT IPC PED

Infection control and antimicrobial stewardship in neonatal and pediatric critical care

Chair	Irja Lutsar (Tartu, Estonia)
-------	------------------------------

E0464	14:45	Colonisation pressure is associated with infant acquisition of ESBL genes on the neonatal unit A. Cook* (London, United Kingdom), M. Berkell, D.R.M. Smith, H. Van Werkhoven, E. Sieswerda, C. Minotti, L. Van Heirstraeten, S. Malhotra-Kumar, J.A. Bielicki			intensive care units: insights from a national survey A. Van Boekel* (Leiden, The Netherlands), B. Bolhuis, R. Bentvelsen, C. Van Den Berg, L. Van Bodegom-Vos, N. Deetman, D. Dongelmans, W. Falkenburg, E. Van De Garde, J. Haringman, E. De Jong, M. Lambregts, D. De Lange, J. Schouten, C. Den Uijl, S. Arbous, M. De Boer, J. Van Paassen
E0465	14:51	First report of a neonatal intensive care unit outbreak linked to <i>Serratia sarumani</i> in Latin America: insights from WGS and IR Biotyper P. Orlandi Barth* (Porto Alegre, Brazil), W. Latosinski Matos, L. Lutz, L. Rita Konkewicz, D. Castro Pereira, L. Czekster Antochewis, J.V. Barboza Cardoso, L. Quadro Stein, A.L. Barth, A. Francisco Martins	E0478	15:15	Long-term impact of a high-intensity multimodal antimicrobial stewardship programme on broad-spectrum antibiotic consumption and resistance in an adult intensive care unit: an interrupted time series analysis (2013–2025) G. Roncancio Villamil* (Medellin, Antioquia, Colombia), G.E. Roncancio-Villamil, A.A. Pineda-Florez, D.A. Diaz-Ospina, A.R. Vargas-Garcia, A.M. Montoya-Duque, C.I. Garcia-Rincon, C.G. Garces-Zamudio
E0466	14:57	Infection prevention surveillance across 29 neonatal units: methods and initial analyses from the NeolPC Surveillance Network G. Karadağ* (Berlin, Germany), A. Bekker, A. Dramowski, B. Loureiro, J. Pérez López, J.I. Pijoan Zubizarreta, P.T. Heath, B. Piening	E0479	15:21	Overcoming implementation challenges: achieving sustained excellence in antimicrobial prescribing through prospective audit and feedback in intensive care units N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, C. Karla, P. Abdi, C. Alessandra
E0467	15:03	What do surveillance cultures really tell us in neonates? P. Favier* (Valencia, Spain), P. Suarez-Urquiza, A. Valentín-Martín, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, E.M. González-Barberá, M. Cernada-Badía	E0480	15:27	Reassessing risk in critical illness: antibiotic de-escalation remains a safe practice without increasing adverse events or mortality M. Inan Hekimoğlu* (Ankara, Türkiye), E. Gülten, E.M. Sarıcaoglu, A.H. Elhan, F. Yörükc
E0468	15:09	Rapid nanopore sequencing and Average Nucleotide Identity (ANI) to guide a <i>Serratia marcescens</i> complex outbreak in a neonatal ward R. Sierra* (Geneva, Switzerland), C. Cave, L. Munoz, C. Ougier Riccio, A. Borghesi, R. Pfister, N. Buetti, D. Andrey	E0481	15:33	Effect of clinical pharmacist-led antibiotic optimisation in a resource limited tertiary ICU in South India lacking dedicated infectious disease physician support A. Mohamed Mohideen* (Chengalpattu, India), D. Ganesh, F. Jose, S. Kurian Mathew, M. George
E0469	15:15	Searching for the needle in the haystack with the right lens: impact of chromogenic <i>Serratia</i> spp. agar to neonatal ICU surveillance P. Favier* (Valencia, Spain), P. Suárez-Urquiza, A. Valentín-Martín, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, M. Cernada-Badía, E.M. González-Barberá	EF069	14:45 – 15:45	Arena 4
E0470	15:21	The caveats and (im)possibilities of tracking outbreaks directly from swabs in neonates S. Ayala Montaña* (Freiburg im Breisgau, Germany), S. Ayala-Montaña, A.O. Afolayan, I.J. Akintayo, R. Kociurzynski, L. Duarte Dos Santos, C. Schneider, T. Nguyen, M. Kuntz, H. Fuchs, G.A. Häcker, S. Reuter			ePoster Flash Session
E0471	15:27	Impact of BARNARDS II: introduction of standard diagnostic protocols on antibiotic stewardship and neonatal outcomes in a NICU S. Naqvi* (Islamabad, Pakistan), S. Riaz, M.A. Khan, R. Zahra, E. Rashid, K. Thomson, T. Walsh, B. Hassan			ANT DX
E0472	15:33	Cefiderocol use in paediatric intensive care and neonatal intensive care units: real-world use, safety, and clinical outcomes in a tertiary hospital A. Estevez Prieto* (Madrid, Spain), A. Estévez, F. Camero, J. Serrano-Lobo, C. Redondo Galán, M. Slöcker-Barrío, E. Zamora-Flores, M. Sánchez-Luna, P. Muñoz			AI-powered pathogen detection and AMR prediction
EF068	14:45 – 15:45	Arena 3			Chair
		ePoster Flash Session			Belen Rodriguez-Sanchez (Madrid, Spain)
		ANT CLN			
		Saving lives, preserving antibiotics: stewardship in the ICU			
		Chair			
		Bhanu Sinha (Groningen, The Netherlands)			
E0473	14:45	Beyond acceptance rates: what makes antimicrobial stewardship work in intensive care? S. Camilleri* (Melbourne, Australia), S. Khumra, A. Thomas, S. Vogrin, A. Batrouney, M. Devchand, S. Motaganahalli, S.J. Warrillow, J.A. Trubiano, G.K. Reynolds, S. Narayanasamy	E0482	14:45	Leveraging machine learning for predicting urine culture outcomes: a multi-centre prospective study Q. Yi* (Beijing, China), X. Zhou, Y. Guo, Y.C. Xu
E0474	14:51	Beyond the 'antibiotic police': ICU clinicians' perspectives on effective antimicrobial stewardship communication S. Khumra* (Melbourne, Australia), S. Camilleri, A. Thomas, A. Batrouney, M. Devchand, S. Motaganahalli, S. Warrillow, J. Trubiano, G. Reynolds, S. Narayanasamy	E0483	14:51	Pilot study for the differentiation of <i>Clostridium botulinum</i> group I and <i>Clostridium sporogenes</i> using MALDI-TOF MS and unsupervised machine learning F. Dematheis* (Munich, Germany), R. Schneider, D. Amort, H. Von Buttler, S. Zange
E0475	14:57	Optimising intravenous to oral antibiotic switch in intensive care units: a multi-site audit using UKHSA IVOS criteria across three West Midlands NHS Trusts N. Agravedi* (Birmingham, United Kingdom), A. Jenkins, A. Brush, S. Gilani	E0484	14:57	A data-driven framework for <i>Streptococcus pneumoniae</i> serotype prediction from mass spectrometry profiles J. Zintgraff* (Barracas, Argentina), N. Sánchez Eluchans, M.A. Moscoloni, C.S. Lara
E0476	15:03	Optimising Prospective Audit Feedback (PAF): hybrid approach combining AI2D (Augmented Intelligence in Infectious Diseases) and rule-based algorithm Y. Zhou* (Singapore, Singapore), J.L. Lim, S. Tang, J.S. Chung, Y.B. Wang, A. Kwa	E0485	15:03	Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant <i>Acinetobacter baumannii</i> from whole genome sequencing and gene expression H. Jia* (Hangzhou, China), X. Li, Y. Zhuang, Q. Yang, Z. Ruan
E0477	15:09	Antimicrobial stewardship implementation across	E0487	15:09	stackPred: AI boosted AMR phenotype prediction for multiple species and antimicrobial agents J. Welling* (Essen, Germany), M. Balzer, L. Consten, S. Bletz, J. Buer, V. Chapot, D. Harmsen, E. Heintschel Von Heinegg, A. Mellmann, W. Pölkling, F. Salhöfer, F. Schaumburg, N. Scherff, N. Wiesmann, F. Meyer
			E0488	15:15	Interpretable machine learning predicts antimicrobial resistance and reveals regulatory mechanisms in ESKAPEE pathogens A. Skoulakis* (Lamia, Greece), K. Danilidis, S. Digenis, C.G. Gkoutinoudis, E. Petinaki, A. Hatzigeorgiou
			E0489	15:21	MicroBIS: a novel artificial intelligence and machine learning-based digital platform for rapid bacterial identification and antimicrobial resistance prediction to strengthen diagnostics, clinical decision-making, and surveillance in resource-limited healthcare settings across Africa A.M. Martin* (Nairobi, Kenya), D. Otieno, K. Sam
			E0486	15:27	Predicting genomics-based antibiotic susceptibilities and treatment-emergent resistance in <i>Acinetobacter baumannii</i> R. Shields* (Pittsburgh, Pa, United States), E. Solares, L. Bledsoe, L. Williams, K. Hall
			ME099	14:45 – 15:45	Hall B0-2

Meet-the-Expert

Pathogens and people: modelling epidemics for preparedness

M0249	14:45	William Hanage (Boston, United States)
M0250	14:57	Vittoria Colizza (Paris, France)

ME098	14:45 – 15:45	Hall ICM 1
-------	---------------	------------

Meet-the-Expert

What's new in Antimicrobial Susceptibility Testing (AST)

M0247	14:45	Erika Matuschek (Växjö, Sweden)
M0248	14:57	Rafael Canton (Madrid, Spain)

Co-organised with: EUCAST Steering Committee

OS070	16:15 – 17:15	Hall A3-2
-------	---------------	-----------

1-hour Oral Session

Turning mechanisms into clinical strategies in chronic viral hepatitis

Chairs *Ruxandra Calin (Paris, France)*
Yogesh Kumar Gupta (Jaipur, India)

O0491	16:15	NTCP-based HBV infection model to define ncRNA drivers of post-transplant HCC recurrence S. Aksoy* (Bursa, Türkiye), S. Ak-Aksoy, İ. Sağlık
O0492	16:27	Distinct hepatitis B virus mutational patterns in hepatocellular carcinoma patients vs chronic hepatitis B patients highlight potential biomarkers for cancer progression E. Gupta* (Delhi, India), S. Maniraj, R. Agarwal, P. Gautam, C. Bihari, M. Sharma
O0493	16:39	Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine? G. De Simone* (Rome, Italy), L. Campogiani, V. Malagnino, E. Teti, T. Mulas, M. Compagno, D. Checchi, A.M. Geretti, L. Sarmati
O0494	16:51	Hepatitis C virus reactivation in cancer patients receiving Bruton tyrosine kinase inhibitors T. Harrys* (Houston, United States), J. Arvelaez Pasucci, K. Mustafayev, P. Jain, Y. Jiang, E. Yopez Guevara
O0495	17:03	Bulevirtide treatment of HBV-HDV coinfecting patients: 12 months of real-life experience G.S. Gherlan* (Bucharest, Romania), R.M. Cretu, A. Blidaru, D.S. Lazar, A. Culinescu, A. Condurache, S.M. Ruta, S.A. Florescu, C.P. Popescu

LB004	16:15 – 17:15	Hall B0-2
-------	---------------	-----------

1-hour Oral Session

Recent and ongoing high impact outbreaks

Chairs *Daniel Grupel (Jerusalem, Israel)*
Barbara Juliane Holzknrecht (Copenhagen, Denmark)

L0021	16:15	The January 2026 Nipah virus outbreak investigation and successful containment in West Bengal, India: direct report from the field S. Banerjee* (Kalyani, India), A. Das, R. Basu, S. Maharatna, R. Sahay, M.K. Kundu, P. Yadav
L0023	16:27	Uncovering a multi-centre outbreak of <i>Candida viswanathii</i> candidaemia caused by contaminated milrinone in Italy A. Mesini* (Genoa, Italy), V. Di Pilato, D. Contu, M. Castignone, M.L. Ciofi Degli Atti, G. Vrenna, L. Ricotta, C. D'amore, V. Fox, P. Bernaschi, G. Travi, M. Merli, C. Vismara, E. Matarazzo, G. Vento, V. Arena, E. Nardi, A. Marchese, R. Bandettini, G. Spiga, E. Castagnola
L0022	16:39	A complete soil-water-air transmission network for urban melioidosis: source identification and successful intervention in Hong Kong T.F. Wong* (Hung Hom, Hong Kong), K.H.G. Siu, W.N.F. Chow
L0024	16:51	Outbreak of NDM-1-producing <i>Burkholderia contaminans</i> bloodstream infections linked to contaminated intravenous metoprolol M. Fantoni*

(Rome, Italy), P. Laurenti, B. Fiori, S. Vincenti, M. Di Donato, R. Murri, M. Wachocka, F. De Maio, M. Cioce, N. Mores, R. Campopiano, C. Pais, G. Vetrugno, T. D'inzeo, B. Posteraro, C. Torti, M. Sanguinetti

L0025	17:03	Ongoing outbreak of <i>Burkholderia stabilis</i> ST480 linked to non-sterile cleansing wipes in the United Kingdom: investigation findings and mitigating patient safety risks R. Stretch* (London, United Kingdom), A. Carroll, D. Blackman, A. Popay, D. Kenna, M. Day, C. Willis, K. Staniforth, D. Williams, K. Osman, G. Russell, J. Pappriill, J. Gordon-Brown, G. Fear, M. Mirfenderesky, D. Jeyaratnam, I. Sinha, C. Searle, C. Patterson, R. Peabody, C. Brown, E. Betts, S. Milligan, J. Elston
-------	-------	---

LB005	16:15 – 17:15	Hall ICM 1
-------	---------------	------------

1-hour Oral Session

New drugs and anti-infective solutions

Chairs *Shampa Das (Liverpool, United Kingdom)*
Alasdair Peter Macgowan (Bristol, United Kingdom)

L0026		A chimeric CXCL8(3–72) K11R/G31P–BPI233 protein modulates neutrophil-driven inflammation and protects against carbapenem-resistant Gram-negative bacteria D. Pu* (Beijing, China), J. Zhao, B. Cao
L0027		Breaking bacterial communication signals: Anti-QS antibodies to block pathogenicity T. Posvai* (Barcelona, Spain), L. Vilaplana, M.P. Marco
L0028		In vivo efficacy and PK/PD of OSUAB-0284: a preclinical candidate for MRSA M. Mitton-Fry* (Columbus, United States), P. Srivastava, A. Landgraf, J. West, C. Mann, R. Kebraie, T. Murphy, D. Andes
L0029		Enzybiotic therapy for species-selective eradication of staphylococcal biofilms M. Yousefi* (Warsaw, Poland), P. Haniewicz, M. Zaród, M. Korzeniowska, J. Kornatowski, E. Jagielska, I. Sabala
L0030		Investigating the antiviral activity of (±)Bay K8644 against Enterovirus D68 J.A. Lee* (Taipei, Taiwan), K.C. Yang, L. Jin-Yi

SY103	16:15 – 17:15	Hall A2-1
-------	---------------	-----------

1-hour Symposium

Implementation of WHO Fungal Priority Pathogens List: landscape and challenges

Chairs *Katrien Lagrou (Leuven, Belgium)*
Rita Oladele (Lagos, Nigeria)

S0258	16:15	Pilot implementation of WHO's global surveillance system for monitoring antimicrobial resistance (GLASS-AMR) in fungal diseases Silvia Bertagnolio (Geneva, Switzerland)
S0259	16:45	WHO global blueprint for the implementation of the Fungal Priority Pathogens List Nelesh Govender (Johannesburg, South Africa)

SY102	16:15 – 17:15	Hall B0-1
-------	---------------	-----------

1-hour Symposium

The future of clinical phage susceptibility testing

Chairs *Saima Aslam (San Diego, United States)*
Frédéric Laurent (Lyon, France)

S0256	16:15	Bacteriophage potency and quality control: guidelines vs. real life Pieter-Jan Ceyssens (Brussels, Belgium)
S0257	16:45	Bacteriophage susceptibility testing: EUCAST perspectives on standardisation Annika Yanina Classen (Cologne, Germany)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), EUCAST Steering Committee

SY101	16:15 – 18:15	Hall A3-1
-------	---------------	-----------

2-hour Symposium

PED VAX

Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses

<i>Chairs</i>	<i>Tina Tan (Chicago, United States)</i> <i>Julie Toubiana (Paris, France)</i>
S0252	16:15 Tracking pertussis: epidemiological trends and global patterns <i>Gayatri Amirthalingam (London, United Kingdom)</i>
S0253	16:45 Pertussis in its most severe forms: risks, realities, and responses <i>Carla Rodrigues (Paris, France)</i>
S0254	17:15 Genomic surveillance and emerging strains <i>Noémie Lefrancq (Basel, Switzerland)</i>
S0255	17:45 Rethinking pertussis immunity: challenges and innovations in vaccine strategy <i>Dimitri Diavatopoulos (Nijmegen, The Netherlands)</i>

EF071	16:15 – 17:15	Arena 1
	ePoster Flash Session	

VAX

Risky business: preventing respiratory virus infection in high-risk groups

<i>Chair</i>	<i>Vana Spoulou (Athens, Greece)</i>
E0496	16:15 Real-world effectiveness of maternal influenza vaccination in children under six months: a retrospective cohort study in a tropical setting <i>N. Goh* (Singapore, Singapore), E.W. Liang, R. Ho, C. Chiew, R. Li, D. Lye, K. Tan</i>
E0498	16:27 Two-season impact of nirsevimab against RSV hospitalisation in Galicia: findings from the NIRSE-GAL study <i>A. Muy Perez* (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieta, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo, N. Mallah, F. Martínón-Torres</i>
E0499	16:33 RSV prefusion F vaccine effectiveness in older adults according to Charlson Comorbidity Index: A prespecified analysis of the DAN-RSV trial <i>K. Feldballe Bernholm* (Copenhagen, Denmark), M.C.H. Lassen, N. Dyrby Johansen, S. H. Christensen, N. Aliabadi, K.G. Skaarup, D. Modin, K. Hyldekær Janstrup, B. L. Claggett, C. S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. G. Lindholm, A.M. Reimer Jensen, M. Dons, F. Soeskov Davidovski, L. S. Duus, C. I. Ottosen, A. B. Nielsen, J. H. Borchsenius, C. Espersen, G. Köse, F. H. Fussing, L. Køber, S. D. Solomon, J.U. Stæhr Jensen, C. Jean-Marie Martel, M. Goeijenbier, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B. D. Gessner, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, E. Begier, T. Biering-Sørensen</i>
E0500	16:39 Immune response and safety of the AS01E- adjuvanted respiratory syncytial virus protein F vaccine (adjuvanted RSVPreF3) in immunocompromised (IC) adults with lung or kidney transplant compared to non-IC adults up to 12 months post-vaccination <i>K. Oluwayi* (London, United Kingdom), C. Small, D. Kumar, A. Abbas, A. Sánchez-Fructuoso, S. Yamanaga, V.L. Pérez-González, H. Karakizlis, M. Nissen, P.G. Choe, V. Paloschi, S. Chadban, H.A. Hailemariam, C. Gerard, M.P. David, D. Descamps, C. Agutu, V. Hulstrøm</i>
E0501	16:45 Effectiveness of the adapted XBB.1.5. COVID-19 vaccine received as a 2023 autumn dose among immunocompromised persons in six EU/EEA countries, a VEBIS EHR network study <i>A. Blake* (Paris, France), J. Humphreys, N. Nicolay, T. Braeye, I. Van Evercooren, C. Holm Hansen, I. Rask, M. Fabiani, A. Mateo-Urdiales, J. Castilla, I. Martínez Baz, A. Machado, A. Brito, R. Ljung, N. Pihlström, S. Monge, K. Olsson, B. Nunes</i>
E0502	16:51 Interim analysis of the effectiveness of conventional and self-amplifying JN.1-adapted mRNA COVID-19 vaccines against symptomatic infection in adults aged 60 years, Japan <i>H. Maeda* (Nagasaki, Japan), A. Igarashi, S. Mitsui, K. Suzuki, T. Kutomi, H. Fujino, T. Onoe, T. Kimura, Y. Ichigi, H. Kozai, T. Komazaki, S.</i>

Kida, K. Morimoto

E0503	16:57 A novel approach assessing the impact of SARS-CoV-2 variant drift on effectiveness and durability of an XBB.1.5-adapted COVID-19 vaccine using the id.DRIVE platform <i>H.R. Volkman* (New York, United States), T.M.P. Tran, M.M. Mustapha, L. De Munter, C. Marques, H. Dunford, J.V. Hernandez-Villena, M. Mitratza, A. Antón, I. Casas Garcia, B. Gruner, G. Icardi, G. Luit Ten Kate, C. Martin, A. Mira-Iglesias, A. Orrico-Sanchez, S. Otero-Romero, G. Rohde, J.L. Nguyen, K. Bollaerts</i>
E0504	17:03 Safety, tolerability, pharmacokinetics, and immunogenicity in a phase I first-in-human study with VYD2311, a SARS-CoV-2-directed monoclonal antibody <i>P. Richmond* (Nedlands, Australia), L. Hu, K. Narayan, K. Tosh, R. Gerlach, I. Yacin, D. Wilfret, M. Wingertzahn</i>

EF072	16:15 – 17:15	Arena 3
	ePoster Flash Session	

DX

Advances in sepsis diagnostics: improving speed and accuracy

<i>Chair</i>	<i>Özlem Kurt Azap (Ankara, Türkiye)</i>
E0505	16:15 True bacteraemia vs contamination in positive blood cultures: development of a prediction model <i>E. Nannini* (Rosario, Argentina), M. Dumas Marucci, J.I. Rodriguez Lia, M. Pallotta, C. Scipione, R. Bonifacio, M. Rinaudo</i>
E0506	16:21 Epidemiology and interpretation of positive blood cultures when polymerase-chain reaction-based blood culture results are "not detected" <i>S. Boettcher* (Detroit, United States), R. Kenney, R. Tibbetts, L. Samuel, S. Davis, M. Veve</i>
E0507	16:27 Modeling a point-of-care diagnostic panel implementation for rapid bloodstream infection identification in remote settings: a cost-effectiveness analysis <i>K. Bagge* (Copenhagen, Denmark), F.H. Jensen, J.G. Lisby</i>
E0508	16:33 Patient factors associated with circulating bacterial DNA in critically ill sepsis patients <i>C. Lannsjö* (Stockholm, Sweden), B. Stammler Jaliff, D. Yu, S. Cajander, A. Bäckman, E. Tina, A. Somell, H. Alpkvist, M. Ullberg, C. Jorns, J. Wernerman, V. Özenci, K. Strålin</i>
E0509	16:39 Culture-free detection of bloodstream bacteria in ICU patients within six hours <i>A. Wijen* (Maastricht, The Netherlands), C. Von Wintersdorff, R. Driessen, S. Van Mens, D. Bergmans, P. Savelkoul</i>
E0510	16:45 From culture to clarity in four hours: accelerating clinical management of bloodstream infections <i>R. Ahmad* (Hamar, Norway), J. Ali, A. Basavaraj Bellankimath, S. Therese Opgård, E. Varman Manivannan, G. Skov Simonsen</i>
E0511	16:51 Rapid pathogen and antimicrobial resistance detection in bloodstream infections using short subculture and nanopore sequencing <i>M. Pitombeira Liborio* (Brisbane, Australia), P. Harris, C. Ravi, K. Ramsay, T. Da Silva Duarte, A. Irwin</i>
E0512	16:57 Rapid identification of bacteraemia-causing microorganisms using MALDI-TOF MS: a comparative study of three in-house methods with two matrices <i>Z.C. Karahan* (Ankara, Türkiye), R. Waheed Osman</i>
E0513	17:03 Four-day vs five-day blood culture incubation: a retrospective study of diagnostic performance using the BACT/ALERT VIRTUO system <i>K. Tron* (Newcastle, United Kingdom), C. Cullerton, J. Lupton, P. Mpwilu, J. Samuel, D. Weiland</i>

EF073	16:15 – 17:15	Arena 4
	ePoster Flash Session	

ANT CLN PHEI

Surveillance of antimicrobial use around the world

<i>Chair</i>	<i>Kalisvar Marimuthu (Singapore, Singapore)</i>
E0514	16:15 The ECRAID Emerging Resistance Index by European region: assessing the index's applicability in different epidemiological contexts <i>J. Garlasco* (Verona, Italy), F. Arieti, M. Morra, D.E. Ortiz, E.</i>

Addis, M. Tebon, O. Awwad, K. Odoj, M.D. Pezzani, S. Harbarth, E. Presterl, G. Kahlmeter, A. Cassini, A. Savoldi, E. Tacconelli

E0515	16:21	Antibiotic use, rapid escalation practices and access in neonatal sepsis across LMIC tertiary care hospitals: findings from the BARNARDS II cohort K. Thomson* (Oxford, United Kingdom), K. Sands, J. Oduwo, C. Achi, R. Farzana, B. Hassan, E. Owino, M. Nziliani, A. Ko, K. Iregebu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, N. Ukaegbu, C. Nzurumike, T. Amin, S. Arefin, T.N. Shatu, A.T. Promi, T. Haque, R. Tasnim, R. Zahra, E. Rashid, M.I. Shah, S. Riaz, S. Naqvi, S. Naeem, M. Haroon Hamid, S. Shabbir, U. Hussain, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, T.R. Walsh
E0516	16:27	Global antibiotic use (AMU) patterns in 2023: insights from WHO's global AMU surveillance system (GLASS-AMU) D. Tong* (Geneva, Switzerland), M. Escher, A. Muller, V. Ivanovska, D. O'doherty, B. Huttner
E0517	16:33	Scaling a national antimicrobial prescribing surveillance programme incorporating an appropriateness assessment to drive policy and practice R. James* (Melbourne, Australia), C. Chen, K. Thursky
E0518	16:39	Being more AWaRe: assessing appropriateness of antimicrobial prescribing against the World Health Organization AWaRe classifications C. Chen* (Melbourne, Australia), N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson, L. Hall, K. Thursky
E0519	16:45	How do we define 'appropriate antimicrobial use' in One Health? A global Delphi survey R. Scarborough* (Parkville, Australia), C. Ierano, K. Bailey, G. Browning, K. Thursky, R. Biezen, B. Hur, B. Mc Mullan, L. Dowson, A. Schermuly, L. Teoh, L. Hardefeldt
E0520	16:51	The context of antibiotic use in commercial poultry farms in Bangladesh: an anthropological exploration S.M.M. Hasan* (Dhaka, Bangladesh), S.A. Prema
E0521	16:57	Real-world use of novel β-lactams in fragile patients with multidrug-resistant Gram-negative infections: insights from an Italian retrospective cohort M. Boggetti* (Milan, Italy), F. Fama, C. Conflitti, F. Brivio, M. Piscaglia, M. Schiavini, M.V. Cossu, S. Vimercati, E. Rossin, C. Pagani, S.G. Rimoldi, A. Gori, M. Colaneri, E. Palomba
E0522	17:03	Strengthening antimicrobial stewardship across Europe: EU-JAMRAI2 on frameworks, implementation, and collaborative action on human health M. Nunez-Nunez* (Granada, Spain), M. Nuñez Nuñez, B. Bradley-Valdenebro, J.L. Trillo-Contreras, A. López-Navas, R. Fernández-Urrusuno

KN100 16:15 – 17:15 Hall ICM 14

CLN

Keynote lecture

From post-mortem discoveries to precision care: the evolution of opportunistic fungal infection management in haematological malignancies

Chairs Murat Akova (Ankara, Türkiye)
Anuradha Chowdhary (Delhi, India)

K0251 16:15 Dimitrios P. Kontoyiannis (Houston, United States)

ME104 16:15 – 17:15 Hall ICM 13a

CLN PHEI

Meet-the-Expert

Crimean-Congo haemorrhagic fever: best practices and advances in therapeutics and vaccines

M0260 16:15 Önder Ergönül (Istanbul, Türkiye)

M0261 16:27 Ali Mirazimi (Stockholm, Sweden)

Co-organised with: ESCMID Emerging Infections Subcommittee

FO105 16:15 – 17:15 Arena 2

Open Forum

CLN PRO

Science in action: implementation science for effective CM/ID practice in diverse settings

Chair Rita Murri (Rome, Italy)

F0262 16:15 **Implementation science fundamentals: a toolkit for CM/ID practice** Fabiana Lorencatto (London, United Kingdom)

F0263 16:25 **Measuring success: metrics that matter** José Molina Gil-Bermejo (Seville, Spain)

F0264 16:35 **Implementing infection control best practices across diverse resource settings** Raheelah Ahmad (London, United Kingdom)

Co-organised with: ESCMID Education Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

OS076 17:30 – 18:30 Hall A3-2

1-hour Case Session

CLN

A zoonotic carnival: masquerade syndromes and unusual presentations

Chairs Loïc Epelboin (Cayenne, French Guiana)
Joseph Papaparaskevas (Athens, Greece)

O0523 17:30 **Buffalopox beyond borders: first imported human case in Europe** L. Soldevila Langa* (Badalona, Spain), L. Soldevila, L. Valerio, A. Plana, X. Vallès, E. Fernández-Pedregal, S. Roure

O0524 17:41 **Fulminant multisystem anthrax with delayed haemorrhagic gastrointestinal involvement: a clinically unique case from an endemic region** M. Javakhadze* (Tbilisi, Georgia), M. Kobakhidze, L. Goliadze, E. Choladze, M. Kanashvili

O0525 17:52 **Imported round cavitory pneumonia: an unusual presentation of murine typhus** J.R. Le Henaff* (Toulouse, France), G. Grouteau, G. Martin-Blondel, D. Pierre, A. Merckx, G. Moulis, L. Cavalié, P. Floch, R. Gueneau

O0526 18:03 **A spectacular differential diagnosis of lung cancer and the elucidation of its origin** S. Zange* (Munich, Germany), K. Kösters, F. Löhr, E. Mantel, M. Hohls, C. Hinz, F. Dematheis, T. Hoffmann, K. Silberreis, M. Seidel, M. Walter, H. Scholz, W. Roman, D. Lang

O0527 18:14 **Seeing the unexpected: intraretinal dirofilariasis** H. Aldhaferi* (Abu Dhabi, United Arab Emirates), G. Rashwan, A.P. Srinivasulu, R.S. Ganeshan, Z.O.E. Babiker

OS074 17:30 – 18:30 Hall ICM 13a

1-hour Oral Session

CLN PHEI TRN

Innovations in vector-borne and zoonotic viral infections

Chairs Casandra Bulescu (Bucharest, Romania)
Ines Ushiro-Lumb (Marlow, United Kingdom)

O0528 17:30 **The role of the host genetic background in tick-borne encephalitis** S. Grygorczuk* (Bialystok, Poland), M. Parczewski, J. Dunaj, P. Czupryna, J. Adamczuk, W. Pawlak-Zalewska, A. Moniuszko-Malinowska

O0529 17:42 **Phenotypic characterisation of emerging neurotropic viruses using embryonic stem cell-derived neural cells and brain organoids** S. Vogiatzis* (Padua, Italy), E. Dal Molin, G. Gori Savellini, R. Pia Falco, M. Severa, C. Lucca, A. Sinigaglia, A. Gianella, G. Ceolotto, M. Bogacheva, I. Weinstein, O. Vapalahti, M. Pacenti, M. Trevisan, E. Coccia, M.G. Cusi, L. Barzon

O0530 17:54 **Exploring haematocrit, platelet and leukocyte count trajectories associated with dengue: pooled analysis from Vietnam** N.L. Vuong* (Ho Chi Minh City, Vietnam), D.T. Trung, T.V. Ngoc, N.M. Nguyet, D.T.H. Tam, N.T. Truong, H.T.L. Duyen, N.T.H. Quyen, N.T.T. Kieu, N.V.V. Chau, L.T.H. Tai, N.T.H. Lan, P.K. Lam, C.P. Simmons, S. Yacoub, R.B. Geskus, B.A. Wills

O0531 18:06 **A novel ARPE-19 cell-based assay for assessing interferon-mediated protection and autoantibody neutralisation in ZIKV infection** A. Ferrari* (Pavia,

Italy), I. Cassaniti, F. Rovida, D. Lilleri, S. Croce, F. Trespidi, A. Gervais, S.Y. Zhang, J.L. Casanova, A. Borghesi, F. Baldanti

00532 18:18 **One health investigation of Tahyna and Batai orthobunyaviruses and Sindbis alphavirus in Northern Italy, 2021-2024** E. Dal Molin* (Padua, Italy), M. Pacenti, D. Murova, A. Sinigaglia, A. Giaretta, A. Lavazza, D. Lelli, F. Gobbo, F. Montarsi, L. Barzon

OS075 17:30 – 18:30 **Hall ICM 13b**

1-hour Oral Session

ANT CLN

Primary care and long-term care facilities: what's going on in stewardship?

Chairs Gaetan Gavazzi (Grenoble, France)
Bradley Langford (Etobicoke, Canada)

00533 17:30 **Evaluation of a national training roll out implementing a stewardship toolkit in primary care in England: a quasi-experimental analysis using hybrid time series modelling** M.X. Lee* (Gloucester, United Kingdom), N.J. Zhu, J. Meadows, R. Ahamad, D.M. Lecky

00534 17:42 **Between-practice differences, rather than patient case-mix, drive variation in antibiotic prescribing in UK primary care: evidence from a three-way variance decomposition** V. Nguyen* (Oxford, United Kingdom), J.V. Robotham, A.S. Walker, D. Eyre, R. Hope, C. Butler, G. Hayward, M. Sharland, K.B. Pouwels

00535 17:54 **Antimicrobial use and stewardship activities in Swiss long-term care facilities: data from a national point-prevalence survey** S. Toppino* (St. Gallen, Switzerland), F. Grässli, S. Kuster, E. Glampedakis, C. Gardiol, T. Kudrnovsky, V. Piezzi, M. Schlegel, P. Kohler, D. Flury

00536 18:06 **Assessment of antibiotic prescribing and AWaRe classification compliance in Dutch nursing homes using national surveillance data** A. Zondag* (Bilthoven, The Netherlands), M. Biesheuvel, J. Polman, K. Halonen, A.P.J. Haenen, S.C. De Greeff

00537 18:18 **Impact of an antimicrobial stewardship intervention in residential aged care: a multi-centre, stepped-wedge cluster randomised trial (START Trial)** N. Jokanovic* (Melbourne, Australia), S.J. Lee, T. Haines, S. Hilmer, Y.H. Jeon, D. Ayton, R.L. Stuart, A. Cheng, A.J. Stewardson, T.N. Peel, A.Y. Peleg

SY111 17:30 – 18:30 **Hall A2-1**

1-hour Symposium

PED VAX

How to tackle congenital viral infections

Chairs Susanne Gjeruldsen Dudman (Oslo, Norway)
Mike Sharland (London, United Kingdom)

S0275 17:30 **Congenital CMV screening: lessons and implications for prevention** Dana Wolf (Jerusalem, Israel)

S0276 18:00 **Opportunities and challenges of vaccination in pregnancy** Chrissie Jones (Southampton, United Kingdom)

SY109 17:30 – 18:30 **Hall B0-1**

1-hour Symposium

CLN DX

New evidence challenging the UTI paradigm

Chairs Merel Lambregts (Leiden, The Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0271 17:30 **Urobiomics: detection and utility in the UTI universe** Nicole De Nisco (Richardson, Texas, United States)

S0272 18:00 **Complicated UTI: diagnosis and treatment strategies** Florian Wagenlehner (Giessen, Germany)

Co-organised with: ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Urinary Tract Infections (ESGUTI)

SY110 17:30 – 18:30 **Hall B0-2**

1-hour Symposium

CLN DX

Dosing by breakpoints vs guidelines: are S/I/R results based on the focus of infection best practice or source of confusion?

Chairs Iva Butic (Zagreb, Croatia)
Sören Gatermann (Bochum, Germany)

S0273 17:30 **Pro: make AST reports as informative as possible, add different S/I/R results per indication** Mandy Wootton (Cardiff, United Kingdom)

S0274 18:00 **Con: don't confuse clinical colleagues, keep S/I/R fixed and add dosages in the guidelines** Miquel Ekkelenkamp (Utrecht, The Netherlands)

Co-organised with: Dutch Committee on Antimicrobial Policy

SY107 17:30 – 18:30 **Hall ICM 1**

1-hour Symposium

CLN DX

Machine learning to fight against MDR *Acinetobacter baumannii*

Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Abhilasha Karkey (Kathmandu, Nepal)

S0267 17:30 **AI approaches to improve diagnosis and treatment of MDR-Ab** Anton Peleg (Melbourne, Australia)

S0268 18:00 **ML algorithms for distinguishing colonisation from infection by MDR-AB** Gert Marais (Cape Town, South Africa)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID)

SY106 17:30 – 18:30 **Hall ICM 14**

1-hour Symposium

DX

Year in clinical microbiology

Chairs Brigitte Lamy (Bobigny, France)
Holger Rohde (Hamburg, Germany)

S0265 17:30 - Belen Rodriguez-Sanchez (Madrid, Spain)

S0266 18:00 - Surbhi Malhotra-Kumar (Antwerp, Belgium)

SY108 17:30 – 18:30 **Hall ICM 5**

1-hour Symposium

TRN VAX

Immunological determinants of host-pathogen interactions in inflammation and immune compromise

Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Pontus Naucler (Stockholm, Sweden)

S0269 17:30 **The host side of the equation: immune response diversity in streptococcal infections** Anna Norrby-Teglund (Stockholm, Sweden)

S0270 18:00 **Modulation of granulocyte effector response in patients with inflammatory and immunodeficiency disorders** Srikanth Mairpady Shambat (Zurich, Germany)

EF077 17:30 – 18:30 **Arena 1**

ePoster Flash Session

CLN DX PHEI

Diagnosing mycobacterial infections across the globe

Chair Jakko Van Ingen (Nijmegen, The Netherlands)

E0538 17:30 **Clinical and microbiological correlation of NTM PCR** N. Shah* (Svs Road, Mahim West, India), S. Shirole, K. Ajbani, B. Jadeja, S. Gore, S. Ganta, S. Naik, C. Rodrigues, S. Basu, A. Bijwe, U. Agrawal, A. Sunavala

E0539 17:36 **Improving tuberculosis diagnosis through AI (CAD4TB) and Stool-Xpert MTB/RIF: a prospective study from Oromia, Ethiopia** G. Guido* (Bari, Italy), B. Gulo, S. Cotugno, W. Nigusso, K. Bobosha, F.V. Segala, B. Zauli, B. Kenate Sori, G. Putoto, F. Cavallin, G. Madeddu, F.A. Bobbio, N. Veronese, A. Biset Asmare, A. Reta, R. Iatta, S. Abata, M.

E0540	17:42	Miressa, F. Gobbi, L. Guglielmetti, M. Tilahun, A. Saracino, A. Alemseged, F. Manenti, F. Di Gennaro A \$26 gold standard <i>Mycobacterium tuberculosis</i> complete genome using long read sequencing A. Osmaston* (London, United Kingdom), C. Leon, O. Romero, D. Taquiri, P. Avellaneda, J.B. Raez Pereyra, J.L. Perez, S. Huaman, J. Coronel, W. Solano, R. Gilman, A. Torres-Ortiz, G. Tan, B. Sobkowiak, P. Sheen, M. Zimic, L. Grandjean
E0541	17:48	Whole genome sequencing-based clonality assessment of <i>Mycobacterium simiae</i> isolates from Lebanon M. Antar* (Beirut, Lebanon), Z. Awad, S. Aqsous, L. Tabet, C. Allam, M. Abifadel, F. Mougari, J. Najjar-Pellet, E. Cambau
E0542	17:54	Machine learning-assisted differentiation of <i>Mycobacterium tuberculosis</i> complex species from MALDI-TOF mass spectra M. Gutiérrez-Pareja* (Madrid, Spain), F. Alcaide, L. Herrera, D. Domingo, V. González-Galán, J. Viñuelas-Bayon, M. Simón-Sacristán, C. Castelló-Abietar, B. Fernández-Pérez, M. Oviaño, L. Fernández-Delgado, A. Candela, E. Abascal, M.J. Ruiz-Serrano, B. Rodríguez-Sánchez, D. Rodríguez-Temporal
E0543	18:00	The last diagnostic line: molecular pathology uncovers missed <i>Mycobacterial</i> infections L. Wang* (Shanghai, China), G. Shang, L. Qin, Y. Ji, Q. Miao, B. Hu
E0544	18:06	Consensus-based diagnostic evaluation of a novel tuberculosis IGRA in a low-endemic population K. Callebaut* (Bruges, Belgium), T. Chin, V. Verbeke, A. Muyldermans, M. Verhulst, M. Reynders
E0545	18:12	Evaluation of <i>Mycobacterium tuberculosis</i> derived cell-free DNA (CF-DNA) based multi-targeted real-time PCR (MRT-PCR) from extrapulmonary (EPTB) samples for diagnosis of extrapulmonary tuberculosis (EPTB) K. Sharma* (Chandigarh, India), M. Modi
E0546	18:18	Targeted next-generation sequencing-a promising approach in the diagnosis of <i>Mycobacterium tuberculosis</i> and drug resistance X. Wu* (Shanghai, China)
EF078	17:30 – 18:30	Arena 2 ePoster Flash Session
		CLN IPC TRN
Prevention and management of implant-associated infections: biofilm control and beyond		
Chair	Biljana Carevic (Oslo, Norway)	
E0547	17:30	Preventing bacterial colonisation of synthetic bone grafts using nanostructured hydroxyapatite and cold atmospheric plasma-treated liquids A. Ruiz Sorribas* (Barcelona, Spain), F. Tampieri, C. Canal, M.P. Ginebra
E0548	17:36	Supercritical CO2 as an innovative method to inactivate biofilms on orthopaedic implants R. Hafjan Al-Homsi* (Madrid, Spain), R. Hafjan, A. Cabañas, P. Sanz, L. Calvo
E0549	17:42	Bilayer sol-gel coating prevents <i>Staphylococcus aureus</i> prosthetic joint infection and improves bone integration in mice J. Aguilera Correa* (Madrid, Spain), B. Toirac, J.J. Aguilera-Correa, A. Solís-Garrido, A. Mediero, F. Muler, O. Velyt-Vepryk, J. Esteban, A. Jiménez-Morales
E0550	17:48	Risk factors for early infection after spinal instrumentation surgery: a multi-centre case-control study M. Muelas-Fernandez* (Barcelona, Spain), J.A. Iribarren, E. Benavent, A. Marron, J.M. Bravo-Ferrer, H. Vilchez, D. Rodríguez-Montserrat, N. Sopena, M. Riera, O. Gasch, A. Lersundi, M.D. Del Toro, O. Murillo
E0551	17:54	Risk stratification and clinical impact of Gram-negative fracture-related infections F. Petrucci* (Rome, Italy), D. De Meo, P. Martini, M. Rivano Capparuccia, G. Iaiani, S. Gumina, C.M. Mastroianni, A. Oliva
E0552	18:00	Keeping it clean when things inflate: evidence gaps in antimicrobial strategies for penile prosthesis surgery R. Ghani* (London, United Kingdom), P. Sangster, W.G. Lee, S. Dewan, P. Panesar, G. Satta
E0553	18:06	Rifampicin combination therapy fails to enhance clearance and induces growth delay in a rat model of <i>Staphylococcus aureus</i> vascular graft infection E.

E0554	18:12	Characteristics, management and outcomes of vascular graft and endograft infections in Eastern Denmark: a retrospective cohort study A.J. Christensen* (Hilleroed, Denmark), S. Bjerrum, K. Söreljus, I.H.M. Mathiesen, C. Moser, J. Helweg-Larsen, B.V. Sandholt, D. Faurholt-Jepsen, C. Kraef
E0555	18:18	Antibiotic and surgical treatment in staphylococcal ventriculoperitoneal shunt infections in adults I. Pelegrín Senent* (Barcelona, Spain), I. Pelegrin, M. Sanz De Mena, J. Gómez-Junyent, C. Iglesias, M.M. Moreno, A. Siverio, S. Gómez-Zorrilla, L. Sorli, M.M. Montero, J.P. Horcajada
EF079	17:30 – 18:30	Arena 3 ePoster Flash Session
		AMR
Molecular epidemiology and genomic evolution of high-priority MDROs		
Chair	Helena Zemlickova (Prague, Czechia)	
E0556	17:30	Antimicrobial susceptibility and molecular characterisation of carbapenem-resistant Enterobacterales (CRE) from European medical centres stratified by country (2020-2024) H.S. Sader* (North Liberty, United States), J.H. Kimbrough, G. Stone, K. Perez, R. Mendes, M. Castanheira
E0557	17:36	Emergence of new variants of OXA-48 in France L. Bientz* (Le Kremlin-Bicêtre, France), R. Nermon, C. Emeraud, T. Naas, R.A. Bonnin, L. Dortet
E0558	17:42	Spread of carbapenemase-producing <i>Serratia</i> spp. in France from 2016 to 2024: a comparative genomic study L. Dortet* (Le Kremlin-Bicêtre, France), I. Rezzoug, S. Bernabeau, K. Ucel, A. Birer, A. Jousset, L.M. Gerald, E. Cécile, D. Laurent
E0559	17:48	Molecular epidemiology and resistome of carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates from five referral centres in South Africa G. Marais* (Cape Town, South Africa), S. Africa, F. Patel, E. Geza, E. Du Toit, F. Franceschi, R.M.A. Da Costa, A. Brink
E0560	17:54	Emergence of vancomycin-variable <i>Enterococcus faecium</i> following the expansion of Vancomycin-resistant <i>E. faecium</i> in Taiwan W.C. Hung* (Kaohsiung, Taiwan)
E0561	18:00	Increase in OXA-48-like carbapenemase-producing Enterobacterales driven by clonal expansion and plasmid dissemination in the Netherlands, 2019-2024 A. Hendrickx* (Bilthoven, The Netherlands), S. Lansu, A. De Haan, S. Witteveen, J. Bos, F. Landman, C.C.H. Wielders, S.C. De Greeff, D.W. Notermans
E0562	18:06	Plasmid population analysis of <i>Klebsiella pneumoniae</i> spanning two decades M. Martin* (Silver Spring, United States), E. Nguyen, A. Sapre, T. Luo, B. Jones, V. Rollins, R. Maybank, A. Ong, Y. Kwak, J. Bennett, P. Mc Gann, F. Lebreton
E0563	18:12	High prevalence of ESBL Enterobacterales colonisation in elderly people with high care needs in Liverpool, UK J.M. Lewis* (Liverpool, United Kingdom), S. Gallichan, E. Picton-Barlow, C. Mckeown, S. Forrest, M. Moore, S. Todd, M. Taegtmeier, F.E. Graf, N.A. Feasey
EF080	17:30 – 18:30	Arena 4 ePoster Flash Session
		ANT TRN
Beyond the cocktail: advances in phage therapy		
Chair	Maria Vehreschild (Frankfurt Am Main, Germany)	
E0565	17:30	Capsule-independent entry route for <i>Acinetobacter baumannii</i> phage infection H. Oliveira* (Braga, Portugal), S. Lorenz, D. Turner
E0567	17:36	Exploiting the natural power of phage lysins as novel enzyme-based antibiotics to treat polymicrobial Gram-negative infections G. Vandermarliere* (Ghent, Belgium), G. Hermans, D. Grimon, Y. Briers, R. Vázquez, V. Stove, J. De Waele
E0568	17:42	Hidden lytic potential of human gut phages: discovery

		of thousands of endolysins and holins M. Khan Mirzaei* (Neuherberg, Germany), A.H.A. Elbeheri, S. Abdullah, B. Neumann, M.K. Mirzaei, L. Deng
E0569	17:48	Engineered phage therapy using parenteral and intravesical delivery of CRISPR-Cas armed phages (SNIPR001) in mice increase survival and reduces infection? A. Gram* (Copenhagen, Denmark), A. Østergaard Petersen, J. Krause Haaber, E. Van Der Helm, A. Troy, J. Hink, C. Grøndahl
E0570	17:54	Rational selection of a synergistic phage combination enabled clearance of mouse gut colonisation by carbapenemase-producing <i>Escherichia coli</i> ST131 F. Laumay* (Lyon, France), G. Dalmasso, R. Beyrouthy, C. Baeza, B. Lapras, M. Bonhomme, P. Martins-Simoes, E. Helluin, L. Blazere, V. Bonnin, L. Guillouard, R. Froissart, M. Medina, C. Kolenda, F. Piro, L. Dortet, R. Bonnin, R. Bonnet, F. Laurent
E0571	18:00	Exploring phage-amikacin combination against metallo-β-lactamase Gram-negative bacteria in a murine thigh infection model P. Paranos* (Athens, Greece), P.C. Georgiou, S. Pournaras, J. Meletiadi
E0572	18:06	A phage cocktail promotes intestinal decolonisation of multidrug-resistant <i>Klebsiella pneumoniae</i>: insights from a 3D <i>in vitro</i> microbiota model M. Calvigioni* (Pisa, Italy), E. Fausti, C. Ferretti, G. Vozzi, E. Ghelardi, M. Di Luca
E0573	18:12	Regional therapeutic phages and genomic correlates of susceptibility in refractory/resistant <i>Pseudomonas</i> infections: findings from a multi-centre Asian cohort A. Kwa* (Singapore, Singapore), Y. Liu, S. Thong, Z.S. Chong, S.H. Tan, Y. Zhong, A. Chan, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo
E0566	18:18	Mechanistic insights and clinical implications of cross-reactive anti-phage antibodies on phage therapeutic failure A. Peleg* (Melbourne, Australia), F. Gordillo Altamirano, D. Subedi, B. Gardiner, J. Hawkey, J. Barr

ME112	17:30 – 18:30	Hall A2-2
	Meet-the-Expert	

Immunisation strategies for vaccine-preventable arboviral diseases: recent advances and future directions

M0277	17:30	Alfonso J. Rodriguez-Morales (Pereira, Colombia)
M0278	17:42	Antonio Carlos De Albuquerque Bandeira (Lauro De Freitas, Brazil)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

Monday, 20 April 2026

EW120	08:30 – 10:30	Hall A2-2
	2-hour Educational Session	

Future of fungi: biomarkers, big data and mycobiome

<i>Chairs</i>		Methee Chayakulkeeree (Bangkok, Thailand) Oliver A. Cornely (Cologne, Germany)
W0390	08:30	Next-gen biomarkers for invasive fungal disease Laura Alcazar Fuoli (Madrid, Spain)
W0391	08:50	AI in action: big data and models in fungal infections Daniele Roberto Giacobbe (Genoa, Italy)
W0392	09:10	Pulmonary mycobiome: a missing link in lung health? Cecile Angebault (Creteil, France)
W0393	09:30	Steroids and risk: quantifying IFI susceptibility Andrés Henao (Aurora, United States)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Austrian Society for Medical Mycology (ÖGMM), Belgian Society of Human and Animal Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED), Asia Fungal Working Group (AFWG), Taiwan Society of Microbiology

EW118	08:30 – 10:30	Hall ICM 13a
	2-hour Educational Session	

Integrating IPC into hospital design: a collaborative approach to safer hospitals

<i>Chairs</i>		Sabiha Essack (Durban, South Africa) Constantinos Tsioutis (Nicosia, Cyprus)
W0382	08:30	Building safer hospitals: what is the role of the IPC? Margreet C. Vos (Rotterdam, The Netherlands)
W0383	08:50	Consult your architect: optimising infection control through hospital layout and design Marco Gola (Milan, Italy)
W0384	09:10	Collaborating with operations: HVAC systems in healthcare, balancing airflow and infection control Jeffrey Siegel (Toronto, Canada)
W0385	09:30	Consult your water hygienist: engineering and planning aspects of water systems for safe patient care Evdokia Katsemi (Frankfurt, Germany)

EW119	08:30 – 10:30	Hall ICM 13b
	2-hour Educational Session	

Your attention, please! Parasitic infections in immunocompromised patients

<i>Chairs</i>		Miriam José Alvarez Martinez (Barcelona, Spain) Hanne Brekke (Oslo, Norway)
W0386	08:30	A deadly duo: immunosuppression and alveolar echinococcosis Ansgar Deibel (Zurich, Switzerland)
W0387	08:50	Please, do not forget: <i>Strongyloides</i> and immunosuppression Dora Buonfrate (Negrar, Italy)
W0388	09:10	Management of visceral leishmaniasis in the immunocompromised Jaya Tapadar Née Chakravarty (Varanasi, India)
W0389	09:30	Double challenge: Chagas diseases and immunosuppression Marisa Liliana Fernandez (Ciudad Autónoma De Buenos Aires, Argentina)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), Latin American Society for Travel Medicine, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

OS081	08:30 – 10:30	Hall B0-2
	2-hour Oral Session	

Hot topics in tuberculosis

<i>Chairs</i>		Emmanuelle Cambau (Paris, France) Christian Wejse (Aarhus, Denmark)
O0574	08:30	A 3D-bioprinted granuloma platform with controlled syringe-based infection for studying Mtb drug response and host-pathogen interactions R. Sorrentino* (Milan, Italy), R. Pinos, P. Miotto, A. Ghodousi, F. Saluzzo, A. Muscetti, C. Scielzo, D.M. Cirillo
O0575	08:42	Airway microbiome signatures accurately discriminate <i>Mycobacterium tuberculosis</i> infection status G. Olweny* (Kampala, Uganda), A. Kayongo, M.L. Ntai
O0576	08:54	A platelet activation signature defines the CSF compartment in early tuberculous meningitis K. Skolimowska* (London, United Kingdom), A.G. Davis, T. Reid, N. Bangani, C. Stek, P. Renner, M. Panchoo, R.J. Wilkinson, J.S. Friedland
O0577	09:06	A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment J. Donovan* (Ho Chi Minh City, Vietnam), N.T.T. Hiep, T.T. Hung, H.D.T. Nghia, L.H.B. Ngoc, N.D. Bang, K. Maharani, P.K.N. Oanh, E. Riwanti, N.T.T. Thuong, E. Kestelyn, D. Imran, R.L. Hamers, R.B. Geskus, N.H. Phu, G.E. Thwaites
O0578	09:18	Genomic epidemiology as a high-resolution tool to investigate local tuberculosis outbreaks M.G. López* (Valencia, Spain), A. Blasco-Molla, P. Cano-Jiménez, J.C. Gascó-Labordá, I. Gómez-Navarro, V. Furió, M. Torres-Puente, F.J. Roig-Sena, J. Bellido-Blasco, I. Comas

00579	09:30	Assessing the diagnostic accuracy of TB transcriptomic signatures in children: insights from the RaPaed-TB study A. Razid* (Munich, Germany), O. Baranov, M. McClean, Z. Franckling-Smith, H. Zar, C. Khosa, D. Banze, I. Sabi, N. Ntinginya, M. Nliwasa, E. Corbett, R. Semphere, V. Verghese, J. Michael, M. Ninan, E. Saathoff, T. Mchugh, S. Graham, R. Song, P. Nabeta, A. Trollip, M. Nicol, M. Ahmed, M. Hoelscher, N. Heinrich, L. Olbrich, C. Geldmacher, K. Held
00580	09:42	Tuberculosis infections among rifampicin-resistant tuberculosis household contact persons: a multi-central prospective cohort study (TCCT study) F. Zhou* (Shanghai, China), Y. Lan, Q. Yang, W. Zhang, Q. Ruan
00581	09:54	Phenotypic drug susceptibility testing of <i>Mycobacterium tuberculosis</i> in less than a day B.M. Tran* (Uppsala, Sweden), J. Larsson, E. Amselem, P. Knagge, J. Elf
00582	10:06	Are WHO recommended rapid diagnostic tests a panacea for the diagnosis of multidrug-resistant tuberculosis? N. Mvelase* (Durban, South Africa), G. Vadivelu, R. Singh, Y. Mahabeer
00583	10:18	Inadequate access to TB and MDR-TB therapies in the EU and the European economic area: the role of regulatory pathways M. Van Der Heijden* (London, United Kingdom), R. Otto-Knapp, C. Árdal

SY116	08:30 - 10:30	Hall A3-1
	2-hour Symposium	

Mobile elements and plasmids in Gram-positive pathogens: new frontiers in structure, function and clinical impact		
Chairs	Kristin Hegstad (Tromso, Norway) Marc Stegger (Copenhagen, Denmark)	

S0374	08:30	Conjugation and host-range in Gram-positive plasmids: barriers and bridges Elisabeth Grohmann (Berlin, Germany)
S0375	09:00	<i>Enterococcus faecium</i>: mobile elements and AMR spread Jia Qi Beh (Melbourne, Australia)
S0376	09:30	The adaptation of <i>Staphylococci</i> for clonal success Maria Miragaia (Oeiras, Portugal)
S0377	10:00	Resolving mobile elements and plasmids in Gram-positive pathogens: what new genomics reveals Jukka Corander (Oslo, Norway)

Co-organised with: ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY117	08:30 - 10:30	Hall A3-2
	2-hour Symposium	

How to maintain the microbial safety of transfusion and transplantation?		
Chairs	Oscar Len (Barcelona, Spain) Anna Papa-Konidari (Thessaloniki, Greece)	

S0378	08:30	Emerging infections and blood safety: urgent matter Heli Harvala (Turku, Finland)
S0379	09:00	Are syphilis and other sexually-transmitted infections a problem for blood safety? Thijs Van De Laar (Amsterdam, The Netherlands)
S0380	09:30	Tools to prevent transmission of HHV-8 via organ transplantation Ines Ushiro-Lumb (Marlow, United Kingdom)
S0381	10:00	Amyloid beta as a novel transmissible agent John Collinge (London, United Kingdom)

Co-organised with: European Society for Clinical Virology (ESCV)

SY115	08:30 - 10:30	Hall B0-1
	2-hour Symposium	

Interconnected microbiomes and resistomes across One Health		
Chairs	Debby Bogaert (Edinburgh, United Kingdom) John W. A. Rossen (Groningen, The Netherlands)	

S0370	08:30	Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention Amy Mathers (Charlottesville, United States)
S0371	09:00	Silent transmission: the genetic bridges between worlds Bruno Gonzalez-Zorn (Madrid, Spain)
S0372	09:30	Into the wild: connectivity of wildliferesistomes and antimicrobial resistance across sectors Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)
S0373	10:00	From barn to city: environmental transmission of livestock-associated microbiota and antimicrobial resistance Myrna Maria Theresia De Rooij (Utrecht, The Netherlands)

SY113	08:30 - 10:30	Hall ICM 1
	2-hour Symposium	

Sepsis 2026: practice-changing insights you can't ignore		
Chairs	Thierry Calandra (Epalinges, Lausanne, Switzerland) Robin Patel (Rochester, Minnesota, United States)	

S0361	08:30	ISF-ESCMID Sepsis Award
S0362	08:45	Reversing sepsis mortality in Uganda's refugee settlements: a solar-powered diagnostic revolution U. Muhumuza* (Kampala, Uganda), Z. Nahumuza, B.B. Nanyange
S0363	09:00	The new surviving sepsis campaign 2026 guidelines Willem Joost Wiersinga (Amsterdam, The Netherlands)
S0364	09:30	Immunotherapy for sepsis: finally there! Eleni Karakike (Athens, Greece)
S0365	10:00	Sepsis: year in review Annelies Zinkernagel (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY114	08:30 - 10:30	Hall ICM 5
	2-hour Symposium	

Barriers to infectious disease control and treatment in resource-limited settings		
Chairs	Nitin Gupta (Manipal, India) Priscilla Rupali (Vellore, India)	

S0366	08:30	Scrub typhus: a neglected tropical disease Winsley Rose (Vellore, India)
S0367	09:00	The impact of recent severe flooding events and global funding shifts on HIV in Malawi Sam Phiri (Lilongwe, Malawi)
S0368	09:30	Polio eradication in Pakistan: health services, violence, and the 'Long Goodbye' Svea Closser (Baltimore, Maryland, United States)
S0369	10:00	Barriers to cholera control in Malawi amidst climate disasters Anat Rosenthal (Beer Sheva, Israel)

EF082	08:30 - 09:30	Arena 2
	ePoster Flash Session	

Chasing resistance to anti(retro)virals		
Chair	Snjezana Zidovec Lepej (Zagreb, Croatia)	

E0584	08:30	Emergence and persistence of RSV-B resistant variants under monoclonal antibody pressure: evidence in a 3D human airway model A. Caillault* (Créteil, France), A. Ly, P. Cappy, A. Soulier, J.M. Pawlotsky, L. Softic, S. Fourati
E0585	08:36	Resistance mutations on M2 gene of A(H5N1) viruses: are adamantanes still useful against avian influenza? I. Sanz* (Valladolid, Spain), I. Sanz-Muñoz, A. Martín-Toribio, M. Toquero-Asensio, S. Galindo-Carretero, L. Sanchez-De Prada, J. Sánchez-Martínez, C. Rodríguez-Crespo, R. Iglesia-Aparicio, C. López-Gonzalo, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, J.M. Eiros
E0586	08:42	Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in

		influenza A viruses circulating in China, 2018–2025 B. Sun* (Shanghai, China), H. Wang, X. Zhao, J. Ai, W. Zhang	
E0587	08:48	Tracking RSV fusion protein variability across seven decades: risks of resistance to prophylactic antibodies F. Serrano Cano* (Antwerp, Belgium), F.I. Serrano-Cano, K. Stobbelaar, S. Van Looy, K. Van Hoorenbeeck, R. Sanjuán, P. Delputte	
E0588	08:54	Integrated viral resistance analysis in participants with COVID-19 treated with remdesivir across six phase III clinical studies C. Hedskog* (Foster City, Ca, United States), L. Rodriguez, J. Moshiri, D. Han, N. Peinovich, T. Aeschbacher, J. Li, R. Martin, J.K. Perry, R.H. Hyland	
E0589	09:00	Ensitrelvir treatment of COVID-19 across multiple global phase III trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound A. Hurt* (England, United Kingdom), H. Nobori, H. Sakaguchi, A. Luetkemeyer, D. Verdi, F. Draica, S. Portsmouth, T. Uehara	
E0591	09:06	APOBEC-context mutations vs true HIV resistance: evidence from a hospital population in Quito, Ecuador G. Sevillano* (Quito, Ecuador), C. Moreno-Izquierdo, M. Granja, J. Zurita, C. Zurita-Salinas	
E0592	09:12	Limited emergence of dolutegravir-associated resistance mutations in HIV-1 across Africa P. Appiah* (Accra, Ghana), M. Adusei-Poku, B.M. Obeng, R. Osei-Yeboah, E.T. Norgbe, P. Omoniyi, M. Akuka, L. Mac-Ankrah, I. Jamfaru, S. Ankamah, K.O. Duedu, K.W.C. Sagoe	

PM001 08:30 – 10:30 Hall A2-1

Pipeline Symposium

DX PHEI

AI in infectious diseases: the future is now

Chairs	Giorgia Carra (Lausanne, Switzerland) Oliver Nolte (Zurich, Switzerland)
D0001	08:30 AI: risks and opportunities Bram Lestrade (Roermond, The Netherlands)
D0002	09:00 AI: experiences in drug discovery Stephan Sieber (Munich, Germany)
D0003	09:30 AI: modelling epidemics and analysing disease outbreaks Moritz U. G. Kraemer (United Kingdom)
D0004	10:00 AI in the regulatory field Radu Botgros (Amsterdam, The Netherlands)

SY121 09:30 – 10:30 Hall ICM 14

1-hour Symposium

PHEI

Year in public health

Chairs	Alexandra Mailles (Saint-Maurice, France) Rita Oladele (Lagos, Nigeria)
S0394	09:30 - David Fisman (Toronto, Canada)
S0395	10:00 - Kurt Hanevik (Bergen, Norway)

EF083 09:30 – 10:30 Arena 1

ePoster Flash Session

AMR DX TRN

Expanding the role of genomics and proteomics against AMR

Chair	Lorena Lopez Cerero (Seville, Spain)
E0593	09:30 Benchmarking antimicrobial resistance gene prediction tools from metagenomic sequencing data of positive blood cultures K. To* (Hong Kong, Hong Kong), A. Li, D. Buhl, A. Chu, W.M. Chan
E0594	09:36 Molecular characterisation of the first CTX-M-15 and OXA-9 β -lactamase-producing <i>Haemophilus influenzae</i> isolates in the Iberian Peninsula I. Cadenas Jiménez* (L'ospitalet De Llobregat, Spain), A. González-Díaz, M. Pinto, I. Cadenas-Jiménez, S. Duarte, C. Ardanuy, M.M. Ribeiro, S. Martí, P. Bajanca-Lavado
E0595	09:42 Genomic surveillance uncovers polyphyletic, high-risk <i>Escherichia coli</i> lineages in apparently healthy

children and household livestock N. Okumu* (Nairobi, Kenya), E. Cook, O. Cumming, A. Moodley, J. Juma, S. Oyola, J. Ngeranwa, D. Muloi

E0596	09:48	<i>In vitro</i> activity of cefiderocol against carbapenemase-producing <i>E. coli</i> : phenomics vs genomics for antimicrobial susceptibility prediction M. Razavi* (Stockholm, Sweden), C. Tellapragada, P. Jonsson, C. Giske
E0597	09:54	Quantifying the association of resistance with antimicrobial resistance genes in <i>Escherichia coli</i> for new β -lactam/ β -lactamase-inhibitor/enhancer combinations J. Takata* (Oxford, United Kingdom), D. Nagy, V. Pennetta, K. Hopkins, A. Roohi, D. Karageorgopoulos, M.B. Avison, A. Mathers, R. Hope, D. Williams, A. Ledda, J. Robotham, C.S. Brown, P. Bejon, G. Mcvean, A.S. Walker, K.L. Hopkins, S. Lipworth, N. Stoesser
E0598	10:00	K-MARVEL: K-Mer-based antimicrobial resistance virtual exploration lab R. Ahmad* (Hamar, Norway), N.S. Mahar, S. Branders, M.G. Grabherr, I. Gupta
E0599	10:06	Early antimicrobial resistance prediction using urinary proteomics and machine learning E. Lemann* (Gothenburg, Sweden), A. Marchi, R. Karlsson, A. Polster
E0600	10:12	Genomic characterisation of carbapenem-resistant Enterobacterales (CRE) reveals high-risk clones and patient-environment transmission in a Nigerian tertiary hospital B.A. Olanipekun* (Ilorin, Kwara State, Nigeria), L.A. Molano, J. Rehner, A. Afolayan, P. Jung, R. Raheem, A. Fadeyi, A. Keller, A. Shittu, C. Nwabuisi, S. Becker
E0601	10:18	A Next-generation platform for culture-free AMR gene identification in human infections T. Mehrotra* (Faridabad, India), B. Das

EF084 09:30 – 10:30 Arena 3

ePoster Flash Session

TRN

From virus to host and back again: exploring retroviruses

Chair	Anna Maria Geretti (London, United Kingdom)
E0602	09:30 Defining the contribution of T lymphocyte activation and proliferation to the HIV reservoir L. Santinelli* (Rome, Italy), L. Bortolani, L. Maddaloni, M. Andreotti, Z. Michelini, C. Falvino, G. Ceccarelli, C.M. Mastroianni, G. D' Ettore
E0603	09:36 Unexpected high prevalence of HTLV-1 in HIV-1 positive patients: a looming crisis? G. Zahra* (Tehran, Iran, Islamic Republic of), A. Letafati, L. Abbasian, S. Sadeghipour Marvi, S.H. Mozgani, B. Sarshari
E0604	09:42 Immune checkpoint LAG3 overexpression reflects T cell dysfunction in PLWH with low CD4/CD8 ratio G. Nunnari* (Catania, Italy), S. Spampinato, G. Scuderi, M. Pinzone, N.L. Parrinello, M. Di Rosa, F. Condorelli, E. Venanzi Rul, A. Marino, R. Bruno, B. Cacopardo, B.M. Cesesia, F. Di Raimondo, P. Fagone
E0605	09:48 Near full genome sequencing of HIV-2 M. Obermeier* (Berlin, Germany), Ö. Yildirim, M. Prentice, R. Ehret
E0607	09:54 Exploring immune correlates of low viral reservoir burden in people living with HIV following early ART initiation: a retrospective longitudinal study from the DZIF TOP-HIV cohort M. Figueroa Orozco* (Munich, Germany), E. Grüner, M. Münchhoff, R. Cohen, T. Trenkner, M. Beiersdorfer, A. Hölzemer, J. Roeder
E0608	10:00 HIV-1 Subtype definition in the era of whole genome sequencing F. Stefanelli* (Genoa, Italy), N. Randazzo, N. Nigro, S. Varesano, M. Ferraris, E. Massaro, V. Paolozzi, M. Ogliastro, L. Taramasso, V. Ricucci
E0609	10:06 Comparison of HIV clusters in metropolitan France and overseas territories B. Visseaux* (Frepillon, France), N. Rybak, G. Wartel, L. Nguyen, M. Niang, E. Hedbaut, S. Teixeira, V. Kailainathan, K. Diallo, S. Lasteré

LB006 11:00 – 12:00 Hall A1-1

1-hour Oral Session

PHEI

Late-breaking disease surveillance approaches

Chairs	Megan Carey (Amsterdam, The Netherlands) Carla Rodrigues (Paris, France)
--------	---

L0031	11:00	Inferring the global risk of dengue outbreaks V. Cabrini* (Singapore, Singapore), M.K.B. Mohamad Rosle, E.L.W. Choo, Y. Chen, J.T. Lim
L0032	11:12	A climate-responsive emerging disease risk projection platform: version 1 release and early adoption opportunities J. Abbate* (Montpellier, France), V. Heurteaux
L0033	11:24	Evaluation of a host-based, pathogen-agnostic viral biomarker for early outbreak detection R. Mehta* (London, United Kingdom), H. Hopkins, D. Mabey, E. Fitchett, P. Randell, A. Mohamed, M. Mayxay, Q. Bassat, J. Chipanga, C. Christopher, L. Papargyris, H. Wagstaff, S. Ascough, S. Hamilton, M. Levine, J. Herberg, O. Ioana-Diana, L. Maslen, M. Valdivia-Garcia, C. Anthony, E. Chekmeneva, S. Sriskandan
L0034	11:36	Metagenomics surveillance collaboration and analysis programme (mSCAPE): preliminary results from a national metagenomics surveillance pilot S. Rokadiya* (London, United Kingdom), N. Groves, R. Graham, A. Aryee, C. Rodrigues, R. Cohring, C. Houlihan, R. Puleston, S.A.J. Wilkinson, T. Brier, J. James, A. Banyard, D. Ward, R. Batra, J. Edgeworth, N.J. Loman, M. Chand
L0035	11:48	Sustained mpox clade I human-to-human spread in DRC calls for continuous variant monitoring E. Kinganda-Lusamaki* (Kinshasa, Congo, the Democratic Republic of the), A. Amuri-Aziza, J.C. Makangara Cigolo, R. Lumembe-Numbi, G. Kabamba-Lungenyi, G. Luakanda-Ndelemo, P. Akil-Bandali, T. Wawina-Bokalanga, S. Ahuka Mundeke, J.J. Muyembe-Tamfum, A. Ayouba, E. Delaporte, M. Peeters, P. Mbala-Kingebeni

OS087 11:00 – 12:00 Hall A1-2
1-hour Oral Session

Hospital- and ventilator-associated pneumonia: new insights on prevention, diagnosis and treatment

Chairs Christian Lanckohr (Muenster, Germany)
Elisabeth Presterl (Vienna, Austria)

O0611	11:00	The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial B. Mitchell* (Gosford, Australia), N. White, P. Russo, A. Cheng, M. Kiernan
O0612	11:12	Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): secondary analysis using desirable outcome ranking with response adjusted for duration antibiotic risk and generalised pairwise comparison A. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, N.A. Binte Mohamed, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo
O0613	11:24	Antibiotic duration-response curve for ventilator-associated pneumonia using a target trial emulation W.C. Tan* (Singapore, Singapore), J. Quah, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, L. Yie Hui, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, J. Chaisurote, P. Poomthong, A. Kawiwangsanon, K. Semram, S. Kitsaran, P. Wongsrikaew, N. Wetchagama, S. Patamatham, A. Rujisirasankul, A. Narmwong, C. Sodapak, S. Nuntalohit, S. Boonsong, J. Nilsakul, J. Moolasart, A. Phunmanee, A. Panitchote, P. Duangthongphon, P. Pisuttimarn, N. Srisurat, Y. Hwee Seng, G. Maclaren, T.W. Lim, K.L. Chew, S.L. Lim, B.W. Teo, T.J. Lim, L.J. Sun, S. Peng, N. Graves, Y.T. Chew, L.M. Ling, P.Y. Chia, Y.W. Chia, W. Huang, Y.K. Chan, P. Roshan, S. Anil, K. Abhilasha, D. Sabina, F.F. Tuon, B.S. Cooper, Y. Mo
O0614	11:36	Trimethoprim/sulfamethoxazole vs vancomycin for MRSA ventilator-associated pneumonia: a retrospective study F. Tuon* (Curitiba, Brazil), A. Salomão, V. Sabbaga Amato, J.P. Telles
O0615	11:48	Impact of antimicrobial stewardship programmes on hospital-acquired and ventilator-associated pneumonia among adults: a systematic review and meta-analysis S. Rachina* (Moscow, Russian Federation), N. Ablakimova, D. Strelkova, A. Suvorov, G. Smagulova

OS088 11:00 – 12:00 Hall A1-3

CLN DX TRN 1-hour Oral Session

Focus on infective endocarditis: from pathogens to prognosis

Chairs Tatjana Lejko Zupanc (Ljubljana, Slovenia)
Parham Sendi (Bern, Switzerland)

O0616	11:00	BlaZ-associated mortality in patients with Staphylococcus aureus endocarditis P. Mathé* (Freiburg, Germany), M.T. Leibenguth, M. Hanke, S. Schuster, J. Camp, D. Hornuss, G. Peyerl-Hoffmann, A.J. Kaasch, I. Joost, H. Seifert, W. Kern, S. Rieg
O0617	11:12	Evaluation of different scores for the prediction of infective endocarditis among patients with Staphylococcus aureus bacteraemia Z. Dennebouy* (Lausanne, Switzerland), M. Padrutt, P. Monney, G. Tzimas, M. Frank, L. Senn, L. Niclauss, M. Kirsch, M. Van Hemelrijck, O. Dzemali, B. Guery, B. Hasse, M. Papadimitriou-Olivgeris
O0618	11:24	Removal of cardiac implanted electronic devices in patients with Staphylococcus aureus bacteraemia without endocarditis is not associated with improved survival D. Macfadden* (Ottawa, Canada), S. Almoosawy, E. Athan, D. Birnie, J. Davis, W. Gold, M. Golian, J. Johnstone, T. Lee, E. McDonald, D. Messika-Zeitoun, S. Ong, M. Cheng, S. Tong, H. Wijeyesundera, C. Yu, N. Daneman, L. Lau
O0619	11:36	Characteristics of infective endocarditis caused by Enterococcus faecium: a study from the GAMES cohort E. Aparicio-Mingujón* (Madrid, Spain), P. Muñoz, M. Machado-Vilchez, M. Valerio-Minero, A. Josune Goikoetxea-Agirre, M.J. Blanco-Vidal, M.Á. Rodríguez-Esteban, C. Hidalgo-Tenorio, G. Ojeda-Burgos, J.M. Miró, R. Parra-Fariñas, V.A. Hortigüela Martín, I. Diego Yagüe, F. López-Medrano
O0620	11:48	Should we extend the use of oral antibiotics in infective endocarditis? the ENDO-ORAL study R. Pouy* (Reims, France), B. Rallet, C. Coutureau, M. Blot, F. Bani-Sadr, T. Sixt, M. Moutel, L. Piroth, M. Hentzien

OS089 11:00 – 12:00 Hall A1-4
1-hour Oral Session

Mechanistic insights into antimicrobial activity and resistance of Gram-negative bacteria

Chairs Kwame Ohene Buabeng (Ho, Ghana)
Thomas Tängdén (Uppsala, Sweden)

O0621	11:00	Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in Escherichia coli M. Murillo Torres* (Seville, Spain), M. Murillo-Torres, K. Alexandre, Á. Pascual, F. Docobo-Pérez, J.M. Rodríguez-Martínez
O0622	11:12	Characterising penicillin-binding protein 2 (PBP2) mutations causing zidebactam resistance in Pseudomonas aeruginosa M.Á. Sastre-Femenia* (Palma, Spain), M.A. Gomis-Font, B. Moya, A. Oliver
O0623	11:24	Spontaneous resistance to siderophore-conjugated β-lactams in Klebsiella pneumoniae: diverse mechanisms and fitness effects G. Zaborskyte* (Oxford, United Kingdom), G. Zaborskyte, A. Lankapalli, A.J.M. Farley, C.J. Schofield, T.R. Walsh
O0624	11:36	Pre-existing β-lactamase gene diversity reduces ESBL-producing Enterobacterales colonisation risk in patients exposed to ceftriaxone Q. Le Bastard* (Nantes, France), R. Gschwind, J. Lao, M.A. Vibet, B. Eric, C. Stéphane, M. Emmanuel, E. Etienne
O0625	11:48	Optimising the treatment regimen with phage cocktails and ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa endotracheal tube biofilms V. Oliveira* (Barcelona, Spain), A. Rocha, A. Soler-Comas, G. Macip, E. Watanabe, M. Ferrer, A. Torres, L. Fernandez-Barat

OS090 11:00 – 12:00 Hall A1-5
1-hour Oral Session

Overcoming diagnostic challenges in low resource settings

Chairs Nitin Gupta (Manipal, India)
Juliette Severin (Rotterdam, The Netherlands)

O0626	11:00	BADLOCK: a rapid, portable, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings D. Roach* (Somerville, United States), P. Sangruji, S. Bhat, R. Bhattacharyya
O0627	11:12	Accelerating bacteraemia management with molecular-AI vs molecular-phenotypic AI antimicrobial recommendations: a prospective study in a resource-limited setting J. Gomez De La Torre* (Lima, Peru), J.C. Gómez De La Torre, A. Frenkel, C. Chavez-Lencinas, A. Rendon, Y. Higuchi, L. Alvarado, J.A. Cáceres-Delaguila, D. Minchon-Vizconde, M. Hueda-Zavaleta
O0628	11:24	Microbiology lab implementation in low-resource settings: does it help clinicians reducing antibiotic prescriptions for hospitalised patients? H. Nguyen Thi* (Ha Noi, Vietnam), T. Hoang Van, H. Tran Thi, C. Dang Quang, H. Tran Thi Bich, H. Phan Quoc, M. Nguyen Duy, H. Nguyen Ba, H. Phan Van, T. Pham Le, G. Bui Thi Huong, T. Pham Thi Thanh, H. Nguyen Thi Thu, D. Pham Minh, H. Dinh Xuan, K. Bui Xuan, H. Nguyen Thi Bich, L. To Duc, H. Nguyen Ngoc, T. Van Dinh, H. Nguyen Thanh, Y. Nguyen Hai, P. Bui Bich, H. Vu Thi Lan, R. Van Doorn, T. Kesteman
O0629	11:36	Addressing diagnostic limitations in enteric fever in resource-limited settings S. Dongol* (Lalitpur, Nepal), N. Maharjan, A. Karkey, C. Parry, B. Basnyat
O0630	11:48	Evaluation of immunochromatographic assays for carbapenemase detection: a multi-centre study within the strengthening a Brazilian system for surveillance and prevention of antimicrobial resistance network (VigIRAM) M. Pillonetto* (São José Dos Pinhais, Brazil), L. Kraft, G.A. Gonçalves, H.R.S. D'espindula, D. Kulek, A.P.S. Chacon, J.M. Cieslinski, R.T. Souza, A.L. Abreu, A.P. Assef, B.R. Sued-Karam, I. Cassiano De Oliveira Santos, G. Santos, M.E. Conde

OS091	11:00 - 12:00	Hall A3-2
	1-hour Oral Session	

Intracellular persistence of Gram-negative pathogens: immune evasion and implications for treatment

Chairs Christian Stephan Lentz (Tromsø, Norway)
Nina Van Sorge (Amsterdam, The Netherlands)

O0631	11:00	OmpA controls intracellular survival of <i>Acinetobacter baumannii</i> through TFEB activation and lysosomal remodeling Á. Rey Hidalgo* (Seville, Spain), A. Rey-Hidalgo, M. Pérez-Pérez, G. Olgiate, C. Atalaya-Rey, I. Molina-Panadero, Y. Smani
O0632	11:12	Intracellular invasion of osteoblasts by Gram-positive bacteria and the impact of vancomycin eluted from orthopaedic cement R. Brull Tuma* (São Paulo, Brazil), L. Batista Campos, M. Muniz De Andrade Silva, M. Neri Lucas Kurihara, I.N. Marcelino Santos, M.A. Midolli Vieira, R.D.C. Sinigaglia, T.A. Tardelli Gomes Do Amaral, M.J. Costa Salles
O0633	11:24	T5SS-Mediated contact-dependent inhibition drives intracellular UPEC persists contributing to recurrent UTI M. Obrebski* (Warsaw, Poland), M. Obrebski, M. Kirzyc, M. Równicki, J. Piwowarski
O0634	11:36	The intracellular state: a fortress of persistence for uropathogenic <i>Escherichia coli</i> J. Atrissi* (Brussels, Belgium), J.F. Ouédraogo, F. Van Bambeke
O0635	11:48	The human bladder microenvironment and urinary fluid dynamics modulate antibiotic and bacteriophage treatment against uropathogenic <i>Escherichia coli</i> J. Rohn* (London, United Kingdom), R. Garcia Maset, A. Crowther, V. Chu, D. Di Grande, R.O.A. Jariah, J. Yoon, D. Blumgart, M.A.E. Hodek, N. Yuen, B.O. Murray, L. Pasquina-Lemonche, S.N.H. Alghamdi, A.D. Millard, G. Lutheryn, M.E.K. Haines, M.R.J. Clokie, E. Stride, D. Carugo

OS085	11:00 - 12:00	Hall ICM 13a
	1-hour Oral Session	

Artificial intelligence: emerging applications for medical mycology

Chairs Toni Gabaldón (Barcelona, Spain)
Maurizio Sanguinetti (Rome, Italy)

O0636	11:00	Machine learning-based predictive model for invasive mould infections in haematology patients: development and validation E. Gras* (Barcelona, Spain), C. Teijón-Lumbreras, P. Monzo-Gallo, B. Glemain, T.F. Aiello, A. Gallardo-Pizarro, A. Martínez-Urrea, C. Terrones, A. Castiella, A. Vergara, C. Martínez, M. Suarez-Lledó, J. Esteve, A. Soriano, C. Garcia-Vidal
O0637	11:12	Machine learning for genomic antifungal susceptibility prediction in <i>Candidozyma auris</i> Y. Zhong* (Liverpool, United Kingdom), G. Alessandro, H. Alex, B. Charlie, H. William
O0638	11:24	Advancing fungal disease impact assessment: development and pilot validation of a semi-automated AI-based surveillance algorithm for invasive aspergillosis S. Kleinsteuber* (Leiden, The Netherlands), M. Van Der Beek, J. Buil, P. Verweij, M. Reijers, R. Bruggemann, M. De Boer
O0639	11:36	Evaluation of the performance of large language models in mycological diagnosis M. Aras* (Istanbul, Türkiye), M.I. Tosun, N. Samancı, I. Caklovica Kucukkaya, S.A. Ozyar Kurtcu, E. Kirbas, B. Sayar, B. Sancak, D.Y. Metin
O0640	11:48	Machine learning-based gene screening unravels key determinants of caspofungin resistance Y. Su* (Beijing, China), Y. Xu

OS086	11:00 - 12:00	Hall ICM 13b
	1-hour Oral Session	

Vaccines: landmark trials and preventive immunisation

Chairs Joel Mossong (Luxembourg, Luxembourg)
Oana Sandulescu (Bucharest, Romania)

O0641	11:00	Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive <i>Escherichia coli</i> disease (IED) in older adults (E.mbrace) K.A. Cohen* (Titusville, United States), C. Mclean, T. Day, M. Peeters, I. Scheys, M.G. Pau, J. Poolman, M. Bonten
O0642	11:12	Avian influenza A (H5N1) clade 2.3.4.4b haemagglutinin-Matrix-M nanoparticle vaccine (H5-MNP) induces neutralising responses and protection against H5N1 challenge in mice C. Bennett* (Gaithersburg, United States), R. Draghia Akli, J.F. Trost, B. Zhou, K. Pyles, T.L. Darling, A.C.M. Boon, G.E. Smith
O0643	11:24	Final results from a phase IIb randomised controlled trial assessing the efficacy and impact of full- and fractional-dose regimens of the RTS,S/AS01E malaria vaccine in Ashanti Region, Ghana and Siaya County, Kenya, September 2019 - November 2024 D. Otieno* (Kisumu, Kenya), K. Sam
O0644	11:36	High-dose vs standard-dose influenza vaccine effectiveness according to frailty risk: a prespecified analysis of the DANFLU-2 trial C. Espersen* (Hellerup, Denmark), N.D. Johansen, D. Modin, K.H. Janstrup, M.M. Løiacono, R.C. Harris, Y. Huang, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M. Dons, L.S. Duus, F.H. Fusing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, G. Gavazzi, T. Biering-Sørensen
O0645	11:48	Effectiveness of PCV10 and PCV13 against invasive pneumococcal disease in Vietnamese children: a multi-centre matched case-control study C. Truong* (Ho Chi Minh, Vietnam), T. Nguyen, N. Speybroeck

SY124	11:00 - 12:00	Hall A2-2
	1-hour Symposium	

Innovations in the management of tuberculosis and non-tuberculous mycobacteria

Chairs Catherine Ong (Singapore, Singapore)
Onya Opota (Lausanne, Switzerland)

S0323	11:00	New diagnostics for mycobacterial infection Daniela Maria Cirillo (Milan, Italy)
S0324	11:30	Applying pharmacokinetics for the optimisation of mycobacterial treatments Elin Svensson (Uppsala, Sweden)

SY125 11:00 – 12:00 Hall A3-1
1-hour Symposium

CLN IPC

Surgical site infections after solid organ transplantation: an underestimated driver of transplant outcome

Chairs Wanessa Clemente (Belo Horizonte, Brazil)
Elda Righi (London, United Kingdom)

S0325 11:00 SSIs after visceral transplantation Nicolas Mueller (Zurich, Switzerland)

S0326 11:30 SSIs after thoracic transplantation Manuela Carugati (Durham, United States)

SY123 11:00 – 12:00 Hall ICM 5
1-hour Symposium

ANT TRN

Going super small: nano-technology in infectious diseases

Chairs Elisa Borghi (Milan, Italy)
Gregor Fuhrmann (Erlangen, Germany)

S0321 11:00 Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery Eleanor Stride (Oxford, United Kingdom)

S0322 11:30 Nanotechnologies for precision immunotherapy and infection treatment Willem Mulder (Eindhoven, The Netherlands)

EF092 11:00 – 12:00 Arena 2
ePoster Flash Session

ANT CLN PHEI

Antimicrobial stewardship in low resource countries: challenges and solutions

Chair Igizeneza Acsa (Kigali, Rwanda)

E0646 11:00 Antimicrobial prescribing in five primary healthcare centres in northern Syria: a global PPS based period prevalence survey F. Abdo* (Amman, Jordan), K. Parikh, Z. Ejelal, A. Boven, A. Versporten, I. Pauwels, E. Vlieghe, A. Luczynska, R. Esguerra, C. Roman

E0647 11:06 Observed vs expected antibiotic use in MSF-supported primary outpatient MSF settings in North-West Syria C. Naim* (Beirut, Lebanon), K. Moussally, P. Garcia-Vello, M. Khalife, C. Arias Vicente, A. Almohamad, Z. Ejelal, A. Wetti, B. Alonso, A. Ali, C. Roman, M. Yaacoub, M. Gazal, A. Comelli, A. Farra

E0648 11:12 A practical observational tool to measure antimicrobial stewardship and infection prevention behaviours in a low-resource hospital setting C. Bonaconsa* (Cape Town, South Africa), T. Makamu, A. Kona, M. Samkele, E. Charani

E0650 11:18 Tailoring empirical antibiotics to local resistance in severely malnourished hospitalised children in Niger: secondary analysis of a prospective cohort C. Langendorf* (Paris, France), A. Delafon-Pariset, N. Peiffer-Smadja, R. Kanapathipillai, C.T. Andersen, S. Garba, N. Sayinzonga-Makombe, E.I. Tassiou, R. Daré, S. Isanaka, C. Amaris Hobson, M. Thy, C. Jimenez, B. Mollo

E0651 11:24 Factors influencing antibiotic use in patients without bacterial infections during the COVID-19 pandemic in a tertiary care centre in a low-middle-income country N. Nasir* (Karachi, Pakistan), W. Fazal, Z. Nasim, N.S. Khan

E0652 11:30 Antimicrobial and corticosteroid prescribing for adults with suspected CNS infection in Botswana and Zimbabwe C. Coughlan* (London, United Kingdom), T. Mwarumba, R. Suresh, K. Ngoni, G. Manenji, R. Doyle, K. Boyd, C. Northcott, J. Penney, M. Kinsella, I. Mechie, S. Ensor, C. Williams, K. Lechiile, S. Siamisang, L. Owen, E. Gwakuba, T. Milton, T. Machiya, H.E. Barton, P. Ponatshego, K.

E0653 11:36 Hospital pharmacists in antimicrobial stewardship in Latin America: roles and challenges E. Zavaleta* (San Jose, Costa Rica), J.P. Diaz, R. Mosmann, P. Lichtenberger, R. Quiros

E0654 11:42 Effects of participatory learning and action with primary care doctors on antibiotic prescribing for acute respiratory infections in Vietnam: a pilot cluster randomised study M.D. Vu* (Hanoi, Vietnam), N.Y. Nguyen, N.T.H. Nguyen, P.B. Bui, V.T. Khuong, H.T.T. Duong, L.V. Le, G. Coact Investigators, H.R. Van Doorn, N.T.T. Do, S. Nagraj, S. Lewycka

EF093 11:00 – 12:00 Arena 3
ePoster Flash Session

AMR

MDR pathogens around the globe: mechanisms, risk, and treatment optimisation

Chair Merica Carev (Split, Croatia)

E0655 11:00 Clinical outcomes and risk factors for mortality in serious infections due to carbapenem-resistant *Acinetobacter baumannii* in Asia Y. Chang* (Kaohsiung City, Taiwan), A. Manesh, L. Mezzadri, X. Hao, Y. Ding, C. Yang, C. Yiyang, S. Kitsaran, H.H. Chua, B. Sotharith, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S.F. Mahmood, A.D. Roman, L. Thwaites, K.A. Nguyen, V.T. Phan, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O.R. Khalid, G.M.S. Mamun, G.S. Rajahram, H. Guterres, N.H. Huynh, V.G. Tran, N.T. Pham, A. Karkey, S. Gunasekara, R.L. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, L. Priya, Y. Doi, H. Hitoshi, B. Baljin, R. Asli, U. Gurjav, L. Ling, A. Dhungana, L.Y. Hsu, Y. Mo, D.L. Paterson

E0656 11:06 Activity of cefiderocol against *Stenotrophomonas maltophilia* clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014 - 2019) and SENTRY (2020 - 2024) Y. Yamano* (Osaka, Japan), C. Longshaw, S.T. Nguen, J.M. Maher, R.E. Mendes, M. Hackel, H. Yamashiro, B.L.M. De Jonge

E0657 11:12 Emergence and characterisation of multi-carbapenemase-producing *Klebsiella pneumoniae* in Italy: genomic features and *in vitro* therapeutic options A. Cornacchia* (Teramo, Italy), S. Comini, F. Pomilio, C. Costa, M. Boattini, G. Bianco

E0658 11:18 Epidemiology of penicillin-binding protein 3 variants in carbapenem-resistant *Escherichia coli* isolates from France I. Mehidi* (Le Kremlin-Bicêtre, France), A. Birer, A. Jacquemin, A.B. Jousset, P. Glaser, R.A. Bonnin, L. Dortet, S. Oueslati, T. Naas

E0659 11:24 Integrating the ECRAID Emerging Resistance Index (ERI) into antibiotic policy for new antibiotics targeting multidrug-resistant Gram-negative bacteria: a proof-of-concept analysis M.D. Pezzani* (Verona, Italy), J. Garlasco, D. Ortiz, K. Odoj, F. Arietti, A. Savoldi, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, E. Tacconelli

E0660 11:30 Tracking *Clostridioides difficile* in Ireland: genomic landscape and antimicrobial resistance profiles of clinical isolates, 2022–present D. Espadinha* (Dublin, Ireland), N. O' Mara, A. Carroll, T.K. Teoh

E0661 11:36 Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms Y. Hong* (Hangzhou, China), Y. Chen

E0662 11:42 Molecular epidemiology and antimicrobial resistance of *Mycoplasma genitalium* in Tokyo, 2023–2025 R. Omachi* (Saitama, Japan), K. Imai, T. Maeda, A. Sato, M. Tanaka, N. Mori

KN122 11:00 – 12:00 Hall ICM 14
Keynote lecture

PHEI TRN

On virus origin, evolution, and the next pandemic threat

Chairs Giulia De Angelis (Rome, Italy)

K0320 11:00 Edward Holmes (Sydney, Australia)

ME127 11:00 – 12:00 Hall B0-1

Meet-the-Expert

DX TRN

Microbiome-based diagnostic tools, are we ready for prime-time?

M0329 11:00 Debby Bogaert (Edinburgh, United Kingdom)

M0330 11:12 Gianluca Ianiro (Rome, Italy)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME128 11:00 – 12:00 Hall B0-2

Meet-the-Expert

CLN DX

The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches

M0331 11:00 Martin Montes (Lima, Peru)

M0332 11:12 Diana Ayoola Mabayoje (London, United Kingdom)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

ME126 11:00 – 12:00 Hall ICM 1

Meet-the-Expert

AMR DX

Applications of machine learning for predicting virulence and resistance by MALDI-TOF MS: opportunities and challenges

M0327 11:00 Adrian Egli (Zurich, Switzerland)

M0328 11:12 Jaroslav Hrabak (Plzen, Czechia)

FO129 11:00 – 12:00 Arena 1

Open Forum

PRO

Panic vs calm: the pivotal roles of trainees in infectious disease responses

Chair Casandra Bulescu (Bucharest, Romania)

F0333 11:00 Being in the frontline: shaping public messaging during outbreaks Ferenc Balázs Farkas (Budapest, Hungary)

F0334 11:10 From crisis to resilience: the role of early career researchers in outbreak response Jules Villa (Paris, France)

F0335 11:20 COVID-19 pandemic memories: what can we learn for future crises? Aleksandra Barac (Belgrade, Serbia)

Co-organised with: ESCMID Emerging Infections Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

PM002 11:00 – 12:00 Hall A2-1

Pipeline Symposium

AMR PHEI

Accelerating access: rethinking HTA to unlock AMR solutions

Chairs Maarten Postma (Groningen, The Netherlands)
Charlotte Vernhes (Brussels, Belgium)

D0005 11:00 Data: what's available today and where are the key gaps? Marlieke De Kraker (Geneva, Switzerland)

D0006 11:15 Full economic value of AMR solutions in HTA Michele Cecchini (Paris, France)

D0007 11:30 EU HTA regulation and AMR solutions: lessons from vaccines Eliana Biundo (Wavre, Belgium)

OS096

13:30 – 14:30

Hall A2-2

1-hour Case Session

CLN DX PHEI

Protozoa and microsporidia: rare and emerging

Chairs Aleksandra Barac (Belgrade, Serbia)
Emmanuel Bottieau (Antwerp, Belgium)O0664 13:30 A *Plasmodium vivax* case identified only by use of next-generation sequencing C.R. Stensvold* (Copenhagen S, Denmark), H.V. Nielsen, J.K. White, J. Szeps, K. Wyss, S. Botero-KleivenO0665 13:41 *Leishmania* (Mundinia) procaviensis as an emerging pathogen: first confirmed human infection identified by target-gene sequencing A. Andrianaki* (Zurich, Switzerland), D. Weller, F. Grimm, M. Concu, B. Nickel, A. Neumayr, M.B. KälinO0666 13:52 Disseminated *Toxoplasma gondii* infection with haemophagocytic lymphohistiocytosis D. Walzer* (Freiburg, Germany), C. Kaech, S. RiegO0667 14:03 Insights from a fatal case of disseminated albendazole refractory *Annacaliia algerae* myositis S. Fernando* (Sydney, Australia), S. Mcginn, S. Ahmer, H.C. Soh, L. Tan, G. Kotsiou

O0668 14:14 Non-resolving cerebral toxoplasmosis in an immunodeficient patient J. Olchowski* (Haifa, Israel), M. Paul

OS094

13:30 – 14:30

Hall ICM 13a

1-hour Case Session

CLN PHEI

Challenging and complicated viral infections

Chairs Alexandra Mailles (Saint-Maurice, France)
Annabel Niessen (Utrecht, The Netherlands)

O0669 13:30 Chronic herpes simplex virus type 2 necrotising granulomatous pachymeningitis after glofitamab: an unusual CNS infection in an immunocompromised patient N. Jain* (Auckland, New Zealand), B.S. Chen, L. Berkahn, M. Strauss, R. Lane

O0670 13:41 First documented case of a fatal autochthonous Usutu virus infection in an immunocompromised patient in Hungary B. Szabo* (Budapest, Hungary), B.G. Szabó, A. Nagy, O. Nagy, A. Koroknai, N. Csonka, D. Korózs, K. Jeszenszky, A. Hardi, N. Deézsi-Magyar, J. Sztikler, Z. Bódi, D. Cadar, G.E. Tóth, L. Veres, E. Barcsay, M. Takács, J. Sinkó

O0671 13:52 But its got to be PML, right? chronic myeloencephalitis 14 year after heart transplant L. Lippert* (Berlin, Germany), S. Albus, D. Grund, M. Witzentrath, L. Sander

O0672 14:03 Long-term survivor of BoDV-1 encephalitis: complex immunotherapy, neuroimaging signatures and late viral reactivation: a case report I. Masouris* (Munich, Germany), I. Wilkens, D. Grabova, M. Chen, H. Klauß, L. Keidel, D. Hauptstein, C. Eckert, V. Ruf, M. Schmutzer-Sondergeld, M. Brendel, R. Forbrig, G. Höglinger, A. Straube, F. Sörgel, M. Bauswein, D. Tappe, F. Schöberl

O0673 14:14 Changing landscape of paediatric influenza-associated neurological complications: a single-centre case series from northern Italy (2024-2025) L. Franzetti* (Milan, Italy), C. Porro, S.M. Bova, C. Giovannini, A. Gadda, A. Rizzo, A. Lombardi, F. Salari, G. Zuccotti, E. Fusco, L. Folgori

OS095

13:30 – 14:30

Hall ICM 13b

1-hour Oral Session

PRO

Precision pedagogy: AI-driven and data-driven education

Chairs Sarah Delliere (Paris, France)
Mary Horgan (Dublin, Ireland)

O0674 13:30 Large Language Model-assisted OSCE stations in infectious diseases: faster, high-quality, and well-received by faculty S. Villard* (Paris, France), C.A. Hobson, Y. Guedj, L. Khider, A. Mageau, J. Mesnier, M. Sanchez, S. Voicu, S. Peiffer-Smadja, N. Burnichon, A. Faye, T. Mirault, Y. Nguyen, B. Oules, A. Pellat, D. Bouzid, M. Thy, N. Peiffer-Smadja

O0675 13:42 Intelligent multi-agent systems for antimicrobial

		stewardship training: a new paradigm in medical education Y. Chen* (Hangzhou, China), L. Sun, X. Du, F. Chiu, Y. Yu
00676	13:54	Large-scale artificial intelligence or medical residency: who achieves greater concordance with ID specialists in antibiogram-guided antibiotic selection? M. Lanna* (São Paulo, Brazil), N. Adiwardana, V. Marchetti, J. Verissimo
00677	14:06	InfectoCast: a digital ecosystem for infectious diseases education and science communication in Brazil K. Faico-Filho* (São Paulo, Brazil), W. Dunke, J. Prats, J. Pinheiro, C. Santos, E. Santos-Junior
00678	14:18	List of Recommended Names (LoRN) for bacteria of medical importance V. Fingerle* (Oberschlossheim, Germany), H. Christensen, M. Göker, M. Kostovski, G. Margos, E. Moore, A. Oren, S. Patrick, U. Reischl, J. Vazquez-Boland

SY132 13:30 – 14:30 Hall A3-2

1-hour Symposium

ANT TRN

Innovative methodologies for advancing PK/PD studies

Chairs Birgit Koch (Rotterdam, The Netherlands)
Sebastian Wicha (Hamburg, Germany)

S0316 13:30 **Development and application of organs on chip to study infectious diseases** Girija Goyal (Boston, United States)

S0317 14:00 **Multi-omics approaches to personalise and improve antibiotic efficacy** Gauri Rao (Rancho Palos Verdes, United States)

SY130 13:30 – 14:30 Hall B0-1

1-hour Symposium

CLN PED

Special issues of IFI in paediatrics

Chair Andreas H. Groll (Münster, Germany)
TBA

S0312 13:30 **Antifungal prophylaxis in neonates in the era of increased resistance to fluconazole** Paolo Manzoni (Turin, Italy)

S0313 14:00 **Implementation of guidelines in different settings: challenges and solutions** Laura Ferreras-Antolin (London, United Kingdom)

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), German-Speaking Mycological Society, Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)

SY131 13:30 – 14:30 Hall B0-2

1-hour Symposium

CLN TRN

Top papers in infections in immunosuppressed patients

Chairs Carlota Gudiol (Barcelona, Spain)
Stefan Schwartz (Berlin, Germany)

S0314 13:30 **Infections in immunocompromised patients: what you need to know** Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)

S0315 14:00 **Shifting evidence in transplant infectious diseases: key studies that change practice** Oriol Manuel (Lausanne, Switzerland)

LB007 13:30 – 15:30 Hall ICM 1

2-hour Oral Session

AMR CLN

The trial run: treatment of ESBL bacteraemia - off to never-never land?

Chairs Angela Huttner (Geneva, Switzerland)
David L. Paterson (Singapore, Singapore)
Steven Tong (Melbourne, Australia)

L0036 13:30 **PipEracillin Tazobactam vs mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacterales (PeterPen)** M. Paul* (Haifa,

Israel), Y. Dishon, L. Leibovici, M. Kristen, K. Afra, C. Condin, T. Bai, J. Strahilevitz, V. Daitch, R. Ben-Ami, M. Chowders, L. Neshet, M. Hershman-Sarafov, A. Carignan, P. Daley, P. Leighanne, J. Eastmond, T. Finn, D. Yahav, T.C. Lee

L0037 13:50 **Ertapenem vs meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: an ASTARTE post hoc analysis** J. Rodríguez-Baño* (Seville, Spain), F. Cogliati Dezza, L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J.M. Bravo-Ferrer, Z.R. Palacios-Baena, M.Á. López Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. López Cardenas, M.C. Gómez Sánchez, I. Pérez Camacho, S.M. Martín Ramos, E. León Jiménez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M. Siller Ruiz, F. Arnaiz De Las Revillas Almajano, L. Gisbert Pérez, J. Goikoetxea Agirre, Á. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero-Sánchez, S. De La Villa, J.R. Yuste Ara, M.Á. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J.A. Fernández, A.M. Barrios Blandino, H.H. Vilchez-Rueda, R. Álvarez-Marín, A. Romero Palacios, E. García Vázquez, E. Nuño Álvarez, C. Rosso-Fernández, B. Gutiérrez-Gutiérrez, Á. Pascual, L. López-Cerero

L0038 14:10 **A decade after the MERINO trial: refusing to grow up?** David L. Paterson (Singapore, Singapore)

L0039 14:20 **When the fairy dust settles: critical appraisal of presented trials** Angela Huttner (Geneva, Switzerland)

L0040 14:30 **Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient?** Steven Tong (Melbourne, Australia)

EF097 13:30 – 14:30 Arena 1

ePoster Flash Session

AMR ANT CLN

Fosfomycin for difficult-to-treat resistant pathogens: is it really a useful weapon?

Chair Andre Kalil (Omaha, United States)

E0679 13:30 **Can the fosfomycin MIC value be used in the evaluation of response to treatment of carbapenemase-producing Enterobacterales infections with fosfomycin-containing regimens?** M. Törüyenler Coskunpinar* (Ankara, Türkiye), D. Ocal, G. Cinar, L.E. Dogangul Doygün, Z. Tekbas

E0680 13:36 **Effectiveness of antibiotic regimens for the treatment of bloodstream infections caused by carbapenem-resistant *Acinetobacter baumannii*: a national, multi-centre study** F. Serapide* (Catanzaro, Italy), A. Russo, S.P. Gulli, A. Vena, L. Spadafora, M. Bernardi, S. Corcione, G. Ceccarelli, F. Alessandri, C.M. Mastroianni, A. Oliva, E. Venanzi-Rullo, G. Caviglia, A. Cortegiani, M.C. Ippolito, G. Nunnari, F. Di Gennaro, A. Saracino, A. Marino, B. Cacopardo, G. Tiseo, M. Falcone, V. Galfo, C. Iaria, G. Pipitone, A. Cascio, S. Carbonara, L. Montemurro, F.S. Serino, N. Boffa, M. Libanore, F.G. De Rosa, A. Mattei, A. Calabresi, M. Tumbarello, L. Fontanelli Sulekova, C. Pallotto, P. Brugnaro, R. Mascianà, B. Tiri, N. Coppola, G. Calabria, A. Bandera, A. Lombardi, P. Vassalini, N. Carannante, V. Scaglione, M. Meschiari, O. Simonetti, A. Mularoni, F. Bar, C. Mussini, M. Bassetti, G. Biondi-Zoccai

E0681 13:42 **Evaluation of fosfomycin including regimens in culture-confirmed carbapenem-resistant Gram-negative pneumonia: analysis of 53 cases** M.B. Özkara* (Izmir, Türkiye), D. Kaya, M. Mert Vahabi, D. Akyol Seyhan, O. Acet, A. Kaya, A.M. Parmaksızoğlu Aydın, M. Ceylan, F.B. Arkan, S. İstek, D. Yaman, B. Süllü, D. Verendağ, H.A. Erdem, H. Sipahi, T. Yamazhan, B. Arda, Ş. Aydemir, O.R. Sipahi

E0682 13:48 **How and why clinicians use intravenous (IV) fosfomycin in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry** G. Zhanel* (Winnipeg, Canada), M. Baxter, M. Wong, Y. Mirzanejad, A. Lee, R. Dhami, J. Kosar, D. Werry, N. Irfan, J.F. Tessier, G. Girouard, C. Tascini, T. Von Den Baumen, M. Savoie, A. Serebryanskyy, J. Chan, M. Kucey, A. Walkty, J. Karlowsky

E0683	13:54	Fosfomycin resistance in Enterobacterales: a comprehensive national surveillance in the Czech Republic K. Chudejova* (Plzen, Czechia), V. Mattioni Marchetti, S. Kanova, V. Zaccaria, I. Bitar, J. Hrabak
E0684	14:00	Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing Enterobacteriaceae J.L. Rodríguez Ochoa* (Santander, Spain), N. Fraile-Valcárcel, S. García-García, M. Siller-Ruiz, D. Pablo-Marcos, S. García-Fernández, M.P. Roiz-Mesones, A. Ocampo-Sosa
E0685	14:06	Evolution of the <i>in vitro</i> activity of fosfomycin against carbapenemase-producing microorganisms in Colombia G.A. Muñeton Lopez* (Bogotá, Colombia), M.F. Rueda, N.C. Mendoza, J.C. Torres, D. Celis-Giraldo, H. Vergara
E0686	14:12	Discovery and characterisation of gfa, a novel fosfomycin resistance gene family already spread in environmental and clinical bacteria N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, A. Prieto, A. Carvalho, E. Vergara, J.A. Escudro
E0687	14:18	In vitro activity of fosfomycin against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i> isolated from urine specimens in Canada: CANWARD surveillance study 2007–2022 J. Karlowsky* (Winnipeg, Canada), G. Zhanel, H. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens

EF098 13:30 – 14:30 Arena 2
ePoster Flash Session

First, do no harm: allergy, kidney safety and length of stay in antimicrobial stewardship
Chair Pilar Retamar Gentil (Seville, Spain)

E0688	13:30	ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy O. Joean* (Jena, Germany), K. Sermet, L. Ashkenazi-Hoffnung, Y. Cakir Kiyimaz, K. Blumenthal, C.M. Bonazzetti, A.M. Chiriac, S. Gomez-Zorrilla, E. Karakike, E. Khatamzas, N. Powell, J.A. Trubiano, R. Wijnakker, J. Sandoe, B. Nagavci, M.G.J. De Boer
E0689	13:36	Direct penicillin allergy de-labelling at a pre-anaesthesia consultation: picking the low-hanging fruit? S. Deryckere* (Ghent, Belgium), P. De Nocker, H. Lapeere, L. De Baerdemaeker, D. Huis In 't Veld
E0690	13:42	Implementation of a penicillin allergy delabelling service in a UK centre: measuring indicators of success B. Morris* (Cambridge, United Kingdom), U. Ahmed, R. Santos, C. Aherne, I. Lowings, X.Y. Thum, S. Nasser, P. Gurugama, T. Gouliouris
E0691	13:48	Penicillin allergy de-labelling by non-specialists in NHS acute care: A UK-wide survey and review of current practice by the PADL-UK survey A. Blanshard* (Manchester, United Kingdom), H. Lewis, N. Fleming, P. Howard, T. Locke, R. Payne
E0692	13:54	Patients' experiences of penicillin allergy evaluation and delabelling process in primary care T. Langeveld* (Bilthoven, The Netherlands), T. Schoffelen, A. Timen, M. Hulscher, N. Milevska-Kostova
E0693	14:00	Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine? M. Scheetz* (Downers Grove, United States), S. Leech, A. Sathyanarayanan, S. Roy, P. Sabourenkov
E0694	14:06	Vancomycin-induced kidney injury in adult oncology: adjudicated incidence and a pragmatic dosing framework derived from AUC-guided care J.P. Telles* (São Paulo, Brazil), D. Coelho Jr, K. Migotto, D. Feriani Da Silva, R. Reghini, G.T. Daiane, F. Lima De Oliveira, P. Caruso, I. França E Silva
E0695	14:12	Development and validation of a prediction model for acute kidney injury risk in patients receiving concomitant vancomycin and piperacillin/tazobactam D. Chen* (Macau Sar, Macao), H. Zhang, X. Luo, M. Yu, J. Kan, A. Zhao, W. Ge
E0696	14:18	Saving beds and budgets: real-world efficacy, safety, and pharmacoeconomics of long-acting lipoglycopeptides in a day hospital setting A. Marino* (Catania, Italy), E. Venanzi Rullo, G. Pipitone, A. Albanese, A. Franzò, A. De Vito, N. Geremia, C. Iaria, G. Madeddu, B. Cacopardo, G. Nunnari

EF099 13:30 – 14:30 Arena 3
ePoster Flash Session

Ask AI how to manage antibiotics!

Chair	Carolina Garcia Vidal (Barcelona, Spain)	
E0697	13:30	Evaluating a machine learning-based decision support tool for early antibiotic discontinuation in Lower Respiratory Tract Infections (LRTI): a randomised controlled trial S. Tang* (Singapore, Singapore), D. Yii, R. Lim, M.P. Chlebicki, J. Chung, A. Kwa
E0698	13:36	Cost-effectiveness of a machine learning (ML) approach for reducing unnecessary antibiotic use in patients with suspected lower respiratory tract infections (LRTI): an economic analysis of a randomised clinical trial Y. Cai* (Singapore, Singapore), N. Nazeha, S. Tang, D. Yii, A.L. Kwa, N. Graves
E0699	13:42	Who's the smartest in the room? benchmarking large language models for antimicrobial stewardship support G. Pellejero* (Zaragoza, Spain), Á. Abejz-Arrizabalaga, J. Schouten, T. Schoffelen, E. Morte-Romea, E. Ruizendaal, J. Origüen, M.T. Pérez-Rodríguez, P. Retamar-Gentil, N. Sisamón-Dolader, B. Franco-García, R. Del Hoyo, S. Letona-Giménez, J.R. Paño-Pardo
E0700	13:48	An antibiotic chatbot for providing guideline-based antimicrobial advice D. Eyre* (Oxford, United Kingdom), R. Corrigan, L. Hookham, S. Lumley, D. Clarke, K. Jeffery, L. Dunsmore, N. Jones
E0701	13:54	Antimicrobial stewardship programme: a data-driven approach to continuously optimised, locally adapted empirical antibiotic guidelines M. Raad* (Sarrebouurg, France), T. Yokoyama, S. Boujaafar, F. Mutisya, C. De Turckheim, P. Berger, L. Vezard, M. Valette, C. Moore
E0702	14:00	Investigating UK online antibiotic provision: a covert simulated patient ethnographic study S. Boyd* (London, United Kingdom), N. Zhu, R. Jain, A. Parmar, A. Matthews, A. Holmes, R. Ahmad
E0703	14:06	UK outpatient parenteral antimicrobial therapy/complex outpatient antimicrobial therapy (OPAT/COpat) point prevalence dashboard S. Khan* (London, United Kingdom), J. Grayson, M. Gilchrist, A. Seaton
E0704	14:12	Performance of a clinical decision support tool on targeted antibiotic treatment in the emergency department: a retrospective study S. Nørgaard Søgaard* (Aabenraa, Denmark), S.N. Sogaard, L. Ward, M.L. Mogensen, C.B. Mogensen, M.B. Cartuliales, H. Skjøt-Arkil
E0705	14:18	Bayesian neural network (BNN) with uncertainty-thresholding for personalised empirical antibiotic guidance, compared to clinician prescribing A. Luk* (Oxford, United Kingdom), K. Yuan, J. Wei, S.A. Walker, D. Eyre
JS003	13:30 – 14:30	Hall A3-1 Journal Session
Late-breaking research from The Lancet: new interventions for more established pathogens		
Chairs	Syeda Saleha Hassan (London, United Kingdom) Onisillos Sekkides (London, United Kingdom)	
J0011	13:30	Clinical effectiveness and bacteriological eradication of three different short-course antibiotic regimens and single dose fosfomycin for uncomplicated lower urinary tract infections in adult women (SCOUT study): a pragmatic, multicentre, multi-arm, open-label, randomised clinical trial Carl Llor (Barcelona, Spain)
J0012	13:42	Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT Annalisa Paviglianiti (Barcelona, Spain)
J0013	13:54	Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysis Rory De Vries

(Rotterdam, The Netherlands)

J0014	14:06	Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blinded phase IV medical device trial <i>Annelies Van Rie (Wilrijk, Belgium)</i>
J0015	14:18	Adjunctive betamethasone treatment of hypoxemic adults hospitalised with mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial <i>Karl Hagman (Göteborg, Sweden)</i>

ME133	13:30 - 14:30	Hall ICM 5
	Meet-the-Expert	

ANT TRN
Membrane vesicles: pathogenic factor and emerging targets for antimicrobial therapies

M0318	13:30	<i>Maria Kaparakis-Liaskos (Melbourne, Australia)</i>
M0319	13:42	<i>Gregor Fuhrmann (Erlangen, Germany)</i>

PM004	13:30 - 14:30	Hall A2-1
	Pipeline Symposium	

PRO PHEI
Science under pressure: is it business as usual?

Chairs	<i>Till T. Bachmann (Edinburgh, United Kingdom)</i> <i>Robert Leo Skov (Copenhagen, Denmark)</i>	
--------	---	--

D0010	13:30	A funder's perspective <i>Ghada Zoubiane (London, United Kingdom)</i>
D0011	14:00	Industry perspective <i>Marc Gitzinger (Basel, Switzerland)</i>

WT009	13:30 - 14:30	Poster area
	Poster Walkthrough	

AMR TRN
Fundamental insights: a guided tour along the best-rated posters in fundamental microbiology and pathogenesis

Chair	<i>Christian Stephan Lentz (Tromsø, Norway)</i>	
-------	---	--

R0082	P3994 - Protective effects of <i>Haemophilus influenzae</i> on epithelial damage induced by <i>Streptococcus pneumoniae</i> <i>Emi Tanaka (Nagoya, Japan)</i>
R0083	P3961 - The biosurvival of <i>Neisseria meningitidis</i> in human saliva vs artificial saliva: nothing beats the real thing <i>Mia Dierks-Treece (Bristol, United Kingdom)</i>
R0084	P4007 - Adaptive evolution of carbapenem-resistant <i>Klebsiella pneumoniae</i> : altered virulence and extensive persistence in the GI tract <i>Jing Wang (Hong Kong, Hong Kong)</i>
R0085	P4134 - Immune correlates of protection in a first-in-human non-typhoidal <i>Salmonella</i> challenge study <i>Anna Rydlova (London, United Kingdom)</i>
R0086	P3991 - Effects of high-fat diet and ApoE gene deficiency on human Coronavirus infection in an ex vivo lung model <i>Hsing-Yu Chen (Taipei, Taiwan)</i>
R0087	P4042 - Synthetic wound fluid modulates antibiotic susceptibility and biofilm formation in wound pathogens <i>Charlotte Morgan (Swansea, United Kingdom)</i>
R0090	P4114 - Immunomodulators GM-CSF and plerixafor are advantageous in the treatment of <i>Pseudomonas aeruginosa</i> wound-derived sepsis in mice <i>Lacie Werner (Silver Spring, Maryland, United States)</i>

WT010	13:30 - 14:30	Poster area
	Poster Walkthrough	

AMR TRN
AMR in LMICs: from mechanisms to surveillance

Chair	<i>Christina Obiero (Kilifi, Kenya)</i>	
-------	---	--

R0091	P1631 - Diverse population of antimicrobial resistant
-------	---

R0092	plasmids carried by Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries <i>Kirsty Sands (Oxford, United Kingdom)</i>
R0093	P2004 - Comparison of mobile genetic elements found in carbapenemase-producing Enterobacteriales isolated from conflict zone clinical samples <i>Olena Moshynets (Kyiv, Ukraine)</i>

R0094	P1441 - Building a national bacteriology and AMR surveillance network by leveraging the existing tuberculosis laboratory network in a resource limited setting: the Benin experience <i>Faridath Massou (Cotonou, Benin)</i>
R0095	P1357 - Pathogen distribution and antimicrobial resistance patterns in bloodstream infections across diverse healthcare settings: findings from the BALANCE study <i>Refath Farzana (Oxford, United Kingdom)</i>

R0096	P1944 - Molecular characteristics and antimicrobial resistance gene profiles of atypical and typical enteropathogenic <i>Escherichia coli</i> from clinical and environmental settings in South Africa <i>Veronica Ueckermann (Pretoria, South Africa)</i>
R0097	P1723 - Resistance plasmidome of neonatal sepsis pathogens in low- and middle-income countries <i>Ngoc Minh Nguyen (Antwerp, Belgium)</i>

R0098	P1965 - Carriage of antimicrobial resistant bacteria in filth flies collected from five hospital sites across Pakistan <i>Teresa Iannetelli (Oxford, United Kingdom)</i>
R0099	P1438 - Genomic characterisation of <i>Staphylococcus epidermidis</i> neonatal sepsis isolates across BARNARDS-II clinical sites in Pakistan and Nigeria <i>Jawaria Aziz (Cardiff, United Kingdom)</i>

R0099	P1261 - Changes in proportions of ESBL-producing <i>E. coli</i> by sequence type after return: a longitudinal follow-up <i>Arttu Nousiainen (Helsinki, Finland)</i>
R0100	P1404 - Prior antibiotic exposure as a hidden bias in neonatal AMR surveillance: evidence from a multicountry LMIC cohort <i>Kathryn Thomson (Oxford, United Kingdom)</i>

WT011	13:30 - 14:30	Poster area
	Poster Walkthrough	

AMR IPC
Hospital transmission and emerging threats: *Candida auris*, environmental reservoirs, and genomic surveillance of antimicrobial resistance

Chair	<i>Ermira Tartari (Msida, Malta)</i>	
-------	--------------------------------------	--

R0101	P3210 - Epidemiological trends in invasive <i>Candida</i> spp. infections before and after an extreme flooding event in Southern Brazil <i>Cezar Vinicius Würdig Riche (Porto Alegre, Brazil)</i>
R0102	P3305 - Characterisation of <i>Candida auris</i> (<i>Candidozyma auris</i>) from a worldwide surveillance program over 12 years <i>Mariana Castanheira (North Liberty, Iowa, United States)</i>
R0103	P3133 - A resistant invader in hospitals: national summary of <i>Candida auris</i> infections in Türkiye <i>Elif Ağiloğlu-Bali (Ankara, Türkiye)</i>
R0104	P1927 - Investigation of a rare human outbreak of mecC-MRSA in Belgium and its genomic links to animal-associated lineages <i>Nicolas Yin (Brussels, Belgium)</i>
R0105	P1987 - Distribution of antimicrobial resistance genes in hospital wastewater, WWTP effluent, and urban surface water in the northeastern part of the Netherlands <i>Carmen Stoffers (Groningen, The Netherlands)</i>
R0106	P2010 - Linking clinical and wastewater settings: a comparative genomic analysis of carbapenemase- and ESBL-producing Enterobacteriales in Northern Spain <i>Mario Sergio Pino Hurtado (Logroño, Spain)</i>
R0107	P3158 - <i>Candidozyma auris</i> in the Netherlands: no evidence of nosocomial transmission supported by effective infection control policies <i>Chiara De Groot (Bilthoven, The Netherlands)</i>
R0108	P1268 - Effectiveness of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine <i>Jale Boral (Malmo, Sweden)</i>
R0109	P1199 - Comprehensive metagenomic surveillance uncovers last-resort antibiotic resistance genes in wastewater <i>Prerna Yadav (New Delhi, India)</i>
R0110	P2006 - Linking antimicrobial resistance between

WT012	13:30 – 14:30	Poster area
	Poster Walkthrough	
	Novel insight into AMR epidemiology in One Health perspective	
Chair	Helena Zemlickova (Prague, Czechia)	
R0111	P1714 - PlasmidNL: a web-based interface for tracking plasmid dissemination in the Netherlands Gijs Teunis (Bilthoven, The Netherlands)	
R0112	P1975 - Stable plasmid populations in sewage spread antibiotic resistance Alberto J. Martin-Rodriguez (Stockholm, Sweden)	
R0113	P2011 - Cross-domain plasmid mediated AMR transmission Rebekka Koeck (Maastricht, The Netherlands)	
R0114	P2030 - Evolutionary dynamics and plasmid epidemiology of <i>Salmonella</i> infantis in Türkiye: focus on the pESI-like megaplasmid Gultekin Unal (Ankara, Türkiye)	
R0115	P1511 - Predicting antimicrobial susceptibility after one hour of antibiotic exposure Ben Nannings (Rotterdam, The Netherlands)	
R0116	P1573 - LC-MS reveals distinct degradation signatures for carbapenemases including β -lactone formation by OXA-48-like enzymes Veronika Pašková (Plzen, Czechia)	
R0117	P3255 - Molecular detection of <i>C. auris</i> : a comparative evaluation of commercial assays including a new selective <i>C. auris</i> broth for clinical laboratory use Alexander Maximilian Aldejohann (Würzburg, Germany)	
R0118	P3308 - Activity of manogepix against <i>Candida auris</i>	
R0119	P1559 - Towards a microfluidic PK/PD system for individualised phenotypic antimicrobial susceptibility testing Jennifer Lawrence (London, United Kingdom)	
R0120	P2017 - Genomic wastewater surveillance program reveals emergence of cefiderocol-resistant Enterobacterales in South America Johana Becerra (São Paulo, Brazil)	
OS103	14:45 – 15:45	Hall A2-2
	1-hour Case Session	
	What did you get in the hospital?	
Chairs	Christina König (Hamburg, Germany) Sara Tomczyk (Berlin, Germany)	
O0706	14:45	Hospital acquired tularemia: a case report of nosocomial transmission of <i>Francisella tularensis</i> O. Arce Garcia* (Pozuelo De Alarcon, Spain), M. Simon Sacristan, A. Collazos Blanco, M.F. Ramos Ferriol, M. Rozas Bellido, I. Darid Y Ceron, S. Sanchez Sanchez, G. Arán Toha, S. Medrano Pardo, M.T. Llorente Rodriguez, O. Arce, G. Ramirez Olivencia
O0707	14:56	<i>Gemella haemolysans</i> endocarditis in a southern Spain hospital P. Monroy* (Malaga, Spain), P. Monroy Moya, L. Balderas Fernández, L. Mora Navas, M.V. Garcia López
O0708	15:07	Nosocomial myiasis: report of two cases and review of the literature D. Verendag* (Izmir, Türkiye), D. Verendağ, D. Kaya, H.A. Erdem, N. Bilgili Korkmaz, B. Arda, O.R. Sipahi
O0709	15:18	Difficult-to-treat Gram-positive health-care associated ventriculitis treated with combination antibiotic therapy including fosfomycin: a series of three cases G. Parruti* (Pescara, Italy), A. Frattari, F. Spagnuolo, C. Di Iorio, E. Polilli, P. Fazii
O0710	15:29	The unusual outbreak of sepsis in a cancer hospital caused by intrinsically contaminated heparin injection vials V. Bajpai Batra* (Varanasi, India), A. Kapoor
OS101	14:45 – 15:45	Hall B0-1
	1-hour Case Session	

Chairs	Zuzanna Drulis-Kawa (Wroclaw, Poland) Spyros Pournaras (Athens, Greece)	
O0711	14:45	Personalised phage therapy for multidrug-resistant infections in thoracic organ transplant recipients C. Kuehn* (Hannover, Germany), E. Rubalskii, L. Sedlacek, S. Ruemke, N. Schwert, J. Gottlieb, A. Haverich, D. Schlüter, G. Hansen, A. Ruhparwar
O0712	14:56	Breaking the cycle of relapse: personalised phage therapy in MDR <i>Pseudomonas aeruginosa</i> LVAD infection S. Ferin* (Udine, Italy), S. Flammini, P. Della Siega, M. Merelli, D. Pecori, S. Giuliano, C. Tascini
O0713	15:07	Novel antibiotic-phage therapy duo rapidly resolves XDR-AB pneumonia after liver transplant W. Wang* (Xian, China)
O0714	15:18	Precision-matched bacteriophage therapy for prosthetic aortic graft infections: a single-centre observational case series E. Rubalskii* (Hannover, Germany), S. Ruemke, L. Sedlacek, A. Haverich, D. Schlüter, A. Ruhparwar, C. Kuehn
O0715	15:29	Phage therapy for refractory, native joint <i>Staphylococcus aureus</i> arthritis with infected bone necrosis M. Dekel* (Tel Aviv, Israel), R. Nir Paz, R. Ben Ami, N. Bishouty, A. Khoury, N. Snir, T. Ben Tov

OS104	14:45 – 15:45	Hall A3-1
-------	---------------	-----------

	1-hour Oral Session	
	Emerging and repurposed therapeutic options in resistant Gram-negatives	
Chairs	Jaroslav Hrabak (Plzen, Czechia) Giusy Tiseo (Pisa, Italy)	

O0716	14:45	Treatment strategies for CRKP central nervous system infections after neurosurgery: a prospective observational study comparing intravenous ceftazidime/avibactam and intraventricular/intrathecal polymyxin B sulphate injections M. Wang* (Shanghai, China), L. Yang, W. Mei-Hua, L. Nan-Yang, C. Wei, F. Ya-Xin, W. Gang, H. Jin, Z. Jing
O0717	14:57	Clinical and genomic insights into emerging resistance to novel β -lactam/ β -lactamase inhibitor combinations in KPC-producing <i>Klebsiella pneumoniae</i> (Italy, 2021–2024) M. Boattini* (Turin, Italy), S. Comini, G. Ricciardelli, R. Casale, L. Guarrasi, R. Cavallo, C. Costa, P. Gaibani, G. Bianco
O0718	15:09	Clinical outcomes and treatment-emergent resistance of bloodstream infections due to AmpC β -lactamase-producing Enterobacterales S. Shah* (Pittsburgh, United States), J. Jawanda, M. O'donnell, R. Shields, L. Clarke, H. Creager, R. Marini, B. Falcione
O0719	15:21	A multi-centre cohort study of tigecycline effectiveness and safety in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> and carbapenem-resistant <i>Acinetobacter baumannii</i> co-infection D. Chen* (Nanjing, China), S. Wang, N. Hu, P. Liang, J. Liu, H. Xie, H. Zhang, J. He
O0720	15:33	Efficacy of minocycline-based combination therapy in <i>Stenotrophomonas maltophilia</i> infections from a randomised controlled trial, and the activity of antimicrobial combinations against isolates as determined by the checkerboard method A. Boonyasiri* (Bangkok, Thailand), T. Pongdumbun, S. Tiengrim, Y. Rongrungruang

OS105	14:45 – 15:45	Hall A3-2
-------	---------------	-----------

	1-hour Oral Session	
	Decoding inflammation and innovating diagnostics of parasitic diseases	
Chairs	Pikka Jokelainen (Copenhagen, Denmark) Martin Montes (Lima, Peru)	
O0721	14:45	Monocyte-dependent antigen specific inflammation in neurocysticercosis is regulated by mitogen activated protein kinases L.M. Toribio* (London, United Kingdom), D.L. Chong, H.H. Garcia, J.S. Friedland
O0722	14:57	First cases of male genital schistosomiasis reported in

		Zambia: a pilot study integrating semen-based parasitology, molecular diagnosis and portable ultrasonography <i>S. España Cueto*</i> (Badalona, Spain), <i>E.C. Sergio, N. Bronwyn, M. Isaac, N. Rhoda, C. Lucas, A. Fiona, V.L. Lisette, W. Bonnie L., C. Maina, M. Tegwen, H. Shinjiro, R. Silvia, P. Roger, K. Sekeleghe, S. J. Russell, S. Kwame, B. Amaya L.</i>	
00723	15:09	Evaluating the diagnostic performance of a recombinase polymerase amplification assay compared to polymerase chain reaction for the diagnosis of female genital schistosomiasis using cervicovaginal self-sample swabs <i>N. Hrouda*</i> (London, United Kingdom), <i>S. Nanyinza, L. Smith, J. Fitzpatrick, R. Ndubani, M. Cheeba, B. Neufeld, K. Shanaube, B. Webster, A. Bustinduy</i>	
00724	15:21	Diagnostic evaluation of parasite-derived microRNAs as serum biomarkers for cystic echinococcosis <i>Y. Akyön Yılmaz*</i> (Ankara, Türkiye), <i>S. Orsten, İ. Baysal, M. Sarıkaya, E. Yagmur, O. Bozkurt, E. Ünal, S. Yabanoğlu Çiftçi, H.A. Dinçer, D. Dirim, D. Akinci, A.B. Doğrul, E. Karaağaoğlu, M. Korkmaz, Y. Akyön, T. Çiftçi, O. Akhan</i>	
00725	15:33	Hookworm infection drives inflammation and tissue destruction in tuberculosis <i>M. Loader*</i> (London, United Kingdom), <i>S.E. Vázquez Alves, M.R. Verástegui, R.H. Gilman, J.S. Friedland</i>	

OS102	14:45 – 15:45		Hall B0-2
		1-hour Oral Session	

Pitfalls in modern HIV therapy

Chairs	<i>Justyna Kowalska</i> (Warsaw, Poland) <i>Milena Stevanovikj</i> (Skopje, North Macedonia)
--------	---

00726	14:45	A plasma proteomic aging clock reflects reversal of accelerated aging in people with HIV under antiretroviral therapy <i>B. Ryan*</i> (Lausanne, Switzerland), <i>M. Ait Oumelloul, S. Rouached, A. Juillerat, L. Giacchetto, I. Schoepf, L. Bartl, C. Dollé, D. Russenberger, P. Nanni, T. Kockmann, M. Stöckle, G. Wandeler, A. Calmy, M. Cavassini, L. Elzi, P. Schmid, J. Fellay, P. Tarr, J. Nemeth</i>	
-------	-------	---	--

00727	14:57	Effect of 1HP on dolutegravir concentrations <i>M. Nicol*</i> (Minneapolis, United States), <i>A. Buzibye, A. Fieberg, B. Dai, P. Nerima, E. Ajilong, C. Waitt, D. Boulware, E. Nalintya, R. Rajasingham</i>	
-------	-------	---	--

00728	15:09	Renal function, HIV reservoir and immune marker changes after one year of long-acting ART <i>L. Maddaloni*</i> (Rome, Italy), <i>L. De Martino, L. Santinelli, C. Falvino, G. Bugani, A. Lazzaro, R. Donà, L. Bortolani, M. Andreotti, Z. Michellini, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D' Ettore</i>	
-------	-------	--	--

00729	15:21	Doravirine: two vs three-drugs based regimens, a multi-centre observational study <i>F. Casari*</i> (Modena, Italy), <i>B. Fontana, A. Cervo, A. Giacomelli, R. Rossotti, M. Menozzi, M. Albertini, G. Menegotto, E. Martini, M.V. Cossu, C. Mussini, G. Guaraldi, C. Gervasoni</i>	
-------	-------	--	--

00730	15:33	No biomarker evidence of CNS injury after switching to dual therapy with dolutegravir/lamivudine in HIV <i>L. Renborg*</i> (Gothenburg, Sweden), <i>A.L. Benedet, A. Yılmaz, S. Nilsson, K. Nyström, K. Blennow, H. Zetterberg, M. Gisslén</i>	
-------	-------	---	--

OS100	14:45 – 15:45		Hall ICM 5
		1-hour Oral Session	

Microbiome-host interplay in intestinal disease and under selection pressure

Chairs	<i>Vincenzo Di Pilato</i> (Genoa, Italy) <i>Ed J. Kuijper</i> (Leiden, The Netherlands)
--------	--

00731	14:45	A hit with a scar: amoxicillin alters the infant gut microbiome long-term but without fungal expansion <i>J. Hurych*</i> (Helsinki, Finland), <i>R. Ventin-Holmberg, J. Honkanen, V. Castrén, A. Nikkonen, J. Koskimäki, V. Peltola, K. Korpela, P. Saavalainen, K.L. Kolho</i>	
-------	-------	--	--

00732	14:57	Protease-induced activation of colonic afferent neurons by gut bacterium <i>Phocaeicola vulgatus</i>, previously associated with inflammatory bowel disease <i>R. Nakhle*</i> (Kingston, Canada), <i>H.M. Wood, K. Blazkova, F.F. Faucher, M. Farquhar, P.M. Sheth, B.L. Schmidt, S.J. Vanner, N.W. Bunnett, M. Bogyo, D.E.</i>	
-------	-------	--	--

			<i>Reed, A.E. Lomax</i>
00733	15:09	Recapturing individual inflammatory responses in IBD microbiomes using an <i>in vitro</i> colonic model (MiGut) <i>I. Moura*</i> (Leeds, United Kingdom), <i>W. Davis Birch, N. Beauchemin, K. Bentley, M. Vulic, M. Henn, A. Buckley, C. Ford, N. Kapur, E. Halvorsen, I. B. Moura</i>	
00734	15:21	Development of antibiotic-associated diarrhea in sepsis patients is associated with dysbiosis at baseline <i>E. Kyriazopoulou*</i> (Athens, Greece), <i>E. Stylianakis, G. Damoraki, A. Spyrou, S. Symbardi, G. Chrysos, G. Adamis, E. Giamarellos-Bourboulis</i>	
00735	15:33	Ecological instability of the gut microbiome during haematopoietic stem cell transplantation <i>C. Hajjar*</i> (Beirut, Lebanon), <i>A. Ibrahim, A. Bazarbachi, M. Abifadel</i>	

SY135	14:45 – 15:45		Hall ICM 13b
		1-hour Symposium	

Resistance redefined: how to analyse biofilms and anaerobes

Chairs	<i>Tom Coenye</i> (Ghent, Belgium) <i>Efthymia Giannitsioti</i> (Athens, Greece)
--------	---

S0338	14:45	Resistance in slow growing anaerobic communities <i>Catalina Suzana Stingu</i> (Leipzig, Germany)	
-------	-------	--	--

S0339	15:15	What <i>in vitro</i> susceptibility testing does (not) tell you about <i>in vivo</i> anti-biofilm activity in the respiratory tract <i>Valerie Waters</i> (Toronto, Canada)	
-------	-------	--	--

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Anaerobic Infections (ESGA)

SY134	14:45 – 15:45		Hall ICM 14
		1-hour Symposium	

Year in infectious diseases

Chairs	<i>Murat Akova</i> (Ankara, Türkiye) <i>Yoav Keynan</i> (Winnipeg, Manitoba, Canada)
--------	---

S0336	14:45	- <i>Dafna Yahav</i> (Ramat-Gan, Israel)	
-------	-------	--	--

S0337	15:15	- <i>Margaret Ip</i> (Hong Kong, Hong Kong)	
-------	-------	---	--

EF106	14:45 – 15:45		Arena 1
		ePoster Flash Session	

Latest trends in vaccinology: from current strategies to next-generation vaccines

Chair	<i>David Chien Lye</i> (Singapore, Singapore)
-------	---

E0736	14:45	Long-term impact of a single-dose inactivated hepatitis A vaccine in Korean military recruits: a nationwide cohort analysis (2011-2024) <i>J.H. Im*</i> (Incheon, Korea, Republic of), <i>J.S. Lee, S. Cho, D.Y. Kang, D.Y. Lee</i>	
-------	-------	--	--

E0737	14:51	Effectiveness of high-dose vs standard-dose influenza vaccine against recurrent hospitalisations and through extended follow-up: a prespecified analysis of the DANFLU-2 trial <i>N.D. Johansen*</i> (Hellerup, Denmark), <i>D. Modin, M.M. Loiacono, R.C. Harris, M. Dufournet, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovskiy, L.W. Davodian, M.F. Dons, L.S. Duus, C. Espersen, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, T. Biering-Sørensen</i>	
-------	-------	--	--

E0738	14:57	Effectiveness of high-dose vs standard-dose influenza vaccine in older adults according to age: a prespecified analysis of the FLUNITY-HD study <i>K. Hosseini*</i> (Copenhagen, Denmark), <i>N. Dyrby Johansen, D. Modin, J. Pardo-Secco, C. Rodriguez-Tenreiro-Sánchez, M. M. Loiacono, R. C. Harris, R. Van Aalst, A. Chit, C. Schade Larsen, L. Larsen, M. Pareek, L. Wiese, M. Dalager-Pedersen, B. L. Claggett, K. Hydekær Janstrup, C. Duran-Parrondo,</i>	
-------	-------	--	--

		M. Piñero-Sotelo, M. Dufournet, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S. D. Solomon, P. Sivapalan, C. Jean-Marie Martel, J. Ulrik Stæhr Jensen, F. Martínón-Torres, T. Biering-Sørensen	
E0739	15:03	Immunogenicity and safety of a higher-dose MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults ≥50 years of age: a phase III randomised controlled trial F.R. Albano* (Melbourne, Victoria, Australia), B.J. Essink, W. Vermeulen, C. Andrade, M. Mazur, C. Jamison, R. De Rooij, E. Heijnen, D. Casula, R. Xing, M. Piedrahita, V. Garner	
E0740	15:09	Predicting COVID-19 vaccination decision-making profiles among Dutch adults: from survey to national administrative data T. Abreu* (Utrecht, The Netherlands), J. Bernardo-Garcia, I. De Wolf, M. Matthijssen, D. Timmermans, V. Buskens	
E0741	15:15	Intramuscular SARS-CoV-2 vaccination fails to induce de novo local antibodies in older adults: a Com-COV randomised substudy R. Shaw* (Oxford, United Kingdom), T. Dinesh, J. Alderson, S. Belij-Rammerstorfer, S. Bibi, E. Clutterbuck, M.R.N.U. Ramasamy, M. Snape, X. Liu, T. Lambe	
E0742	15:21	Vaccines insight, beliefs, and experiences in school-aged children and parents: a questionnaire and structured interview in UK families (VIBES) W. Carroll* (Uttoxeter, United Kingdom), A. Jagadish, F. Gilchrist, R. Horne	
E0743	15:27	Next-generation vaccines for hepatitis E virus J. Situ* (Hongkong, China), X. Ma, Y. Liang, S. Wu, S. Sridhar	

EF107	14:45 – 15:45	Arena 2
	ePoster Flash Session	

Infection control and prevention around the world: risks, behaviours, and solutions

Chair Maria João Lopes (Amadora, Portugal)

E0745	14:45	Perception vs practice in hospital cleaning: assessing task-prioritisation between hospital cleaning staff and IPC practitioners, an interim analysis A. Kearney* (Dublin, Ireland), M. Fallon, J. Doyle, B. Fletcher, A.F. Talento, R. Cunney, C. Cahir, D. Fitzgerald Hughes, B. Mitchell, M. Kiernan
E0746	14:51	Environmental reservoirs of carbapenemase-producing organisms (CPO) in intensive care unit (ICU) hand hygiene (HH) sinks and haemodialysis (HD) wall boxes: investigation and control measures J. Guerrero* (Scarborough, Canada), S. Paramalingam, J. Lerma, M. Pekelny, S. Arefin, A. Garga, M. O'connor, R. Lovinsky
E0747	14:57	Hospital surfaces as reservoirs of carbapenemase- and ESBL-producing bacteria in hospitals across Bangladesh, Nigeria and Pakistan A. Cooke* (Oxford, United Kingdom), J. Rzaska, R. Farzana, B. Hassan, C. Achi, M. Nieto-Rosado, L. Wilson, S. Langhorne, A. Sindhu, J. Oduwo, E. Owinoh, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, H. Naz, A. Muhammad, S. Ali, W. Sombul, M. Khan, S.U. Nisa, A. Khan, S. Riaz, S. Naqvi, J. Zafar, H. Hamid, A. Sajid, R. Razzaq, K. Iregbu, N. Medugu, T. Akujobi, F.Z.Z. Abdu, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Panti, O. Oduyebo, O. Olutekunbi, F. Okenla, I. Nwafia, P. Nwachukwu, S. Chukwuma, T. Sultana, S. Arefin, P.I. Disha, N. Tasnim, T. Hossain, T. Haque, T.R. Walsh, K. Sands, K.M. Thomson
E0748	15:03	CRE colonisation as a marker for CRE ventilator-associated pneumonia (VAP): insights from a 15-month ICU cohort in Rome L. Campogiani* (Rome, Italy), A.M.A. Crea, L. Alborghetti, P. Vitale, I. Spalliera, M. Zordan, A.M. Geretti, V. Malagnino, M. Iannetta, L. Sarmati
E0749	15:09	Behavioral insights and motivational challenges within infection control committees: mixed-methods study using COM-B and TDF frameworks T. Yanik Yalçın* (Ankara, Türkiye), A. Pehlivanlı, B. Gönülal, F. Callak Oku, B. Madran, E. Sargin Altunok, Ş. Keske, M. Aydın, Ö. Kurt Azap, Ö. Ergönül, H. Akalin
E0750	15:15	Candidozyma auris colonisation: point-prevalence and long-term outcomes in a tertiary university hospital M. Gamaletsou* (Athens, Greece), D. Basoulis, A. Karapanou, E. Apostolidi, S. Zerva, A.R. Andritsou, K. Panteli, C. Psarakis, K. Reppas, A. Rigatou, D. Stefani, A. Strikou, D. Mpora, D. Petraki,

E0751	15:21	A 20-year single-centre retrospective study on the impact of hospital environmental factors on the incidence of candidaemia A. Bedini* (Modena, Italy), G. Franceschi, S. Esperti, S. Generoso, L. Benassi, U. Calvi, M. Meschiari, E. Franceschini, C. Venturelli, C. Mussini
E0752	15:27	Swiss minimum requirements for infection prevention and control: results of a national survey A. Sonpar* (Zurich, Switzerland), C. Balmelli, M. Eder, A. Metsini, Z. Zhang, W. Zingg
E0753	15:33	A multi-modal intervention with patient engagement to reduce Multidrug-Resistant Organisms (MDROs) in post-acute care L. Mody* (Ann Arbor, United States), M. Cassone, K. Gibson, G. Vijayasiri, E. Snitkin, S. Saint, S. Krein, M. Janevic, J. Thiel, A. Nguyen, T. Bej, O. Hicks, N. El Chakhtoura, L. Min, A. Galecki, T. Greene, M.C. Roghmann, L. Chigurupati, F. Perez, R. Jump

EF108	14:45 – 15:45	Arena 3
	ePoster Flash Session	

Little patients, big challenges: tackling bacterial infections in children

Chair Christina Obiero (Kilifi, Kenya)

E0754	14:45	Klebsiella pneumoniae: a leading cause of neonatal sepsis from 13 hospitals in Nigeria, Pakistan and Bangladesh K. Sands* (Oxford, United Kingdom), K. Thomsom, C. Achi, R. Farzana, B. Hassan, A. Cooke, J. Rzaska, A.K. Lankapalli, J. Oduwo, E. Owinoh, N. Haque, R. Farzana, T.A. Sumi, P.I. Disha, S.K. Sara, T. Haque, K. Iregbu, N. Medugu, T. Akujobi, K. Abdulraheem, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Adamu, O. Oduyebo, O. Olutekunbi, O. Ogunsanya, I. Nwafia, S. Chukwuma, P. Nwachukwu, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, S. Ali, S. Amin, M. Khan, S. Arif, S.U. Nisa, S. Riaz, S. Naqvi, I. Zeb, M. Haroon Hamid, U. Hussain, S. Shabbir, T.R. Walsh
E0755	14:51	Antibiotic dosing practices in neonates in low- and middle-income countries: model-based comparison with guidelines and implications for target attainment and toxicity W. Van Os* (Leiden, The Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, C.R. Achi, B. Hassan, R. Farzana, E. Owinoh, J. Oduwo, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, S.M. Zainu, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, J. Unigwe, C. Onyijekwe, T.A. Sumi, B. Majumder, S.B. Prama, T. Haque, R. Khatun, T. Hossain, E. Rashid, R. Zahra, M.I. Shah, A. Mehboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, S. Riaz, S. Naqvi, R. Hamza, M.H. Hamid, M. Malik, R. Temur, R. Sajjad, J.G.C. Van Hasselt
E0756	14:57	Antibiotic resistance genes in meconium of newborns very early after admission to neonatal intensive care unit A. Ftergioti* (Thessaloniki, Greece), M. Simitsopoulou, A. Kontou, K. Sarafidis, E. Roilides, E. Iosifidis
E0757	15:03	Stool-based real-time PCR platform as a non-invasive frontline diagnostic tool for paediatric pulmonary tuberculosis: a cross-sectional study from a tertiary care paediatric centre A. Soni* (Noida, India), S. Nandwani, S.B. Mathur, B. Kumar
E0758	15:09	Predictors of outcomes of paediatric diphtheria in sub-Saharan Africa: a systematic review and meta-analysis I.A. Rufai* (Sokoto, Nigeria), S. Abubakar, F. Shagari
E0759	15:15	Post-pandemic resurgence and epidemiology of group A Streptococcus infection in children N. Tan* (Singapore, Singapore), W.J.W.H. Goh, C.Y. Chong, J. Li, C.F. Yung, K.C. Thoon, K.Q. Kam, K.D. Nadua, C.W.X. Seow, Y. Yelen, M. Maiwald, S.B. Yusof, K.P.L. Wong, C.Y. Woo, N.W.S. Tee, L. Cui, M. Ang
E0760	15:21	IPSCC 2005 and Phoenix Sepsis Score in children under 60 days: strengths and diagnostic pitfalls L. Di Meglio* (Rome, Italy), G. Lorenzetti, M. Roversi, C. Tripiciano, S. Mercadante, M. Di Giuseppe, S. Chiurchiù, M. De Luca

E0762 15:33 **Epidemiology and antibiotic use for pertussis and pertussis-like cough in Italian children: a population study (2010–2024, PEDIANET)** *E. Gres** (Padua, Italy), *G. Sturniolo, S. Masenello, D. Dona, G. Brigadoi, A. Cantarutti, C. Giaquinto, V. Baldo, E. Barbieri*

PM005 14:45 – 15:45 **Pipeline Symposium** Hall A2-1

PRO PHEI

From AI for evidence synthesis to decision making

Chairs *David Eyre* (Oxford, United Kingdom)
Holger Rohde (Hamburg, Germany)

D0012 14:45 **AI decision support in antibiotic prescribing - novel aspects and direction** *Daniele Roberto Giacobbe* (Genoa, Italy)

D0013 15:15 **AI for ESCMID guideline development - a perspective on feasibility and safety** *José Molina Gil-Bermejo* (Seville, Spain)

MOVIE 14:45 – 18:30 **Special Session** Hall ICM 13a

PRO PHEI

Behind the scenes: don't look up

Chairs *Diane Ashiru-Oredope* (London, United Kingdom)
Ana Raquel Freitas (Porto, Portugal)
William Hanage (Boston, United States)
Holger Rohde (Hamburg, Germany)
Luigia Scudeller (Pavia, Italy)
Sotirios Tsiodras (Athens, Greece)

OS110 16:15 – 17:15 **1-hour Case Session** Hall A2-2

ANT CLN TRN

New and novel approaches to complex infections

Chairs *Rekha Pai Mangalore* (Melbourne, Australia)
Jacques Simkins (Miami, United States)

O0763 16:15 **Allogeneic cytomegalovirus-specific T cell therapy in a small-bowel transplant recipient with multidrug-resistant CMV infection** *L. Van Den Bogaart** (Lyon, France), *E. Frobert, T. Antonini, J.H. Dalle, J.Y. Mabrut, T. Perpoint, L. Reppel, D. Bensoussan, F. Ader*

O0764 16:26 **Faecal Microbiota Transplantation (FMT) as a novel therapy for refractory chronic norovirus infection in immunocompromised hosts: clinical response and metagenomic analysis** *K. Chaw** (Brisbane, Australia), *K. Garnham, M. Buller, S. Schlebusch, T. Badrick, V. Grey, M. Sullivan, A. Sai, B. Koh, I. Gosbell*

O0765 16:37 **Cycloheptasin: a novel antimicrobial peptide from *Periplaneta americana* for combating Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) I.** *Iheukwumere** (Uli, Nigeria)

O0766 16:48 **Daratumumab and belimumab for patients with neutralising anti-interferon- γ autoantibodies mediated adult-onset immunodeficiency: a case series** *Y.T. Weng** (Taipei, Taiwan), *M.T. Tsai, H.Y. Sun, K.Y. Lin, Y.S. Huang, W.T. Tsai, C.Y. Yao, B.C. Guo, J.T. Wang, S.C. Chang, A. Cheng*

O0767 16:59 **Refractory resistant *Salmonella* empyema successfully treated with compassionate adjunctive bacteriophage therapy** *J. Chung** (Singapore, Singapore), *Y.Y. Chua, E.C.Y. Sng, J.M.F. Chien, A. Taha, W.M. Chew, K.J. Goh, S. Thong, N.G.S. Chua, A.L.H. Kwa*

OS109 16:15 – 17:15 **1-hour Case Session** Hall ICM 13b

CLN PHEI

Melioidosis finds new destinations

Chairs *Yogesh Kumar Gupta* (Jaipur, India)
Maria João Lopes (Amadora, Portugal)

O0768 16:15 **First documented blood culture-confirmed melioidosis case in Mozambique: implications for awareness, surveillance, and diagnosis** *S. Cruz** (Beira, Mozambique), *C. Raimundo, L. Andela, N. Joao, J. Marcos, C. Joyce, Z. Seni, M. Barrios, A. Dicko, C. Monjane, A. Comelli, F. Gordillo, P. Garcia-Vello*

O0769 16:26 **Saving the spleen: importance of timely diagnosis in relapsing melioidosis** *W. Khot** (Navimumbai, India)

O0770 16:37 **Rhino-orbital melioidosis masquerading as invasive fungal sinusitis: a case report** *N. Kaur** (Jodhpur, India), *T. Kanagiri, D. Kumar, V. Tak, G.K. Bohra*

O0771 16:48 **Ruptured aneurysm unmasking disseminated melioidosis: a case report** *M.L. Panes** (Manila, Philippines), *J. Poblete, C. Ramos*

O0772 16:59 **A rare case of melioidosis reactivation in Germany twelve years after travel to Thailand** *T. Cronen** (Berlin, Germany), *S. Schaber, F. Bremer, H. Müller-Redetzky, A. Uhrig*

OS111 16:15 – 17:15 **1-hour Oral Session** Hall A3-2

AMR ANT DX

Novel aspects of susceptibility testing methods

Chairs *Arjana Tambic Andrasevic* (Zagreb, Croatia)
Andreas Voss (Groningen, The Netherlands)

O0773 16:15 **Prospective assessment of heteroresistance to first-line β -lactams in Gram-negative bloodstream infections** *D. Squitieri** (Rome, Italy), *G. Menchinelli, B. Berinson, N. Degel-Brossmann, B. Posteraro, M. Sanguinetti, H. Rohde*

O0774 16:27 **Comparative evaluation of agar dilution and Etest against broth microdilution for ceftobiprole susceptibility testing in methicillin-resistant *Staphylococcus aureus*: a multi-centre study in China** *F. Zhu** (Hangzhou, China), *Y. Chen*

O0775 16:39 **Implementation of cost-effective antimicrobial susceptibility testing in resource-constrained settings: lessons from the BALANCE study R.** *Farzana** (Oxford, United Kingdom), *E. Carretto, N. Haque, M. Rahman, A. Monir, R.A. Ansary, S. Shahid, S.T. Reza, N. Haque, E. Kibaru, G. Ganda, D. Adera, K. Onjuro, C. Achi, K. Iregbu, P. Nwajobi-Princewill, K. Abdulraheem, F. Kilani, J. Udeh, A. Aminu, A.M. Idris, J.D. Joshua, I.N. Nwafia, A. Nkiruka, C.I. Chiedu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, G. Fatima, R. Siddiqi, M. Idrees, A. Khattak, N. Rehman, K. Hoog, C. Abdellaoui, S. Langhorne, A. Sindhu, M. Christodoulou, E. Owinoh, F. Demetrio, T.R. Walsh*

O0776 16:51 **An innovative fluorogenic assay for reliable detection of staphylococcal penicillinase C.** *Dupieux** (Lyon, France), *P. Martins-Simoes, B. Youenou, G. Antoniotti, F. Vandenesch, A. Tristan, F. Laurent*

O0777 17:03 **Comparison of piperacillin/tazobactam susceptibility testing with a Microscan system and the novel rapid system QuickMIC L.** *Lopez Cerero** (Seville, Spain), *M. Sánchez-Ruiz De La Muela, M. Oliva-Sánchez, L. Monge-Olivares, I. Portillo-Calderón, M. Pulido, L. López-Cerero, A. Pascual*

SY139 16:15 – 17:15 **1-hour Symposium** Hall A3-1

PHEI


Setbacks to strength: re-imagining global health partnerships at times of geopolitical uncertainty


Chairs *Tetiana Melnyk* (Paris, France)
Marc Jean Struelens (Rochefort, Belgium)


S0347 16:15 **Effects on the global HIV pandemic** *Mosa Moshabela* (Cape Town, South Africa)

S0348 16:45 **Come back stronger: WHO's strategic plans for fighting infections in a globalised world** *Maria Van Kerkhove* (Geneva, Switzerland)

Co-organised with: Dutch Society for Medical Microbiology (NVMM), ESGPHM, ESGVM, Médecins Sans Frontières (MSF), European AIDS Clinical Society (EACS)

SY138	16:15 – 17:15	Hall B0-1
	1-hour Symposium	
		
Bacteriophages in implant-related infections: translating a century-old concept into a modern solution for AMR		
Chairs	Gina Suh (Rochester, Minnesota, United States) Andrej Trampuz (Brisbane, Australia)	
S0345	16:15	Bacteriophage therapy in cardiac and orthopaedic device-related infection Tristan Ferry (Lyon, France)
S0346	16:45	Challenges and future directions of phagotherapy in multidrug-resistant implant infections Thomas Fintan Moriarty (Davos, Switzerland)
Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)		


SY137	16:15 – 18:15	Hall B0-2
	2-hour Symposium	
		
Stronger together: rational design and use of antibiotic combination therapies		
Chairs	Sandrine Marchand (Poitiers, France) Anouk Edwina Muller (The Hague, The Netherlands)	
S0341	16:15	Combination therapies in tuberculosis: how to design and evaluate new regimen Elin Svensson (Uppsala, Sweden)
S0342	16:45	Towards rational breakpoints for antibiotic combination therapies Sebastian Wicha (Hamburg, Germany)
S0343	17:15	Antibiotic combination therapies: can we suppress resistance? Linda Aulin (Leiden, The Netherlands)
S0344	17:45	Optimal off-patent antimicrobial combinations regimens for Gram-negative infections Joe Standing (London, United Kingdom)

EF112	16:15 – 17:15	Arena 1
	ePoster Flash Session	
		
Respiratory bacterial infections: challenges and advances		
Chair	Margaret Ip (Hong Kong, Hong Kong)	
E0785	16:15	Evolution of the respiratory microbiological profile in people with cystic fibrosis undergoing treatment with elexacaftor/tezacaftor/ivacaftor B.S. Orena* (Milan, Italy), F. Girardi, E. Tomassini, D. Girelli, M. D'accico, F. Blasi, V. Daccò, A. Callegaro, L. Cariani
E0778	16:21	Invasive pneumococcal disease in a Portuguese hospital: 19-year retrospective study C. Batista* (Oporto, Portugal), S. Araújo, C. Azeredo, C. Bacelar, J. Oliveira, F. Reis, L. Neto, T. Dos Santos, E. Pena, M.J. Gonçalves, F. Duarte, S. Rocha, S. Jordão, M. Guimarães, A. Read, R. Correia De Abreu, C. Soeiro
E0779	16:27	Re-emergence of Chlamydia pneumoniae after the COVID-19 pandemic: a retrospective PCR-based study in a Spanish tertiary hospital (2019–2025) P. Suárez Urquiza* (Valencia, Spain), E. Cortés Giménez, E. Gremaldos Mira, P. Suarez-Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz
E0780	16:33	Procalcitonin and lung ultrasonography-guided antibiotherapy in patients with lower respiratory tract infection in Swiss emergency departments: a pragmatic stepped-wedge cluster-randomised trial: The PLUS-IS-LESS study N. Boillat-Blanco* (Lausanne, Switzerland), C. Bessat, E. Garcia, R. Bingisser, M. Schwendinger, T. Bulaty, Y. Fournier, V. Della Santa, M. Pfeil, D. Schwab, J. D. Leuppi, N. Geigy, S. Steuer, F. Roos, M. Christ, A. Sirova, A. Atzl, F. Napieralski, O. Manuel, I. Locatelli, W. Albrich, O. Hugli
E0781	16:39	Effect of clarithromycin on inflammatory proteomic expression in community-acquired pneumonia: secondary analysis of the ACCESS trial E. Stylianakis* (Athens, Greece), K. Tsiakos, V. Tzavara, L. Skorda, K. Iliopoulou, G. Adamis, G. Niotis, K. Akinosoglou, N. Kakavoulis, G. Chrysos, S. Gerakari, T. Kontopoulou, G.N. Dalekos, I.C. Papanikolaou, M.G.

E0782	16:45	Antimicrobial-associated acute kidney injury in patients hospitalised with community-acquired pneumonia R.S. Knudsen* (Hvidovre, Denmark), C. Leding, H. Løvendahl Jørgensen, M. Fally, P. Ravn, L. Kolte, S. Bastrup Israelsen, T. Benfield
E0783	16:51	Efficacy of β -lactam monotherapy vs clindamycin or addition of metronidazole in peritonsillar abscess: an observational study with a focus on <i>Fusobacterium necrophorum</i> D. Nygren* (Lund, Sweden), M. Loggarfve, E. Lindberg, K. Holm, M. Gisselson-Solén
E0784	16:57	A randomised, double-blind, placebo-controlled trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis participants chronically colonised with <i>Pseudomonas aeruginosa</i> P. Tamma* (Philadelphia, United States), T. Hamasaki, M. Souli, D. Van Tyne, D. Pride, S. Nayak, K. Moon, E. Raterman, K. Greenwood-Quaintance, D. Ellison, A. Filippov, M. Nikolich, T. Lodise, D. Conrad, A. Jaunarajs, Z. Wintrob, D. Albon, P. Allyn, T. Barto, J. Billings, L. Caverly, A. Graham, W. Hunt, R. Jain, J. Koff, K. Mcbennett, D. Miller, P. Mohabir, B. Morrissey, K. Patel, J. Wang, N. West, M. Bates, J. Leonard, G. Sah, M. Chiu, B. Evans, H. Geres, C. Koscianski, U. Rappo, J. Fackler, H. Chambers, S. Evans, R. Patel, V. Fowler, R. Schooley

EF113	16:15 – 17:15	Arena 2
	ePoster Flash Session	
		
Parasitic diseases in a changing world: climate, mobility, and clinical impact		
Chair	Camilla Rothe (Munich, Germany)	

E0788	16:15	Estimating unreported malaria cases in England: a capture-recapture study P. Charlotte* (London, United Kingdom), C. Patterson, A. Simbo, D. Turner, S. Leinster, P. Katwa, P. Veal, A. Checkley, C. Redman, C.A. Gibb, C. Williams, P. Chiodini
E0789	16:21	Paediatric imported malaria infections with a non-falciparum species: a 2011–2023 retrospective study in France C. Melenotte* (Paris, France), V. Joste, M. Thellier, F. Gay, F. Sorge, J. Toubiana, O. Lortholary, F. Lanternier, P.H. Consigny, L. Musset, B. Pradines, P. Buffet, S. Houzé
E0791	16:27	The PK6 project: a test-and-treat operational strategy for <i>Plasmodium vivax</i> elimination among hard-to-reach illegal gold miners in French Guiana D. Patarot* (Cayenne, French Guiana), M. Oberlis, T. Levarato, M. Rozé, P. Feller, L. Houssais, A. Carfantan, M. Boutrou, Y. Lazrek, L. Musset, F. Mubenga, C. Michaud, L. Epelboin
E0792	16:33	Leishmaniasis as an opportunistic infection in HIV patients in Europe: lack of guidelines harmonisation and limited diagnostic arsenal G. Zaremba* (Warsaw, Poland), A. Papadopoulos, K. Protopapas, M. Stevanovikj, N. Yancheva, S. Dragaš, A.Č. Ćinkaya, C. Oprea, J. Begovac, Z. Bartovská, M. Zlámal, O. Beran, D. Jilich, A. Schembri, R. Matullionyte, I. Gmizic, D. Maric, J. Tomažič, E. Golovco, H. Tiberiu, B. Lakatos, T. Balayan, A. Vassilenko, A. Verhaz, N. Bolokadze, V. Krasniqi, J. Kowalska, A. Harxhi
E0793	16:39	Leishmaniasis in a Spanish tertiary hospital (2018–2025): epidemiological trends, clinical and diagnostic characteristics of a re-emerging disease E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, A. Ruiz Gaitán, P. Suárez Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz
E0794	16:45	Serum circulating anodic antigen as test-of-cure for schistosomiasis in migrants: what is the impact? L.C. Vaccari* (London, United Kingdom), I. Chaudhry, J. Martin, C. Sen, N. Longley, G. Godbole, S. Eisen, L. Nabarro
E0795	16:51	Three decades of echinococcosis in southern Madrid: insights into an endemic zoonosis A.N. Ruiz Benito* (Leganes, Spain), V. Anton Berenguer, K.M. Pinto Tapia, M.D. Martín Rodrigo, S.M. Quevedo Soriano, S. Gómez De Frutos, F.J. Merino Fernández, J.M. Rubio Muñoz, M.D. Flores Chávez

EF114	16:15 – 17:15	Arena 3
	ePoster Flash Session	
		

Controlling *Clostridioides difficile* infections and hospital related challenges

Chair Kerrie Davies (Leeds, United Kingdom)

E0796	16:15	Most recurrent <i>Clostridioides difficile</i> infections reflect persistent infection or repeat exposure: findings from whole genome sequencing in Wales, UK R. Polani Chandrasekar* (Cardiff, United Kingdom), L. Campbell, T. Connor, N. Craine, V. Daniel, H. Hughes, V. McClure, T. Morris, M. Perry, R. Phillips, D. Williams, M. Morgan
E0797	16:21	Evaluation and comparison of three methods for the detection of <i>Clostridioides difficile</i> toxin in faecal samples R. Asif* (Cardiff, United Kingdom), P. Talagtag, F. Ismail, S. Mitchell, M. Perry, S. Jones
E0798	16:27	Gut microbiome characterisation in inflammatory bowel disease and <i>Clostridioides difficile</i> infection E. Reigadas* (Madrid, Spain), S. Vázquez-Cuesta, I. Marín, M. Díaz-Navarro, G. Álvarez-Calatayu, C. Sánchez, M. Guembe, A. Visedo, E. Bouza, P. Muñoz, L. Menchén, R. Samaniego, R. Bañares
E0799	16:33	Screening for asymptomatic carriage of <i>Clostridium difficile</i> : results from a two year intervention M. Gilboa* (Ramat Gan, Israel), N. Barde, E. Meltzer, Y. Peretz, I. Levy, S. Amit, G. Rahav, N. Pinas-Zade, B. Mechnik, G. Regev-Yochay
E0800	16:39	<i>Clostridioides difficile</i> infection in Europe: are we meeting best practices? M. Krutova* (Prague, Czechia), J. Prehn, W.K. Smits, O. Burduniuc, M. Wilcox, E. Kuijper
E0801	16:45	Epidemiological trends in <i>Clostridioides difficile</i> infections in France, 2019-2024: TRACE national population-based study M. Decalonne* (Tours, France), M.H. Pham-Hi, C. Gaborit, C. Salpérier, N. Khanafer, C. Daniau, F. Barbut, L. Grammatico-Guillon
E0802	16:51	Exploring patient experiences of infection prevention and control across a range of healthcare associated infections: the stories behind the numbers M. Skally* (Dublin, Ireland), J. Strawbrige, C. Cox, J. Heritage, S. Rajesh, A. Walsh, C. Finn, P. Conran, K. Bennett, H. Humphreys, F. Fitzpatrick
E0803	16:57	From insight to impact: leveraging opportunity mapping to drive system-wide reductions in CLABSI, CAUTI, <i>C. difficile</i> , and MRSA over a three-year period G. Rosello* (Miami, United States), J. Somani, C. Ghaemmaghami, D. Zambrana, H. Clark, C. Biggs, L. Abbo
E0804	17:03	Wipe-based solutions for hand hygiene: do they really work? A. Barry* (Salisbury, United Kingdom), G. Moore

KN136 16:15 - 17:15 Hall ICM 14

Keynote lecture

**Viral infection in the immunocompromised: from discovery to emerging therapies**Chairs Maddalena Giannella (Bologna, Italy)
Monica Slavin (Melbourne, Australia)

K0340 16:15 Hans H. Hirsch (Tromsø, Norway)

ME140 16:15 - 17:15 Hall ICM 1

Meet-the-Expert

**Artificial intelligence in antimicrobial stewardship and infection control: from prediction to precision**

M0349 16:15 Damien Ming (London, United Kingdom)

M0350 16:27 José Ramón Paño-Pardo (Zaragoza, Spain)

ME141 16:15 - 17:15 Hall ICM 5

Meet-the-Expert

**Children are not small adults: interactive paediatric cases**

M0351 16:15 Julie Toubiana (Paris, France)

M0352 16:27 Ulrich Von Both (Munich, Germany)

PM006 16:15 - 18:15 Hall A2-1

Pipeline Symposium

**The value of diagnostics and enhancing utilisation**Chairs Till T. Bachmann (Edinburgh, United Kingdom)
Betsy Wonderly Trainor (Boston, United States)

D0014 16:15 Adoption and implementation in infection diagnostics – the long and winding road Jane Freeman (Leeds, United Kingdom)

D0015 16:45 Beyond the test: social and organizational realities of implementing RTI diagnostics in primary care Sibyl Anthierens (Wilrijk, Belgium)

D0016 17:15 What are diagnostics actually worth? Rethinking value beyond accuracy Brooke Nichols (Boston, United States)

D0017 17:45 From great science to routine clinical use Matthew Mckillip (Chicago, United States)

ART 16:15 - 17:15 Hall A1-3

Special Session

The art of food safetyChairs Leonard Leibovici (Yahud, Israel)
Joel Mossong (Luxembourg, Luxembourg)

LB008 17:30 - 18:30 Hall A1-4

1-hour Oral Session

**Late-breaking trials in surgical infection prevention**Chairs Ili Margalit (Ramat Gan, Israel)
Eli Perencevich (Iowa City, Iowa, United States)L0041 17:30 Improvement in staff behavior during surgical procedures to prevent postoperative complications (ARIBO²): a cluster randomised trial. G. Birgand* (Nantes, France), N. Jacquet, E. Tavernier, C. Gaborit, T. Haudebourg, N. Mauduit, C. Leux, D. Lepelletier, L. Grammatico-Guillon, J.C. Lucet, B. GiraudeauL0042 17:42 Polyhexanide vs mupirocin and chlorhexidine for pre-operative *Staphylococcus aureus* decolonisation in elective spine surgery (SPADE): a pilot randomised controlled trial R. Sommerstein* (Lucerne, Switzerland), J. Krebs, M. Grigorov, T. Poetzel, F. Michael, D. Bratelj, C. Capone, X. Zhou, J. Stoyanov

L0043 17:54 One day of antibiotic treatment is non-inferior to four to seven days in patients with acute cholangitis after adequate biliary drainage: a multi-centre randomised controlled trial (COBRA) A. Overdeest* (Amsterdam, The Netherlands), E. Sieswerda, S. Haal, J.A. Bogaards, K.S. Boparai, F. Ter Borg, M.A. Brink, F. Van Delft, V.K. Dik, L.P.L. Gilissen, M. Hadithi, W.L. Hazen, F. Van Der Heide, W.J. Den Hollander, A. Inderson, P.J.F. De Jonge, S.D. Kuiken, J.M. Munneke, B. Opsteeg, L.E. Perk, A.C. Poen, J.W. Poley, R. Quispel, R.C.H. Scheffer, D.W. Schölvinck, E.J. Van Soest, A.C.I.T.L. Tan, W.J. Thijs, N.G. Venneman, R.C. Verdonk, F.P. Vleggaar, W. Van De Vrie, J.M. Vrolijk, R.L.J. Van Wanrooij, P.W. Weijnenborg, M.G.W. Dijkgraaf, J.M. Prins, R.P. Voermans

L0045 18:06 Effectiveness of an AI-based augmented reality tool for hand hygiene: preliminary findings of a cluster randomised controlled trial L. Yang* (Hong Kong, Hong Kong), Y. Lai, J. Meng, Y. Li, J. Lu, S. Lu, J. Chen, C.F. Ho, E. Tartari, G. Birgand

L0044 18:18 Epidemiology, medical-surgical approach, and clinical and functional outcomes in fracture-related infection: an international multi-centre study from ESGIAI M. Del Toro* (Seville, Spain), B. Dahiri, R. García, M. Papadimitriou-Olivgeris, H. Ernandes, F. Almeida, J. Gomez-Junyent, O. Lesens, T. Martinez-Pascual, I. Contadini, D. Vaznaisiene, J.A. Iribarren-Loyarte, G.

OS116	17:30 – 18:30	Hall A2-2
1-hour Oral Session		
AMR CLN TRN		
Challenging the status quo in herpesvirus therapy		
Chairs	Sylviane Defres (Liverpool, United Kingdom) Dionysios Neofytos (Geneva, Switzerland)	
00805	17:30	ABI-5366-101: a phase Ib study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpes M. Bloch* (Sydney, New South Wales, Australia), E. Gane, C. Sellwood, A. Edwards, W. Hayter, T. Tonkin, K. Kaluhin, D. Smith, G. Wang, J. Liu, S. Knox, K. Zomorodi, K. Kitrinis, A. Gaggar, J. Sasadeusz
00806	17:42	Helicase-primase inhibitor adibelivir (IM-250) shows potent antiviral activity against HSV clinical and acyclovir-resistant isolates and achieves therapeutic exposure in phase I/Ib studies G. Kleymann* (Munich, Germany), A. Blank, M. Bergamino, J. Burhenne, D. Czock, C. Gege, Z. Haiying, A.C. Pérez-Osorio, B. Madarampalli, K.R. Jerome, N. Pretzsch, D. Huzly, V. Falcone, T. Hoffmann
00807	17:54	Updated use of CHARMD, a comprehensive herpesviruses antiviral resistance mutation database and HSA tool for easy cytomegalovirus genotyping interpretation S. Alain* (Limoges, France), V. Tilloy, D. Díaz-Gonzalez, S. Chou, G. Andrei, F. Baldanti, G. Boivin, H. Hirsch, T. Lazzarotto, M. Marcos-Angeles, D. Michel, W.D. Rawlinson, S. Hantz
00808	18:06	Clinical experience of maribavir use for the treatment of refractory or resistant cytomegalovirus infection in solid-organ transplant recipients M. Jayne* (London, United Kingdom), A. Stafford, K. Fung, G. Jones, R. Evans, M. Harber, R. Westbrook, J. Ryan, J. Potts, A. Marshall, M. Lanzman, N. Kanani Alvir, D. Cunningham, T. Haque, J. Hart, B. Patterson
00809	18:18	Delayed treatment alters pharmacodynamics of anti-CMV drugs L. Sudarsono* (Leiden, The Netherlands), K. Puspitasari, X. Liu, C. Van Hasselt, A.G. Märtson

OS117	17:30 – 18:30	Hall A3-2
1-hour Oral Session		
ANT CLN TRN		
PK/PD-based antimicrobial dosing optimisation in children		
Chairs	William Couet (Poitiers, France) Iris K. Minichmayr (Vienna, Austria)	
00810	17:30	Population pharmacokinetics of cefotaxime for optimising dosing in paediatric meningitis and bacteraemia Z.X. Mun* (Melbourne, Australia), A. Boast, A. Lei, A. Di Carlo, R. Chiletta, A. Daley, D. Fuhs, G. Gonis, B. Mcwhinney, A. Moody, R. Nation, J. Ungerer, C. Landersdorfer, A. Gwee
00811	17:42	Ceftazidime/avibactam in neonates and infants < three months old: population pharmacokinetic (PopPK) analysis and PopPK model application E. Soto* (Sandwich, United Kingdom), J.L. Yan, P. Irani, R. England
00812	17:54	Population pharmacokinetic/pharmacodynamic analyses of cefiderocol for paediatric patients D. Yamaguchi* (Osaka, Japan), T. Katsube
00813	18:06	Optimising posaconazole dosing in children through population PK modelling and simulation M.L. Vuong* (Leuven, Belgium), O. Elkayal, J. Standing, S. Boonsathorn, Z. Kane, S. Bentley, A. Tragiannidis, A. Groll, J. Nickless, A. Brothers, A. Uyttebroeck, R. Valenzuela, J. Morales, I. Spriet, E. Dreesen
00814	18:18	Evaluation of optimal empirical antibiotic combinations for neonatal sepsis in low- and middle-income countries: a pharmacokinetic/pharmacodynamic approach W. Van Os* (Leiden, The Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, R. Zahra, G. Chan, D. Bekele, S. Solomon, A. Rucogoza, J.B. Mazarati, K. Ireghu, S.N.C. Uwaezuoke, A.B. Mairami, F.Z. Modibbo, L.I. Audu, S. Gambo, A. Aliyu, J.G.C. Van Hasselt

OS115	17:30 – 18:30	Hall ICM 1
1-hour Oral Session		
CLN DX TRN		
Functional and translational advances in microbiome analysis		
Chairs	Lena Biehl (Cologne, Germany) Maurizio Sanguinetti (Rome, Italy)	
00815	17:30	Validation of microbiome-guided fluorescence <i>in situ</i> hybridisation (MG-FISH) in clinical microbiology: integrating next-generation sequencing with molecular microbiome imaging J. Kikhney* (Leipzig, Germany), Z. Xiong, K. Sarbandi, M. Muchova, D. Von Schöning, A. Moter
00816	17:42	Machine learning-based optimisation of long-read 16S rRNA sequencing parameters enhances species-level microbiome classification A.K. Bari* (Groningen, The Netherlands), B.J. Olij, J.H.E. De Lange, T.T. Severs, B. Sinha, J.W.A. Rossen, B.B. Xavier
00817	17:54	Salivary host-microbe interactions reveal pathogenic signatures in early colorectal cancer S. Rezasoltani* (Aachen, Germany), H. Asadzadeh Aghdaei, G. Conrads
00818	18:06	Culturomics-guided bacterial extracellular vesicle profiling reveals the gut microbiota's role in patients with CTLA4 deficiency R. Magdy Wasfy* (Montreal, Canada), C. Morin, M. Naegele Aranguren, C. Masse, J. Poudrier, E.L. Falcone
00819	18:18	Site-stratified multi-omics profiling reveals body site specific microbiome immune signatures for clinical state classification D. Sebukpor* (Chandigarh, India), I. Odezligbo, M. Nagey, M. Chukwuka, O. Akinsuyi

SY144	17:30 – 18:30	Hall A3-1
1-hour Symposium		
AMR CLN		
Update on STIs: epidemiology, drug resistance and role of DoxyPEP		
Chairs	Arjan Harxhi (Tirana, Albania) Jean-Michel Molina (Paris, France)	
S0357	17:30	The impact of travel on the global epidemiology of STIs Zofia Bartovska (Prague, Czechia)
S0358	18:00	Impact of DoxyPEP on the human microbiome and resistome Victoria Chu (San Francisco, California, United States)
Co-organised with: ESCMID Education Subcommittee, ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)		

SY143	17:30 – 18:30	Hall B0-1
1-hour Symposium		
DX PHEI		
The future of pathogen surveillance: molecular data without borders		
Chairs	Adrian Egli (Zurich, Switzerland) Paula Mölling (Örebro, Sweden)	
S0355	17:30	The Swiss Pathogen Surveillance Platform: a model for international collaboration and data sharing Tim-Christoph Roloff (Zurich, Switzerland)
S0356	18:00	Lessons learned from the Trakka Data Sharing Ecosystem in Australia and beyond Benjamin Peter Howden (Melbourne, Australia)
Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)		

SY142	17:30 – 18:30	Hall ICM 13b
1-hour Symposium		
PHEI		
Redefining One Health		
Chairs	Pikka Jokelainen (Copenhagen, Denmark) Sonja Lofmark Behrendtz (Solna, Sweden)	

S0353	17:30	New theoretical frameworks for One Health <i>Julianne Meisner (Seattle, United States)</i>
S0354	18:00	New operational frameworks for One Health <i>Jakob Zinsstag (Basel, Switzerland)</i>

EF118 17:30 – 18:30 Arena 1
ePoster Flash Session

Beyond culture: spectroscopy for pathogen identification and typing
Chair Angela Novais (Porto, Portugal)

E0820 17:30 FTIR spectral fingerprinting for rapid identification of high-risk Shiga toxin-producing *Escherichia coli* serotypes
L. Díaz-Formoso (A Coruna, Spain), S. Sánchez, G. Bou, M. Oviaño*

E0821 17:36 Automated discrimination of *E. coli* from *Shigella* spp. using FT-IR spectroscopy and machine learning
M. Cordovana (Bremen, Germany), N. Mauder, A.B. Pranada, C. Hess, W. Geissdoerfer, F. Pankok, U. Loderstaedt, S. Scheithauer, D. Dekker, A.E. Zautner, J. Overhoff, M. Werner, A. Wille, P. Warnke, T. Koeller, P. Morales, M. Suleiman, A. Perez-Lopez, J. Jiménez-Rodríguez, P. Garcia, G. Da Silva Collar, N. Kehl Moreira, A.L. Barth, J. Caierao, O. Join-Lambert, A.A. Muntean, C. Ghituiescu, C. Daniela, M.I. Popa, R.M. Hagen, U. Schotte, H. Frickmann*

E0823 17:48 Development of surface-enhanced Raman spectra coupled with machine learning analysis for differentiation of closely related species within *Enterobacter cloacae* complex
Y. Li (Beijing, China), M. Zhou, X. Xu, Y. Xu, B. Gu, J. Gu*

E0824 17:54 Discriminating old from new: application of Fourier-transform infrared spectroscopy (FTIR) to the reappearance of *Pseudomonas aeruginosa* in cystic fibrosis and primary ciliary dyskinesia
M. Rossitto (Rome, Italy), S. Raimondi, M. Cristiano, G. Vrenna, V. Fox, V. Tuccio Guarna Assanti, N. Essa, M.S. Lepanto, G. Foglietta, E. Montemiro, F. Alghisi, F. Majo, L. Cristiani, A. Boni, N. Ullmann, R. Cutrera, C.F. Perno, P. Bernaschi*

E0825 18:00 Performance of a machine learning algorithm for FTIR-based typing of NDM-producing *Klebsiella pneumoniae* in a hospital outbreak
C. Garrido (Santiago, Chile), J. Jimenez, M. Lecerasi, A. Wozniak, G. Arratia, P. Garcia*

E0826 18:06 Serotyping of *Haemophilus influenzae* strains and *Yersinia enterocolitica* by Fourier-transform infrared (FTIR) spectroscopy
S. Zimmermann (Heidelberg, Germany), C. Janssen, J. Rau, M. Cordovana, N. Mauder, T.T. Lam*

E0827 18:12 Fourier-transform infrared spectroscopy as a tool for *Streptococcus pneumoniae* serotyping: optimisation of the PCV15-classifier (Version 2.0)
J. Caierão (Porto Alegre, Brazil), G. Rosa Da Cunha, C. Tondolo Romero, N. Kehl Moreira, A.L. De Oliveira Gonçalves, J. Cover Salvador, A. Luis Barth, C.A. Gomes Dias*

E0828 18:18 Comparative evaluation of FTIR spectroscopy and whole genome sequencing for typing *Salmonella enteritidis*
S. Suto (Zagreb, Croatia), S. Šuto, N. Pražić, T. De Zan, M. Kvaternik Celjak, J. Knežević, J. Vraneš*

EF119 17:30 – 18:30 Arena 2
ePoster Flash Session

When fungi break the rules: rare pathogens in unusual sites
Chair Johan Maertens (Leuven, Belgium)

E0829 17:30 *Candida* prosthetic joint infections, including multidrug-resistant *Candida auris*, at Hospital La Fe: a 15-patient 15-year experience (2010–2025)
L. Brusca Vidao (Valencia, Spain), S. Giner Almaraz, J. Frasset, P. Suárez Urquiza, P. Muñoz Brell, E. Gremaldos, C. Castillo Martínez, J.L. López Hontangas, A. Ruiz-Gaitán*

E0830 17:36 Clinical features and outcomes of cryptococcosis associated with Bruton tyrosine kinase inhibitors: a multi-centre retrospective study and literature review
R. Manchon (Paris, France), C. Julien, D. Roos-Weil, B. Elodie, B. Charlotte, P. Thomas, O.*

Lortholary, C. Sharon, F. Lanternier, S. Monica, O. Paccoud

E0831 17:42 Beyond hepatosplenic candidiasis: the changing face of paediatric chronic disseminated yeast infection
M. Husain (Paris, France), F. Alby Laurent, J. Guitard, M. Gits-Muselli, B. Brethon, F. Lanternier*

E0832 17:48 Refazungin for *Candida* osteoarticular infections: the REZ-GEIO project
S. De La Villa Martínez (Madrid, Spain), S. De La Villa, J. Guinea, J. Gómez Junyent, L. Ramos Merino, R. Escudero Sánchez, B. Sobrino, M.J. Moya, A. Muñoz, E. Múñez, M. Sánchez Somolinos, P. Sanz Ruiz, P. Muñoz*

E0833 17:54 From detection to decision-making: clinical utility of plasma microbial cell-free DNA sequencing for invasive mould infections
M. Al Mohajer (Houston, United States), R. Berger, N. Howard, S. Grant*

E0834 18:00 Prospective evaluation of itraconazole for the treatment of Jorge Lobo's disease (lobomycosis)
A. Nishikaku (São Paulo, Brazil), J. Nobrega De Almeida Jr, F. Gonçalves, R.R. Durlacher, M.R. De Sousa Trindade, A. Panizza Jalkh, M. De Melo Teixeira, M.D.V. Martino, A. Satie Nishikaku*

E0835 18:06 Severe histoplasmosis in intensive care units: a multi-centre retrospective study in France
L. Chantelot (Paris, France), H. Kallel, L. Camous, E. Dufranc, L. Zafrani, T. Urbina, A. Curtiaud, F. Boissier, P. Szychowiak, D. Roux, A. Rouze, A. Robert, N. Heming, F. Pene, R. Sonnevill, S. Hraiech, G. Voiriot, G. Martin Blondel, J. Hayon, G. Jolly, N. Issa, E. Blanchard, F. Ader, M. Decavele, B. Peiffer, F. Botterel, A. Adenis, F. Lanternier, K. Razazi*

E0836 18:12 Multi-centre outbreak of both *Magnusiomyces capitatus* and *Magnusiomyces clavata* in Italy
B. Spruijtenburg (Nijmegen, The Netherlands), E. De Carolis, C. Magri, M. Sanguinetti, T. De Groot, V. Di Pilato, M. Mikulska, J.B. Buil, E.F.J. Meijer*

EF120 17:30 – 18:30 Arena 3
ePoster Flash Session

Advances in AMR diagnostics
Chair Tomislav Kostyanev (Esbjerg, Denmark)

E0838 17:30 Evaluation of a new CRISPR-Cas-based assay for the detection of *bla*KPC in bacterial isolates
A. Valêncio Siqueira (Massachusetts, United States), A. VALÊNCIO Siqueira, A.C. Gales, P.J.M. Bispo*

E0840 17:36 PathCrisp: a next-generation CRISPR diagnostic platform for rapid detection of antimicrobial resistance
M. Naik (Bengaluru, India), K. Bs, S. Annes, D. Hafiz, D. Bhagchandani, V. Hegde, V. Chandru, V. Gupta, R. Arora*

E0841 17:42 Rapid aptamer-based biosensor for identifying *K. pneumoniae* strains and testing meropenem-colistin susceptibility
K.N. Yilmaz (Kars, Türkiye), N. Ciftci, Z.O. Uygun*

E0842 17:48 Digital AST Annotator: standardising Kirby-Bauer reading with an open-source app
A. Guerrero-López (Zurich, Switzerland), A. Diversi, E. Sosa, A.G. Monsalve, A. Egli*

E0843 17:54 Comparative evaluation of a real-time PCR assay vs conventional culture for detecting carbapenemase-producing Gram-negative bacteria in rectal swabs
A. Tychala (Thessaloniki, Greece), P. Trikoupi, Z. Sereni, Z. Tsinaris, G. Kagkalou, O. Vasilaki, K. Kouirouxis, P. Mantzana, E. Protonotariou, L. Skoura*

E0844 18:00 MIC creep in the shadows: an interactive dashboard for forecasting MIC trends in newer antimicrobials against MDR pathogens across WHO regions
N. Nityadarshini (New Delhi, India), J. Biswas, T. Bordoloi*

E0845 18:06 Explaining phenotypic carbapenem resistance in GeneXpert-negative Gram-negative bacteria and evaluating concordance with whole genome sequencing
S. Alotaibi (Riyadh, Saudi Arabia), A. Alomani, S. Alharbi, M. Alghoribi, L. Faqih, T. Abdulrahman, F. Alasmari*

ME145 17:30 – 18:30 Hall ICM 5
Meet-the-Expert

Implementing WHO hepatitis guidelines in LMICs: challenges and

perspectives

M0359 17:30 *Olufunmilayo Lesi (Geneva, Switzerland)*
 M0360 17:42 *Zeinab Said (Cairo, Egypt)*
 Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Society for the Study of liver Diseases in Africa (SOLDA), Slovenian Society for Infectious Diseases, British Infection Association (BIA)

PM007 17:30 – 18:30 Arena 4
 Policy Forum

AMR PHEI

From global research priorities to national and local impact: implementing AMR priority research agendas

Chair *Benedikt Huttner (Geneva, Switzerland)*

D0018 17:30 **Challenges and opportunities on the implementation of the OHPRA Sabiha Essack (Durban, South Africa)**
 D0019 17:45 **Implementing global research agendas on AMR: tracking research projects and activities Lesley Ann Ogilvie (Berlin, Germany)**
 D0020 18:00 **Aligning national research projects with global research agendas Gloria Cordoba (Copenhagen, Denmark)**
 D0021 18:15 **Promoting global research agendas for policy makers Geneviève Boily-Larouche (Toronto, Canada)**

Tuesday, 21 April 2026

OS122 08:30 – 09:30 Hall A1-2
 1-hour Oral Session

CLN DX

Moving from culture to molecular diagnostics in implant-associated infections

Chairs *Thomas Fintan Moriarty (Davos, Switzerland)*
Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)

O0847 08:30 **Rapid novel molecular method for enhanced detection of periprosthetic joint infection E. Morreel* (Maastricht, The Netherlands), P. Savelkoul, I. Van Loo**
 O0848 08:42 **Enhancing diagnostics in orthopaedic infections: clinical impact of syndromic multiplex PCR compared to traditional culture F. De Winter* (Turnhout, Belgium), N. Van Beek, J. Frans, T. Goegebuer, W. Schuermans, E. Van Even, P. Verbeeck, D. Van Der Beek, H. Naillis**
 O0849 08:54 **Optimising culture strategies in chronic orthopedic device-related infections: do blood culture bottles deliver? J. Van Heuverswyn* (Ghent, Belgium), H. Hamerlinck, D. Huis In 't Veld, S. Vandendriessche, B. Verhasselt, J. Boelens**
 O0850 09:06 **Pathogen spectrum of aortic graft infections uncovered by combined microbiologic testing and in situ metagenomic sequencing Q. Miao* (Shanghai, China), J. Yue, Y. Chen, Y. Luo, H. Liu, Y. Kan, B. Hu**
 O0851 09:18 **Utility of metagenomic sequencing of microbial cell-free DNA as a diagnostic tool in vascular graft and endograft infections: a cross-sectional study R.A. Nielsen* (Aarhus, Denmark), M. Eneberg, A.M.F. Eskildsen, M. Albertsen, N.P. Jørgensen, J. Budtz-Lilly, L.J. Østergaard, N.B. Stærke**

LB009 08:30 – 09:30 Hall A1-3
 1-hour Oral Session

CLN

Late-breaking clinical trials in sepsis management

Chairs *Jean-Francois Timsit (Paris, France)*
Steven Tong (Melbourne, Australia)

L0046 08:30 **Imipenem/cilastatin-funobactam for hospital-acquired/ventilator-associated bacterial pneumonia:**

a multinational phase III trial (REITAB-2) K. Chang* (Beijing, China), Y. Wang, C. Wang, Z. Tang, J. Yin, J. Zhao, Y. Wang, T. Mei, A. Li, H. Li, Q. Jiang, P. Wang, F. Ye, L. Ding, Z. Liu, F. Yin, X. Mo, H. Gu, Y. Xia, J. Wang, J. Wu, S. Yang, R. Lin, G. Lv, H. Luo, B. Liu, J. Gu, F. Wei, J. Zhu, H. Liang, S. Qiu, H. Mai, X. Zhu, R. Yu, G. Han, T. Lou, H. Wang, J. Zhang, Y. Li, H. Wang, H. Lu, T. Xin, C. Li, X. Wang, X. Zhang, H. Gao, H. Wang, A. Pan, Q. Wang, J. Cao, Y. Zhu, Z. Xiao, L. Pan, S. Peng, X. Ding, Q. Chi, H. Xu, F. Liu, A. Guo, J. Zhan, Q. Zhang, R. Guo, J. Li, D. Zhu, H. Zhao, A. Cano Yuste, T. Huynh, I. Biney, K. Remy, B. Cao

L0047 08:42 **LOW-dose CT cOmPared to Lung UltraSonography vs standard of care-based strategies for the diagnosis of pneumonia in the elderly: a multi-centre randomised controlled trial (OCTOPLUS) V. Prendki* (Geneva, Switzerland), N. Garin, A. Platon, E. Bernasconi, T. Ruder, A. Poncet, J. Stirnemann, W. Hautz**

L0048 08:54 **A multi-centre, randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in severely ill neonates and children: BENEFICIAL trial P. De Cock* (Ghent, Belgium), R. Colman, A. Smits, F. Piersigilli, M. Renard, A. Van Damme, A. Clarysse, E. Dhont, S. Vanhaesebrouck, V. Bordon, L. Boland, B. De Wilde, A. Amza, L. Vanlanduyt, T.V.A. Nguyen, F. Cools, J. Van Der Werff Ten Bosch, D. Vens, F. Derriks, L. Houtekie, M. Reiner, D. Van Der Linden, P. Schelstraete**

L0049 09:06 **Use of procalcitonin point-of-care test to guide de-escalation of empiric antibiotic therapy in adult patients with sepsis in a tertiary hospital in Bangladesh (PROCALBAN): a randomised, controlled, open-label trial F.U.H. Chowdhury* (Oxford, United Kingdom), R.A.M.E. Uddin, M. Ali, P.K. Dutta, D. Das, A.H. Hanif, M. Kar, F.B. Jahangir, S.I. Khan, M.M. Huq, A.A. Sayeed, M.H.O. Roshid, N.U. Chy, M.A. Hossain, M.A. Sattar, M. Schilstra, E. De Jong, C. Schultz, M. Nijsten, M.J. Uddin, A. Ghose, K. Plewes, L. Pisani, P. Guerin, M. Mukaka, A.M. Dondorp**

L0050 09:18 **Adjunctive clindamycin for treatment of Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP) A. Bowen* (Wembley, Australia)**

EW152 08:30 – 10:30 Hall A3-1
 2-hour Educational Session

PED VAX

Vaccination during pregnancy: for the mother, and for the child

Chairs *Olivier Epaulard (Grenoble, France)*
Ulrich Heininger (Basel, Switzerland)
 W0479 08:30 **Burden of vaccine-preventable infections in pregnant women Shamez Ladhani (London, United Kingdom)**
 W0480 08:50 **Mother-to-child transmission of antibodies: how and when Marta Nunes (Lyon, France)**
 W0481 09:10 **Vaccination of pregnant women to protect the child: successes and hurdles Pawel Stefanoff (Stockholm, Sweden)**
 W0482 09:30 **Vaccination during pregnancy: from doctors to mother-to-be, who is hesitant? Emilie Karafillakis (London, United Kingdom)**

Co-organised with: ESCMID Vaccine Study Group (EVASG)

EW151 08:30 – 10:30 Hall ICM 13a
 2-hour Educational Session

DX PHEI

Bird flu is no longer just for birds: from strategic planning to public health readiness

Chairs *Edoardo Colzani (Solna, Sweden)*
Barbara Rath (New Orleans, United States)
 W0475 08:30 **What drives pandemic risk? Virus, population and policy factors influencing Influenza H5N1 spread Benjamin Cowling (Pokfulam, Hong Kong)**
 W0476 08:50 **Surveillance in action: diagnostic tools for early detection of zoonotic influenza human infections Kanta Subbarao (Quebec City, Canada)**
 W0477 09:10 **Zoonotic influenza: from signals to public health response actions Angeliki Melidou (Stockholm, Sweden)**

W0478 09:30 Antivirals and vaccines: readiness for a future influenza pandemic Marco Cavaleri (Amsterdam, Belgium)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV), European Centre for Disease Prevention and Control (ECDC)

OS121 08:30 - 10:30 Hall B0-1
2-hour Oral Session

AMR

Genomic epidemiology and emerging bacterial resistance

Chairs Valeria Bortolaia (Copenhagen, Denmark)
João Pires (Oslo, Norway)

O0852 08:30 Long-term persistence and cross-reservoir transmission of antimicrobial resistant *Serratia marcescens*: a genomic epidemiology study J. Lay* (Melbourne, Australia), J. Lacey, R. Patwa, A.Y. Peleg, B. Vezina, N. Macesic

O0853 08:42 High prevalence of NDM-5-producing *Escherichia coli* with Penicillin-Binding Protein 3 Mutations in Germany: An emerging threat? J.B. Hans* (Berlin, Germany), L.M. Höfken, S. Möller, N. Pfennigwerth, F. Reichert, M. Sandfort, M.A. Fischer, T. Semmler, T. Eckmanns, G. Werner, S. Haller, S. Gatermann

O0854 08:54 A decade of evolving *Pseudomonas aeruginosa* resistance: epidemiology and antimicrobial trends (2014–2024) D. Mendes Pedro* (Lisbon, Portugal), M. Meneses, C. Mimoso Santos, A. Bruschy Fonseca, A. Ayres Pereira, E. Valadas, J. Melo Cristiano, C. Caneiras

O0855 09:06 Associations between antidepressant prescribing and antibiotic resistance in *Escherichia coli* urinary tract infections in Scotland L. Ciaccio* (Dundee, United Kingdom), B.J. Parcell, H. Wang, J. Danial, F. Kerr, J. Mcewen, A. Morrison, D. O'driscoll, A. Seaton, K.N. Barnett, C.A. Marwick

O0856 09:18 Integrated genomic surveillance of carbapenemase-producing *Klebsiella pneumoniae* in Germany in 2023-2024 revealed frequent case imports from abroad and local outbreaks M. Sandfort* (Berlin, Germany), L.M. Höfken, F. Reichert, M.A. Fischer, S. Möller, J.B. Hans, H. Öhler, D. Said, N. Pfennigwerth, T. Eckmanns, G. Werner, S.G. Gatermann, S. Haller

O0857 09:30 The emergence and spread of NDM-type carbapenemase-producing *Acinetobacter baumannii* clones in Hungary A. Hanczvikkel* (Budapest, Hungary), D. Göbhardt, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Holub, L. Majoros, K. Kamotsay, M. Farkas, A. Kark, K. Mályi, B. Roskó, M.A. Peti, Á. Tóth

O0858 09:42 Clonal complex 398 emerging as community- and healthcare-associated methicillin-resistant *Staphylococcus aureus* in the Czech Republic 2017-2024 J. Tkadlec* (Prague, Czechia), A. Rozsypalkova, S. Polivkova, P. Drevinek, J. Gooskens, M. Krutova

O0859 09:54 Epidemiological and molecular insights of community- and hospital-acquired MRSA in Antwerp, Belgium D. De Smet* (Antwerp, Belgium), S. Van Goethem, P. Van Lint, W. Verstrepen, B.B. Xavier, R. Naesens

O0860 10:06 Antimicrobial resistance in the zoonotic pathogen *Capnocytophaga canimorsus*: global distribution of resistance genes and their phenotypic impact Z. Germuskova* (Zurich, Switzerland), E. Pronzini, T. Roloff, H. Seth-Smith, K.K. Søgaard, E.M. Broens, F. Renzi, A. Egli

O0861 10:18 Comprehensive genomic surveillance of invasive *Salmonella* in India reveals plasmid evolution and expanding antimicrobial resistance V. Shamanna* (Bengaluru, India), P.R. Sowmya, S. Varun, C. Natacha, N. Geetha, K.L. Ravikumar

SY148 08:30 - 10:30 Hall A1-1
2-hour Symposium

CLN DX

Advancing diagnostic strategies for detecting bacteraemia across the globe

Chairs Christina Obiero (Killifi, Kenya)
Agnes Maria Sonnevend (Pécs, Hungary)

S0463 08:30 Rethinking bacteraemia: how diagnostic innovation is

improving outcomes Kai Sohn (Stuttgart, Germany)
S0464 09:00 From PCR to whole genome: the molecular revolution in bacteraemia diagnosis Kwan Ki Karrie Ko (Singapore, Singapore)

S0465 09:30 Low-tech blood culture techniques and protocols: what is truly necessary? Liselotte Hardy (Antwerp, Belgium)

S0466 10:00 Needs and barriers for performing blood cultures in resource limited settings Makeda Semret (Montreal, Canada)

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

SY149 08:30 - 10:30 Hall A2-1
2-hour Symposium

CLN TRN

The role of the microbiome in shaping clinical outcomes in immunocompromised patients

Chairs Nicolas Benech (Lyon, France)
Maria Vehreschild (Frankfurt Am Main, Germany)

S0467 08:30 The role of the microbiome in immune reconstitution after cancer therapy Kate Markey (Seattle, United States)

S0468 09:00 Targeting the gut microbiome: an emerging trend in haematopoietic stem cell transplantation Jonathan Peled (New York, United States)

S0469 09:30 Optimising cancer treatment through gut microbiome modulation Maria Rescigno (Pieve Emanuele, Italy)

S0470 10:00 Role of microbiome in GVHD Mette Hazenberg (Amsterdam, The Netherlands)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY150 08:30 - 10:30 Hall A2-2
2-hour Symposium

DX

The real-world impact of IVDR on patient care: threat or opportunity?

Chairs Antti Hakanen (Turku, Finland)
David Ong (Rotterdam, The Netherlands)

S0471 08:30 Implications of IVDR on clinical decision making and patient care Erlangga Yusuf (Rotterdam, The Netherlands)

S0472 09:00 IVDR impact on molecular diagnostic workflows Maurizio Sanguinetti (Rome, Italy)

S0473 09:30 How metrology can support IVDR and outbreak response Esmeralda Valiente (Berlin, Germany)

S0474 10:00 IVDR from a European policy perspective Gülşen Özkaya Şahin (Lund, Sweden)

Co-organised with: Clinical Microbiologists of Finland, Dutch Society for Medical Microbiology (NVMM), ESCMID Ethics Advisory Committee, ESCMID Professional Affairs Subcommittee, Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), UEMS, Biomed Alliance

SY147 08:30 - 10:30 Hall ICM 1
2-hour Symposium

ANT CLN

The what and how of using AI in antimicrobial stewardship

Chairs Mark G. J. De Boer (Leiden, The Netherlands)
Mark Gilchrist (London, United Kingdom)

S0459 08:30 An introduction and overview of the evolving use of AI in antimicrobial stewardship Bradley Langford (Etobicoke, Canada)

S0460 09:00 Responsible use of AI in prediction modeling for real-life clinical practice tools Pontus Naucner (Stockholm, Sweden)

S0461 09:30 The role of ChatGPT and AI chatbots in optimising antibiotic therapy: believe or disbelieve? Alexis Maillard (Paris, France)

S0462 10:00 Is AI the key to acceleration of Antimicrobial Stewardship in LMICs? Mike Nsubuga (Bristol, United

Kingdom)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Society of Infectious Diseases Pharmacists (SIDP)

SY146 08:30 – 10:30 Hall ICM 5

CLN DX TRN

2-hour Symposium

Fungal OMICS: from bench to bedside

Chairs Lottie Brown (London, United Kingdom)
Josh Nosanchuk (Bronx, United States)

- S0455 08:30 Evolutionary genomics of emerging fungal pathogens Toni Gabaldón (Barcelona, Spain)
- S0456 09:00 Host transcriptome response to *Candida auris* extracellular vesicles Lysangela Ronalte Alves (Curitiba, Brazil)
- S0457 09:30 How *Candida* drives oral cancers: host and pathogen omics Attila Gacser (Szeged, Hungary)
- S0458 10:00 Functional consequences of mycobiota on host immunity Tobias Hohl (New York, United States)

EF123 08:30 – 09:30 Arena 2

CLN

ePoster Flash Session

Novel aspects on epidemiology and therapeutics of urinary tract infections

Chair Suzanne Geerlings (Amsterdam, The Netherlands)

- E0863 08:30 Characterising complicated urinary tract infections (POS-cUTI): preliminary results of a multinational prospective cohort (POST-cUTI / ECRAID) J.M. Bravo-Ferrer* (Seville, Spain), E. Rubio Martin, N. Maldonado, B. Gallego, E. Moreno, F. Cogliati Dezza, R. Compagnone, I. Portillo, A. Barac, F. Arieti, O. Awwad, P. De Nardo, A. Cano, P. Clevenbergh, N. Merchante, A. Hernandez-Torres, E. Frangou, E. Merino, T. Lafon, T. Ten Doesschate, O. Sandulescu, B. Koprivica, P. Andrade, A. Ternhag, M. Samarkos, M. Bokhari, A. Bandera, L. Jacquin, E. Iosifidis, E. Durante-Mangoni, D. Chadwick, J. Rupp, P. Muñoz-García, A. Røder, D. Viglino, J. Van Laethem, B. Kjurichikj, G. Marchetti, S. Tsiodras, M. David, A.R. Veiga-Ferraz, J.R. Paño-Pardo, C. Kirakli, N. Catorze, M. Tumbarello, M. Akova, I. Gentile, A. Bartoloni, L. Radulovic, C. Constantinou, M. Bonten, L.P.G. Derde, E. Cappelli, E. Tacconelli, J. Rodríguez-Baño
- E0864 08:36 Clinical effectiveness of four different short-course antibiotic regimens in adult women with bacteriological confirmation of urinary tract infection R. Monfà* (Barcelona, Spain), R. Monfà, A. García-Sangenis, R. Morros, C. Llor, D. Ouchi, S. Fernández-García, C. Miranda-Jiménez, A. Moragas, M. Aguilar-Sánchez, A. Leiva, A. Troncoso-Mariño, J. Marín-Cañada, R. Rodríguez, J.M. Molero, M.A. Sánchez-Calavera
- E0865 08:42 Proteomic endotypes in patients with *Escherichia coli* pyelonephritis L. Bolinder* (Stockholm, Sweden), T. Sutantiwanichkul, A. Reepalu, A. Linder, L. Mellhammar, M. Sundqvist, D. Nestor, C. Unge, A. Färnert, H. Janols, M. Lipcsey, J. Sundén-Cullberg, S. Cajander, M. Uhlén, F. Edfors, K. Strålin
- E0866 08:48 Predicting antibiotic resistance risk in urinary tract infections using machine learning to support safer empirical prescribing in hospitalised children and adults L. Aerts* (Basel, Switzerland), D. Malpetti, S. Bouizaguen, C. Berchtold, P. Neuschwander, G. Greub, L. Azzimont, J.A. Bielicki
- E0867 08:54 Nitrofurantoin for *Neisseria gonorrhoeae* urethritis? an *in vitro* and *in vivo* study in *Galleria mellonella* C. Kenyon* (Antwerp, Belgium), I. Kanesaka, I. De Baetselier, S. Abdellati, T. De Block, T. Vanbaelen, R. Naesens, B. Britto Xavier, S. Manoharan-Basil
- E0868 09:00 The effectiveness of a weekly antimicrobial stewardship intervention on antibiotic prescriptions in Dutch nursing homes: a randomised controlled trial L. Van Buul* (Amsterdam, The Netherlands), K. Paap, M. Schim Van Der Loeff, S. Kuil
- E0869 09:06 In private facilities, expensive medications are sometimes used as a first choice: attitudes and practice of health care workers in the management of

UTIs in Kampala, Uganda J. Kapsi* (Kampala, Uganda), D. Ekusai-Sebatta, N. Miriam, P. Kirabo, J. Enomot, M. Iwami, H. Kajumbula, F. Kitutu, C.E. Moore

E0870 09:12 Clinical symptom improvement and resolution following uUTI treatment with gepotidacin: a post-hoc subgroup analysis J. Diaz-Regañon* (Madrid, Spain), K. Gupta, D. Powell, R. Banerjee, J. Bablani, S. Janmohamed, M. Ramirez

CGR 08:30 – 10:30 Hall ICM 14

Special Session

CLN

Clinical grand rounds

Chair Robert C. Read (Southampton, United Kingdom)

Chairs Yoav Keynan (Winnipeg, Manitoba, Canada)
Nina Khanna (Basel, Switzerland)
Dimitrios P. Kontoyiannis (Houston, United States)
David L. Paterson (Singapore, Singapore)
Priscilla Rupali (Vellore, India)
Monica Slavin (Melbourne, Australia)

CGR01 08:30 Case 1 R. Gorfinkel* (Beer Sheva, Israel), O. Rouvio, L. Neshar

CGR02 08:40 Case 2 S. Showalter* (Aurora, Co, United States), J. Boguniewicz

CGR03 08:50 Case 3 R. Patel* (London, United Kingdom), E. Jabbari, T. Bharucha, L. Nabarro, T. Saifee, G. Banerjee, S. De Saram, C. Hoskote, R. Jager, J. Jones, G. Godbole, H. Manji

CGR04 09:00 Case 4 L. Saint* (Chapel Hill, North Carolina, United States)

CGR05 09:10 Case 5 J. Erber* (Munich, Germany), L. Hinterwaldner, C. Corredor Obregon, J. Schneider, S. Zange, C.D. Spinner, T. Lahmer

CGR06 09:20 Case 6 P.M.I. Chabert* (Dumbea, New Caledonia), J. Colot, E. Couadau

CGR07 09:30 Case 7 T. Cartau* (Caen, France), A. Dujardin, R. Verdon

Co-organised with: Infectious Disease Society of America (IDSA)

OS125 09:30 – 10:30 Hall A1-4

1-hour Oral Session

TRN

Regulatory, metabolic, and evolutionary mechanisms shaping *Staphylococcus aureus* pathogenesis

Chairs Frédéric Laurent (Lyon, France)
Marc Stegger (Copenhagen, Denmark)

O0871 09:30 Investigating antibiotic tolerance among clonal pairs of *Staphylococcus aureus* derived from cystic fibrosis lung infections A. Deventer* (St Andrews, United Kingdom), J. Pearson, J. Hobbs

O0872 09:42 Whole genome CRISPRi-seq reveals a cation-proton antiporter as a critical determinant of *Staphylococcus aureus* survival in monocytes like cells A. Iizuka* (Basel, Switzerland), M.V. Mazzuoli, E. Demirbilek, A.K. Woischnig, D. Bumann, J.W. Veening, A. Zinkernagel, N. Khanna

O0873 09:54 Integrating phylodynamics and GWAS to uncover drivers of meticillin-sensitive *Staphylococcus aureus* bacteraemia and colonisation D. Aggarwal* (London, United Kingdom), A.J. Van Tonder, L. Du Plessis, W. Figueroa, B. Blane, K.L. Bellis, C. Raisen, X. Ba, E. Lay, E. Nickerson, L. Bedford, R. Saunderson, W. Smith, B. Warne, T. Gouliouris, M.E. Torok, M.A. Holmes, J. Parkhill, F. Coll, S.J. Peacock, E.M. Harrison

O0874 10:06 *Streptococcus pneumoniae* weaponises its own electrical signature to launch ROS attack against *Staphylococcus aureus* X. Wu* (Hangzhou, China), L. Liu, Y. Wang, Y. Jiang, Y. Yu

O0875 10:18 Simple sequence repeats power *Staphylococcus aureus* adaptation R. Guérillot* (Melbourne, Australia), A.S. Hayes, A. Hachani, S.G. Giulieri, L. Donovan, L.M. Judd, L.K. Sharkey, A. Gonçalves Da Silva, T. Seemann, T.P. Stinear, B.P. Howden

OS124 09:30 – 10:30 Hall ICM 13b

ANT CLN 1-hour Oral Session

Facing severe bacterial infections in neonates and children		
Chairs	Dana Danino (Beer Sheva, Israel) Johannes Hübner (Munich, Germany)	
00876	09:30	Appropriateness of empirical antibiotic therapy and mortality in neonatal sepsis across LMIC hospitals K. Thomson* (Oxford, United Kingdom), C. Achi, B. Hassan, R. Farzana, K. Sands, O.B. Spiller, L.C. Jones, J. Rzaska, A. Cooke, J. Aziz, C. Farley, C. Philips, J. Spencer, J. Oduwo, E. Owinoh, K. Iregbu, N. Medugu, C. Chieze, K. Abdulraheem, F.Z. Zango Abdi, A. Aminu, R.Y. Khalid, M. Bello, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, S. Ihezuruoha, U. Ibekwe, N. Haque, S.B. Proma, S. Arefin, S. Khatun Sara, R. Khatun, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, S. Arif, S. Riaz, S.S. Gul, S. Naqvi, H. Hamid, R. Sajjad, A. Sajid, T.R. Walsh
00877	09:42	Revising vancomycin dosing recommendations in critically ill children using a population PK approach based on unbound concentrations A.T.V. Nguyen* (Ghent, Belgium), S. Carter, F. Klopogge, J. Standing, V. Stove, D. Sarah, E. Dhont, D. Vens, P. De Paepe, P. De Cock
00878	09:54	Epidemiology and vaccine coverage of group B streptococcal disease in infants zero-three months old in the Netherlands, 1987-2023 M. Groenveld* (Amsterdam, The Netherlands), D. Jamroz, M.C. Brouwer, D.H. Visser, D. Van De Beek, M.W. Bijlsma, N.M. Van Sorge
00879	10:06	Population validation of Phoenix criteria for identifying paediatric sepsis S.H. He* (Hong Kong, China), J.Z. Zhang, L.C.N. Chan, A. Lin, K.Y. Yeung, M.C.I. Kuok, J.W.C.H. Cheng, D.C.Y. Au, C.Y. Chow, T.W. Wong, W.K. Wong, E. Chan, H.M. Young, E.M. Wong, K.M. Ho, A. Lee, C. Rhee, H.S. Lam, L. Ling
00880	10:18	Oral step-down antibiotic therapy in children with infective endocarditis: the EndoChild retrospective study M. Husain* (Paris, France), M. Potie, P. Labe, P. Parize, J. Cohen, E. Bille, D. Khraiche, J. Toubiana

SY153	09:30 - 10:30	Hall A3-2
1-hour Symposium		

AMR PHEI Pro/con debate: is One Health essential or a distraction in AMR related policies?

Chairs	Elena Carrara (Verona, Italy) Timothy R. Walsh (Oxford, United Kingdom)	
--------	--	--

S0483	09:30	AMR is the quintessential One Health issue Sabiha Essack (Durban, South Africa)
-------	-------	--

S0484	10:00	One Health is distracting us from addressing policy gaps Heiman Wertheim (Nijmegen, The Netherlands)
-------	-------	---

EF126	09:30 - 10:30	Arena 1
-------	---------------	---------

CLN DX TRN ePoster Flash Session

Clinical and diagnostic insights into invasive fungal diseases

Chair	Cecile Angebault (Creteil, France)	
-------	------------------------------------	--

E0881	09:30	Detection of Mucorales antigen in serum samples using a newly developed lateral-flow device J. Rousselot* (Besançon, France), L. Millon, E. Scherer, A.P. Bellanger, C.R. Thornton
-------	-------	---

E0882	09:36	High rates of <i>Candida</i> colonisation in European neonates: a sub-analysis of the NeoVanc randomised controlled trial L.F. Hill* (London, United Kingdom), L. Ferreras-Antolin, M.N. Clements, F. Shahed, J. Fermin Luque, I. Monahan, T. Planche, M.A. Turner, I. Lutsar, E. Roilides, M. Sharland, J.A. Lindsay, P.T. Heath
-------	-------	--

E0883	09:42	Epidemiology, resistance patterns, and outcomes of candidaemia acquired in Italian intensive care units: insights from the GIVITI Network (2020-2024) G. Scaglione* (Milan, Italy), M. Colaneri, M. Offer, G. Montrucchio, C.G.I. Genovese, B. Viaggi, F.
-------	-------	--

Dore, G. Tricella, L. Dalfino, G. Monti, A. Gori, E.P.I. Palomba, S. Finazzi
--

E0884	09:48	CandEYE: serial non-mydratric funduscopy in patients with candidaemia I. Reinhold* (Cologne, Germany), J. Müller, L. Altay, A. Lentzsch, K. Löw, E. Mackevic, J. Salmanton-Garcia, C. Cursiefen, O.A. Cornely, R. Sprute
-------	-------	---

E0885	09:54	Clinical, laboratory and financial evaluation of diagnostic testing for invasive <i>Aspergillus</i> infections in haematology patients with neutropenic fever in a large U.K. teaching hospital J. Moore* (Cambridge, United Kingdom), W. Hamilton, P. Patel, A. King, J. Mason, D. Enoch
-------	-------	--

E0886	09:54	Diagnostic value of galactomannan in tracheobronchial aspirate for <i>Aspergillus</i> infection in lung transplant recipients (the GALACTBAS study) A. Monforte Pallares* (Barcelona, Spain), A. Monforte, M.T. Martín-Gómez, C. Berastegui, E. Márquez-Algaba, J. Sacanell, J. Rosado, A. Falcó-Roget, G. Escudero, J. Casanovas, C. Kirkegaard-Biosca, B. Sáez-Giménez, V. Monforte, J. Gavalda, O. Len, I. Los-Arcos
-------	-------	--

E0887	10:00	Fungal diagnostic approach among hospitalised patients receiving polyene vs azole in US, 2021-2024 E. Harvey* (Baltimore, United States), M. Zilberberg, A. Knee, G. Andan, B. Nathanson, T. Sandison, K. Marr, A. Shorr
-------	-------	---

E0888	10:12	<i>Pneumocystis jirovecii</i> pneumonia in solid organ transplant recipients: a cross-sectional study in France A. Alanio* (Paris, France), K. Sitbon, T. Obadia, M. Desnos-Ollivier, D. Garcia-Hermoso, V. Bru, G. Desoubreux, E. Guemas, M.F. Durieux, F. Morio, F. Robert-Gangneux, J. Bonhomme, F. Lanterrier, O. Lortholary
-------	-------	---

E0889	10:18	A qPCR identification scheme to detect the most common mycetoma causative agents in Africa W. Van De sanDe* (Rotterdam, The Netherlands), A. Watson, S. Bakhiet, E. Siddig, C. Pab Minlekib, R. Mohammed, W. Zandijk, M. Konings, A. Fahal, M. Faye, F. Mazraati Tajabadi, J. Errington, D. Sow
-------	-------	--

EF127	09:30 - 10:30	Arena 3
-------	---------------	---------

AMR DX IPC ePoster Flash Session

Genomic surveillance for infection prevention and outbreak investigation

Chair	Richard V. Goering (Omaha, Nebraska, United States)	
-------	---	--

E0890	09:30	From potential to practice: an internationally transferable roadmap for implementing whole genome sequencing in infection prevention and control J. Price* (Brighton, United Kingdom), J. Otter, E. Jauneikaite
-------	-------	--

E0892	09:36	Exploring filth flies as sentinels of hospital environments in 16 countries and regions: high prevalence of clinically relevant antimicrobial-resistant bacteria observed in resource-limited settings K. Sands* (Oxford, United Kingdom), E.A. Portal, T. Iannetelli, S. Premchand-Branker, T. Beard, M. Li, K. Cook, A.K. Lankapalli, V. Dougnon, A. Gaye, A. Opazo-Capurro, A.M. Soliman, M.H. Legese, J. Acolatse, E. Carretto, E.G. Kibaru, O. Sy, K. Iregbu, A. Zukowska, M.C. Seck, A.R. Mansaray, H. Kuo, C. Graham, P. Nel, C. Achi, T.R. Walsh
-------	-------	---

E0893	09:42	Genomic insights into carbapenem-resistant <i>Klebsiella pneumoniae</i> from bloodstream infections in Crete, Greece K. Tryfinopoulou* (Heraklion, Greece), G.C. Karfaki, D. Marinopoulou, T. Iatridi, M. Malliarou, E. Skliva, D. Stafylaki, E. Chatzidospyridaki, S. Karakonstantis, P. Ioannou, D. Kofteridis, A. Psaroulaki, D. Chochlakis
-------	-------	---

E0894	09:48	ST11 on the move: recurrent capsule switching and the rise of KL62 Y. Feng* (Chengdu, China), Z. Zong
-------	-------	--

E0895	09:54	Outbreak of carbapenemase-carrying plasmids in Urology: implications of bladder irrigation pipe systems A. Freijo Cancio* (Seville, Spain), A. Freijo, M. Delgado-Valverde, J. Rodríguez-Baño, R. López-Marquez, A. Pascual, L. López-Cerero
-------	-------	---

E0896	10:06	Genomic epidemiology of multidrug-resistant <i>Enterobacteriaceae</i> in intensive care units: a one year prospective study in adult intensive care units of three French university hospitals F. Gravey* (Caen, France), C. Bernachot, K. Le Neindre, D. Ducheyron, J.B. Decros, F. Tamion, S. Boyer, T.
-------	-------	--

			<i>Clavier, J. Maizel, H. Dupont, N. Lemaitre, J. Brochart, H. Marini, S. Galopin, M. Godet, S. Le Hello, C. Jeanne-Leroy, O. Join-Lambert</i>
E0897	10:12		Evaluation of the applicability of nanopore-only whole genome sequencing for <i>Pseudomonas aeruginosa</i> outbreak investigation in the ICU setting: a multi-centre study <i>J. Dingemans* (Hasselt, Belgium), S. Vandersanden, P. Hilken, F. Crombé, D. De Geyter, A.M. Van Den Abeele, P. Bruynseels, J. Frans, P. Vandecandelaere, A. Boel, R. Cartuyvels, K. Magerman</i>
E0898	10:18		<i>Pseudomonas aeruginosa</i> genome adaptations in bleached sink traps <i>D. Hocquet* (Besançon, France), T. Chautrand, L. Masson, C. Couchoud, B. Valot</i>

EF128 09:30 - 10:30 Arena 4

CLN PED TRN

ePoster Flash Session

CNS infections at a crossroad: rising lineages, host susceptibility and novel mechanisms

Chair *Maria Diletta Pezzani (Verona, Italy)*

E0899	09:30		Epidemiology, clinical characteristics and outcomes of invasive meningococcal disease caused by two hypervirulent serogroup W strains belonging to the ST11 clonal complex in England (2010-2019) <i>C. Isitt* (Stockholm, Sweden), H. Campbell, J. Lucidarme, S. Clark, P.T. Heath, R. Borrow, S.N. Ladhani</i>
E0900	09:36		Antimicrobial exposure but not vaccination predicts oropharyngeal <i>Neisseria meningitidis</i> clearance among men who have sex with men <i>M.F. Lucente* (Milan, Italy), F. Ranaldi, A.R. Raccagni, N. Capra, R. Lolatto, C. Candela, M. Ripa, G. Catalano, A. Castagna, S. Nozza</i>
E0901	09:42		Global expansion of a CTX-M-15-chromosomally integrated <i>Escherichia coli</i> ST1193 sublineage (ST1193-B1-Rx) identified in neonatal meningitis in France, 2000-2023 <i>Y. Benhadid-Brahmi* (Paris, France), K. La, G. Geslain, J. De Larminat, P. Bidet, A. Cointe, L. Armand, C. Courroux, S. Bonacorsi, A. Birgy</i>
E0903	09:48		Asplenia and functional hyposplenia in community-acquired bacterial meningitis in adults <i>E. Schepers* (Amsterdam, The Netherlands), V. Boon, E. Drost, M. Brouwer, D. Van De Beek</i>
E0904	09:54		Neurological manifestations attributable to <i>Mycoplasma pneumoniae</i> in adults during the 2023-2024 epidemic: clinical features, management, and outcomes <i>M. Holub* (Paris, France), A. Gavaud, C. Louapre, A. Bleibtreu, C. Cazanave, V. Pourcher, M. Le Marechal, G. Martin Blondel, R. Palich</i>
E0905	10:00		Increasing importance of <i>Streptococcus anginosus</i> group as a cause of invasive streptococcal infection in the UK: a retrospective longitudinal observational study <i>E. Gil* (London, United Kingdom), J. Hatcher, S. De Saram, T. Patel, T. Lamagni, R. Guy, M. Marks, J. Brown</i>
E0906	10:06		In experimental neurolisteriosis, the matrix metalloproteinases inhibitor cipemastat protects the brain from apoptotic neuronal injury <i>D. Grandgirard* (Bern, Switzerland), E. Stahovic, M. Erhardt, S.L. Leib</i>
E0907	10:12		Rhbd12 modulates inflammation, coagulation and vascular responses in experimental pneumococcal meningitis <i>D. Bakker* (Amsterdam, The Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Beek</i>

OS131 11:00 - 12:00 Hall A1-1

TRN

1-hour Oral Session

Bacterial adaptation: from colonization to pathogenesis

Chairs *Michael Bachman (Ann Arbor, Michigan, United States)*
Elisabeth Grohmann (Berlin, Germany)

O0908	11:00		<i>Listeria monocytogenes</i> clonality within the brain revealed by sequence tag-based analysis of microbial populations (STAMP) <i>K. Toms* (Paris, France), P.</i>
-------	-------	--	--

			<i>Gastineau, J. Gaillard, P. Thouvenot, S. Levallois, M. Lecuit</i>
O0909	11:12		Integrated multi-omics reveals coordinated <i>Staphylococcus aureus</i> metabolic, iron transport, and stress responses to human serum <i>A. Hachani* (Melbourne, Australia), W. Mujchariyakul, C. Walsh, S. Giulieri, C. Cramond, K.A. Leca, T. Stinear, B. Howden, R. Guerrillot</i>
O0910	11:24		IgaA mutation enhances extracellular polysaccharides production and virulence via Rcs phosphorelay in <i>Enterobacter cloacae</i> complex <i>Y. Li* (Beijing, China), M. Zhou, Y. Xu</i>
O0911	11:36		Transcriptional reprogramming driving enterococcal persistence unveiled by RNA-sequencing <i>J. Guerreiro* (Lisboa, Portugal), C. Galdes, C. Silva, F. Vale, E. Cunha, L. Tavares, J. Fernandes Guerreiro, M. Oliveira</i>
O0912	11:48		Polymicrobial biofilm communities potentiate host damage in a 3D human bladder microtissue model <i>R. Garcia Maset* (Oxford, United Kingdom), A. Crowther, V. Chu, I. White, L. Pasquina-Lemonche, M. Hadjifrangiskou, E. Stride, D. Carugo, J. Rohn</i>

OS132 11:00 - 12:00 Hall A1-3

IPC

1-hour Oral Session

Modernising surgical site infection surveillance: AI, automation and patient-centred monitoring

Chairs *Gabriel Birgand (Nantes, France)*
Martin Wolkewitz (Freiburg, Germany)

O0913	11:00		Impact of a computerised decision support system on the adequacy of surgical antibiotic prophylaxis (SAP) and surgical site infections (SSI) <i>A. Agostinho* (Geneva, Switzerland), L. Hermant, E. Chalot, J. Sobel, W. Rey, D. Teixeira, J. Goncerut, A. Freitas, J. Achcar, F. Bellissimo-Rodrigues, S. Harbarth</i>
O0914	11:12		Transforming free text into usable data: large language models to support automated surgical site infection surveillance <i>E. Chalot* (Geneva, Switzerland), A. Agostinho, J. Sobel, D. Teixeira, S. Harbarth, M. Abbas</i>
O0915	11:24		Explainable artificial intelligence models for predicting surgical site infections: a scoping review of predictive features and model transparency <i>S. Lu* (Hong Kong, China), R. Sun, Y. Liu, E. Tartari Bonnici, L. Yang, L. Zhou</i>
O0916	11:36		National surveillance of surgical site infections in Belgium: results and evolution of the Sciensano NSIH-SSI program <i>T. Tamminga* (Brussels, Belgium), K. Mertens, L. Van Imshoot</i>
O0917	11:48		Patient-reported, prospective, and digital surveillance of post-caesarean surgical site infections in the outpatient setting: the SECURE Sectio study <i>K. Last* (Bonn, Germany), M.N. Kröncke, M. Jaskolski, E. Früchtl, F. Droop, N. Scholten, N.T. Mutters, B. Strizek</i>

OS133 11:00 - 12:00 Hall A1-5

ANT CLN PHEI

1-hour Oral Session

Community-acquired pneumonia: know your enemies, treat them well

Chairs *Aurélien Dinh (Garches, France)*
Annabel Niessen (Utrecht, The Netherlands)

O0918	11:00		Pneumococcal pneumonia in adults, re-emergence of vaccine serotypes: a prospective multi-centre cohort study in Germany, 2020-2023 <i>C. Bahrs* (Vienna, Austria), N. Rose, G. Barten-Neiner, C. Fleischmann-Struzek, M.P.G. Van Der Linden, G. Rohde, J. Rupp, M. Witzernath, J. Rademacher, M.W. Pletz</i>
O0919	11:12		Incidence and burden of medically and non-medically-attended <i>Mycoplasma pneumoniae</i>, 2024-2025 <i>J. King* (Marshfield, United States), J. Petrie, B. Kieke, O. Alonge, W. Meng, Z. Zheng, I. Leony Lasso, Y. Park, E.C. Newbern, C. Canan, J. Meece, E. Viscidi, E.J. Anderson, H. Nguyen</i>
O0920	11:24		Genomic surveillance reveals global spread of macrolide-resistant <i>Bordetella pertussis</i> linked to vaccine changes <i>J. Feng* (Shanghai, China), C. Min</i>

00921	11:36	Real-world applicability of a three-day antibiotic regimen for community-acquired pneumonia: a ten-year retrospective study across four Swiss university centres T. Brahier* (Lausanne, Switzerland), J. Regina, G. Carra, M. Méan, N. Boillat Blanco
00922	11:48	Cardiovascular risk of clarithromycin use in patients hospitalised with community-acquired pneumonia S. Bastrup Israelsen* (Hvidovre, Denmark), M. Fally, P. Ravn, L. Kolte, M. Schmidt, T. Benfield, A. Matthews

OS134 11:00 – 12:00 Hall A2-2
1-hour Oral Session

CLN DX

Changing landscape of opportunistic infections in the immunocompromised host

Chairs Malgorzata Mikulska (Genoa, Italy)
Lior Neshet (Beersheba, Israel)

00923 11:00 **MUCOPS interventional trial: blood Mucorales PCR screening in high-risk haematology patients** Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, E. Boon, T. Mercier, A. Schauvlieghe, K. Beuselinck, K. Lagrou, J. Maertens

00924 11:12 **Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)** T. Morris* (Saint-Etienne, France), A. Fayard, V. Dupont, E. Daguene, C. Thieblemont, E. Bachy, G. Manson, C. Herbaut, I. Yakoub-Agha, T. Gastinne, D. Blaise, L. Roulin, F.X. Gros, P. Bories, R. Houot, S. Le Gouill, E. Botelho-Nevers, L. Fouillet, J. Cornillon

00925 11:24 **Strategies for management of human cytomegalovirus (HCMV) reactivation in haematopoietic stem cell transplant recipients (HSCTr) in the era of letermovir** D. Lilleri* (Pavia, Italy), I. Cassaniti, D. Mele, M. Michele, F. Zavaglio, G. Grassia, N. Polverelli, D. Russo, A. Algarotti, T. Lazzarotto, F. Bonifazi, P. Chiusolo, F. Baldanti

00926 11:36 **Transplantation and geographic medicine: analysis of data from the Spanish National Transplant Organisation (ONT), 2015-2024** F. Norman* (Madrid, Spain), B. Mahillo, M.D. Corbacho-Loarte, M. Gonzalez-Sanz, S. Chamorro-Tojeiro, F. Gioia, D. Gayoso-Cantero, B. Dominguez-Gil, J. Fortun, P. Martin-Davila

00927 11:48 **Risk factors for invasive mold infections in heart transplant recipients: a nationwide matched case-control study** B. Hoellinger* (Strasbourg, France), E. Epailly, F. Vuotto, V. Letscher-Bru, S. Loidant, C. Goeminne, R. Coelho, G. Laurent, S. Guendouz, G. Melica, F. Bottere, D. Maubon, A. Boignard, S. Pattier, F. Morio, C. Chabanne, J.P. Gangneux, K. Blanchart, J. Bonhomme, S. Grosjean, F. Dalle, C. Nafeh-Bizet, L. Favennec, B. Pilmis, J. Guilhaire, A. Gigandon, G. Pasquier, V. Dupasquier, C. Vignals, M. Lefranc, P. Tirard-Collet, L. Sebbag, L. Van Den Bogaart, F. Lanternier, M. Saito, F. Danion

OS135 11:00 – 12:00 Hall A3-2
1-hour Oral Session

AMR PHEI

Harnessing wastewater for surveillance of AMR

Chairs Henry-Michel Cauchie (Belvaux, Luxembourg)
Amy Mathers (Charlottesville, United States)

00928 11:00 **Longitudinal wastewater metagenomics allows genomic and clinical surveillance of human-associated viruses** M. Karatas* (Leuven, Belgium), M. Bloemen, J. Swinnen, L. Close, M. Van Ranst, E. Wollants, J. Matthijnsens

00929 11:12 **From influent to effluent: antibiotic resistance gene dynamics in WWTPs** C. Stoffers* (Groningen, The Netherlands), M. Lokate, L. Gard, A. Voss, J.W.A. Rossen

00930 11:24 **Associations between antimicrobials and antimicrobial resistance genes in urban wastewater** M. Penney* (Calgary, Canada), D. Kuzma, K. Aleshia, M. Kayla, O. Christine, D. Kristine, A. Emily,

A. Nicole, W. Barbara, L. Jangwoo, W. Benson, C. Rhonda, M. Janine, V. Laura, P. Chloe, R.M. Elissa, D. Bruce, N. Diego, B. Herman, C. John, K.H. Susana, H. Casey, P. Michael

00931 11:36 **Hospital use of ciprofloxacin and sulfamethoxazole correlates with their concentrations in hospital wastewater in Norway, 2019-2025** H.J. Espvik* (Oslo, Norway), M. Grung, C. Vogelsang, K.M. Gravningen

00932 11:48 **Cross-compartment genomic epidemiology of cephalosporin- and carbapenem-resistant Enterobacterales: an international multi-centre study in patients, hospital aquatic environments and wastewater** N. Macesic* (Melbourne, Australia), N. Hassoun-Kheir, M. Andre, D. Andrey, M. Beiers, X. Bertrand, B. Burri, D. Haber, S. Harbarth, J. Hawkey, M. Karram, L. Opatowski, M. Paul, R. Patwa, R. Sierra, K. Van Hoorde, M. De Kraker, A. Peleg

OS129 11:00 – 12:00 Hall ICM 13a
1-hour Oral Session

ANT TRN

Making phages GMP-ready: the manufacturing challenge

Chair Jean-Paul Pirnay (Brussels, Belgium)
TBA

00933 11:00 **Consensus-based guideline on personalised bacteriophage therapy** S. Würstle* (Frankfurt, Germany), S. Lieberknecht-Jouy, M. Vehreschild, A. Classen

00935 11:12 **Virulent phage infection triggers prophage induction and lysogenic conversion in *Staphylococcus aureus*: implications for therapeutic phage production safety and virulence dynamic** P.A. Pastouriaux* (Lyon, France), M. Bonhomme, P. Martins-Simoes, L. Blazere, E. Helluin, K. Royet, M. Medina, C. Kolenda, F. Laurent, F. Laumay

00936 11:24 **Tailoring the next generation bacteriophage therapy with a cell-free system** S.C. Nang* (Melbourne, Australia), H.H.Y. Yu, H. Wickremasinghe, X. Li, J. Zhao, J. Li

00937 11:36 **Implementation of the first French public platform for the production of GMP-grade therapeutic phages at reasonable cost** F. Laurent* (Lyon, France), L. Frédéric, M. Medina, B. Lapras, C. Kolenda, C. Marchand, F. Laumay, C. Merienne, M. Bonhomme, F. Piro

OS130 11:00 – 12:00 Hall ICM 13b
1-hour Oral Session

CLN PHEI

Navigating clinical realities in travelers and migrant populations

Chairs Andreas Neumayr (Basel, Switzerland)
Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)

00938 11:00 **Safety of the dengue vaccine TAK-003 and risk factors for developing adverse events in travellers from non-endemic areas: a real-world prospective multi-centre pharmacovigilance study in Spain** D. Camprubi-Ferrer* (Barcelona, Spain), D. Camprubi Ferrer, M. Saloni, L. Valerio, J. Villar, V. Lopez-Lopez, C. Bertran-Cobo, D. Garcia, E. Jurado, M.L. Machado, C. Masuet, S. Cuevas Marin, I. Gonzalez Nieto, D. Herena Garcia, R. Morales, A. Gomila-Grange, I. Vera, F. Vila, N. Martin, T. De Alba, N. Morales Llorente, E. Gorriiz Hidalgo, J. Muñoz

00939 11:12 **Cluster of rash dominant dengue fever in newly arrived Chinese expatriates at Bangalore (India): a sentinel event in travel health** A. Mb* (Bangalore Rural, India), S. Banti, D. Shobha, R. Surendran

00940 11:24 **AdMiRE study: development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe: a multicountry Delphi and psychometric study on behalf of ESGITM group** G. Guido* (Bari, Italy), A. Abbara, M. Asaduzzaman, F.B. Farkas, K. Diabate, A. Duvignaud, V. Holmberg, S. Ibrahim, S. Jordao, R. Papagni, L. Jung, B. Lakatos, M. Orcutt, A. Saracino, A. Requena-Méndez, E. Romanenco, M. Schiavone, C. Shortall, C. Napoli, D. Mosca, P. Luga, J. Llenas Garcia, E. Nicastri, A. Corpulongo, P. Bodenman, E. Florence, F. Eick, L. Závorszky, S. Severoni, C.M. Wejse, F. Di Genaro

00941 11:36 **Imported leishmaniasis in Europe (2000-2024): a systematic review of travel-related case reports** J.

00942 11:48 **Acosta España*** (Quito, Ecuador), S.M. Alcocer-Veintimilla, V.A. Pillajo-Gangotena, J.D. Acosta-España, A. Abbara, M. González-Sanz, A. Rodríguez-Morales
Seroprevalence of *Burkholderia pseudomallei* among international travelers: a preliminary result Q.M. Ali* (Bangkok, Thailand), G. Zschebek, C.M.S. Cagape, N. Saiprom, S. Tandhavanant, R. Phunpang, M.N. Burtnick, P.J. Brett, T. Siripoon, H.A. Imad, C. Chewapreecha, W. Cheirakul, N. Chantratita, W. Matsee

SY158 11:00 – 12:00 Hall A1-4
 1-hour Symposium

Detecting parasites using metagenomics and proteomics

Chairs Hanne Brekke (Oslo, Norway)
 Dora Buonfrate (Negrar, Italy)

S0439 11:00 **Unmasking hidden worlds: the power of metagenomics in parasitology** Francesco Asnicar (Trento, Italy)

S0440 11:30 **From proteomics to the bench** Momar Ndao (Montreal, Quebec, Canada)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY159 11:00 – 12:00 Hall A2-1
 1-hour Symposium

To AI or not to AI: latest trends in digital innovation for respiratory virus detection and management

Chairs Benjamin Cowling (Pokfulam, Hong Kong)
 Esmeralda Valiente (Berlin, Germany)

S0441 11:00 **Using AI-enabled diagnostics to strengthen biosecurity and address gaps in servicing remote populations** Holly Seale (Sydney, Australia)

S0442 11:30 **Latest trends in AI-supported respiratory virus surveillance and monitoring** Jude Kong (Toronto, Canada)

Co-organised with: Australasian Society for Infectious Diseases (ASID), ESCMID Study Group for Respiratory Viruses (ESGREV), International Pediatric Association (IPA)

SY160 11:00 – 12:00 Hall A3-1
 1-hour Symposium

Emerging resistance to new antibiotics: are we already losing the newest tools?

Chairs Ana Gales (São Paulo, Brazil)
 Thomas Tängdén (Uppsala, Sweden)

S0443 11:00 **Current prevalence and clinical impact of resistance to new drugs** Timothy R. Walsh (Oxford, United Kingdom)

S0444 11:30 **How to minimise resistance to new drugs** Elena Carrara (Verona, Italy)

SY157 11:00 – 12:00 Hall B0-1
 1-hour Symposium

Personalised antimicrobial stewardship for resistant pathogens: beyond clinical trials

Chairs Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)
 Tomislav Kostyanev (Esbjerg, Denmark)

S0437 11:00 **bla_{NDM}-producing Enterobacterales: optimal selection of adjuvant β -lactamase inhibitors** Jacob Strahilevitz (Jerusalem, Israel)

S0438 11:30 ***Mycobacterium tuberculosis* mutations associated with drug resistance: the way forward** Iñaki Comas (Valencia, Spain)

SY155 11:00 – 12:00 Hall ICM 1
 1-hour Symposium

Year in paediatric ID

Chairs Julia Anna Bielicki (London, United Kingdom)
 Hervé Haas (Nice, France)

S0433 11:00 **Epidemiology, diagnosis, treatment** Ulrich Von Both (Munich, Germany)

S0434 11:30 **Infection prevention and vaccines** Dana Danino (Beer Sheva, Israel)

SY156 11:00 – 12:00 Hall ICM 5
 1-hour Symposium

Decoding resistance: the new ESCMID guidelines to halt transmission of multidrug-resistant Gram-negatives

Chairs Ana Budimir (Zagreb, Croatia)
 Andreas Voss (Groningen, The Netherlands)

S0435 11:00 **The ESCMID blueprint for prevention: a deep dive into the new guidelines** Evelina Tacconelli (Verona, Italy)

S0436 11:30 **Making the guidelines stick: innovative implementation strategies for effective uptake** Bianca Albers (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

EF136 11:00 – 12:00 Arena 2
 ePoster Flash Session

Novel aspects in antimicrobial susceptibility testing and resistance detection

Chair Alberto Antonelli (Florence, Italy)

E0943 11:00 **Rapid MALDI-TOF MS synergy testing to guide combination therapy in critical infections** M. Bexkens* (Rotterdam, The Netherlands), S. Van Den Berg, C. De Vogel, W. De Jong, A. Muller

E0944 11:06 **NANOMUR: innovative nanomotion technology for antibiotic susceptibility testing: a game-changer for urinary tract infections?** A. Delfino* (Lausanne, Switzerland), D.C. Cân, O.Y. Chén, A. Sturm, D. Cichocka, G. Greub

E0945 11:12 **Not all MIC plates are equal: method-driven shifts in cefiderocol susceptibility for NDM-producing Enterobacterales** M. Bouillon* (Caen, France), C. Isnard, S. Le Hello, F. Gravey

E0946 11:18 **A multi-centre evaluation of routine susceptibility testing methods for linezolid using a clinical *Enterococcus* strain collection** S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, J. Boelens, N. Botteldoorn, P.J. Ceysens, M. Chemais, C. Deckers, S. Desmet, S. Gils, T.D. Huang, B. Lissoir, K. Magerman, C. Meex, K. Floré, A.M. Van Den Abeele, E. Van Honacker, K. Vernelen, I. Verstreken, V. Matheussen, S. Vandamme

E0947 11:24 **Challenges of phenotypic antimicrobial susceptibility testing of *Enterococcus faecium* for vancomycin using semi-automated systems and their causes** T. Ruegamer* (Cologne, Germany), C. Arz, A. Hiergeist, R. Arazo Del Pino, U. Reischl, P.G. Higgins, A. Gessner, A. Dudakova, M. Simon, J. Jantsch

E0948 11:30 **Waiting for the answer: validation of newly implemented VITEK 2 automated susceptibility testing cards can cause treatment delays in an intensive care unit population** S. Boettcher* (Detroit, United States), A. Abed, N. Everson, R. Kenney, R. Tibbetts, L. Samuel, M. Veve

E0949 11:36 **Utility of tetracycline susceptibility as a predictor of doxycycline activity in non-diphtheriae *Corynebacterium*: a retrospective analysis** K. Barrett* (Rochester, United States), O. Abu Saleh, M. Fida

E0950 11:42 ***In vitro* evaluation of cefiderocol against *Achromobacter xylosoxidans* isolates from people with cystic fibrosis** F. Tollo* (Verona, Italy), G. Toccia, A. Bertonecchi, A. Mazzariol

E0951 11:48 **Rethinking ESBL Detection in Enterobacterales:**

EF137 11:00 – 12:00 Arena 3

VAX

ePoster Flash Session

Bacterial vaccine pipeline: focus on *Staphylococcus* and *Klebsiella*

Chair Guido Werner (Wernigerode, Germany)

E0952 11:00 **AntiPan: a genome-informed in silico pipeline for advancing subunit vaccine discovery against *Staphylococcus aureus*** M. Elhadidy* (Giza, Egypt), M.S. Ibrahim, J.A. Fahmy, M.A. Helal, F.T. Hakim, L.R. Sidarous, N.E. Attallah, S. Abouelhadid, E. Badr

E0954 11:12 **Kp-OMV4: a broadly active OMV vaccine against *Klebsiella pneumoniae*** B. Cano Castaño* (Madrid, Spain), B. Cano-Castaño, S. Prieto Martin-Gil, A. Tajuelo Moreno-Palancas, E. Gato, P. Miguella-Villoldo, D. Fousteris, A. Peláez García, F. Docando, D. Megias, A.J. Martín-Galiano, A. Pérez, M.J. McConnell

E0955 11:18 **Wide strain coverage and protection predicted for K-Vax, a vaccine for prevention of disease by *K. pneumoniae* presenting OmpA and OmpK36 assembled into chimeric LPS-null whole-cells of *A. baumannii*** A. Rodríguez Rosado* (Dos Hermanas, Spain), A.I. Rodríguez-Rosado, A. Alonso-Del Valle, J. Sa Pessoa, R. Calderon-Gonzalez, M. Garcia-Lopez, L. Del Pozo-Acebo, M. Cordero-Alba, M.J. McConnell, J.A. Bengoechea, J.J. Infante

E0956 11:24 **Broad computational and experimental screening of antigenic loops in the *Klebsiella pneumoniae* porinome** A. Pérez Gómez* (Madrid, Spain), S. Prieto Martin-Gil, A. Tajuelo, B. Cano, D. Fousteris, L. Vaughan, P. Miguella-Villoldo, E. Gato, A. Pérez, A.J. Martín Galiano, M.J. Mcconnel

E0957 11:30 **Assessment of KpiD as a promising antigen for vaccine development against *Klebsiella pneumoniae*** A. Tajuelo Moreno-Palancas* (Madrid, Spain), A. Tajuelo, S. Prieto Martin-Gil, L. Vaughan, B. Cano-Castaño, P. Miguella-Villoldo, D. Fousteris, V. Mas, A.J. Martín-Galiano, M.J. McConnell, A. Pérez, E. Gato

E0958 11:36 **Developing an outer membrane vesicle-based vaccine against *Klebsiella pneumoniae*** K. Winter* (Vancouver, Canada), K. Chu, N. Wilks, S. Cai, A. Tejani, W.L. Kuan, I. Hadad, L. Presley, T. Harn, M. Lo, M. Sadarangani

E0959 11:42 **Cost-effectiveness analysis of PCV21, an adult specific 21-valent pneumococcal conjugate vaccine, vs PCV20 in adults in Germany** L. Lang* (Munich, Germany), P. Mueller, M. Simuzingili, M. De Lepper, K. Owusu-Edusei

E0960 11:48 **Development of a non-invasion intranasal vaccine for *Klebsiella pneumoniae* urinary tract infection** L.K. Siu* (Zhunan, Taiwan), M.H. Huang

EF138 11:00 – 12:00 Arena 4

VAX

ePoster Flash Session

Pneumococcal vaccines: impact and serotype dynamics

Chair Ron Dagan (Beer-Sheva, Israel)

E0961 11:00 **The first comprehensive whole genome sequencing of *Streptococcus pneumoniae* from the Arabian Gulf region: Implications for vaccine strategies** A. Senok* (Dubai, United Arab Emirates), S. Verma, L. Mohamed, E. Kaambo, S. Boucherabine, M. Senghore, A. Nabi, M. Habou, F. Jabeen, A. Alatoom, N. Abdulrazzaq, W. Jamal, R. Nassar, E. Mokaddas, D. Everett

E0962 11:06 **Dominance of PCV13-nonPCV10 serotypes in paediatric invasive pneumococcal infections in Serbia after sequential PCV programs** N. Vuckovic Opavski* (Belgrade, Serbia), M. Jovicevic, J. Kabic, D. Kekic, Z. Vasiljevic, O. Hadzic Simovic, S. Laban Nestorovic, T. Djordjevic, D. Medic, L. Ranin, I. Gajic

E0963 11:12 **Serotype evolution and sequence types of *Streptococcus pneumoniae* meningitis isolates before and after PCV13 introduction in Algeria** S. Bouheraoua* (Algiers, Algeria), A.E. Deghmane, K.

E0964 11:18 **Assessing the impact of different pneumococcal conjugate vaccine (PCV) programs on invasive pneumococcal disease (IPD) using population based surveillance in Ontario** A. McGeer* (Toronto, Canada), A. Shigayeva, Z. Zhong, C. Amirov, A. Belhaj, S. Chakrabarti, D. Chen, W. Gold, A. Golden, L. Goneau, C. Kandel, S. Krajden, R. Lovinsky, I. Martin, L. Matukas, T. Mazzulli, M. Muller, J. Nadarajah, K. Ostrowska, N. Rau, D. Ricciuto, D. Richardson, D. Rose, M. Saffie, V. Sales, A. Simor, C. Vermeiren

E0965 11:24 **Would implementing a risk-based or an age-based PCV20 vaccination program in adults 60+ years in Brazil be cost effective and budget saving?** L. Huang* (Collegeville Pa, United States), R.F. Alexandre, A. Claro, R. Ferreira, D. Pachito

E0966 11:30 **Estimated impact of pneumococcal conjugate vaccine implementation on disease burden and mortality: strategies to guide PCV program introduction in low-resource settings** T. Ngamprasertchai* (Bangkok, Thailand), V. Mahd-Adam, W. Pan-Ngum

E0967 11:36 **Long-term persistence of pneumococcal antibodies five years after sequential PCV13 and PPSV23 vaccination in kidney transplant recipients: indications for revaccination** L. Van De Sand* (Essen, Germany), B. Wilde, K. Völk, O. Witzke, M. Lindemann, N. Mülling

E0968 11:42 **Effect of introducing pneumococcal conjugate vaccines into national immunisation programmes on antimicrobial-resistant *Streptococcus pneumoniae* disease burden across 188 countries: a synthetic-control study** Z. Chen* (Shanghai, China), C. Zhihui, L. Zhonghua, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong

KN154 11:00 – 12:00 Hall ICM 14

TRN VAX

Keynote lecture

Genetics underlying susceptibility and immunity to infection

Chairs Jan A.J.W. Kluytmans (Utrecht, The Netherlands) Gülşen Özkaya Şahin (Lund, Sweden)

K0432 11:00 Filomeen Haerynck (Ghent, Belgium)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME161 11:00 – 12:00 Hall A1-2

CLN

Meet-the-Expert

Clinical challenges and management strategies for slowly progressing cutaneous infections

M0445 11:00 Maria Luisa Aznar (Barcelona, Spain)

M0446 11:12 Richard Odame Phillips (Kumasi, Ghana)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

F0162 11:00 – 12:00 Arena 1

PRO

Open Forum

Integrating Sustainable Development Goals (SDGs) 3 and 5 in policy and practice

Chair Sabine Bélard (Tübingen, Germany)

F0447 11:00 **From policy to practice: gender equality in the SDG framework** Irit Nachtigall (Berlin, Germany)

F0448 11:10 **Gender and access to infectious disease diagnostics and treatment** Daniela Fusco (Hamburg, Germany)

F0449 11:20 **Integrating gender and community realities into AMR for SDGs 3 & 5 in Sub-Saharan Africa** Judith Asin (Nairobi, Kenya)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

OS140	13:30 – 14:30	Hall A1-1	
	1-hour Oral Session		
	CLN DX		
Transforming diagnostic microbiology with AI			
Chairs	<i>Benjamin Peter Howden (Melbourne, Australia)</i> <i>Mariska Leeflang (Amsterdam, The Netherlands)</i>		
O0970	13:30	Democratising MALDI-TOF AMR prediction: from Transformers to simple Neural Networks without accuracy loss, reducing energy costs via knowledge distillation <i>A. Guerrero-López* (Zurich, Switzerland), L. De Ancos Villa</i>	
O0971	13:42	A novel auditable diagnostic support system using constrained retrieval-augmented generation improves accuracy and efficiency in parasitology morphology identification <i>C.C. Hung* (New Taipei, Taiwan)</i>	
O0972	13:54	ParaScout: microscopic helminth detection using AI <i>R. Zonneveld* (Amsterdam, The Netherlands), S. Slavenburg, C. Tieken, R. Koelewijn, L. Van Lieshout, I. Feoktistov, J. Van Hellemond</i>	
O0973	14:06	Transformer AI in clinical microbiology: ProkBERT improves detection of plasmids and mobile genetic elements <i>G. Lorenzin* (Trento, Italy), M. Carlin, D. Krizsán, B. Ligeti</i>	
O0974	14:18	Accuracy of Gram stain interpretation by smartphone-based computer-aided diagnosis app in blood culture samples <i>K. Ebisawa Furui* (Kobe, Japan), G. Ohji, K. Yamamoto, I. Miyatsuka, A. Moriya, K. Akamatsu, H. Nomoto, M. Kurokawa, K. Ohnuma, M. Kusuki, Y. Uemura, N. Ohmagari</i>	

SY166	13:30 – 14:30	Hall A1-4	
	1-hour Symposium		
	IPC PHEI		
One Health beyond AMR: the challenge of <i>Clostridioides difficile</i> infection control outside the hospital			
Chairs	<i>Marcela Krutova (Prague, Czechia)</i> <i>Ana Vale (Dublin, Ireland)</i>		
S0406	13:30	<i>Clostridioides difficile</i> in extra-human sources <i>Mónica Oleastro (Lisbon, Portugal)</i>	
S0407	14:00	Dynamics of transmission of <i>Clostridioides difficile</i> within and outside the hospital <i>Semeh Bejaoui (Bologna, Italy)</i>	
Co-organised with: ESCMID Study Group for <i>Clostridioides difficile</i> (ESGCD), ESCMID Study Group for Veterinary Microbiology (ESGVM)			

SY165	13:30 – 14:30	Hall B0-1	
	1-hour Symposium		
	AMR TRN		
Beneath the caspale of <i>Klebsiella pneumoniae</i>: hypervirulence, fitness and adaptive evolution			
Chairs	<i>Christian Stephan Lentz (Tromsø, Norway)</i> <i>Shiri Navon-Venezia (Ariel, Israel)</i>		
S0404	13:30	What constitutes hypervirulence during <i>Klebsiella pneumoniae</i> infection? <i>Yunn-Hwen Gan (Singapore, Singapore)</i>	
S0405	14:00	Adaptive evolution and in-host dissemination of <i>Klebsiella pneumoniae</i> <i>Michael Bachman (Ann Arbor, Michigan, United States)</i>	

EW169	13:30 – 15:30	Hall A2-1	
	2-hour Educational Session		
	CLN		
UTIs off the beaten path: complex patients, complex choices			
Chairs	<i>Suzanne Geerlings (Amsterdam, The Netherlands)</i> <i>Angela Huttner (Geneva, Switzerland)</i>		

W0416	13:30	UTI in kidney-transplant patients: what's new and what's safe? <i>Dionysios Neofytos (Geneva, Switzerland)</i>	
W0417	13:50	UTI and bacteriuria in pregnancy: two and the	

			same? <i>Barbara Trautner (St. Louis, United States)</i>
W0418	14:10	UTI in patients with stones and stents: rocks and hard places <i>Lorenz Leitner (Zurich, Switzerland)</i>	
W0419	14:30	UTI in neurogenic bladder/spinal cord injury patients <i>Ruxandra Calin (Paris, France)</i>	
Co-organised with: ESCMID Study Group for Urinary Tract Infections (ESGUTI)			

EW170	13:30 – 15:30	Hall A2-2	
	2-hour Educational Session		
	CLN DX		
Take the right path: tips on HIV resistance management in the era of new antiretrovirals			
Chairs	<i>Claudia Cortes (Santiago, Chile)</i> <i>Botond Lakatos (Budapest, Hungary)</i>		
W0420	13:30	State-of-the art approach to HIV resistance analysis <i>Ivailo Alexiev (Sofia, Bulgaria)</i>	
W0421	13:50	Epidemiology of HIV resistance in Europe and beyond <i>Dimitrios Paraskevis (Athens, Greece)</i>	
W0422	14:10	HIV resistance management in the era of long-acting antivirals <i>Dan Otelea (Bucharest, Romania)</i>	
W0423	14:30	Drug resistance testing for optimising HIV management <i>Anna Maria Geretti (London, United Kingdom)</i>	
Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Dat'AIDS Working Group			

EW171	13:30 – 15:30	Hall A3-1	
	2-hour Educational Session		
	ANT CLN		
Managing bloodstream infections and endocarditis in the context of drug injection or homelessness			
Chairs	<i>Brigitte Lamy (Bobigny, France)</i> <i>Aneta Nyčová (Praha, Czechia)</i>		
W0424	13:30	Epidemiology and features of bloodstream infections among PWID <i>Asko Jarvinen (Helsinki, Finland)</i>	
W0425	13:50	Alternative antibiotic regimens and delivery strategies for infective endocarditis in PWID <i>Burcu Isler (Gold Coast, Australia)</i>	
W0426	14:10	Is combination treatment necessary for <i>Staphylococcus aureus</i> infections? <i>Sara Grillo (Barcelona, Spain)</i>	
W0427	14:30	Oral antibiotics for bacteraemia in people who use drugs <i>Pierre Tattevin (Rennes, France)</i>	
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)			

EW172	13:30 – 15:30	Hall A3-2	
	2-hour Educational Session		
	CLN DX		
Transplant infectious diseases: real-world challenges through the eyes of the next generation			
Chairs	<i>Roy Chemaly (Houston, United States)</i> <i>Nathan Peiffer-Smadja (Paris, France)</i>		
W0428	13:30	Understanding and applying cell-mediated immunity in transplant infectious diseases <i>Carla Walti (Basel, Switzerland)</i>	
W0429	13:50	CNS complications in patients treated with CAR-T cells <i>Marjorie Batista (São Paulo, Brazil)</i>	
W0430	14:10	How much is enough? Rational empiric therapy in febrile immunocompromised patients <i>Yuri Vanbiervliet (Leuven, Belgium)</i>	
W0431	14:30	Challenges for diagnostic stewardship in transplant recipients <i>Ankit Mittal (Hyderabad, India)</i>	
Co-organised with: ESCMID Study Group for Antimicrobial Stewardship (ESGAP), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)			

EW167	13:30 – 15:30	Hall ICM 13a
	2-hour Educational Session	
PRO		
Inside the black box: leading and developing clinical guidelines		
Chairs	<i>Blin Nagavci (Gjakova, Kosovo)</i> <i>Luigia Scudeller (Pavia, Italy)</i>	
W0408	13:30	How to chair a guideline panel and survive <i>Mark G. J. De Boer (Leiden, The Netherlands)</i>
W0409	13:50	Deconstructing guidelines: how to ensure and assess their trustworthiness <i>Mical Paul (Haifa, Israel)</i>
W0410	14:10	Pitfalls in developing guidelines: conflicts of interest, panel composition, and updating <i>José Ramón Paño-Pardo (Zaragoza, Spain)</i>
W0411	14:30	More than a logo: the strategic role of societies in guideline development <i>Marcus Zervos (Detroit, United States)</i>
Co-organised with: ESCMID Guidelines Subcommittee, CMI Board of Editors		

EW168	13:30 – 15:30	Hall ICM 13b
	2-hour Educational Session	
CLN DX		
A diagnostic odyssey: how to enhance diagnostic stewardship		
Chairs	<i>Polona Maver Vodincar (Ljubljana, Slovenia)</i> <i>Neven Papic (Zagreb, Croatia)</i>	
W0412	13:30	Should I order an IGRA test? Could this be a mycobacterial infection? <i>Christoph Lange (Borstel, Germany)</i>
W0413	13:50	Do I have antibodies or just anxiety? Gen Z gets real about serology <i>Jean-Luc Murk (Blaricum, The Netherlands)</i>
W0414	14:10	PCR tests: the superheroes of infection detection... or just really good sidekicks? <i>Snjezana Zidovec Lepej (Zagreb, Croatia)</i>
W0415	14:30	Serum, culture, PCR: but wait, fungi still have a few tricks up their sleeve! <i>Katrien Lagrou (Leuven, Belgium)</i>

OS139	13:30 – 15:30	Hall ICM 5
	2-hour Oral Session	
CLN DX TRN		
Clinical metagenomics: from sample processing to actionable results		
Chairs	<i>Hege Vangstein Aamot (Lørenskog, Norway)</i> <i>John W. A. Rossen (Groningen, The Netherlands)</i>	
00975	13:30	From sample to treatment in four hours: bringing metagenomics precision to complicated UTI diagnostics and management <i>R. Ahmad* (Hamar, Norway), A.B. Bellankimath, S. Branders, K. Isabell, A. Jawad, A. Fatemeh, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner</i>
00976	13:42	Multi-centre evaluation of the EasySeq Full-Length 16S Sequencing kit for bacterial identification in clinical samples <i>T.T. Severs* (Zwolle, The Netherlands), L. Gard, J.W.A. Rossen, L.B. Van Alphen, R.M. Koeck, P.W. Smit, R.Y. Yahiaoui, S.P.F. Matamoros, B. Van Den Bosch, P. Koopman, R. Cartuyvels, J. Dingemans, M.J.R. Ivens, S.D. Pas, S.A. Boers</i>
00977	13:54	Rapid species identification in community-acquired bacteraemia using a short pre-culturing step followed by 16S nanopore sequencing <i>D. Nestor* (Orebro, Sweden), M. Ekström, S. Cajander, P. Mölling, M. Sundqvist</i>
00978	14:06	Insights from over 11,000 clinical samples in over five years of routine metagenomics in Germany <i>S. Grumaz* (Duisburg, Germany), J. Becher, C. Disqué, K. Rensing, J. Bottlang, D. Borda-Molina, P. Stevens</i>
00979	14:18	MetaGENomic Sequencing to detect Infections in SOTR (Solid Organ Transplant Recipients): interim analysis of the mGENiSIS registry <i>S. Khalil* (Houston, United States), A. Chandorkar, D.W. Charles, L. Fontana, T. Taylor, I. Kaur, D.R. Kaul, Z. Raglow, J. Schaanman, K. Obeid, S. Nair, C.E. Harris, R.O. Adekunle, A. Mills, S. Yang, J.R. Shah, L. Ogawa, H.</i>

00980	14:30	Implementation of respiratory metagenomics during the 2024/25 autumn/winter season in a large UK specialist referral hospital <i>M. Ibrahim* (Southampton, United Kingdom), S. Green, N. Norton, E. Pelosi, J. Swabe, C. Mckenzie, A. Alcolea-Medina, L.B. Snell, D. Ward, A. Dushianthan, M. Grocott, J. Edgeworth, K. Saeed</i>
00981	14:42	Rapid hybridisation capture workflow for targeted metagenomics of respiratory infections <i>O.E. Torres Montaguth* (London, United Kingdom), A. Busam, L.M. Martin Bernal, T. Brooks, I. Ringue, G. Kuczmar, A. Kopec, S. Buddle, L. Ahmed, R. Williams, J. Brown, S. Morfopoulou, J. Breuer</i>
00982	14:54	Ultra-rapid µCaler hybrid-capture tNGS with a fully automated workstation for comprehensive detection of respiratory pathogens <i>W. Feili* (Beijing, China), Y. Liping, G. Shan, X. Bangxiang, Z. Jiaying, Z. Lili, Z. Yulin</i>
00983	15:06	The world's first direct from raw sample to report NGS platform: delivering rapid BSI pathogen ID and AMR from whole blood clinical samples <i>S. Reed* (London, United Kingdom), R. Samuel, E. Brown, D. Seth, D. Dylan, E. Oscar, S. Yazmine, P. Hannah, P. Maria, S. Laura, E. Liz, M.B. Joanna, M. Raegan, L. William, P. Marie, G. Flavia, S. Shagun, D. Jennifer, S. Peter, G. Hailey, C. Giselle, K. Daniel, W. Jason, C. Brandon, N. Cristian, R. Jonathan, M. Christian, P. Shane, V. Steven, D. Miroslav, J. Isaac, M.C. Fraser, M. Daniel, W. David, W. Graham, W. Michele</i>
00984	15:18	An open-source, on-site nanopore sequencing workflow for rapid microbial cell-free DNA (mcfDNA) detection in bloodstream infections <i>M. Banz* (Jena, Germany), S. Hagel, M. Pletz, C. Brandt</i>

SY164	13:30 – 15:30	Hall A1-2
	2-hour Symposium	
PED VAX		
From childhood to adulthood: overcoming barriers in vaccine prevention		
Chairs	<i>Hervé Haas (Nice, France)</i> <i>Tina Tan (Chicago, United States)</i>	
S0400	13:30	Meningococcal disease: how and why do vaccination schedules differ across Europe? <i>Adam Finn (Bristol, United Kingdom)</i>
S0401	14:00	Measles: lessons learned from a recent epidemic in the era of vaccine hesitancy <i>Adriana Pistol (Bucharest, Romania)</i>
S0403	14:30	Pneumococcal disease prevention: a lifespan approach <i>Robert Cohen (Creteil, France)</i>

Co-organised with: Société de Pathologie Infectieuse de Langue Française, French Pediatric Infectious Diseases Group (GPIP), Infectious Diseases Society of America (IDSA)		
SY163	13:30 – 15:30	Hall ICM 1
	2-hour Symposium	
AMR		
Global landscape of AMR surveillance in Gram-negative bacteria		
Chairs	<i>Patrick Mcgann (Silver Spring, Maryland, United States)</i> <i>Paul A. Tambyah (Singapore, Singapore)</i>	
S0396	13:30	Insights from the genomic surveillance of CRE in Europe: ongoing challenges <i>Lemonia Skoura (Thessaloniki, Greece)</i>
S0397	14:00	Current epidemiology of CRAB in Europe: diagnostic advances <i>Paul G. Higgins (Cologne, Germany)</i>
S0398	14:30	Revolutionising informal AMR data sources vs traditional interfaces <i>Tin Tin Myaing (Bangkok, Thailand)</i>
S0399	15:00	Genomic insights into AMR surveillance: lessons from South and South-East Asia <i>Balaji Veeraraghavan (Vellore, India)</i>
Co-organised with: AMR Action Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Public Health Microbiology (ESGPHM), ECDC, International Society for Infectious Diseases		

EF141	13:30 - 14:30	Arena 2
	ePoster Flash Session	
		
New threats to occupational health		
Chair	<i>Biljana Carevic (Oslo, Norway)</i>	
E0985	13:30	SIREN RespOME study: <i>Staphylococcus aureus</i> nasal and throat colonisation in a UK healthcare worker cohort V. Hall* (London, United Kingdom), S. Foulkes, K. Bellis, A. Atti, E.M. Harrison, J. Islam
E0986	13:36	Healthcare worker KAP tools regarding flu and COVID-19 vaccination: reliability and structural stability pre- and post-campaign M. Latorre-Millán* (Saragossa, Spain), A. Milagro, I. Ezpeleta, J.M. Álvarez-Zarate, L. Clusa
E0987	13:42	Healthcare workers' infection prevention strategies in primary healthcare facilities of rohingya refugee camps in Bangladesh S.M.M. Hasan* (Dhaka, Bangladesh), S.A. Prema
E0989	13:48	Late diagnosis of infectious diseases and disease transmission among health care workers in a tertiary care hospital R. Tafveez* (Karachi, Pakistan), A. Ali, S. Farhan, N. Virani, R. Roshan, S.F. Mahmood
E0990	13:54	Prioritising healthcare workers for Lassa fever vaccination in Nigeria D. Smith* (Paris, France), T.D. Hollingsworth, K. Holohan, O.O. Ayodeji, K.B. Pouwels, S. Okogbenin
E0991	14:00	Do we spread bacteria when 'shooting' disposable gloves after use? F. Schaumburg* (Münster, Germany), J. Skorning, T. Grebe, P. Neuhaus
E0992	14:06	Bridging the know-do gap: evaluation of a multimodal intervention to increase infection prevention competency of healthcare workers in Bangladeshi hospitals S.A. Sumon* (Dhaka, Bangladesh), M.G.D. Harun
E0993	14:12	Evaluating mask performance through total inward leakage: a human volunteer study K. Lassing* (Nijmegen, The Netherlands), H. Wertheim, P. Scheepers

EF142	13:30 - 14:30	Arena 3
-------	---------------	---------

ePoster Flash Session

 **Next-generation diagnostics for reproductive health**

Chair	<i>Mauricio Farfan (Santiago, Chile)</i>	
E0995	13:30	Hologic Panther system in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and <i>Trichomonas vaginalis</i> vaginitis N. Aparisi* (Valencia, Spain), N. Aparisi Valero, M. Palomeque Matos, A. Orts Fullana, L. Andrés Eslava, J.L. Ramos Martí, V. Marqués Nova, L. Suarez Lopez, M.G. Ferrando Cerda, M.J. Lahiguera Abalos, N. Talón Costa, L. Sempere Mira, C. Gimeno Cardona, D. Ocete Mochón
E0997	13:36	High-throughput multiplex PCR for detection of infertility-associated STIs in gynecologist-referred patients B. Cullhaj* (Tirana, Albania), I. Marku, D. Sino
E0998	13:42	Diagnostic accuracy of Xpert CT/NG assay at the point-of-care for the detection of neonatal <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infection: cohort study in Papua New Guinea L. Braunack-Mayer* (Bern, Switzerland), M.A. Riddell, A. Mengi, L.M. Vallely, P.H. Cunningham, M. Starr, H. Wand, B.D. Spycher, R. Guy, M. Laman, W.S. Pomat, A.J. Vallely, N. Low
E0999	13:48	Detection of <i>Treponema pallidum</i> in saliva and its application to molecular epidemiology K. Imai* (Saitama, Japan), Y. Ohama, A. Sato, M. Tanaka, R. Omachi, S.I. Nakayama, M. Tokano, N. Tarumoto, T. Maeda, Y. Akeda
E1000	13:54	Expanding diagnostic options for STIs: qPCR screening using routine liquid cytology samples H. Alonso* (San Mateo De Gallego, Spain), E. Teresa, E. Villarreal, M. Lopez, S. Aznar, S. Lucea, M. Barco
E1001	14:00	A pragmatic approach to scaling STI screening in low-resource settings: pooled '3-in-1' Xpert® CT/NG testing achieves high predictive performance at reduced costs among Indonesian MSM R. Hamers* (Jakarta, Indonesia), S. Suwanti, Y.W. Anggraini, N.

E1002	14:06	Large-scale molecular surveillance of bacterial STIs in Brazil: a four-year multi-state analysis of over 335,000 RT-PCR tests for <i>Chlamydia trachomatis</i>, <i>Neisseria gonorrhoeae</i>, and <i>Mycoplasma genitalium</i> V. Passarelli* (São Paulo, Brazil), P. Cappellano, C. Dos Santos Lazar, F. Goldemberg, M. Chiarastelli Salomão, A. Martins Fontes, F. Marques Rodrigues, J. De Sá, F.H. Da Silva, C. Granato, G. Hughes, S. Figueiredo Costa
-------	-------	--

SY173	14:30 - 15:30	Hall A1-5
-------	---------------	-----------

1-hour Symposium

 **Future-proofing IPC: smarter strategies for tomorrow's challenges**

Chairs	<i>Elisabeth Presterl (Vienna, Austria)</i> <i>Andreas F. Widmer (Füllinsdorf, Switzerland)</i>	
--------	--	--

S0451	14:30	Advancing prevention of catheter-associated infections: from care bundles to integrated multimodal IPC strategies <i>Camelia Bogaert (Gent, Belgium)</i>
-------	-------	---

S0452	15:00	From firefighting to foresight: shifting IPC from reactive to proactive <i>Nico Tom Mutters (Bonn, Germany)</i>
-------	-------	--

EF143	14:30 - 15:30	Arena 1
-------	---------------	---------

ePoster Flash Session

   **Shaping policy for antimicrobial use and AMR**

Chair	<i>Benedikt Huttner (Geneva, Switzerland)</i>	
-------	---	--

E1004	14:30	An intersectionality-based policy analysis of antimicrobial resistance in national action plans in WHO European region E. Magrini* (Rome, Italy), C. Shortall, C. Naim, E. Short, A. Abbara
-------	-------	--

E1005	14:36	Carbon impact of blood-culture utilisation changes during a global supply constraint E. Chan* (Melbourne, Australia), P. Kinsella, C. O'shea, K. Cronin, K. Bond, S. Mcalister, F. Mcgain
-------	-------	--

E1006	14:42	The environmental impact of antibiotic treatment: a life-cycle analysis of intravenous-inpatient, -outpatient and oral treatment options P. Elders* (Amsterdam, The Netherlands), B. Joosten, T. De Vries, L. Kouwenberg, E. Cohen, E. Van Bree, F. De Haes, S. Geerlings, J. Hovius, K. Sigaloff
-------	-------	--

E1007	14:48	Towards a global health equity framework for antimicrobial resistance: mapping indicators across disciplines, domains, and levels of aggregation T. Makamu* (Cape Town, South Africa), C. Bonaconsa, S. Mkhumbuzi, A. Kona, M. Mendelson, E. Charani
-------	-------	---

E1008	14:54	Strengthening public health policies for antimicrobial resistance: insights from the EU-JAMRAI 2 sustainability guidance tool B. Davido* (Paris, France), D. Merillon, M. Fuentes-Braesch
-------	-------	--

E1009	15:00	Valuing sustainable access to antibiotics: stakeholder reasoning on trade-offs, preparedness, and ethical priorities in Sweden, Italy, and Bulgaria M. Torre* (Rome, Italy), M. Ancillotti, D. Mascalzoni, R. Biasiotto, A. Diukendjieva, G. Kyosovska, C. Munthe, E. Baraldi, S. Wagrell
-------	-------	--

E1011	15:06	Impact of World Health Organization's AWaRe antibiotics on the gut microbiome: a systematic review and meta-analysis A. Di Gallo* (Milan, Italy), E. Crivellaro, A. Banfi, L. Barcellini, S. Panelli, C. Giaroni, E. Fusco, G. Zuccotti, M. Sharland, L. Folgori
-------	-------	---

EF144	14:30 - 15:30	Arena 4
-------	---------------	---------

ePoster Flash Session

  **Clinical and epidemiological perspectives on neglected parasitic and fungal diseases**

Chair	<i>Jaya Tapadar Née Chakravarty (Varanasi, India)</i>	
-------	---	--

E1012	14:30	Effectiveness of PAIR and aspiration for hepatic hydatid cysts: ten years of experience from a UK referral centre L. Blundell* (London, United Kingdom), M. Bojorquez-Segura, M. James, D. Lawrence, T. Pissanou, G. Godbole, Z. Amin, L. Nabarro
E1013	14:36	Structured treatment interruption in alveolar echinococcosis: patient selection and predictors of successful outcome A.L. Allgaeuer* (Ulm, Germany), L. Heinzmann, L. Peters, W. Jiang, B. Gruener
E1014	14:42	Epidemiological and molecular study of relapse cases of infection with the microsporidia <i>Enterocytozoon bieneusi</i> C. Nourrisson* (Clermont-Ferrand, France), M. Moniot, P. Combes, F. Dalle, D. Costa, P. Poirier
E1015	14:48	Intestinal microsporidiosis in immunocompetent individuals: data from the French NRC CMAP (2018–2024) P. Poirier* (Clermont-Ferrand, France), C. Nourrisson, P. Combes, M. Moniot, L. Favennec, F. Dalle, D. Costa
E1016	14:54	The skin to heart connection: linking scabies and skin infections to rheumatic heart disease in a New Zealand national cohort study S. Gupta* (Auckland, New Zealand), S. Thornley
E1017	15:00	Scabies prevalence in children under five years old in Ecuadorean remote indigenous communities after the cessation of ivermectin administration A. Garcia Mingo* (London, United Kingdom), A. Garcia-Mingo, M. Castro Aliaga, M. Caicedo Orobio, E. Salazar, R. Basu Roy, V. Velasco Tirado, M. Cáceres Alonso, M. González Sanz
E1018	15:06	Epidemiological shifts in visceral leishmaniasis incidence, relapse, and mortality in Brazil: analysis using National Notifiable Diseases Information System D.G. Assefa* (Dilla, Ethiopia), G. Cota, J.P. Wilson, J.A. Mendes, C. Naylor, R. Peplow, S. Singh-Phulgenda, M.S. Saito, P.J. Guerin, P. Dahal
E1019	15:12	Epidemiological and clinical features of leishmaniasis in a tertiary hospital in Brazil O.H. Pradi Guenther* (Curitiba, Brazil), E. Dyminski Parente Ribeiro, F. Tomiotto-Pellissier
E1020	15:18	A ten-year follow-up of <i>Leishmania donovani</i> transmission dynamics during the visceral leishmaniasis elimination campaign in India A.K. Singh* (Varanasi, India), S. Sundar, E. Hasker

ME174 14:30 – 15:30 Hall A1-3

Meet-the-Expert

CLN DX

How to use serological tests for Lyme borreliosis

M0453 14:30 Mariska Leeftang (Amsterdam, The Netherlands)

M0454 14:42 Ram B. Dessau (Slagelse, Denmark)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)